<SEC-DOCUMENT>0001193125-14-194964.txt : 20140512
<SEC-HEADER>0001193125-14-194964.hdr.sgml : 20140512
<ACCEPTANCE-DATETIME>20140512164352
ACCESSION NUMBER:		0001193125-14-194964
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20140331
FILED AS OF DATE:		20140512
DATE AS OF CHANGE:		20140512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		14833926

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d722563d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended March&nbsp;31, 2014 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 001-33221 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HERON
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2875566</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>123 Saginaw Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, CA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94063</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:</B> <B>(650)&nbsp;366-2626</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp; Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check
mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter)
during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp; Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of the registrant&#146;s common stock, par value $0.01 per share, outstanding as of April&nbsp;28, 2014 was 23,901,497. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
QUARTERLY PERIOD ENDED MARCH 31, 2014 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">PART I. FINANCIAL INFORMATION</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;1.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_1">Condensed Financial Statements &#151; Unaudited</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_2">Condensed Balance Sheets as of March 31, 2014 and December 31, 2013</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">1</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_3">Condensed Statements of Operations for the three months ended March 31, 2014 and 2013</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">2</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_4">Condensed Statements of Cash Flows for the three months ended March 31, 2014 and 2013</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">3</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_5">Notes to Condensed Financial Statements</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">4</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;2.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_6">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">10</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;3.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_7">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">15</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;4.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_8">Controls and Procedures</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">15</TD></TR>
<TR>
<TD HEIGHT="24" COLSPAN="5"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">PART II. OTHER INFORMATION</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;1.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_9">Legal Proceedings</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">16</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;1A.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_10">Risk Factors</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">16</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;2.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_11">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">32</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;3.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_12">Defaults Upon Senior Securities</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">32</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;4.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_13">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">32</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;5.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_14">Other Information</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">32</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">ITEM&nbsp;6.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><A HREF="#toc722563_15">Exhibits</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">33</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#toc722563_16">SIGNATURES</A></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">34</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>PART&nbsp;I.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL INFORMATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_1"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONDENSED FINANCIAL STATEMENTS </B>&#151;<B> UNAUDITED </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC.
</B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc722563_2"></A>Condensed Balance Sheets </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">March&nbsp;31,<br>2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<br>2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(Note 2)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>ASSETS</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</U></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable to related parties, net of discount</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc722563_3"></A>Condensed Statements of Operations </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in
thousands, except per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ended<br>March&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,322)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,752)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(216)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,538)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,953)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc722563_4"></A>Condensed Statements of Cash Flows </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in
thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ended<br>March&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,538)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,953)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used for operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,624)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,011)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,713)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,961)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from warrant exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,812)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,784)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPUETICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc722563_5"></A>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Business </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) (the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148;) is a
specialty pharmaceutical company developing product candidates using its proprietary Biochronomer&#153; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by
converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead
product candidate, SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (formerly known as APF530), is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (&#147;CINV&#148;) for patients undergoing both
moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature
discontinuation of treatment. There is only one injectable 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical
need. SUSTOL contains the 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist granisetron formulated in our proprietary Biochronomer polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for
five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and
efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2009, we filed the original New Drug Application (&#147;NDA&#148;) seeking approval for SUSTOL with the U.S. Food and Drug
Administration (&#147;FDA&#148;). The FDA issued a Complete Response Letter for the SUSTOL NDA in March 2010. In September 2012, we resubmitted our NDA for SUSTOL and, in March 2013, we received a second Complete Response Letter, which identified
several remaining issues that need to be addressed prior to approval of the SUSTOL NDA. We are currently working on addressing these issues and expect to resubmit the SUSTOL NDA in mid-2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own the worldwide rights to SUSTOL and are in the early stages of building the commercial infrastructure necessary to commercialize SUSTOL in the U.S. on
our own, assuming approval by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to resubmitting the SUSTOL NDA, we are seeking to expand the labeled indication for SUSTOL following
its potential approval. In 2014, we initiated a Phase 3 clinical study with SUSTOL for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy, an indication for which no 5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3 </SUB>antagonist is approved. The 1,000 patient study is expected to be completed in late 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our core
Biochronomer technology, on which SUSTOL and our other product candidates are based, consists of bioerodible polymers designed to release drugs over a defined period of time. We have completed over 100 <I>in vivo</I> and <I>in vitro</I> studies
demonstrating that our Biochronomer technology is potentially applicable to a range of therapeutic areas, including, among others, prevention of CINV, pain management and control of inflammation. We have also completed comprehensive animal and human
toxicology studies that have established that our Biochronomer polymers are safe and well tolerated. Furthermore, our Biochronomer technology can be designed to deliver drugs over periods varying from days to potentially multiple weeks. We are
exploring the potential use of our Biochronomer polymer with other drugs and intend to pursue the clinical development of one or more other drug candidates based on our proprietary delivery platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, we initiated a program to expand our pipeline of sustained-release products, including a new program targeting the relief of post-surgical
pain. Preliminary animal studies indicate that formulations using our Biochronomer polymer-based drug delivery platform provided sustained analgesic effects for three to five days. We plan to formalize optimization in 2014 and initiate a Phase 1
study in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mid-2014. As of 2012, approximately 25 million<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> procedures associated with post-operative pain were conducted in the U.S. In addition,
post-operative pain market sales were approximately $3.1 billion<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> in 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2014, we
changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. Effective January&nbsp;13,&nbsp;2014, we effected a 1-for-20 reverse split of our outstanding common stock (&#147;Reverse Stock Split&#148;) (See Note 5). All historical share and
per share amounts have been adjusted to reflect the Reverse Stock Split. All stock options, convertible notes and warrants outstanding were appropriately adjusted to give effect to the Reverse Stock Split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses
and negative cash flows from operations and we have an accumulated deficit of $256.4 million as of March&nbsp;31, 2014. During 2011, 2012 and 2013, we completed a total of four rounds of equity and/or debt financings, which provided us with cash of
approximately $135.4 million, net of issuance costs, to fund operations (see Notes 4 and 5). As of March&nbsp;31, 2014, we had cash on hand of $57.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical
studies prior to 2015 or begin preparations for potential commercialization of SUSTOL, we will need to raise additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient
financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of Presentation </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in
the United States (&#147;GAAP&#148;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete
financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&nbsp;31,&nbsp;2014 are
not necessarily indicative of the results that may be expected for other quarters or the year ending December&nbsp;31, 2014. The condensed balance sheet at December&nbsp;31, 2013 has been derived from the audited financial statements as of that
date, but does not include all of the information and disclosures required by GAAP. The presentation of prior year amounts was reclassified to conform to the current year presentation. For more complete financial information, these unaudited
condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended December&nbsp;31, 2013 included in the Company&#146;s Annual Report on Form&nbsp;10-K for the fiscal year
ended December&nbsp;31, 2013 filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;7, 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accounting Policies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of
condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.
We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates on historical experience and on assumptions that it believes to be reasonable under
the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under
different assumptions or conditions. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Custom Research Project by Design Resources completed in 2013. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decision Resources, Acute Pain, December 2012. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We had cash of $57.5
million and $72.3 million at March&nbsp;31, 2014 and December&nbsp;31, 2013, respectively. There were no cash equivalents as of both dates. Our bank accounts have been placed under a control agreement in accordance with the April&nbsp;2011
convertible note financing (see Note 4). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnings Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic earnings per share (&#147;EPS&#148;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period,
without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method.
For purposes of this calculation, stock options, warrants and common stock underlying convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have incurred a net loss for both periods presented in the unaudited condensed statements of operations, outstanding stock options, warrants and
common stock underlying convertible notes are not included in the computation of net loss per share because their effect would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table includes the number of outstanding stock options, warrants and common stock underlying convertible notes not included in the computation for the three months ended March&nbsp;31, 2014 and 2013 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock underlying convertible notes outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Income (Loss) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our
comprehensive net loss for both periods presented was comprised solely of its net loss and there were no other changes in equity from non-owner sources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect that
the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Convertible Notes to Related Parties </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5 million in Senior Secured Convertible
Notes (&#147;Notes&#148;). We received a total of $4.3 million, net of issuance costs, from the issuance of these Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes are secured by
substantially all of our assets, including placing our bank accounts under a control agreement. The Notes bear interest at 6%&nbsp;per annum, payable quarterly in cash or in additional principal amount of Notes, at the election of the purchasers.
The Notes mature on May&nbsp;2, 2021, however, the holders of the Notes may require prepayment of the Notes at any time, at each holder&#146;s option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal
and accrued interest due under the Notes. There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the
Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, we were in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes,
the holders of the Notes have the right to require us to redeem all or a portion of their Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We filed a registration statement with the SEC to
register for resale 3.5&nbsp;million shares (as adjusted for the Reverse Stock Split) underlying the Notes. The registration statement was declared effective on July&nbsp;29, 2011. The Purchasers have agreed to waive their right to require us to
maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for
every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance
dates and we began amortizing the resultant debt discount over the respective 10-year term of the Notes. During the three months ended March&nbsp;31, 2014, accrued interest of approximately $75,000 was paid-in-kind and rolled into the Note principal
balance, which resulted in an additional debt discount of approximately $75,000. For the three months ended March&nbsp;31, 2014 and 2013, interest expense relating to the stated rate was approximately $77,000 and $71,000, respectively, and interest
expense relating to the amortization of the debt discount was approximately $139,000 and $130,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, the carrying
value of the Notes was approximately $1,164,000, which is comprised of the $5,108,000 principal amount of the Notes outstanding, less debt discount of $3,944,000. If the $5.1&nbsp;million principal amount of Notes is converted, we would issue
6.4&nbsp;million shares of our common stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stockholders&#146; Equity </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendments to Articles of Incorporation &#150; Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc. and to effect a 1-for-20 reverse
split of our outstanding common stock. The name change and Reverse Stock Split were approved by our stockholders on September&nbsp;19,&nbsp;2013. As a result of the Reverse Stock Split, the total authorized shares of common stock were reduced from
1,500,000,000 to 75,000,000 shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2011 Private Placement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2011, we sold 8.0&nbsp;million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For
each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July&nbsp;1,&nbsp;2016. The warrants may be exercised
for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless
exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by
any particular purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;29, 2011, we filed a registration statement with the SEC to register for resale the shares and the
shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August&nbsp;4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to
sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (&#147;Rule 144&#148;). There is currently only one investor who is an affiliate of ours
and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise. If we fail to keep the
registration statement continuously effective for a designated time (with limited exceptions) during the period we are obligated to maintain the registration statement, we may be obligated to pay to the investors liquidated damages in an amount
equal to 1.0%&nbsp;per month of such investor&#146;s pro rata interest in the total purchase price of the 2011 private placement, capped at a total penalty of 6.0%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2014, one warrant holder exercised 144,040 warrants under the cashless exercise provision in the warrant
agreement, which resulted in the net issuance of 108,409&nbsp;shares of common stock and no net cash proceeds to the Company. During the three months ended March&nbsp;31, 2013, we received $0.6 million for cash exercises of these warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2012 Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2012, we sold
5.1&nbsp;million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1 million in issuance costs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective
on September&nbsp;6, 2012. If we fail to keep the registration statement continuously effective for a designated time (with limited exceptions), we may be obligated to pay to each investor an amount equal to 1.5%&nbsp;per month of the aggregate
purchase price of the unregistered shares held by such investor, capped at a total penalty of 9.0%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2013 Common Stock Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, we entered into an underwriting agreement, pursuant to which we sold a total of approximately 8.6&nbsp;million shares of our common stock to
the underwriters at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9 million in issuance costs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering was made pursuant to the Company&#146;s effective registration statement on Form S-3 (Registration No.&nbsp;333-190550), which was previously
filed with the SEC and was declared effective, and a prospectus supplement filed with the SEC. The offering was not registered under any state blue sky laws and was limited to &#147;Qualified Institutional Buyers&#148; (as defined in Rule 144A under
the Securities Act of 1933, as amended) and certain other institutional and accredited investors, as permitted under applicable law. In the underwriting agreement, the Company agreed to indemnify the underwriters against certain liabilities,
including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Exercises </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended
March&nbsp;31, 2014, approximately 215,000 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to the Company of approximately $958,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock-based compensation expense for the three months ended March&nbsp;31, 2014 and 2013 related to stock options and Employee
Stock Purchase Plan (&#147;ESPP&#148;) purchase rights by expense category (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, there was approximately $45.4 million of total unrecognized compensation cost related to
non-vested, stock-based payment awards granted under all of the Company&#146;s equity compensation plans. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize this
compensation cost over a period of 2.5&nbsp;years, which is the weighted-average vesting period for all stock-based compensation awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
estimated the fair value of each option grant on the grant date using the Black-Scholes option valuation model with the following weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>Options:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of each purchase right granted under the ESPP at the beginning of each new offering
period using the Black-Scholes option valuation model. A new offering period begins every six months in May and November of each year. For the three months ended March&nbsp;31, 2014 and 2013, there were no new offering periods or ESPP purchase
rights granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the stock option activity for the three months ended March&nbsp;31, 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying
values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company&#146;s ability to generate future taxable income and consequently realize such deferred income tax assets, a full
valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of March&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained
upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There have been no material changes in the Company&#146;s unrecognized tax benefits since
December&nbsp;31, 2013 and as such, disclosures included in the Company&#146;s 2013 Annual Report on Form&nbsp;10-K continue to be relevant for the period ended March&nbsp;31, 2014. </P>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_6"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited
condensed financial statements and related notes included in this quarterly report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December&nbsp;31, 2013 included in our Annual Report on Form 10-K for
the year ended December&nbsp;31, 2013 filed with the Securities and Exchange Commission, or SEC, on March&nbsp;7,&nbsp;2014. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This
Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148;
&#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;assume&#148; and other expressions which predict or indicate future events and trends and which do not
relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company. These risks, uncertainties and other
factors may cause the actual results, performance or achievements of the Company to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Factors that might cause these differences include the following: </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>the anticipated progress of our research, development and clinical programs and timing of, and prospects for, regulatory approval and commercial introduction of SUSTOL<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> and other future product candidates; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>estimates of the timing of our resubmission of the New Drug Application (&#147;NDA&#148;) for SUSTOL; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>if approved, the timing of market introduction of SUSTOL or other future product candidates; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>our ability to successfully market, commercialize and achieve market acceptance for SUSTOL or other future product candidates; </I></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>our ability to successfully develop other drug candidates utilizing our proprietary Biochronomer polymer-based drug delivery platform; </I></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>our ability to establish collaborations for our technology, SUSTOL and other future product candidates; </I></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>uncertainties associated with obtaining and enforcing patents; </I></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>our estimates for future performance; and </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>our estimates regarding our capital
requirements and our needs for, and ability to obtain, additional financing.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>These forward-looking statements were based on
information, plans and estimates at the date of this Form 10-Q, and we assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes. In
addition, please see the &#147;Risk Factors&#148; section of this Form 10-Q. These risk factors may be updated from time to time by our future filings under the Securities Exchange Act of 1934. You should carefully review all of these factors.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise noted, all historical information in this Item&nbsp;2 regarding share amounts of our common stock, prices per share
of our common stock and loss per share has been adjusted to reflect, on a retroactive basis, the application of the 1-for-20 reverse stock split of our common stock that we effected on January&nbsp;13,&nbsp;2014 (the &#147;Reverse Stock
Split&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron
Therapeutics, Inc. (formerly A.P. Pharma, Inc.) (the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148;) is a specialty pharmaceutical company developing product candidates using its proprietary Biochronomer&#153; polymer-based
drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only
once every one or two weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (formerly known as
APF530), is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (&#147;CINV&#148;) for patients undergoing both moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV for patients
undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. SUSTOL contains the 5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB> antagonist granisetron formulated in our proprietary Biochronomer polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single
subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2009, we filed the original NDA seeking approval for SUSTOL with the U.S. Food and Drug Administration (&#147;FDA&#148;). The FDA
issued a Complete Response Letter for the SUSTOL NDA in March 2010. In September 2012, we resubmitted our NDA for SUSTOL and, in March 2013, we received a second Complete Response Letter, which identified several remaining issues that need to be
addressed prior to approval of the SUSTOL NDA. We are currently working on addressing these issues and expect to resubmit the SUSTOL NDA in mid-2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own the worldwide rights to SUSTOL and are in the early stages of building the commercial infrastructure necessary to commercialize SUSTOL
in the U.S. on our own, assuming approval by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to resubmitting the SUSTOL NDA, we are seeking to expand the labeled
indication for SUSTOL following its potential approval. In 2014, we initiated a Phase 3 clinical study with SUSTOL for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy, an indication for which no 5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3 </SUB>antagonist is approved. The 1,000 patient study is expected to be completed in late 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core Biochronomer technology, on which SUSTOL and our other product candidates are based, consists of bioerodible polymers designed to
release drugs over a defined period of time. We have completed over 100 <I>in vivo</I> and <I>in vitro</I> studies demonstrating that our Biochronomer technology is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potentially applicable to a range of therapeutic areas, including, among others, prevention of CINV, pain management and control of inflammation. We have also completed comprehensive animal and
human toxicology studies that have established that our Biochronomer polymers are safe and well tolerated. Furthermore, our Biochronomer technology can be designed to deliver drugs over periods varying from days to potentially multiple weeks. We are
exploring the potential use of our Biochronomer polymer with other drugs and intend to pursue the clinical development of one or more other drug candidates based on our proprietary delivery platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, we initiated a program to expand our pipeline of sustained-release products, including a new program targeting the relief of
post-surgical pain. Preliminary animal studies indicate that formulations using our Biochronomer polymer-based drug delivery platform provided sustained analgesic effects for three to five days. We plan to formalize optimization in 2014 and initiate
a Phase 1 study in mid-2014. As of 2012, approximately 25 million<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> procedures associated with post-operative pain were conducted in the U.S. In addition, post-operative pain market sales were
approximately $3.1 billion<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> in 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Critical Accounting Policies and Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been
prepared in accordance with accounting principles generally accepted in the United States, known as GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base
our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
have been no material changes to the critical accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013 filed with the Securities and Exchange Commission on March&nbsp;7, 2014.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note&nbsp;2 to the unaudited condensed financial statements included in Item&nbsp;1 of this Quarterly Report on Form&nbsp;10-Q. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Custom Research Project by Design Resources completed in 2013. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Decision Resources, Acute Pain, December 2012. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations for the Three Months Ended March&nbsp;31, 2014 and 2013 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Research and Development Expense </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SUSTOL related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New product development related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2014, research and development expense increased to $11.8 million
from $7.1 million for the same period in 2013. The increase in research and development expense for the three months ended March&nbsp;31, 2014 was primarily the result of an increase in SUSTOL related costs of approximately $2.5 million due to the
initiation of a Phase 3 label expansion study of SUSTOL in 2014 and costs associated with addressing the issues raised by the FDA in the 2013 Complete Response Letter. In addition, the increase in research and development expense was due to costs
associated with new product development, including our new pain management program targeting the relief of post-surgical pain which was initiated in November 2013. Finally, the increase in research and development expense was due to an increase in
personnel and related costs of approximately $0.8&nbsp;million mainly due to additional headcount and infrastructure to support the increased development activities noted above, as well as an increase in non-cash, stock-based compensation expense of
approximately $1.0 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>General and Administrative Expense </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense remained consistent at $5.6 million for the three months ended March&nbsp;31, 2014 and 2013. General and
administrative expenses consist primarily of salaries and related expenses, professional fees, directors&#146; fees, investor relations costs, pre-commercialization costs, insurance expense and related overhead cost allocation. General and
administrative expense for the year 2014 is expected to be higher as compared to 2013, due to increased costs to support anticipated commercialization activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Interest Expense </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
was $0.2 million for both the three months ended March&nbsp;31, 2014 and 2013. Interest expense consists primarily of interest expense and amortization of debt discount related to the convertible notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Resources and Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2014, we had approximately $57.5 million in cash, compared to $72.3 million as of December&nbsp;31, 2013. The net decrease
in cash of approximately $14.8 million was primarily due to the use of cash to fund our continued development of SUSTOL, personnel costs and for other general corporate purposes, partially offset by cash proceeds received from stock option exercises
of approximately $1.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have financed our operations, including technology and product research and development,
primarily through sales of our common stock and other securities, royalties, revenues from collaboration arrangements, proceeds received from the sale of discontinued operations and interest earned on short-term investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2011, we entered into definitive agreements for a convertible note financing of up to
$4.5&nbsp;million. We received a total of approximately $4.3 million, net of issuance costs, whereby $4.5 million aggregate principal amount of convertible notes were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2011, we closed a unit financing where each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common
stock; whereby the Company received approximately $22.8 million of proceeds, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we closed a common
stock financing whereby the Company received approximately $50.5 million of proceeds, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, we closed
a common stock offering whereby the Company received approximately $57.8 million of proceeds, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our
current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies prior to 2015 or begin preparations for potential commercialization of SUSTOL, we will need to raise
additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. Our capital
requirements going forward will depend on numerous factors, including: an approval decision by the FDA with respect to SUSTOL; the timing of and costs associated with the commercial launch of SUSTOL, if approved; the degree of commercial success of
SUSTOL; the number and characteristics of product development programs we pursue and the pace of each program including the timing of clinical trials to expand our pipeline of sustained-release products; the scope, rate of progress, results and
costs of preclinical testing and clinical trials, including our Phase 3 clinical trial of SUSTOL for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy; the time, cost and outcome involved in seeking other regulatory
approvals; scientific progress in our research and development programs; the magnitude and scope of our research and development programs; our ability to establish and maintain strategic collaborations or partnerships for research, development,
clinical testing, manufacturing and marketing of our product candidates; the cost and timing of establishing sales, marketing and distribution capabilities for a specialty sales force if we commercialize other products independently; the cost of
establishing clinical and commercial supplies of our product candidates and any products that we may develop; and general market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to raise sufficient additional capital when we need it on favorable terms, or at all. The sale of additional equity in the
future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be required to curtail operations significantly or to obtain funds by entering into financing, supply or collaboration agreements on
unattractive terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no current means of generating material cash flows from operations. There can be no assurance that our
product development efforts related to any of our product candidates will be successfully completed, that required regulatory approvals will be obtained, or that any products, if introduced, will be successfully marketed or achieve commercial
acceptance. Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through public or private equity offerings, debt financings and corporate collaboration and licensing arrangements, as well as through
interest income earned on cash balances. We cannot be certain that additional funding will be available to us on acceptable terms, or at all. Our ability to obtain new financing may be constrained by unfavorable economic conditions currently
affecting financial markets and numerous other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of fixed payments related to certain contractual obligations (in millions), consisting solely of our operating lease
obligations. This table excludes amounts already recorded on our balance sheet as current liabilities as of March&nbsp;31, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payment due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the convertible notes issued in May 2011 and May 2012 may require prepayment of the Notes at
any time at each holder&#146;s option. See Note 4 of Notes to Condensed Financial Statements included in Item&nbsp;1 of this Quarterly Report on Form 10-Q. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also enter into agreements from time to time with clinical sites and contract research organizations for the conduct of our clinical
trials. We make payments to these sites and organizations based in part upon the number of patients enrolled and the length of their participation in the clinical trials. Under certain of these agreements, we may be subject to penalties in the event
that we prematurely terminate these agreements. At this time, due to the variability associated with clinical site and contract research organization agreements, we are unable to estimate with certainty the future costs we will incur. We intend to
use our current financial resources to fund our obligations under these commitments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition,
expenses, results of operations, liquidity, capital expenditures or capital resources. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_7"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not hold any
marketable securities at March&nbsp;31, 2014. Our debt obligations of our convertible debt, which carries a fixed interest rate and, as a result, we are not exposed to interest rate risk on our convertible debt. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_8"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are
designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms, and
that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the
disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a
reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon
certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes
in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost- effective control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management,
including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the
reasonable assurance level. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no change in our internal control over financial reporting during our most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>PART&nbsp;II.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER INFORMATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_9"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL PROCEEDINGS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material changes to the legal proceedings
described in the Company&#146;s Annual Report on Form 10-K for the period ended December&nbsp;31, 2013. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_10"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RISK FACTORS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the following information about risks and
uncertainties that may affect us or our business, together with the other information appearing elsewhere in this quarterly report on Form 10-Q and in our other filings with the SEC. If any of the following events, described as risks, actually
occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part
of your investment in our securities. An investment in our securities is speculative and involves a high degree of risk. You should not invest in our securities if you cannot bear the economic risk of your investment for an indefinite period of time
and cannot afford to lose your entire investment. The risks described below may include certain additions and revisions to the risks set forth in our annual report on Form 10-K for the fiscal year ended December&nbsp;31, 2013 and our subsequent
filings with the SEC. Risk factors containing such additions and revisions are marked with an asterisk. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related To Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>*We are substantially dependent upon the success of our SUSTOL product candidate. Clinical trial results and the NDA resubmission for this product may
not lead to regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our time and financial resources in the development of
our most advanced product candidate, SUSTOL, for which we are initially seeking FDA approval for the prevention of acute chemotherapy-induced nausea and vomiting (&#147;CINV&#148;) associated with both moderately and highly emetogenic chemotherapy
and for the prevention of delayed CINV associated with moderately emetogenic chemotherapy (&#147;MEC&#148;). We currently also plan to conduct a Phase 3 study which, if successful, may allow us to expand our product label to include delayed CINV
associated with highly emetogenic chemotherapy (&#147;HEC&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our near-term ability to generate revenues and our future success, in large part, depends on the
approval and successful commercialization of SUSTOL. We will not be able to commercialize SUSTOL until we obtain regulatory approval in the United States or foreign countries. In order to satisfy FDA approval standards for the commercial sale of
SUSTOL, we must first successfully resolve the issues identified in the Complete Response Letter received from the FDA in March 2013. This letter identified several issues that precluded the approval of SUSTOL NDA, including issues relating to:
manufacturing of SUSTOL, the administration of SUSTOL and our analysis of efficacy data for SUSTOL under more recent guidelines classifying chemotherapy regimens. Although we are currently working to address these issues and currently expect to
resubmit the SUSTOL NDA in mid-2014, there can be no assurance that these responses will be sufficient or that we will be able to resubmit within this time period. Further, the FDA&#146;s review of our resubmission may not produce positive decisions
as to whether: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">SUSTOL is safe and effective in its proposed use(s) and whether its benefits outweigh the risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proposed labeling for SUSTOL has our desired product indication regarding acute and delayed-onset CINV, as well as HEC and MEC regimens; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the methods used in manufacturing SUSTOL and the controls used to maintain its quality are adequate to preserve its identity, strength, quality and purity. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deficiencies on any of the above, or other factors, could prevent or delay obtaining regulatory approval of SUSTOL, which would negatively
affect our potential revenues, increase our costs and potentially impair our ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>*We may not obtain regulatory
approval for SUSTOL or any of our product candidates. Regulatory approval may also be delayed or cancelled or may entail limitations on the indicated uses of a proposed product. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process for obtaining approval of an NDA is time consuming, subject to unanticipated delays and costs, and requires the commitment of
substantial resources. The regulatory process, particularly for pharmaceutical product candidates like ours, is uncertain, can take many years and requires the expenditure of substantial resources. Any product that we or our collaborative partners
develop must receive all relevant regulatory agency approvals or clearances, if any, before it may be marketed in the United States or other countries. In particular, human pharmaceutical products are subject to rigorous preclinical and clinical
testing and other requirements by the FDA in the United States and similar health authorities in foreign countries. We may not receive necessary regulatory approvals or clearances to market SUSTOL or any other product candidate. In September 2012,
we resubmitted the NDA seeking approval for SUSTOL with the FDA. In March 2013, we received a second Complete Response Letter, which identified several issues that precluded the approval of the SUSTOL NDA. We are currently working to address these
issues and intend to resubmit the SUSTOL NDA in mid-2014. Our NDA resubmission for SUSTOL may not be approved, or approval may be delayed, as a result of changes in FDA policies for drug approval prior to the FDA&#146;s decision on our NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, although many drug products have been approved by the FDA in recent years under Section&nbsp;505(b)(2) of the Federal Food, Drug,
and Cosmetic Act, objections have been raised to the FDA&#146;s interpretation of Section&nbsp;505(b)(2). If challenges to the FDA&#146;s interpretation of Section&nbsp;505(b)(2) are successful, the FDA may be required to change its interpretation,
which could delay or prevent the approval of our NDA for SUSTOL. The review of our resubmitted NDA may also be delayed due to the FDA&#146;s internal resource constraints. Additionally, data obtained from preclinical and clinical activities are
susceptible to varying interpretations that could delay, limit or prevent regulatory agency approvals or clearances. For example, the FDA may require additional clinical data to support approval, such as confirmatory studies and other data or
studies to address questions or concerns that may arise during the FDA review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in obtaining regulatory approval for
SUSTOL, or the issuance of a third Complete Response Letter, would, among other consequences, delay the launch of SUSTOL and adversely affect our ability to generate revenue from sales of this product and adversely affect our ability to raise
additional capital that would be necessary to sustain our operations. Given the additional delays that we would face prior to obtaining approval for SUSTOL, if such approval is ever granted, we may need significant additional capital to fund our
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if granted, regulatory approvals may include significant limitations on the uses for which products may be marketed.
Failure to comply with applicable regulatory requirements can, among other things, result in warning letters, imposition of civil penalties or other monetary payments, delay in approving or refusal to approve a product candidate, suspension or
withdrawal of regulatory approval, product recall or seizure, operating restrictions, interruption of clinical trials or manufacturing, injunctions and criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the marketing and manufacturing of drugs and biological products are subject to
continuing FDA review, and later discovery of previously unknown problems with a product, its manufacture or its marketing may result in the FDA requiring further clinical research or restrictions on the product or the manufacturer, including
withdrawal of the product from the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If SUSTOL is approved, but does not attain market acceptance by healthcare professionals and patients,
our business prospects and results of operations will suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if SUSTOL receives regulatory approval for commercial sale, the
revenue that we may receive from the sale of SUSTOL may be less than expected and will depend on many factors that are outside of our control. Factors that may affect revenue from SUSTOL, if approved, include; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of our approved product label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">perception of physicians and other members of the health care community of the safety and efficacy relative to that of competing products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient and physician satisfaction with the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to manufacture commercial product successfully and on a timely basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost and availability of raw materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market size for the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reimbursement policies of government and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable publicity concerning the product or similar drugs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the introduction, availability and acceptance of competing treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse event information relating to the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product liability litigation alleging injuries relating to the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling or product insert language required by the FDA or regulatory authorities in other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the regulatory developments related to the manufacture or continued use of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extent and effectiveness of sales and marketing and distribution support for the product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our collaborators&#146; decisions as to the timing of product launches, pricing and discounting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product revenue will be adversely affected if, due to these or other factors, the products we or our collaborators are able to
commercialize do not gain significant market acceptance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>*We have a history of losses, we expect to generate losses in the near future, and we may
never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred recurring losses and had an accumulated deficit of $256.4 million
through March&nbsp;31, 2014. Even if SUSTOL is approved, we expect to continue to generate substantial losses over at least the next several years as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build a sales force and commence commercialization of SUSTOL, if approved; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand drug product development and commercialization efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct preclinical development and clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue additional applications for our existing delivery technologies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve and sustain
profitability, we must, alone or with others, successfully develop, obtain regulatory approval for, manufacture, market and sell our products. If SUSTOL is approved for commercialization, we must successfully launch and commercialize the product. If
SUSTOL is not approved, we will likely experience significant delays before we begin to recognize meaningful levels of revenue, if ever. We will incur substantial expenses in our efforts to develop and commercialize products and we may never
generate sufficient revenue to become profitable or to sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>*Additional capital may be needed to enable us to implement our
business plan, and we may be unable to raise capital, which would force us to limit or cease our operations and related product development programs. Raising such capital may have to be accomplished on unfavorable terms, likely causing dilution to
our existing stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At March&nbsp;31, 2014, the Company had cash and cash equivalents in the amount of $57.5 million. We
believe that our current working capital balance is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies prior to 2015 or begin commercialization of SUSTOL, we will need to raise
additional capital. We may require additional capital to fund our development pipeline programs. We are pursuing commercialization of SUSTOL without a partner for the U.S. market, which will likely require us to obtain additional funding and
resources to sustain our operations until we can achieve profitability. The need for and amount of additional funding that we may require depends on various factors, including the results of the on-going regulatory review by the FDA of our SUSTOL
NDA resubmission, the time and costs related to manufacturing of SUSTOL, if approved, technological and market developments of drugs that may compete with SUSTOL and the timing of clinical trials to expand our pipeline of sustained-release products.
There can be no assurance that SUSTOL will be approved and, if approved, that we will be successful in obtaining the additional necessary financial resources and expertise, with or without a partner, that will be required to launch SUSTOL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to raise sufficient additional capital when we need it on favorable or any terms. If we are unable to obtain adequate
funds, we may be required to curtail significantly or cease operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing and degree of any future capital requirements will
depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product development programs we pursue and the pace of each program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress, results and costs of preclinical testing and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the time, cost and outcome involved in seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific progress in our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the magnitude and scope of our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales, marketing and distribution capabilities for a specialty sales force if we commercialize any products independently; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue additional equity securities or securities convertible
into equity securities to raise funds, our stockholders will suffer dilution of their investment, and such issuance may adversely affect the market price of our common stock. Any debt financing we enter into may involve covenants that restrict our
operations. These restrictive covenants may include, among other things, limitations on borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends, redeem capital stock or make
investments. In the event that additional funds are obtained through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies, product candidates or products on terms that are not
favorable to us or require us to enter into a collaboration arrangement that we would otherwise seek to develop and commercialize ourselves. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or
more of our product development programs and reduce personnel-related and other costs, which will have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The general economic environment in which we operate is experiencing continued weakness and volatility. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to secure the additional capital that may be necessary for implementation of our longer-term business plans may be diminished due
to the continuing volatile business conditions and financial markets. For example, the difficulty in obtaining additional capital necessary to develop our other product candidates has led us to temporarily suspend certain development programs in
recent years. If the economic environment continues its weak recovery and financial markets continue to experience significant volatility, we may have increasing difficulty in raising additional capital when needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may depend on collaborators as a source of capital and to help us complete the process of developing and testing our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy for the development, clinical testing and commercialization of our products may require entering into collaborations with
corporate partners, licensors, licensees and others. These collaborations may be critical to funding our operations and our success in bringing our products and product candidates to the market and promoting such marketed products profitably. We
could be dependent upon the subsequent success of these other parties in performing their respective responsibilities and the cooperation of our partners. Our collaborators may not cooperate with us or perform their obligations under our agreements
with them. We cannot control the amount and timing of our collaborators&#146; resources that will be devoted to our research activities related to our collaborative agreements with them. Our collaborators may choose to pursue existing or alternative
technologies in preference to those being developed in collaboration with us. We may prioritize other programs ahead of collaboration activities such that funding from these other parties could be reduced or deferred. Failure to make or maintain
these arrangements, or a delay in a collaborative partner&#146;s performance, or factors that may affect our partner&#146;s sales may materially adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under agreements with collaborators, we may rely significantly on them, among other activities, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fund research and development activities with us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay us fees upon the achievement of milestones; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market for or with us any commercial products that result from our collaborations. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>*Clinical trials are expensive and may not result in commercially viable products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting clinical trials is a lengthy, time-consuming and expensive process. For example, we have incurred significant expenses in developing
SUSTOL and, even if approved, it may not result in a commercially viable product. We have initiated a Phase 3 study of SUSTOL designed to demonstrate the utility of SUSTOL in the treatment of delayed-onset CINV in patients receiving HEC regimens. If
successful, we intend to submit the results of the study to the FDA to expand the label of SUSTOL to include delayed HEC. There can be no assurance that this study will be successful or that the FDA will grant any such label expansion. Before
obtaining regulatory approvals for the commercial sale of any products, we, or our partners, must demonstrate through preclinical testing and clinical trials that our product candidates are safe and effective for their intended uses in humans. We
have incurred and will continue to incur substantial expense and devote a significant amount of time to preclinical testing and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business, results of operations and financial condition may be materially adversely affected by any delays in, or termination of, our
clinical trials. Factors impacting our ability to generate commercially viable products through the conduct of clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient funds to conduct clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to find partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of clinical trials to demonstrate the safety and efficacy of our product candidates to the extent necessary to obtain regulatory approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or third-party investigators, contract research organizations, or other third parties involved in the research to adhere to regulatory requirements applicable to the conduct of clinical trials;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of preclinical testing and early clinical trials to predict results of later clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay in completion of clinical trials, resulting in increased costs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain regulatory approval of our product candidates following completion of clinical trials, or delays in obtaining such approvals. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that if our clinical trials are successfully initiated and completed we will be able to obtain approval by the FDA
in the United States or similar regulatory authorities elsewhere in the world in a timely manner, if at all. If we fail to successfully develop and commercialize one or more of our product candidates, we may be unable to generate sufficient revenues
to attain profitability and our reputation in the industry and in the investment community would likely be damaged, each of which would cause our stock price to decrease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical testing could increase our costs and delay our ability to obtain regulatory approval and commercialize our product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before we, or our collaborators, can receive regulatory approval for the commercial sale of our potential products, the FDA
requires extensive preclinical safety testing and clinical trials to demonstrate their safety and efficacy. Significant delays in preclinical and clinical testing could materially impact our product development costs and delay regulatory approval of
our product candidates. Completing clinical trials in a timely manner depends on, among other factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining clinical materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement on acceptable clinical study terms with prospective sites and clinical research organizations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining institutional review board approval to conduct a study at a prospective site; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recruiting patients to participate in a study. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials,
and their failure to perform their obligations in a timely and competent manner may delay development and commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We used clinical research organizations in the United States, Asia and Europe to oversee our clinical trials for SUSTOL and we expect to use
the same or similar organizations for our future clinical trials and pipeline programs. There are numerous alternative sources to provide these services; however, we may face delays outside of our control if these parties do not perform their
obligations in a timely or competent fashion, or if we are forced to change service providers. Different cultural and operational issues in foreign countries could cause delays or unexpected problems with patient enrollment or with the data obtained
from those locations. If we experience significant delays in the progress of our clinical trials or problems with the quality of data derived from clinical trials, the prospects for approval would decrease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have yet to demonstrate the full commercial viability of our delivery technology, and we cannot be certain that attainment of such a goal can be
accomplished. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bioerodible drug delivery technology is at an early stage of development. We may not be able to substantiate the
capability of our drug delivery technology for a variety of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selection of inappropriate therapeutic compound for delivery; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selection of inappropriate use or application for the particular product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to receive regulatory approval on a timely basis or at all; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties with manufacturing in commercial quantities at an acceptable cost. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful development of
delivery technologies requires significant preclinical and clinical testing prior to regulatory approval. Because of these scientific, regulatory and commercial hurdles, any program could be abandoned or otherwise fail, even after significant
resources have been expended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our suppliers and contract manufacturers fail to complete pre-commercialization manufacturing development
activities for SUSTOL on a timely basis or fail to comply with stringent regulatory requirements, we will face delays in our ability to obtain regulatory approval for, and to commercialize, SUSTOL, and our costs will increase. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not manufacture SUSTOL and do not currently plan to develop any capacity to do so. Instead, we have relied on third parties to
manufacture and perform important pre-commercialization manufacturing development activities for SUSTOL. As part of the process for obtaining regulatory approval, we must demonstrate that the facilities, equipment and processes used to manufacture
SUSTOL are capable of consistently producing a product that meets all applicable quality criteria, and that is comparable to the product that was used in our clinical trials. We must also provide the FDA with information regarding the validation of
the manufacturing facilities, equipment and processes of our third-party suppliers and manufacturers, and data supporting the stability of SUSTOL. If our third-party suppliers and manufacturers are not in compliance with current Good Manufacturing
Practice (&#147;cGMP&#148;) requirements, the approval of our marketing application may be delayed, existing product batches may be compromised, and we may experience delays in the availability of SUSTOL for commercial distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our most recent Complete Response Letter from the FDA regarding our NDA resubmission for SUSTOL stated that the NDA could not be
approved due to, among other issues, deficiencies observed during an inspection of the facilities used by our third-party suppliers and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers to produce SUSTOL. If the FDA is not satisfied with our response and any corrective actions taken by these third parties, we may be required to complete additional manufacturing
development activities or provide other information to the FDA, which could cause substantial delays in obtaining regulatory approval for SUSTOL, increase our costs and have a material adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We depend on contract manufacturers and collaborators for manufacturing our products and provide them with technical expertise on the manufacturing
process; we also perform quality control testing of the product; if we and our contract manufacturers do not perform as expected, our revenue and customer relations will suffer. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of any product. Our ability to
develop and commercialize any products we may develop will depend in part on our ability to manufacture, or arrange for collaborators or other parties to manufacture, our products at a competitive cost, in accordance with regulatory requirements,
and in sufficient quantities for clinical testing and eventual commercialization. We do not intend to develop or acquire facilities to manufacture any of our product candidates for clinical trials or commercial purposes in the foreseeable future. We
rely on a small number of third-party manufacturers to produce our compounds and expect to continue to do so to meet the preclinical and clinical requirements of our potential products and for all of our commercial needs, some of which are our sole
source suppliers at present. We have no long-term agreements with any of these third parties. We may not be able to extend these agreements on satisfactory terms, or at all, and we may not be able to find a replacement contract manufacturer on
satisfactory terms or on a timely basis. Additionally, difficult economic conditions may cause operational and financial problems for our third-party suppliers, resulting in their failure and disruption to our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we, along with our contract manufacturers and our collaborators, are required to comply with FDA requirements related to product
testing, quality assurance, manufacturing and documentation. Our contract manufacturers, or our collaborators, may not be able to comply with the applicable FDA regulatory requirements. They may be required to pass an FDA preapproval inspection for
conformity with cGMPs before we can obtain approval to manufacture and will be subject to ongoing, periodic, unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP, and other applicable government
regulations and corresponding foreign standards. If we and our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with cGMP regulations, we may experience manufacturing errors resulting in patient injury
or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our products, cost overruns or other problems that
could seriously harm our business. Not complying with FDA requirements could result in a Warning Letter or an enforcement action such as product seizure, recall, or injunction, prevent commercialization of our product candidates and impair our
reputation and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our contract manufacturers or by us could delay clinical
development or regulatory approval of product candidates or commercialization of our future products, depriving us of potential product revenue and resulting in additional losses. In addition, our dependence on a third party for manufacturing may
adversely affect our future profit margins and limit our ability to commercialize products on a timely and competitive basis. Our ability to replace an existing manufacturer may be difficult because the number of potential manufacturers is limited,
and the FDA must approve any replacement manufacturer before we can begin manufacturing SUSTOL or any of our other product candidates. Such approval would require new testing and compliance inspections. It may be difficult or impossible for us to
identify and engage a replacement manufacturer on acceptable terms in a timely manner, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL or any of our other product
candidates may be in competition with other products for access to the facilities of third parties. Consequently, SUSTOL or any of our other product candidates may be subject to manufacturing delays if collaborators or outside contractors give other
companies&#146; products greater priority than our products. For this and other reasons, our collaborators or third-party service providers may not be able to manufacture SUSTOL or any of our other product candidates in a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cost-effective or timely manner. If not manufactured in a timely manner, the clinical development of any of our product candidates or their submission for regulatory approval could be delayed,
and our ability to deliver products to market on a timely basis could be impaired or precluded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, SUSTOL has been manufactured in
small quantities for preclinical studies and clinical trials. If in the future SUSTOL or any of our product candidates are approved for commercial sale, we will need to manufacture our products in larger quantities. Significant scale-up of
manufacturing may require additional process development and validation studies, which the FDA must review and approve. The commercial success of our products, including SUSTOL in the near-term, will be dependent upon the ability of our contract
manufacturers to produce a product in commercial quantities at competitive costs of manufacture. The ability to do so cannot be presumed. Significant additional development work is required prior to any commercial launch of a product. In the case of
SUSTOL, the high viscosity of the product creates particularly challenging factors relative to attainable production rates and cost of manufacture. If SUSTOL receives regulatory approval, we plan to scale-up manufacturing for SUSTOL in order to
realize important economies of scale. These scale-up activities would take time to implement, require additional capital investment, process development and validation studies, and FDA approval. We cannot guarantee that we will be successful in
achieving competitive manufacturing costs through such scale-up activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales and marketing capabilities or enter
into agreements with third parties to sell and market any products we may develop, we may be unable to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have a sales organization for the sales, marketing and distribution of pharmaceutical products. In order to commercialize
any products, we must build our sales, marketing, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We have started to establish internal sales and marketing capabilities
for SUSTOL, but may enter into agreements with third parties to sell and market other products we may develop. Although we have hired sales and marketing personnel with prior commercial experience, our company has no direct experience in developing,
training or managing a marketing and sales force. The establishment and development of a sales force to market SUSTOL will be expensive and time consuming and could delay product launch, and we cannot be certain that we will be able to successfully
develop this capacity. If we are unable to establish our sales and marketing capability or any other nontechnical capabilities necessary to commercialize SUSTOL, we will need to contract with third parties to market and sell such products we may
develop. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with continuing federal, state and foreign regulations, we could lose our approvals to
market drugs, and our business would be seriously harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following initial regulatory approval of any drugs we may develop,
including SUSTOL, we will be subject to continuing regulatory review, including review of adverse drug experiences and clinical results that are reported after our drug products become commercially available. This would include results from any
post-marketing tests or continued actions required as a condition of approval. The manufacturer and manufacturing facilities we use to make any of our drug candidates will be subject to periodic review and inspection by the FDA. If a previously
unknown problem or problems with a product or a manufacturing and laboratory facility used by us is discovered, the FDA or foreign regulatory agency may impose restrictions on that product or on the manufacturing facility, including requiring us to
withdraw the product from the market. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. We and our contract manufacturers will be
subject to ongoing FDA requirements for submission of safety and other post-market information. If we and our contract manufacturers fail to comply with applicable regulatory requirements, a regulatory agency may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose civil or criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw our regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or terminate any of our ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications filed by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">close the facilities of our contract manufacturers; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain products or require a product recall. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, such regulatory review
covers a company&#146;s activities in the promotion of its drugs, with significant potential penalties and restrictions for promotion of drugs for an unapproved use. Sales and marketing programs are under scrutiny for compliance with various
mandated requirements, such as illegal promotions to healthcare professionals. We are establishing a sales force to market SUSTOL, which may include contracting with third parties to market and sell such products we may develop, and may be unable to
ensure that our own employees as well as any third-party employees adhere to legal and regulatory requirements for product advertising and promotion. We are also required to submit information on our open and completed clinical trials to public
registries and databases; failure to comply with these requirements could expose us to negative publicity, fines and penalties that could harm our business. If SUSTOL is approved, we will also be required to comply with the requirements to submit to
governmental authorities information on payments to physicians and certain other third parties; failure to comply with these requirements could expose us to negative publicity, fines and penalties that could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to recruit and retain skilled employees, we may not be able to achieve our objectives. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on a small number of key management and technical personnel. Retaining our current employees and recruiting qualified scientific
personnel to perform future research and development and commercialization work will be critical to our success. While recent pharmaceutical and biotechnology industry layoffs have somewhat mitigated a usual shortage of skilled personnel in our
industry, competition is always present for experienced scientists, and an inability to recruit or retain sufficient skilled personnel could result in delays to product development or approval, loss of sales and diversion of management resources. If
we lose members of our senior management team, we may not be able to find suitable replacements and our business may be harmed as a result. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face
intense competition from other companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL is expected to face significant competition for the prevention of CINV,
principally from Eisai&#146;s Aloxi (palonosetron). In addition to Aloxi, SUSTOL will compete with entrenched generic forms of granisetron (formerly marketed by Roche as Kytril) and ondansetron (formerly marketed by GlaxoSmithKline as Zofran).
Generic versions of Aloxi may become available after its scheduled patent expiration date, which was recently extended to 2024. We are aware, however, of ongoing litigation challenging these patents and, if such challenges are successful, it is
possible that generic versions of Aloxi could become available sooner. We are also aware of several companies that have developed, or are developing, both generic and new formulations of granisetron, including transdermal formulations such as
ProStrakan&#146;s Sancuso<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (granisetron transdermal patch), which was approved in 2008. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several companies that are developing new formulations of existing drugs across various therapeutic areas using novel drug delivery
technologies. Many of these companies have substantially greater financial, research and development, manufacturing, sales and marketing and distribution resources and experience than we do. The following are some notable companies among drug
delivery system developers: Alkermes, Inc., Durect Corporation, and Pacira Pharmaceuticals, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller or early stage companies and research institutions may also prove to be significant
competitors, particularly through collaborative arrangements with large and established pharmaceutical companies. We will also face competition from these parties in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, and acquiring and in-licensing technologies and products complementary to our programs or potentially advantageous to our business. If any of our competitors succeed in
obtaining approval from the FDA or other regulatory authorities for their products sooner than we do or for products that are more effective or less costly than ours, our commercial opportunity could be significantly reduced. Major technological
changes can happen quickly in the biotechnology and pharmaceutical industries, and the development of technologically improved or different products or drug delivery technologies may make our product candidates or platform technologies obsolete or
noncompetitive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we cannot establish pricing of our product candidates acceptable to the United States or foreign governments, insurance
companies, managed care organizations and other payors, or arrange for favorable reimbursement policies, any product sales will be severely hindered. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continuing efforts of the United States and foreign governments, insurance companies, managed care organizations and other payors of health
care costs to contain or reduce costs of health care may adversely affect our ability to generate adequate revenues and gross margins to make the products we develop commercially viable. Our ability to commercialize any product candidates
successfully will depend in part on the extent to which governmental authorities, private health insurers and other organizations establish appropriate reimbursement levels for the cost of such products and related treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain foreign markets, the pricing of prescription pharmaceuticals is subject to government control. In the United States, given recent
federal and state government initiatives directed at lowering the total cost of health care, the U.S. Congress and state legislatures will likely continue to focus on health care reform, the cost of prescription pharmaceuticals and on the reform of
the Medicare and Medicaid systems. The trend toward managed health care in the United States, which could significantly influence the purchase of health care services and products, as well as legislative proposals to reform health care, control
pharmaceutical prices or reduce government insurance programs, may result in lower prices for our product candidates. While we cannot predict whether any legislative or regulatory proposals affecting our business will be adopted, the announcement or
adoption of these proposals could have a material and adverse effect on our potential revenues and gross margins. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business strategy includes
the entry into additional collaborative agreements. We may not be able to enter into additional collaborative agreements or may not be able to negotiate commercially acceptable terms for these agreements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current business strategy includes the entry into additional collaborative agreements for the development and commercialization of our
delivery technologies. The negotiation and consummation of these types of agreements typically involve simultaneous discussions with multiple potential collaborators and require significant time and resources from our officers, business development
and research and development staff. In addition, in attracting the attention of pharmaceutical and biotechnology company collaborators, we compete with numerous other third parties with product opportunities as well as the collaborators&#146; own
internal product opportunities. We may not be able to consummate additional collaborative agreements, or we may not be able to negotiate commercially acceptable terms for these agreements. If we do not consummate additional collaborative agreements,
we may consume money more rapidly on our product development efforts, continue to defer certain development activities or forego the exploitation of certain geographic territories, any of which could have a material adverse effect on our business.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our collaborators cannot arrange for adequate third-party reimbursement for our products, our
future revenue will suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both domestic and foreign markets, sales of our potential products, including SUSTOL, will depend
in substantial part on the availability of adequate reimbursement from third-party payors such as government health administration authorities, private health insurers and other organizations. Third-party payors often challenge the price and
cost-effectiveness of medical products and services and such pressure may increase in the future. Significant uncertainty exists as to the adequate reimbursement status of newly approved health care products. Any products we are able to successfully
develop may not be reimbursable by third-party payors. In addition, our products may not be considered cost-effective and adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize a profit.
Legislation and regulations affecting the pricing of pharmaceuticals may change before our products are approved for marketing and any such changes could further limit reimbursement. Reimbursement policies utilized by our collaborators or ourselves
may be challenged by regulatory entities, with resultant fines, negative publicity and the need to implement changes that reduce the utilization of our products. If any products we develop do not receive adequate reimbursement, our revenue will be
severely limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our inability to obtain specialized materials could slow down our product development process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the critical materials and components used in producing SUSTOL are sourced from a single supplier. An interruption in supply of a key
material could significantly delay our research and development process or increase our expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specialized materials must often be
manufactured for the first time for use in drug delivery technologies, or materials may be used in the technologies in a manner different from their customary commercial uses. The quality of materials can be critical to the performance of a drug
delivery technology, so a reliable source of a consistent supply of materials is important. Materials or components needed for our drug delivery technologies may be difficult to obtain on commercially reasonable terms, particularly when relatively
small quantities are required or if the materials traditionally have not been used in pharmaceutical products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to adequately
protect or enforce our intellectual property rights or secure rights to third-party patents, we may lose valuable assets, experience reduced market share or incur costly litigation to protect our rights or our third-party collaborators may choose to
terminate their agreements with us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our ability to obtain patents and maintain trade secret
protection, as well as successfully defending these patents against challenges, while operating without infringing the proprietary rights of others. We have filed a number of U.S. patent applications on inventions relating to the composition of a
variety of polymers, specific products, product groups and processing technology. At December&nbsp;31, 2013, we had a total of 15 issued U.S. patents and an additional 38 issued (or registered) foreign patents. The patents on the bioerodible
technologies expire between January 2016 and April 2026. The product SUSTOL is covered by patents owned by Heron Therapeutics, Inc. that are granted in the United States and in foreign countries. Currently, the product SUSTOL is covered by six
patents issued in the United States and by seven patents issued in foreign countries including Brazil, Canada, EU, Japan, and Taiwan. U.S. patents covering SUSTOL have expiration dates ranging from January 2016 to September 2024; foreign patents
covering SUSTOL have expiration dates ranging from January 2017 to September 2025. Granted patents include claims covering the product composition, methods of use and methods of preparation. Our existing patents may not cover future products,
additional patents may not be issued, and current patents, or patents issued in the future, may not provide meaningful protection or prove to be of commercial benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical companies, including ours, are uncertain and involve complex legal and factual questions. In addition,
the coverage claimed in a patent application can be significantly reduced before the patent is issued. Consequently, our patent applications, or those that are licensed to us, may not issue into patents, and any issued patents may not provide
sufficient protection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for our product candidates or provide sufficient protection to afford us a commercial advantage against competitive technologies or may be held invalid if challenged or circumvented. Patent
applications in the United States are maintained in confidence for at least 18 months after their filing. Consequently, we cannot be certain that the patent applications we are pursuing will lead to the issuance of any patent or be free from
infringement or other claims from other parties. Our competitors may also independently develop products similar to ours or design around or otherwise circumvent patents issued to us or licensed by us. In addition, the laws of some foreign countries
may not protect our proprietary rights to the same extent as U.S. laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to collaborative agreements. These agreements
subject us to obligations which must be fulfilled and require us to manage complex relationships with third parties. If we are unable to meet our obligations or manage our relationships with our collaborators under these agreements or enter into
additional collaboration agreements or if our existing collaborations are terminated or not extended on terms as beneficial as we anticipate, our revenue may decrease. The loss or diminution of our intellectual property rights could result in a
decision by our third-party collaborators to terminate their agreements with us. In addition, these agreements are generally complex and contain provisions that could give rise to legal disputes, including potential disputes concerning ownership of
intellectual property and data under collaborations. Such disputes can lead to lengthy, expensive litigation or arbitration, requiring us to divert management time and resources to such dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely upon trade secrets, technical know-how and continuing technological innovation to develop and maintain our competitive position.
We require our employees, consultants, advisors and collaborators to execute appropriate confidentiality and assignment-of-inventions agreements with us. These agreements typically provide that all materials and confidential information developed or
made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances, and that all inventions arising out of the individual&#146;s
relationship with us shall be our exclusive property. These agreements may be breached, and in some instances, we may not have an appropriate remedy available for breach of the agreements. Furthermore, our competitors may independently develop
substantially equivalent proprietary information and techniques, reverse engineer our information and techniques, or otherwise gain access to our proprietary technology. We may be unable to meaningfully protect our rights in trade secrets, technical
know-how and other non-patented technology. We may have to resort to litigation to protect our intellectual property rights, or to determine their scope, validity or enforceability. In addition, interference proceedings declared by the U.S. Patent
and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications. Enforcing or defending our proprietary rights is expensive, could cause diversion of our resources and may not prove successful.
In addition, courts outside the United States may be less willing to protect trade secrets. Costly and time consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary rights. Any failure to enforce or
protect our rights could cause us to lose the ability to exclude others from using our technology to develop or sell competing products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may
infringe on the intellectual property rights of others, and any litigation could force us to stop developing or selling potential products and could be costly, divert management attention and harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must be able to develop products without infringing the proprietary rights of other parties. Because the markets in which we operate involve
established competitors with significant patent portfolios, including patents relating to the composition of a variety of polymers, specific products, product groups and processing technology, it could be difficult for us to use our technologies or
develop products without infringing the proprietary rights of others. We may not be able to design around the patented technologies or inventions of others and we may not be able to obtain licenses to use patented technologies on acceptable terms,
or at all. If we cannot operate without infringing the proprietary rights of others, we will not be able to develop or commercialize some or all of our product candidates, and consequently will not be able to earn product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to defend ourselves in a lawsuit, we could incur substantial costs and the lawsuit could divert management attention,
regardless of the lawsuit&#146;s merit or outcome. These legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actions could seek damages and seek to enjoin testing, manufacturing and marketing of the accused product or process. In addition to potential liability for significant damages, we could be
required to obtain a license to continue to manufacture or market the accused product or process and any license required under any such patent may not be made available to us on acceptable terms, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we review publicly available information regarding the development efforts of others in order to determine whether these efforts
may violate our proprietary rights. We may determine that litigation is necessary to enforce our proprietary rights against others. Such litigation could result in substantial expense, regardless of its outcome, and may not be resolved in our favor.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are exposed to risks and increased expenses as a result of laws requiring filers to evaluate internal controls over financial reporting.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (&#147;Section 404&#148;) requires management to evaluate the effectiveness of
our internal controls over financial reporting as of the end of each fiscal year and to include a management report assessing the effectiveness of our internal control over financing reporting in our annual report on Form 10-K for each fiscal year.
Our independent registered public accounting firm is required to report on the effectiveness of our internal control over financial reporting. We and our independent registered public accounting firm may not be able to conclude on an ongoing basis
that we have effective internal controls over financial reporting in accordance with Section&nbsp;404. We have implemented an ongoing program to perform the system and process evaluation we believe to be necessary to comply with these requirements.
However, we cannot assure you that we will be successful in our efforts. We expect to incur increased expense and to devote additional management resources to Section&nbsp;404 compliance. Any failure to implement required new or improved controls,
or difficulties encountered in the implementation or operation of these controls, could harm our operating results and cause us to fail to meet our financial reporting obligations, which could adversely affect our business and reduce our stock
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls over
financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. We cannot assure you
that we or our independent registered public accounting firm will not identify a material weakness in our internal controls in the future, which would require management and our independent registered public accounting firm to evaluate our internal
controls as ineffective. If our internal controls over financial reporting are not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the price of our stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative actions, potential new accounting pronouncements and higher insurance costs are likely to impact our future financial position or results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future changes in financial accounting standards may cause adverse, unexpected fluctuations in the timing of the
recognition of revenue or expenses and may affect our financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with frequency and may occur in the future, and we may make changes in
our accounting policies in the future. Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses. Changing laws, regulations and standards relating to corporate governance and public
disclosure, including the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act, new SEC regulations and the Public Company Accounting Oversight Board pronouncements, are creating uncertainty for companies such as ours and insurance, accounting and
auditing costs are increasing as a result of this uncertainty and other factors. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, we intend to invest all reasonably necessary resources to
comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be exposed to significant product liability claims that could be time consuming and costly to
defend, divert management attention and adversely impact our ability to obtain and maintain insurance coverage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing,
manufacture, marketing and sale of our products involve an inherent risk that product liability claims will be asserted against us. Although we are insured against such risks up to an annual aggregate limit in connection with clinical trials and
commercial sales of our products, our present product liability insurance may be inadequate and may not fully cover the costs of any claim or any ultimate damages we might be required to pay. Product liability claims or other claims related to our
products, regardless of their outcome, could require us to spend significant time and money in litigation or to pay significant damages. Any successful product liability claim may prevent us from obtaining adequate product liability insurance in the
future on commercially desirable or reasonable terms. In addition, product liability coverage may cease to be available in sufficient amounts or at an acceptable cost. An inability to obtain sufficient insurance coverage at an acceptable cost or
otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our products. A product liability claim could also significantly harm our reputation and delay market acceptance of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our use of hazardous materials could subject us to liabilities, fines and sanctions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our laboratory and clinical testing sometimes involve use of hazardous, radioactive or otherwise toxic materials. We are subject to federal,
state and local laws and regulations governing how we use, manufacture, handle, store and dispose of these materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe
that our safety procedures for handling and disposing of such materials comply in all material respects with all federal, state and local regulations and standards, there is always the risk of accidental contamination or injury from these materials.
In the event of an accident, we could be held liable for any damages that result and such liability could exceed our financial resources. If we fail to comply with these regulations and standards or with the conditions attached to our operating
licenses, the licenses could be revoked, and we could be subjected to criminal sanctions and substantial financial liability or be required to suspend or modify our operations. Compliance with environmental and other laws may be expensive and
current or future regulations may impair our development or commercialization efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Earthquake damage to our facilities could delay our research
and development and quality control testing efforts and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our facility in Redwood City, California,
is located in a seismic zone, and there is the possibility of an earthquake, which could be disruptive to our operations and result in delays in our research and development efforts and supplies of SUSTOL, if approved. In the event of an earthquake,
if our facilities or the equipment in our facilities are significantly damaged or destroyed, we may not be able to rebuild or relocate our facility or replace any damaged equipment in a timely manner and our business, financial condition and results
of operations could be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related To Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock has been and may continue to be volatile and our reverse stock split may further increase volatility or cause a decline in
value. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock markets, in general, and the markets for drug delivery and pharmaceutical stocks, in particular, have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock. In addition, the limited trading volume of
our stock may contribute to its volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our stock price may be subject to additional volatility as a result of our Reverse
Stock Split and relisting on The NASDAQ Capital Market. Following reverse splits, the prices of the stocks often trade below the immediate post-split value, resulting in a net loss in value for stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the market price of a particular company&#146;s
securities, litigation has often been brought against that company. If litigation of this type is brought against us, it could be extremely expensive and divert management&#146;s attention and our company&#146;s resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our certificate of incorporation, our bylaws and Delaware law contain provisions that could discourage another company from acquiring us and may prevent
attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of Delaware law, our certificate of
incorporation and our bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may
frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include authorizing the issuance of
&#147;blank check&#148; preferred stock without any need for action by stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of Delaware General
Corporation Law may discourage, delay or prevent a change in control of our company by prohibiting stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us, unless certain approvals are obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Further concentration in stockholder ownership could influence strategic actions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, principal stockholders and affiliated entities currently beneficially own or control a majority of our
outstanding securities. Tang Capital Partners, LP and its affiliates&#146; beneficial ownership in our common stock, as determined in accordance with Rule 13d-3 of the Exchange Act, was approximately 18% as of November 2013, excluding potential
further concentration underlying outstanding warrants and our convertible note facility. Kevin C. Tang, the Managing Director of Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP, is also chairman of our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such a concentration of common stock ownership could significantly influence corporate actions on various strategic matters,
including, for example, receptivity to collaborations and merger or sale overtures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock may cause our stock price to
decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal stockholders and affiliated entities hold a substantial number of shares of our common stock that they are
able to sell in the public market. In addition, they currently own convertible notes and outstanding warrants for additional shares of our common stock. The exercise of these warrants, conversion of the notes or the sale by our current stockholders
of a substantial number of shares, or the expectation that such exercises or sales may occur, could significantly reduce the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>*Future utilization of net operating loss carry-forwards may be impaired due to recent changes in ownership. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our net operating losses and tax attributes may be subject to limitation under Section&nbsp;382 of the Internal Revenue Code of
1986. As a result, our deferred tax assets, and related valuation allowance, have been reduced for the estimated impact of the net operating losses and credits that we currently estimate may expire unused. Utilization of our remaining net operating
loss and research and development credit carry-forwards may still be subject to substantial annual limitations due to ownership change limitations provided by the Internal Revenue Code and similar state provisions for ownership changes after
December&nbsp;31, 2013, including those that may come in conjunction with future equity financings or market trades by our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_11"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_12"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFAULTS UPON SENIOR SECURITIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_13"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MINE SAFETY DISCLOSURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_14"></A>ITEM&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER INFORMATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc722563_15"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Extension Definition</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc722563_16"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Heron Therapeutics, Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;12, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(On behalf of the Registrant)</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Brian G. Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Vice President, Finance and Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(As Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Extension Definition</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d722563dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Barry D.
Quart, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Heron Therapeutics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to
us by others within this entity, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;12, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d722563dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Brian G.
Drazba, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Heron Therapeutics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to
us by others within this entity, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;12, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Brian G. Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Vice President, Finance and</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer (As</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Principal
Financial and Accounting Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d722563dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the undersigned, in his capacity as Chief Executive Officer and Chief Financial Officer, respectively, of Heron Therapeutics, Inc. (the
&#147;Registrant&#148;), hereby certifies, for purposes of 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Quarterly Report of the Registrant on Form 10-Q for the quarter ended March&nbsp;31,&nbsp;2014 (the &#147;Report&#148;), which accompanies this certification, fully complies with the requirements of
Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information contained in the Report fairly presents, in all material respects, the financial condition of the Registrant at the end of such quarter and the results of operations of the Registrant for such quarter.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;12, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brian G. Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vice President, Finance and Chief Financial Officer (As Principal Financial and Accounting Officer)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification accompanies the Report to which it relates, is not deemed to be filed with the Securities and
Exchange Commission and is not to be incorporated by reference into any filing of Heron Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the
Report), irrespective of any general incorporation language contained in such filing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top">A signed original of this written statement required by Section&nbsp;906 has been provided to Heron Therapeutics, Inc. and will be retained by Heron Therapeutics, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>hrtx-20140331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue May 06 22:49:29 UTC 2014 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:hrtx="http://herontx.com/20140331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:compsci="http://compsciresources.com" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="hrtx-20140331.xsd"/>
  <context id="c0_AsOf31Mar2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="c1_AsOf31Dec2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="c2_From1Jan2014To31Mar2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c3_From1Jan2013To31Mar2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c4_AsOf31Dec2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="c5_AsOf31Mar2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="c6_AsOf28Apr2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2014-04-28</instant>
    </period>
  </context>
  <context id="c7_From1Jan2014To13Jan2014_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-13</endDate>
    </period>
  </context>
  <context id="c8_From1Jan2011To31Dec2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="c9_From1Jan2014To31Mar2014_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c10_From1Jan2013To31Mar2013_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c11_From1Jan2014To31Mar2014_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c12_From1Jan2013To31Mar2013_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2014To31Mar2014_ConvertibleDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2013To31Mar2013_ConvertibleDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c15_AsOf30Apr2011_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c16_AsOf30Apr2011_InitialClosingAmountMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">hrtx:InitialClosingAmountMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c17_AsOf30Apr2011_PurchaseOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">hrtx:PurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-04-30</instant>
    </period>
  </context>
  <context id="c18_From1Jun2011To30Jun2011_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="c19_From1Apr2011To30Apr2011_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="c20_From1Apr2011To30Apr2011_PrincipalAmountMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hrtx:PrincipalAmountMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-04-30</endDate>
    </period>
  </context>
  <context id="c21_From28Jul2011To29Jul2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2011-07-28</startDate>
      <endDate>2011-07-29</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2014To31Mar2014_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c23_AsOf31Mar2014_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Mar2014_InCaseOfDebtConversionMember_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">hrtx:InCaseOfDebtConversionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="c25_From1Jan2014To31Mar2014_InCaseOfDebtConversionMember_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">hrtx:InCaseOfDebtConversionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c26_AsOf13Jan2014_ScenarioPreviouslyReportedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-01-13</instant>
    </period>
  </context>
  <context id="c27_AsOf13Jan2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <instant>2014-01-13</instant>
    </period>
  </context>
  <context id="c28_From1Jun2011To30Jun2011_PrivatePlacement2011Member_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="c29_AsOf30Jun2011_PrivatePlacement2011Member_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="c30_AsOf30Jun2011_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="c31_From1Jun2011To30Sep2013_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-06-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c32_From1Jul2011To29Jul2011_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-07-29</endDate>
    </period>
  </context>
  <context id="c33_From1Jan2014To31Mar2014_PrivatePlacement2011Member_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c34_From1Jan2014To31Mar2014_PrivatePlacement2011Member_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c35_From1Jan2013To31Mar2013_PrivatePlacement2011Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c36_From1Jul2012To31Jul2012_PrivatePlacement2012Member_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2012Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="c37_AsOf31Jul2012_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-07-31</instant>
    </period>
  </context>
  <context id="c38_From1Jul2012To30Sep2013_PrivatePlacement2012Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2012Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="c39_From1Nov2013To30Nov2013_CommonStockMember_JefferiesLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hrtx:JefferiesLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-30</endDate>
    </period>
  </context>
  <context id="c40_AsOf30Nov2013_CommonStockMember_JefferiesLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hrtx:JefferiesLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="c41_From1Jan2014To31Mar2014_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c42_From1Jan2013To31Mar2013_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c43_From1Jan2014To31Mar2014_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="c44_From1Jan2013To31Mar2013_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="c45_From1Jan2013To31Dec2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">57475000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">72287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">2262000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">638000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">59737000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">72925000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">2926000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">2882000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">130000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">130000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">62793000</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">75937000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">3603000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">1264000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">2617000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">4703000</us-gaap:AccruedLiabilitiesCurrent>
  <hrtx:ConvertibleNotesPayableRelatedPartiesCurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">1164000</hrtx:ConvertibleNotesPayableRelatedPartiesCurrent>
  <hrtx:ConvertibleNotesPayableRelatedPartiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">1025000</hrtx:ConvertibleNotesPayableRelatedPartiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">7384000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">6992000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">239000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">237000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">311578000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">307578000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">-256408000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">-238870000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">55409000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">68945000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-3">62793000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2013" decimals="-3">75937000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">11771000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">7140000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">5551000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">5612000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">17322000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">12752000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">-17322000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">-12752000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">216000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">201000</us-gaap:InterestExpense>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">-17538000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">-12953000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c2_From1Jan2014To31Mar2014" decimals="2">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c3_From1Jan2013To31Mar2013" decimals="2">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">23686000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">15254000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">114000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">70000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">2969000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">1835000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">1624000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">-157000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">2238000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">1330000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">-2011000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">1470000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">-15713000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">-7961000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">57000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">435000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">-57000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">-435000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">600000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">12000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">958000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">612000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">-14812000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">-7784000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31Dec2012" decimals="-3">53506000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c5_AsOf31Mar2013" decimals="-3">45722000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <dei:EntityRegistrantName contextRef="c2_From1Jan2014To31Mar2014">HERON THERAPEUTICS, INC. /DE/</dei:EntityRegistrantName>
  <dei:DocumentType contextRef="c2_From1Jan2014To31Mar2014">10-Q</dei:DocumentType>
  <dei:CurrentFiscalYearEndDate contextRef="c2_From1Jan2014To31Mar2014">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c6_AsOf28Apr2014" decimals="INF">23901497</dei:EntityCommonStockSharesOutstanding>
  <dei:AmendmentFlag contextRef="c2_From1Jan2014To31Mar2014">false</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey contextRef="c2_From1Jan2014To31Mar2014">0000818033</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c2_From1Jan2014To31Mar2014">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers contextRef="c2_From1Jan2014To31Mar2014">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory contextRef="c2_From1Jan2014To31Mar2014">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c2_From1Jan2014To31Mar2014">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:DocumentFiscalYearFocus contextRef="c2_From1Jan2014To31Mar2014">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="c2_From1Jan2014To31Mar2014">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentPeriodEndDate contextRef="c2_From1Jan2014To31Mar2014">2014-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1285&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Business&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1287&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) (the &amp;#8220;Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us&amp;#8221; and &amp;#8220;our&amp;#8221;) is a specialty pharmaceutical company developing product candidates using its proprietary Biochronomer&amp;#8482; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1289&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Our lead product candidate, SUSTOL&lt;sup style=&quot;vertical-align: baseline; position: relative; bottom: .33em&quot;&gt;TM&lt;/sup&gt; (formerly known as APF530), is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (&amp;#8220;CINV&amp;#8221;) for patients undergoing both moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. SUSTOL contains the 5-HT3 antagonist granisetron formulated in our proprietary Biochronomer polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for
      five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1021-0&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In May 2009, we filed the original New Drug Application (&amp;#8220;NDA&amp;#8221;) seeking approval for SUSTOL with the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;). The FDA issued a Complete Response Letter for the SUSTOL NDA in March 2010. In September 2012, we resubmitted our NDA for SUSTOL and, in March 2013, we received a second Complete Response Letter, which identified several remaining issues that need to be addressed prior to approval of the SUSTOL NDA. We are currently working on addressing these issues and expect to resubmit the SUSTOL NDA in &lt;font style=&quot;COLOR: #000000&quot;&gt;mid-&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;2014.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1293&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We own the worldwide rights to SUSTOL and are in the early stages of building the commercial infrastructure necessary to commercialize SUSTOL in the U.S. on our own, assuming approval by the FDA.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1295&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In addition, to resubmitting the SUSTOL NDA, we are seeking to expand the labeled indication for SUSTOL following its potential approval. In 2014, we initiated a Phase 3 clinical study with SUSTOL for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy, an indication for which no 5-HT3 antagonist is approved. The 1,000 patient study is expected to be completed in late 2014.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1297&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Our core Biochronomer technology, on which SUSTOL and our other product candidates are based, consists of bioerodible polymers designed to release drugs over a defined period of time. We have completed over 100 &lt;i&gt;in vivo&lt;/i&gt; and &lt;i&gt;in vitro&lt;/i&gt; studies demonstrating that our Biochronomer technology is potentially applicable to a range of therapeutic areas, including, among others, prevention of CINV, pain management and control of inflammation. We have also completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymers are safe and well tolerated. Furthermore, our Biochronomer technology can be designed to deliver drugs over periods varying from days to potentially multiple weeks. We are exploring the potential use of our Biochronomer polymer with other drugs and intend to pursue the clinical development of one or more other drug candidates based on our
      proprietary delivery platform.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In November 2013, we initiated a program to expand our pipeline of sustained-release products, including a new program targeting the relief of post-surgical pain. Preliminary animal studies indicate &lt;font style=&quot;COLOR: #000000&quot;&gt;that&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;formulations using &lt;font style=&quot;COLOR: #000000&quot;&gt;our&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Biochronomer polymer-based drug delivery platform provided sustained analgesic effects for three to five days. We plan to formalize optimization in 2014 and initiate a Phase 1 study in mid-2014. As of 2012, approximately 25 million&lt;font style=&quot;COLOR: #000000&quot;&gt;&lt;sup style=&quot;vertical-align: baseline; position: relative; bottom:.33em;&quot;&gt;1&lt;/sup&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;procedures associated with post-operative pain were conducted in the U.S. In addition, post-operative pain market sales were approximately $3.1 billion&lt;font style=&quot;COLOR: #000000&quot;&gt;&lt;sup style=&quot;vertical-align: baseline; position: relative; bottom:.33em;&quot;&gt;2&lt;/sup&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;in 2012.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1301&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In January 2014, we changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. Effective January&amp;#160;13,&amp;#160;2014, we effected a 1-for-20 reverse split of our outstanding common stock (&amp;#8220;Reverse Stock Split&amp;#8221;) (See Note 5). All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split. All stock options, convertible notes and warrants outstanding were appropriately adjusted to give effect to the Reverse Stock Split.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1302&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1304&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We have incurred significant operating losses and negative cash flows from operations and we have an accumulated deficit of $256.4 million as of March 31, 2014. During 2011, 2012 and 2013, we completed a total of four rounds of equity and/or debt financings, which provided us with cash of approximately $135.4 million, net of issuance costs, to fund operations (see Notes 4 and 5). As of March 31, 2014, we had cash on hand of $57.5 million.&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1307&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We believe that our current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies prior to 2015 or begin preparations for potential commercialization of SUSTOL, we will need to raise additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 unitRef="pure" contextRef="c7_From1Jan2014To13Jan2014_CommonStockMember" decimals="0">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet unitRef="usd" contextRef="c8_From1Jan2011To31Dec2013" decimals="-5">135400000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
  <us-gaap:BasisOfAccounting contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1309&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basis of Presentation&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1311&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&amp;#160;31,&amp;#160;2014 are not necessarily indicative of the results that may be expected for other quarters or the year ending December&amp;#160;31, 2014. The condensed balance sheet at December 31, 2013 has been derived from the audited financial statements as of that date, but does not include all of the
      information and disclosures required by GAAP. The presentation of prior year amounts was reclassified to conform to the current year presentation. For more complete financial information, these unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended December&amp;#160;31, 2013 included in the Company&amp;#8217;s Annual Report on Form&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&amp;#160;10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on March 7, 2014&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1313&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accounting Policies&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1315&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1317&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions &lt;font style=&quot;COLOR: #000000&quot;&gt;that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates on historical experience and on assumptions that it believes to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1319&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1321&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively. There were no cash equivalents as of both dates. Our bank accounts have been placed under a control agreement in accordance with the April&amp;#160;2011 convertible note financing (see Note 4).&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1323&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Earnings Per Share&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1325&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1327&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Because we have incurred a net loss for both periods presented in the unaudited condensed statements of operations, outstanding stock options, warrants and common stock underlying convertible notes are not included in the computation of net loss per share because their effect would be anti-dilutive.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1329&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The following table includes the number of outstanding stock options, warrants and common stock underlying convertible notes not included in the computation for the three months ended March 31, 2014 and 2013 (in thousands):&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1345&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1345.finRow.1&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1331&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1332&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1345.finRow.2&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1334&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1335&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1345.finRow.3&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 9%&quot; id=&quot;TBL1345.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 9%&quot; id=&quot;TBL1345.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1345.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1336&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Stock options outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.amt.2&quot;&gt;
          7,273
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.amt.3&quot;&gt;
          4,461
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1345.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1339&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Warrants outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.amt.2&quot;&gt;
          3,825
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.amt.3&quot;&gt;
          4,052
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1345.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1342&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Common stock underlying convertible notes outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.amt.2&quot;&gt;
          6,385
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.amt.3&quot;&gt;
          6,016
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1347&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Comprehensive Income (Loss)&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1349&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of its net loss and there were no other changes in equity from non-owner sources.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1351&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1353&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;We do not expect that the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1315&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1317&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions &lt;font style=&quot;COLOR: #000000&quot;&gt;that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates on historical experience and on assumptions that it believes to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1319&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1321&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively. There were no cash equivalents as of both dates. Our bank accounts have been placed under a control agreement in accordance with the April&amp;#160;2011 convertible note financing (see Note 4).&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:LiquidityDisclosureTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1321&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:LiquidityDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1323&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Earnings Per Share&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1325&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Basic earnings per share (&amp;#8220;EPS&amp;#8221;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1327&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Because we have incurred a net loss for both periods presented in the unaudited condensed statements of operations, outstanding stock options, warrants and common stock underlying convertible notes are not included in the computation of net loss per share because their effect would be anti-dilutive.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1329&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The following table includes the number of outstanding stock options, warrants and common stock underlying convertible notes not included in the computation for the three months ended March 31, 2014 and 2013 (in thousands):&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1345&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1345.finRow.1&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1331&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1332&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1345.finRow.2&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1334&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1335&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1345.finRow.3&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 9%&quot; id=&quot;TBL1345.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 9%&quot; id=&quot;TBL1345.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1345.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1336&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Stock options outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.amt.2&quot;&gt;
          7,273
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.amt.3&quot;&gt;
          4,461
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1345.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1339&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Warrants outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.amt.2&quot;&gt;
          3,825
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.amt.3&quot;&gt;
          4,052
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1345.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1342&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Common stock underlying convertible notes outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.amt.2&quot;&gt;
          6,385
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.amt.3&quot;&gt;
          6,016
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1347&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Comprehensive Income (Loss)&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1349&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of its net loss and there were no other changes in equity from non-owner sources.&lt;/font&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1351&quot;&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1353&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;We do not expect that the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1345&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1345.finRow.1&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1331&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1332&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1345.finRow.2&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1334&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1335&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1345.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1345.finRow.3&quot;&gt;
        &lt;td style=&quot;WIDTH: 76%&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 9%&quot; id=&quot;TBL1345.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 9%&quot; id=&quot;TBL1345.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;WIDTH: 1%&quot; id=&quot;TBL1345.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1345.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1336&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Stock options outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.amt.2&quot;&gt;
          7,273
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.amt.3&quot;&gt;
          4,461
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1345.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1339&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Warrants outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.amt.2&quot;&gt;
          3,825
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.amt.3&quot;&gt;
          4,052
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1345.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1342&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Common stock underlying convertible notes outstanding&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.amt.2&quot;&gt;
          6,385
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.amt.3&quot;&gt;
          6,016
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1345.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c9_From1Jan2014To31Mar2014_StockOptionMember" decimals="-3">7273000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c10_From1Jan2013To31Mar2013_StockOptionMember" decimals="-3">4461000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c11_From1Jan2014To31Mar2014_WarrantMember" decimals="-3">3825000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c12_From1Jan2013To31Mar2013_WarrantMember" decimals="-3">4052000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c13_From1Jan2014To31Mar2014_ConvertibleDebtSecuritiesMember" decimals="-3">6385000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c14_From1Jan2013To31Mar2013_ConvertibleDebtSecuritiesMember" decimals="-3">6016000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtDisclosureTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1355&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;4. Convertible Notes to Related Parties&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1357&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5 million in Senior Secured Convertible Notes (&amp;#8220;Notes&amp;#8221;). We received a total of $4.3 million, net of issuance costs, from the issuance of these Notes.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1359&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Notes are secured by substantially all of our assets, including placing our bank accounts under a control agreement. The Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Notes, at the election of the purchasers. The Notes mature on May 2, 2021, however, the holders of the Notes may require prepayment of the Notes at any time, at each holder&amp;#8217;s option.&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1361&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes. There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1363&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;As of March 31, 2014, we were in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require us to redeem all or a portion of their Notes.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot;&gt;
      We filed a registration statement with the SEC to register for resale 3.5 million shares (as adjusted for the Reverse Stock Split) underlying the Notes. The registration statement was declared effective on July 29, 2011. The Purchasers have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.&amp;#160;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1367&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates and we began amortizing the resultant debt discount over the respective 10-year term of the Notes. During the three months ended March 31, 2014, accrued interest of approximately $75,000 was paid-in-kind and rolled into the Note principal balance, which resulted in an additional debt discount of approximately $75,000. For the three months ended March 31, 2014 and 2013, interest expense relating to the stated rate was approximately $77,000 and $71,000, respectively, and interest expense relating to the
      amortization of the debt discount was approximately $139,000 and $130,000, respectively.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1369&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;As of March 31, 2014, the carrying value of the Notes was approximately $1,164,000, which is comprised of the $5,108,000 principal amount of the Notes outstanding, less debt discount of $3,944,000. If the $5.1&amp;#160;million principal amount of Notes is converted, we would issue 6.4 million shares of our common stock.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <hrtx:ConvertibleDebtIssuableInConnectionWithPrivatePlacement1 unitRef="usd" contextRef="c15_AsOf30Apr2011_NotesPayableOtherPayablesMember" decimals="-5">4500000</hrtx:ConvertibleDebtIssuableInConnectionWithPrivatePlacement1>
  <hrtx:NotesAuthorizedUnderPrivatePlacementInitialClosing unitRef="usd" contextRef="c16_AsOf30Apr2011_InitialClosingAmountMember" decimals="-5">4300000</hrtx:NotesAuthorizedUnderPrivatePlacementInitialClosing>
  <hrtx:PurchaseOptionUnderPrivatePlacement unitRef="usd" contextRef="c17_AsOf30Apr2011_PurchaseOptionMember" decimals="2">0.06</hrtx:PurchaseOptionUnderPrivatePlacement>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c18_From1Jun2011To30Jun2011_NotesPayableOtherPayablesMember">2021-05-02</us-gaap:DebtInstrumentMaturityDate>
  <hrtx:DebtInstrumentConversionRatioShares unitRef="shares" contextRef="c19_From1Apr2011To30Apr2011_CommonStockMember" decimals="INF">1250</hrtx:DebtInstrumentConversionRatioShares>
  <hrtx:DebtInstrumentConversionRatioMultipleOfPrincipal unitRef="usd" contextRef="c20_From1Apr2011To30Apr2011_PrincipalAmountMember" decimals="0">1000</hrtx:DebtInstrumentConversionRatioMultipleOfPrincipal>
  <hrtx:BeneficialOwnershipAfterConversion unitRef="pure" contextRef="c18_From1Jun2011To30Jun2011_NotesPayableOtherPayablesMember" decimals="4">0.0999</hrtx:BeneficialOwnershipAfterConversion>
  <hrtx:NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes contextRef="c18_From1Jun2011To30Jun2011_NotesPayableOtherPayablesMember">P61D</hrtx:NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes>
  <hrtx:CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes unitRef="shares" contextRef="c21_From28Jul2011To29Jul2011" decimals="-5">3500000</hrtx:CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes>
  <us-gaap:PaidInKindInterest unitRef="usd" contextRef="c22_From1Jan2014To31Mar2014_NotesPayableOtherPayablesMember" decimals="0">75000</us-gaap:PaidInKindInterest>
  <us-gaap:DebtInstrumentUnamortizedDiscount unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="0">75000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:InterestExpenseDebtExcludingAmortization unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="0">77000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="0">71000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="0">139000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="0">130000</us-gaap:AmortizationOfDebtDiscountPremium>
  <hrtx:ConvertibleNotesPayableRelatedPartiesCurrent unitRef="usd" contextRef="c23_AsOf31Mar2014_NotesPayableOtherPayablesMember" decimals="0">1164000</hrtx:ConvertibleNotesPayableRelatedPartiesCurrent>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c23_AsOf31Mar2014_NotesPayableOtherPayablesMember" decimals="0">5108000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentUnamortizedDiscount unitRef="usd" contextRef="c23_AsOf31Mar2014_NotesPayableOtherPayablesMember" decimals="0">3944000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c24_AsOf31Mar2014_InCaseOfDebtConversionMember_NotesPayableOtherPayablesMember" decimals="-5">5100000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments unitRef="pure" contextRef="c25_From1Jan2014To31Mar2014_InCaseOfDebtConversionMember_NotesPayableOtherPayablesMember" decimals="-5">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqBhR1cOw37qdfT/PN3Se6viq8MEgNf1gK37o5+ZijZsLc4+wNvBpwajV6eaQx1qjwa9+whSMP+kLc8NsgnKtqDc2PLzk2yBherwevrarle1sr1GHzC4E6g8ls9RpTpiP/M3Z1PM7a4k/ich6+p8LJcOvYMgwt9LOJi5bQt+cy3qqHgilafPjoPQ==] CSR-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1371&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;5.&amp;#160;&amp;#160; Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1373&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;&lt;b&gt;Amendments to Articles of Incorporation&lt;/b&gt;&lt;/i&gt; &lt;b&gt;&amp;#8211; &lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1375&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Effective January 13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc. and to effect a 1-for-20 reverse split of our outstanding common stock. The name change and Reverse Stock Split were approved by our stockholders on September&amp;#160;19,&amp;#160;2013. As a result of the Reverse Stock Split, the total authorized shares of common stock were reduced from 1,500,000,000 to 75,000,000 shares.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1377&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;&lt;b&gt;2011 Private Placement&lt;/b&gt;&lt;/i&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1379&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In June 2011, we sold 8.0 million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July&amp;#160;1,&amp;#160;2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular
      purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period.&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1381&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;On July 29, 2011, we filed a registration statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August 4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (&amp;#8220;Rule 144&amp;#8221;). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise. If we fail to keep the registration statement continuously effective for a designated time
      (with limited exceptions) during the period we are obligated to maintain the registration statement, we may be obligated to pay to the investors liquidated damages in an amount equal to 1.0% per month of such investor&amp;#8217;s pro rata interest in the total purchase price of the 2011 private placement, capped at a total penalty of 6.0%.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;During the three months ended March 31, 2014, one warrant holder exercised 144,040 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 108,409 shares of common stock and no net cash proceeds to the Company. During the three months ended March 31, 2013, we received $0.6 million for cash exercises of these warrants.&amp;#160;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1385&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;&lt;b&gt;2012 Private Placement&lt;/b&gt;&lt;/i&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1387&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In July 2012, we sold 5.1 million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1 million in issuance costs).&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1029-0&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;On August 24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September 6, 2012. If we fail to keep the registration statement continuously effective for a designated time (with limited exceptions), we may be obligated to pay to each &lt;font style=&quot;COLOR: #000000&quot;&gt;investor&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;an amount equal to 1.5% per month of the aggregate purchase price of the unregistered shares held by such &lt;font style=&quot;COLOR: #000000&quot;&gt;investor&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;, capped at a total penalty of 9.0%.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1391&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;&lt;b&gt;2013 Common Stock Offering&lt;/b&gt;&lt;/i&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1030-0&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;In November 2013, we entered into an underwriting agreement, pursuant to which we sold a total of approximately 8.6 million shares of our common stock to the underwriters at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9 million in issuance costs).&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1031-0&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The offering was made pursuant to the Company&amp;#8217;s effective registration statement on Form S-3 (Registration No. 333-190550), which was previously filed with the SEC and was declared effective, and a prospectus supplement filed with the SEC. The &lt;font style=&quot;COLOR: #000000&quot;&gt;offering&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;was not registered under any state blue sky laws and was limited to &amp;#8220;Qualified Institutional Buyers&amp;#8221; (as defined in Rule 144A under the Securities Act of 1933, as amended) and certain other institutional and accredited investors, as permitted under applicable law. In the &lt;font style=&quot;COLOR: #000000&quot;&gt;underwriting agreement&lt;/font&gt;&lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;, the Company agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of
      1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1397&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;&lt;b&gt;Stock Option Exercises&lt;/b&gt;&lt;/i&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1032-0&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;For the three months ended March 31, 2014, approximately 215,000 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to the Company of approximately $958,000.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1403&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1405&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The following table summarizes stock-based compensation expense for the three months ended March&amp;#160;31, 2014 and 2013 related to stock options and Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;) purchase rights by expense category (in thousands):&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1424&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1424.finRow.1&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1407&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1408&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1424.finRow.2&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1410&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1411&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1424.finRow.3&quot;&gt;
        &lt;td&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1424.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1412&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Research and development&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.amt.2&quot;&gt;
          1,262
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.amt.3&quot;&gt;
          249
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1415&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;General and administrative&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.amt.2&quot;&gt;
          1,707
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.amt.3&quot;&gt;
          1,586
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1424.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1418&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Stock-based compensation expense included in operating expenses&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.amt.2&quot;&gt;
          2,969
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.amt.3&quot;&gt;
          1,835
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7&quot;&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1424.finRow.8&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1421&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Impact on basic and diluted net loss per share&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.amt.2&quot;&gt;
          0.13
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.amt.3&quot;&gt;
          0.12
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1426&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;As of March 31, 2014, there was approximately $45.4 million of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of the Company&amp;#8217;s equity compensation plans. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize this compensation cost over a period of 2.5&amp;#160;years, which is the weighted-average vesting period for all stock-based compensation awards.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1428&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option valuation model with the following weighted-average assumptions:&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1446&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1446.finRow.1&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1430&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;Options:&lt;/i&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1431&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1446.finRow.2&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1432&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1433&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1446.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1434&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Risk-free interest rate&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.amt.2&quot;&gt;
          2.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.amt.3&quot;&gt;
          1.1
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1446.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1437&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Dividend yield&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.amt.2&quot;&gt;
          0.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.amt.3&quot;&gt;
          0.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1446.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1440&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Volatility&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.amt.2&quot;&gt;
          153.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.amt.3&quot;&gt;
          152.4
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1446.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1443&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Expected life (years)&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.amt.2&quot;&gt;
          6
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 117pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.amt.3&quot;&gt;
          6
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1448&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;The Company estimates the fair value of each purchase right granted under the ESPP at the beginning of each new offering period using the Black-Scholes option valuation model. A new offering period begins every six months in May and November of each year. For the three months ended March 31, 2014 and 2013, there were no new offering periods or ESPP purchase rights granted.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1450&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;The following table summarizes the stock option activity for the three months ended March 31, 2014:&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1490&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1490.finRow.1&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1468&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Shares (in thousands)&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1469&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.lead.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1470&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.trail.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1490.finRow.2&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1471&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Balance at January 1, 2014&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.amt.2&quot;&gt;
          6,356
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.amt.3&quot;&gt;
          8.22
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.amt.4&quot;&gt;
          8.14
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1490.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1475&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Granted&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.amt.2&quot;&gt;
          1,203
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.amt.3&quot;&gt;
          9.99
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1490.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1478&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Exercised&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.amt.2&quot;&gt;
          (275
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1480&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.amt.3&quot;&gt;
          6.17
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1490.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1482&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Expired and forfeited&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.amt.2&quot;&gt;
          (11
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1484&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.amt.3&quot;&gt;
          17.32
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1490.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1486&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Balance at March 31, 2014&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.amt.2&quot;&gt;
          7,273
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.amt.3&quot;&gt;
          8.57
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.amt.4&quot;&gt;
          8.42
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c26_AsOf13Jan2014_ScenarioPreviouslyReportedMember" decimals="INF">1500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c27_AsOf13Jan2014" decimals="INF">75000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c28_From1Jun2011To30Jun2011_PrivatePlacement2011Member_CommonStockMember" decimals="-5">8000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights unitRef="shares" contextRef="c29_AsOf30Jun2011_PrivatePlacement2011Member_CommonStockMember" decimals="-5">22800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c28_From1Jun2011To30Jun2011_PrivatePlacement2011Member_CommonStockMember" decimals="-5">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
  <hrtx:SharesAvailablePerWarrantExercised unitRef="shares" contextRef="c28_From1Jun2011To30Jun2011_PrivatePlacement2011Member_CommonStockMember" decimals="INF">0.5</hrtx:SharesAvailablePerWarrantExercised>
  <hrtx:ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit unitRef="usdPershares" contextRef="c30_AsOf30Jun2011_PrivatePlacement2011Member" decimals="2">3.60</hrtx:ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit>
  <hrtx:LimitationOnExercisableWarrants unitRef="pure" contextRef="c31_From1Jun2011To30Sep2013_PrivatePlacement2011Member" decimals="4">0.0999</hrtx:LimitationOnExercisableWarrants>
  <hrtx:EffectiveRateOfLiquidatedDamages unitRef="pure" contextRef="c32_From1Jul2011To29Jul2011_PrivatePlacement2011Member" decimals="3">0.010</hrtx:EffectiveRateOfLiquidatedDamages>
  <hrtx:PrivatePlacementCappedPenatly unitRef="pure" contextRef="c32_From1Jul2011To29Jul2011_PrivatePlacement2011Member" decimals="3">0.060</hrtx:PrivatePlacementCappedPenatly>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised unitRef="shares" contextRef="c33_From1Jan2014To31Mar2014_PrivatePlacement2011Member_WarrantMember" decimals="INF">144040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c34_From1Jan2014To31Mar2014_PrivatePlacement2011Member_CommonStockMember" decimals="INF">108409</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c34_From1Jan2014To31Mar2014_PrivatePlacement2011Member_CommonStockMember" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c35_From1Jan2013To31Mar2013_PrivatePlacement2011Member" decimals="-5">600000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c36_From1Jul2012To31Jul2012_PrivatePlacement2012Member_CommonStockMember" decimals="-5">5100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c37_AsOf31Jul2012_PrivatePlacement2012Member" decimals="2">10.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c36_From1Jul2012To31Jul2012_PrivatePlacement2012Member_CommonStockMember" decimals="-5">50500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c36_From1Jul2012To31Jul2012_PrivatePlacement2012Member_CommonStockMember" decimals="-5">3100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <hrtx:EffectiveRateOfLiquidatedDamages unitRef="pure" contextRef="c38_From1Jul2012To30Sep2013_PrivatePlacement2012Member" decimals="3">0.015</hrtx:EffectiveRateOfLiquidatedDamages>
  <hrtx:PrivatePlacementCappedPenatly unitRef="pure" contextRef="c38_From1Jul2012To30Sep2013_PrivatePlacement2012Member" decimals="3">0.090</hrtx:PrivatePlacementCappedPenatly>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c39_From1Nov2013To30Nov2013_CommonStockMember_JefferiesLLCMember" decimals="-5">8600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c40_AsOf30Nov2013_CommonStockMember_JefferiesLLCMember" decimals="2">8.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c39_From1Nov2013To30Nov2013_CommonStockMember_JefferiesLLCMember" decimals="-5">57800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c39_From1Nov2013To30Nov2013_CommonStockMember_JefferiesLLCMember" decimals="-5">3900000</us-gaap:PaymentsOfStockIssuanceCosts>
  <hrtx:StockIssuedDuringPeriodSharesStockOptionsExercisedNet unitRef="shares" contextRef="c2_From1Jan2014To31Mar2014" decimals="INF">215000</hrtx:StockIssuedDuringPeriodSharesStockOptionsExercisedNet>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="0">958000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized unitRef="usd" contextRef="c0_AsOf31Mar2014" decimals="-5">45400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c2_From1Jan2014To31Mar2014">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1424&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1424.finRow.1&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1407&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1408&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/font&gt; &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1424.finRow.2&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1410&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1411&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot; id=&quot;TBL1424.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1424.finRow.3&quot;&gt;
        &lt;td&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td id=&quot;TBL1424.finRow.3.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1424.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1412&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Research and development&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.amt.2&quot;&gt;
          1,262
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.amt.3&quot;&gt;
          249
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1415&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;General and administrative&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.amt.2&quot;&gt;
          1,707
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.amt.3&quot;&gt;
          1,586
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1424.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1418&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Stock-based compensation expense included in operating expenses&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.amt.2&quot;&gt;
          2,969
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.amt.3&quot;&gt;
          1,835
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7&quot;&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.lead.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.symb.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.amt.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.trail.B2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.lead.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.symb.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.amt.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1424.finRow.7.trail.B3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1424.finRow.8&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1421&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Impact on basic and diluted net loss per share&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.symb.2&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.amt.2&quot;&gt;
          0.13
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.amt.3&quot;&gt;
          0.12
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1424.finRow.8.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c41_From1Jan2014To31Mar2014_ResearchAndDevelopmentExpenseMember" decimals="-3">1262000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c42_From1Jan2013To31Mar2013_ResearchAndDevelopmentExpenseMember" decimals="-3">249000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c43_From1Jan2014To31Mar2014_GeneralAndAdministrativeExpenseMember" decimals="-3">1707000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c44_From1Jan2013To31Mar2013_GeneralAndAdministrativeExpenseMember" decimals="-3">1586000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">2969000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c3_From1Jan2013To31Mar2013" decimals="-3">1835000</us-gaap:AllocatedShareBasedCompensationExpense>
  <hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare unitRef="usdPershares" contextRef="c2_From1Jan2014To31Mar2014" decimals="2">0.13</hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare>
  <hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare unitRef="usdPershares" contextRef="c3_From1Jan2013To31Mar2013" decimals="2">0.12</hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1446&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1446.finRow.1&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1430&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;i&gt;Options:&lt;/i&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.1.amt.D3&quot; colspan=&quot;6&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1431&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr id=&quot;TBL1446.finRow.2&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1432&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1433&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.2.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1446.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1434&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Risk-free interest rate&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.amt.2&quot;&gt;
          2.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.amt.3&quot;&gt;
          1.1
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.3.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1446.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1437&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Dividend yield&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.amt.2&quot;&gt;
          0.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.amt.3&quot;&gt;
          0.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1446.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1440&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Volatility&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.amt.2&quot;&gt;
          153.0
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.amt.3&quot;&gt;
          152.4
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          %
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1446.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1443&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Expected life (years)&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.amt.2&quot;&gt;
          6
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.symb.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 117pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.amt.3&quot;&gt;
          6
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1446.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c2_From1Jan2014To31Mar2014" decimals="3">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c3_From1Jan2013To31Mar2013" decimals="3">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c2_From1Jan2014To31Mar2014" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c3_From1Jan2013To31Mar2013" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c2_From1Jan2014To31Mar2014" decimals="3">1.530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c3_From1Jan2013To31Mar2013" decimals="3">1.524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c2_From1Jan2014To31Mar2014">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c3_From1Jan2013To31Mar2013">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;table style=&quot;TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot; id=&quot;TBL1490&quot; border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt;
      &lt;tr id=&quot;TBL1490.finRow.1&quot;&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.lead.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.amt.D2&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1468&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Shares (in thousands)&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.trail.D2&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.lead.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.amt.D3&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1469&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.trail.D3&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.lead.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.amt.D4&quot; colspan=&quot;2&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1470&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/b&gt;&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.1.trail.D4&quot;&gt;
          &lt;b&gt;&amp;#160;&lt;/b&gt;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1490.finRow.2&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1471&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Balance at January 1, 2014&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.amt.2&quot;&gt;
          6,356
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.amt.3&quot;&gt;
          8.22
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.amt.4&quot;&gt;
          8.14
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.2.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1490.finRow.3&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1475&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Granted&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.amt.2&quot;&gt;
          1,203
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.amt.3&quot;&gt;
          9.99
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.3.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1490.finRow.4&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1478&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Exercised&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.amt.2&quot;&gt;
          (275
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1480&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.amt.3&quot;&gt;
          6.17
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.4.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #ffffff&quot; id=&quot;TBL1490.finRow.5&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1482&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Expired and forfeited&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.amt.2&quot;&gt;
          (11
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1484&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.amt.3&quot;&gt;
          17.32
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.lead.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.symb.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.amt.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.5.trail.B4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style=&quot;BACKGROUND-COLOR: #cceeff&quot; id=&quot;TBL1490.finRow.6&quot;&gt;
        &lt;td style=&quot;TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot;&gt;
          &lt;p style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1486&quot;&gt;
            &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt&quot;&gt;Balance at March 31, 2014&lt;/font&gt;
          &lt;/p&gt;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.lead.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.symb.2&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.amt.2&quot;&gt;
          7,273
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.trail.2&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.lead.3&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.symb.3&quot;&gt;
          $
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.amt.3&quot;&gt;
          8.57
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.trail.3&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.lead.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.symb.4&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
        &lt;td style=&quot;TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.amt.4&quot;&gt;
          8.42
        &lt;/td&gt;
        &lt;td style=&quot;BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom&quot; id=&quot;TBL1490.finRow.6.trail.4&quot; nowrap=&quot;nowrap&quot;&gt;
          &amp;#160;
        &lt;/td&gt;
      &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c4_AsOf31Dec2012" decimals="-3">6356000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_AsOf31Dec2012" decimals="2">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c45_From1Jan2013To31Dec2013">P8Y51D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">1203000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_From1Jan2014To31Mar2014" decimals="2">9.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">275000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_From1Jan2014To31Mar2014" decimals="2">6.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c2_From1Jan2014To31Mar2014" decimals="-3">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_From1Jan2014To31Mar2014" decimals="2">17.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c0_AsOf31Mar2014" decimals="-3">7273000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_AsOf31Mar2014" decimals="2">8.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c2_From1Jan2014To31Mar2014">P8Y153D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c2_From1Jan2014To31Mar2014">&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1494&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;&lt;b&gt;6. Income Taxes&lt;/b&gt;&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1496&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company&apos;s ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of March 31, 2014.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt&quot; id=&quot;PARA1498&quot;&gt;
      &lt;font style=&quot;FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt&quot;&gt;The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There have been no material changes in the Company&amp;#8217;s unrecognized tax benefits since December&amp;#160;31, 2013 and as such, disclosures included in the Company&amp;#8217;s 2013 Annual Report on Form&amp;#160;10-K continue to be relevant for the period ended March 31, 2014.&lt;/font&gt;
    &lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>hrtx-20140331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue May 06 22:49:29 UTC 2014 -->
<xs:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://herontx.com/20140331" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:hrtx="http://herontx.com/20140331" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" elementFormDefault="qualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="hrtx-20140331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="hrtx-20140331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="hrtx-20140331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="hrtx-20140331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://herontx.com/role/ConsolidatedBalanceSheet" id="hrtx_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/ConsolidatedIncomeStatement" id="hrtx_r_ConsolidatedIncomeStatement">
        <link:definition>002 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/ConsolidatedCashFlow" id="hrtx_r_ConsolidatedCashFlow">
        <link:definition>003 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note1Business" id="hrtx_r_Note1Business">
        <link:definition>004 - Disclosure - Note 1 - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note2BasisofPresentation" id="hrtx_r_Note2BasisofPresentation">
        <link:definition>005 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note3AccountingPolicies" id="hrtx_r_Note3AccountingPolicies">
        <link:definition>006 - Disclosure - Note 3 - Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note4ConvertibleNotestoRelatedParties" id="hrtx_r_Note4ConvertibleNotestoRelatedParties">
        <link:definition>007 - Disclosure - Note 4 - Convertible Notes to Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note5StockholdersEquity" id="hrtx_r_Note5StockholdersEquity">
        <link:definition>008 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note6IncomeTaxes" id="hrtx_r_Note6IncomeTaxes">
        <link:definition>009 - Disclosure - Note 6 - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/AccountingPoliciesByPolicy" id="hrtx_r_AccountingPoliciesByPolicy">
        <link:definition>010 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note3AccountingPoliciesTables" id="hrtx_r_Note3AccountingPoliciesTables">
        <link:definition>011 - Disclosure - Note 3 - Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note5StockholdersEquityTables" id="hrtx_r_Note5StockholdersEquityTables">
        <link:definition>012 - Disclosure - Note 5 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note1BusinessDetails" id="hrtx_r_Note1BusinessDetails">
        <link:definition>013 - Disclosure - Note 1 - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note3AccountingPoliciesDetails" id="hrtx_r_Note3AccountingPoliciesDetails">
        <link:definition>014 - Disclosure - Note 3 - Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqBhR1cOw37qdfT/PN3Se6viq8MEgNf1gK37o5+ZijZsLc4+wNvBpwajV6eaQx1qjwa9+whSMP+kLc8NsgnKtqDc2PLzk2yBherwevrarle1sr1GHzC4E6g8ls9RpTpiP/M3Z1PM7a4k/ich6+p8LJcOvYMgwt9LOJYwJF7t5h37kb+nMlAV/mwA==] CSR-->
      <link:roleType roleURI="http://herontx.com/role/EquityExcludedFromCalculationofDilutedEarningsPerShareTable" id="hrtx_r_EquityExcludedFromCalculationofDilutedEarningsPerShareTable">
        <link:definition>015 - Disclosure - Note 3 - Accounting Policies (Details) - Equity Excluded From Calculation of Diluted Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note4ConvertibleNotestoRelatedPartiesDetails" id="hrtx_r_Note4ConvertibleNotestoRelatedPartiesDetails">
        <link:definition>016 - Disclosure - Note 4 - Convertible Notes to Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/Note5StockholdersEquityDetails" id="hrtx_r_Note5StockholdersEquityDetails">
        <link:definition>017 - Disclosure - Note 5 - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/StockbasedCompensationExpenseTable" id="hrtx_r_StockbasedCompensationExpenseTable">
        <link:definition>018 - Disclosure - Note 5 - Stockholders' Equity (Details) - Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/OptionValuationAssumptionsTable" id="hrtx_r_OptionValuationAssumptionsTable">
        <link:definition>019 - Disclosure - Note 5 - Stockholders' Equity (Details) - Option Valuation Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/OptionSummaryTable" id="hrtx_r_OptionSummaryTable">
        <link:definition>020 - Disclosure - Note 5 - Stockholders' Equity (Details) - Option Summary</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://herontx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Disclosure - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="CurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_CurrentAssetsAbstract"/>
  <xs:element name="CurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_CurrentLiabilitiesAbstract"/>
  <xs:element name="ConvertibleNotesPayableRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent"/>
  <xs:element name="OperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_OperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract"/>
  <xs:element name="ChangesInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="InvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_InvestingActivitiesAbstract"/>
  <xs:element name="FinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_FinancingActivitiesAbstract"/>
  <xs:element name="EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract"/>
  <xs:element name="StockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_StockBasedCompensationExpenseAbstract"/>
  <xs:element name="ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare"/>
  <xs:element name="OptionValuationAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_OptionValuationAssumptionsAbstract"/>
  <xs:element name="OptionSummaryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_OptionSummaryAbstract"/>
  <xs:element name="Note1BusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="hrtx_Note1BusinessDetailsTable"/>
  <xs:element name="Note1BusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_Note1BusinessDetailsLineItems"/>
  <xs:element name="Note4ConvertibleNotestoRelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable"/>
  <xs:element name="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
  <xs:element name="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
  <xs:element name="NotesAuthorizedUnderPrivatePlacementInitialClosing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
  <xs:element name="PurchaseOptionUnderPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="hrtx_PurchaseOptionUnderPrivatePlacement"/>
  <xs:element name="DebtInstrumentConversionRatioShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_DebtInstrumentConversionRatioShares"/>
  <xs:element name="DebtInstrumentConversionRatioMultipleOfPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal"/>
  <xs:element name="BeneficialOwnershipAfterConversion" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_BeneficialOwnershipAfterConversion"/>
  <xs:element name="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
  <xs:element name="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
  <xs:element name="Note5StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="hrtx_Note5StockholdersEquityDetailsTable"/>
  <xs:element name="Note5StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_Note5StockholdersEquityDetailsLineItems"/>
  <xs:element name="SharesAvailablePerWarrantExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_SharesAvailablePerWarrantExercised"/>
  <xs:element name="ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
  <xs:element name="LimitationOnExercisableWarrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_LimitationOnExercisableWarrants"/>
  <xs:element name="EffectiveRateOfLiquidatedDamages" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_EffectiveRateOfLiquidatedDamages"/>
  <xs:element name="PrivatePlacementCappedPenatly" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_PrivatePlacementCappedPenatly"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsExercisedNet" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet"/>
  <xs:element name="DisclosureAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="hrtx_DisclosureAxis"/>
  <xs:element name="EmployeeStockPurchasePlan1997Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_EmployeeStockPurchasePlan1997Member"/>
  <xs:element name="EquityIncentivePlan2007Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_EquityIncentivePlan2007Member"/>
  <xs:element name="InCaseOfDebtConversionMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_InCaseOfDebtConversionMember"/>
  <xs:element name="InitialClosingAmountMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_InitialClosingAmountMember"/>
  <xs:element name="JefferiesLLCMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_JefferiesLLCMember"/>
  <xs:element name="PrincipalAmountMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_PrincipalAmountMember"/>
  <xs:element name="PrivatePlacement2011Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_PrivatePlacement2011Member"/>
  <xs:element name="PrivatePlacement2012Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_PrivatePlacement2012Member"/>
  <xs:element name="PurchaseOptionMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_PurchaseOptionMember"/>
  <xs:element name="SubjectToLimitationsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_SubjectToLimitationsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="hrtx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>hrtx-20140331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue May 06 22:49:29 UTC 2014 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedBalanceSheet" roleURI="http://herontx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedIncomeStatement" roleURI="http://herontx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedCashFlow" roleURI="http://herontx.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqBhR1cOw37qdfT/PN3Se6viq8MEgNf1gK37o5+ZijZsLc4+wNvBpwajV6eaQx1qjwa9+whSMP+kLc8NsgnKtqDc2PLzk2yBherwevrarle1sr1GHzC4E6g8ls9RpTpiP/M3Z1PM7a4k/ich6+p8LJcOvYMgwt9LOJZ33f9KKVOLojV0qf/x+jEQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>hrtx-20140331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue May 06 22:49:29 UTC 2014 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedBalanceSheet" roleURI="http://herontx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedIncomeStatement" roleURI="http://herontx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedCashFlow" roleURI="http://herontx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note1Business" roleURI="http://herontx.com/role/Note1Business"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note2BasisofPresentation" roleURI="http://herontx.com/role/Note2BasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note3AccountingPolicies" roleURI="http://herontx.com/role/Note3AccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note4ConvertibleNotestoRelatedParties" roleURI="http://herontx.com/role/Note4ConvertibleNotestoRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note5StockholdersEquity" roleURI="http://herontx.com/role/Note5StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note6IncomeTaxes" roleURI="http://herontx.com/role/Note6IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_AccountingPoliciesByPolicy" roleURI="http://herontx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note3AccountingPoliciesTables" roleURI="http://herontx.com/role/Note3AccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note5StockholdersEquityTables" roleURI="http://herontx.com/role/Note5StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_EquityExcludedFromCalculationofDilutedEarningsPerShareTable" roleURI="http://herontx.com/role/EquityExcludedFromCalculationofDilutedEarningsPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_StockbasedCompensationExpenseTable" roleURI="http://herontx.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_OptionValuationAssumptionsTable" roleURI="http://herontx.com/role/OptionValuationAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_OptionSummaryTable" roleURI="http://herontx.com/role/OptionSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note1BusinessDetails" roleURI="http://herontx.com/role/Note1BusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note3AccountingPoliciesDetails" roleURI="http://herontx.com/role/Note3AccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note4ConvertibleNotestoRelatedPartiesDetails" roleURI="http://herontx.com/role/Note4ConvertibleNotestoRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note5StockholdersEquityDetails" roleURI="http://herontx.com/role/Note5StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#DocumentAndEntityInformation" roleURI="http://herontx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_CurrentAssetsAbstract" xlink:href="hrtx-20140331.xsd#hrtx_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="hrtx_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentAssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentAssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_CurrentLiabilitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="hrtx_CurrentLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentLiabilitiesAbstract" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_CurrentLiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_OperatingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_OperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_OperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_InvestingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_InvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_InvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_FinancingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_FinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_FinancingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note1Business">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note2BasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note3AccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note4ConvertibleNotestoRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note5StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note6IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note3AccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note5StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/EquityExcludedFromCalculationofDilutedEarningsPerShareTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/StockbasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqBhR1cOw37qdfT/PN3Se6viq8MEgNf1gK37o5+ZijZsLc4+wNvBpwajV6eaQx1qjwa9+whSMP+kLc8NsgnKtqDc2PLzk2yBherwevrarle1sr1GHzC4E6g8ls9RpTpiP/M3Z1PM7a4k/ich6+p8LJcOvYMgwt9LOJhmkQ0OESjSEdhf98ck19uA==] CSR-->
    <loc xlink:type="locator" xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" xlink:href="hrtx-20140331.xsd#hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/OptionValuationAssumptionsTable">
    <loc xlink:type="locator" xlink:label="hrtx_OptionValuationAssumptionsAbstract" xlink:href="hrtx-20140331.xsd#hrtx_OptionValuationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionValuationAssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/OptionSummaryTable">
    <loc xlink:type="locator" xlink:label="hrtx_OptionSummaryAbstract" xlink:href="hrtx-20140331.xsd#hrtx_OptionSummaryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note1BusinessDetails">
    <loc xlink:type="locator" xlink:label="hrtx_Note1BusinessDetailsLineItems" xlink:href="hrtx-20140331.xsd#hrtx_Note1BusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="hrtx_Note1BusinessDetailsTable" xlink:href="hrtx-20140331.xsd#hrtx_Note1BusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrtx_Note1BusinessDetailsLineItems" xlink:to="hrtx_Note1BusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note1BusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note1BusinessDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note1BusinessDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note1BusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note1BusinessDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note3AccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note4ConvertibleNotestoRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:href="hrtx-20140331.xsd#hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:href="hrtx-20140331.xsd#hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtSecurityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtSecurityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_InitialClosingAmountMember" xlink:href="hrtx-20140331.xsd#hrtx_InitialClosingAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:to="hrtx_InitialClosingAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_PurchaseOptionMember" xlink:href="hrtx-20140331.xsd#hrtx_PurchaseOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:to="hrtx_PurchaseOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_PrincipalAmountMember" xlink:href="hrtx-20140331.xsd#hrtx_PrincipalAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="hrtx_PrincipalAmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:href="hrtx-20140331.xsd#hrtx_InCaseOfDebtConversionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="hrtx_InCaseOfDebtConversionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:href="hrtx-20140331.xsd#hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_PurchaseOptionUnderPrivatePlacement" xlink:href="hrtx-20140331.xsd#hrtx_PurchaseOptionUnderPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_PurchaseOptionUnderPrivatePlacement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_DebtInstrumentConversionRatioShares" xlink:href="hrtx-20140331.xsd#hrtx_DebtInstrumentConversionRatioShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_DebtInstrumentConversionRatioShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:href="hrtx-20140331.xsd#hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_BeneficialOwnershipAfterConversion" xlink:href="hrtx-20140331.xsd#hrtx_BeneficialOwnershipAfterConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_BeneficialOwnershipAfterConversion" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:href="hrtx-20140331.xsd#hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:href="hrtx-20140331.xsd#hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_PaidInKindInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/Note5StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:href="hrtx-20140331.xsd#hrtx_Note5StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="hrtx_Note5StockholdersEquityDetailsTable" xlink:href="hrtx-20140331.xsd#hrtx_Note5StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_Note5StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note5StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note5StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note5StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hrtx_Note5StockholdersEquityDetailsTable" xlink:to="dei_LegalEntityAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_PrivatePlacement2011Member" xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacement2011Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrtx_PrivatePlacement2011Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_PrivatePlacement2012Member" xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacement2012Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrtx_PrivatePlacement2012Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_JefferiesLLCMember" xlink:href="hrtx-20140331.xsd#hrtx_JefferiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="hrtx_JefferiesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_SharesAvailablePerWarrantExercised" xlink:href="hrtx-20140331.xsd#hrtx_SharesAvailablePerWarrantExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_SharesAvailablePerWarrantExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:href="hrtx-20140331.xsd#hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_LimitationOnExercisableWarrants" xlink:href="hrtx-20140331.xsd#hrtx_LimitationOnExercisableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_LimitationOnExercisableWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_EffectiveRateOfLiquidatedDamages" xlink:href="hrtx-20140331.xsd#hrtx_EffectiveRateOfLiquidatedDamages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_EffectiveRateOfLiquidatedDamages" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_PrivatePlacementCappedPenatly" xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacementCappedPenatly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_PrivatePlacementCappedPenatly" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:href="hrtx-20140331.xsd#hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://herontx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>hrtx-20140331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue May 06 22:49:29 UTC 2014 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_AssetsAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_CurrentAssetsAbstract" xlink:label="hrtx_CurrentAssetsAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CurrentAssetsAbstract" xlink:to="hrtx_CurrentAssetsAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_CurrentAssetsAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CurrentAssetsAbstract" xlink:to="hrtx_CurrentAssetsAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <label xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <label xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_CurrentLiabilitiesAbstract" xlink:label="hrtx_CurrentLiabilitiesAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CurrentLiabilitiesAbstract" xlink:to="hrtx_CurrentLiabilitiesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_CurrentLiabilitiesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CurrentLiabilitiesAbstract" xlink:to="hrtx_CurrentLiabilitiesAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <label xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <label xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible notes payable to related parties, net of discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#x2019; equity:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#x2019; equity: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <label xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <label xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#x2019; equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#x2019; equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <label xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <label xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing basic and diluted net loss per share (in Shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_OperatingActivitiesAbstract" xlink:label="hrtx_OperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_OperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_OperatingActivitiesAbstract" xlink:to="hrtx_OperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_OperatingActivitiesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_OperatingActivitiesAbstract" xlink:to="hrtx_OperatingActivitiesAbstract_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_NetIncomeLoss_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:label="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <label xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:label="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used for operating activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_InvestingActivitiesAbstract" xlink:label="hrtx_InvestingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_InvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InvestingActivitiesAbstract" xlink:to="hrtx_InvestingActivitiesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_InvestingActivitiesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InvestingActivitiesAbstract" xlink:to="hrtx_InvestingActivitiesAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used for investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_FinancingActivitiesAbstract" xlink:label="hrtx_FinancingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_FinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_FinancingActivitiesAbstract" xlink:to="hrtx_FinancingActivitiesAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_FinancingActivitiesAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities: [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_FinancingActivitiesAbstract" xlink:to="hrtx_FinancingActivitiesAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <label xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercises</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash at beginning of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash at end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <label xlink:label="us-gaap_BasisOfAccounting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <label xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" xlink:label="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Excluded From Calculation of Diluted Earnings Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" xlink:to="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Excluded From Calculation of Diluted Earnings Per Share [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" xlink:to="hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator"/>
    <label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares excluded</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_StockBasedCompensationExpenseAbstract" xlink:label="hrtx_StockBasedCompensationExpenseAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_StockBasedCompensationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_StockBasedCompensationExpenseAbstract" xlink:to="hrtx_StockBasedCompensationExpenseAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_StockBasedCompensationExpenseAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based Compensation Expense [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_StockBasedCompensationExpenseAbstract" xlink:to="hrtx_StockBasedCompensationExpenseAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator"/>
    <label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" xlink:type="locator"/>
    <label xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact on basic and diluted net loss per common share.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" xlink:to="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact on basic and diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" xlink:to="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_OptionValuationAssumptionsAbstract" xlink:label="hrtx_OptionValuationAssumptionsAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_OptionValuationAssumptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Valuation Assumptions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_OptionValuationAssumptionsAbstract" xlink:to="hrtx_OptionValuationAssumptionsAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_OptionValuationAssumptionsAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Valuation Assumptions [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_OptionValuationAssumptionsAbstract" xlink:to="hrtx_OptionValuationAssumptionsAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_OptionSummaryAbstract" xlink:label="hrtx_OptionSummaryAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_OptionSummaryAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Summary</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="hrtx_OptionSummaryAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_OptionSummaryAbstract_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Summary [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_OptionSummaryAbstract" xlink:to="hrtx_OptionSummaryAbstract_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired and forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired and forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_Note1BusinessDetailsTable" xlink:label="hrtx_Note1BusinessDetailsTable" xlink:type="locator"/>
    <label xlink:label="hrtx_Note1BusinessDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Business (Details) [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_Note1BusinessDetailsTable" xlink:to="hrtx_Note1BusinessDetailsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_Note1BusinessDetailsLineItems" xlink:label="hrtx_Note1BusinessDetailsLineItems" xlink:type="locator"/>
    <label xlink:label="hrtx_Note1BusinessDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Business (Details) [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_Note1BusinessDetailsLineItems" xlink:to="hrtx_Note1BusinessDetailsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Capital Securities, Net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt Securities [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtConversionNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:label="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:type="locator"/>
    <label xlink:label="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Convertible Notes to Related Parties (Details) [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:label="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:type="locator"/>
    <label xlink:label="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Convertible Notes to Related Parties (Details) [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:type="locator"/>
    <label xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Issuable In Connection With Private Placement1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:label="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:type="locator"/>
    <label xlink:label="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Authorized Under Private Placement Initial Closing</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:to="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_PurchaseOptionUnderPrivatePlacement" xlink:label="hrtx_PurchaseOptionUnderPrivatePlacement" xlink:type="locator"/>
    <label xlink:label="hrtx_PurchaseOptionUnderPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Option Under Private Placement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PurchaseOptionUnderPrivatePlacement" xlink:to="hrtx_PurchaseOptionUnderPrivatePlacement_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_DebtInstrumentConversionRatioShares" xlink:label="hrtx_DebtInstrumentConversionRatioShares" xlink:type="locator"/>
    <label xlink:label="hrtx_DebtInstrumentConversionRatioShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Ratio, Shares (in Shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioShares" xlink:to="hrtx_DebtInstrumentConversionRatioShares_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:type="locator"/>
    <label xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Ratio, Multiple of Principal</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_BeneficialOwnershipAfterConversion" xlink:label="hrtx_BeneficialOwnershipAfterConversion" xlink:type="locator"/>
    <label xlink:label="hrtx_BeneficialOwnershipAfterConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial Ownership After Conversion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_BeneficialOwnershipAfterConversion" xlink:to="hrtx_BeneficialOwnershipAfterConversion_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:type="locator"/>
    <label xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:type="locator"/>
    <label xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares Registered For Resale In Connection With Convertible Notes (in Shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:type="locator"/>
    <label xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator"/>
    <label xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value of Notes Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent_lbl1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible debt issuable in connection with private placement.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes authorized under private placement initial closing.</label>

    <!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqBhR1cOw37qdfT/PN3Se6viq8MEgNf1gK37o5+ZijZsLc4+wNvBpwajV6eaQx1qjwa9+whSMP+kLc8NsgnKtqDc2PLzk2yBherwevrarle1sr1GHzC4E6g8ls9RpTpiP/M3Z1PM7a4k/ich6+p8LJcOvYMgwt9LOJMXMKfpj7AKxQJz58Zjnj4Q==] CSR-->
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:to="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_PurchaseOptionUnderPrivatePlacement_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase option under private placement.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PurchaseOptionUnderPrivatePlacement" xlink:to="hrtx_PurchaseOptionUnderPrivatePlacement_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_DebtInstrumentConversionRatioShares_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares per $1,000 of principal of note.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioShares" xlink:to="hrtx_DebtInstrumentConversionRatioShares_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The multiple of principal used in calculating the number of shares converted from the notes.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_BeneficialOwnershipAfterConversion_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage amount the holder would beneficially own of the company's outstanding common stock.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_BeneficialOwnershipAfterConversion" xlink:to="hrtx_BeneficialOwnershipAfterConversion_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notice period associated with beneficial ownership percentage limitation, convertible notes.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common shares registered for resale in connection with convertible notes.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <label xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_Note5StockholdersEquityDetailsTable" xlink:label="hrtx_Note5StockholdersEquityDetailsTable" xlink:type="locator"/>
    <label xlink:label="hrtx_Note5StockholdersEquityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Stockholders' Equity (Details) [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_Note5StockholdersEquityDetailsTable" xlink:to="hrtx_Note5StockholdersEquityDetailsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_Note5StockholdersEquityDetailsLineItems" xlink:label="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:type="locator"/>
    <label xlink:label="hrtx_Note5StockholdersEquityDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Stockholders' Equity (Details) [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_Note5StockholdersEquityDetailsLineItems" xlink:to="hrtx_Note5StockholdersEquityDetailsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs (in Dollars)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_SharesAvailablePerWarrantExercised" xlink:label="hrtx_SharesAvailablePerWarrantExercised" xlink:type="locator"/>
    <label xlink:label="hrtx_SharesAvailablePerWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Available Per Warrant Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_SharesAvailablePerWarrantExercised" xlink:to="hrtx_SharesAvailablePerWarrantExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:label="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:type="locator"/>
    <label xlink:label="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Share)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:to="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_LimitationOnExercisableWarrants" xlink:label="hrtx_LimitationOnExercisableWarrants" xlink:type="locator"/>
    <label xlink:label="hrtx_LimitationOnExercisableWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limitation On Exercisable Warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_LimitationOnExercisableWarrants" xlink:to="hrtx_LimitationOnExercisableWarrants_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_EffectiveRateOfLiquidatedDamages" xlink:label="hrtx_EffectiveRateOfLiquidatedDamages" xlink:type="locator"/>
    <label xlink:label="hrtx_EffectiveRateOfLiquidatedDamages_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Rate Of Liquidated Damages</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EffectiveRateOfLiquidatedDamages" xlink:to="hrtx_EffectiveRateOfLiquidatedDamages_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacementCappedPenatly" xlink:label="hrtx_PrivatePlacementCappedPenatly" xlink:type="locator"/>
    <label xlink:label="hrtx_PrivatePlacementCappedPenatly_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Capped Penatly</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacementCappedPenatly" xlink:to="hrtx_PrivatePlacementCappedPenatly_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock (in Dollars)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises (in Dollars)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <label xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues (in Dollars)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <label xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:type="locator"/>
    <label xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised (in Dollars)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_SharesAvailablePerWarrantExercised_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of shares available to be exercised per warrant.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_SharesAvailablePerWarrantExercised" xlink:to="hrtx_SharesAvailablePerWarrantExercised_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Price Unit (1 Warrant to Purchase 0.5 shares of Common Stock)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:to="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_LimitationOnExercisableWarrants_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">There is no right to exercise the Warrants to the extent that the holder would beneficially own in excess of the stated percentage of The Company's outstanding shares of common stock.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_LimitationOnExercisableWarrants" xlink:to="hrtx_LimitationOnExercisableWarrants_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_EffectiveRateOfLiquidatedDamages_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Failure to keep the registration statement continuously effective for a designated time will result in the rated penalty of liquidated damages</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EffectiveRateOfLiquidatedDamages" xlink:to="hrtx_EffectiveRateOfLiquidatedDamages_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_PrivatePlacementCappedPenatly_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of penalty that may not exceed stated percentage of original purchase price of Private Placement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacementCappedPenatly" xlink:to="hrtx_PrivatePlacementCappedPenatly_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet_lbl0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share options (or share units) exercised during the current period, net of shares retained for cashless exercises.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtSecurityAxis" xlink:label="us-gaap_DebtSecurityAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_DebtSecurityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <label xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="us-gaap_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <label xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:type="locator"/>
    <label xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_DisclosureAxis" xlink:label="hrtx_DisclosureAxis" xlink:type="locator"/>
    <label xlink:label="hrtx_DisclosureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DisclosureAxis" xlink:to="hrtx_DisclosureAxis_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_DisclosureAxis_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DisclosureAxis" xlink:to="hrtx_DisclosureAxis_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_EmployeeStockPurchasePlan1997Member" xlink:label="hrtx_EmployeeStockPurchasePlan1997Member" xlink:type="locator"/>
    <label xlink:label="hrtx_EmployeeStockPurchasePlan1997Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 1997 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EmployeeStockPurchasePlan1997Member" xlink:to="hrtx_EmployeeStockPurchasePlan1997Member_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_EmployeeStockPurchasePlan1997Member_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 1997 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EmployeeStockPurchasePlan1997Member" xlink:to="hrtx_EmployeeStockPurchasePlan1997Member_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_EquityIncentivePlan2007Member" xlink:label="hrtx_EquityIncentivePlan2007Member" xlink:type="locator"/>
    <label xlink:label="hrtx_EquityIncentivePlan2007Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2007 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EquityIncentivePlan2007Member" xlink:to="hrtx_EquityIncentivePlan2007Member_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_EquityIncentivePlan2007Member_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2007 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EquityIncentivePlan2007Member" xlink:to="hrtx_EquityIncentivePlan2007Member_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_InCaseOfDebtConversionMember" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:type="locator"/>
    <label xlink:label="hrtx_InCaseOfDebtConversionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Case Of Debt Conversion [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InCaseOfDebtConversionMember" xlink:to="hrtx_InCaseOfDebtConversionMember_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_InCaseOfDebtConversionMember_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Case of Debt Conversion [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InCaseOfDebtConversionMember" xlink:to="hrtx_InCaseOfDebtConversionMember_lbl0" xlink:type="arc"/>
    <label xlink:label="hrtx_InCaseOfDebtConversionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">When the debt principal is converted into the underlying securities.</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InCaseOfDebtConversionMember" xlink:to="hrtx_InCaseOfDebtConversionMember_lbl1" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_InitialClosingAmountMember" xlink:label="hrtx_InitialClosingAmountMember" xlink:type="locator"/>
    <label xlink:label="hrtx_InitialClosingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Closing Amount [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InitialClosingAmountMember" xlink:to="hrtx_InitialClosingAmountMember_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_InitialClosingAmountMember_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Closing Amount [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InitialClosingAmountMember" xlink:to="hrtx_InitialClosingAmountMember_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_JefferiesLLCMember" xlink:label="hrtx_JefferiesLLCMember" xlink:type="locator"/>
    <label xlink:label="hrtx_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies LLC [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_JefferiesLLCMember" xlink:to="hrtx_JefferiesLLCMember_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_JefferiesLLCMember_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jefferies LLC [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_JefferiesLLCMember" xlink:to="hrtx_JefferiesLLCMember_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_PrincipalAmountMember" xlink:label="hrtx_PrincipalAmountMember" xlink:type="locator"/>
    <label xlink:label="hrtx_PrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Amount [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrincipalAmountMember" xlink:to="hrtx_PrincipalAmountMember_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_PrincipalAmountMember_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Amount [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrincipalAmountMember" xlink:to="hrtx_PrincipalAmountMember_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacement2011Member" xlink:label="hrtx_PrivatePlacement2011Member" xlink:type="locator"/>
    <label xlink:label="hrtx_PrivatePlacement2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2011 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacement2011Member" xlink:to="hrtx_PrivatePlacement2011Member_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_PrivatePlacement2011Member_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement 2011 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacement2011Member" xlink:to="hrtx_PrivatePlacement2011Member_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacement2012Member" xlink:label="hrtx_PrivatePlacement2012Member" xlink:type="locator"/>
    <label xlink:label="hrtx_PrivatePlacement2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2012 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacement2012Member" xlink:to="hrtx_PrivatePlacement2012Member_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_PrivatePlacement2012Member_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement 2012 [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacement2012Member" xlink:to="hrtx_PrivatePlacement2012Member_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_PurchaseOptionMember" xlink:label="hrtx_PurchaseOptionMember" xlink:type="locator"/>
    <label xlink:label="hrtx_PurchaseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PurchaseOptionMember" xlink:to="hrtx_PurchaseOptionMember_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_PurchaseOptionMember_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PurchaseOptionMember" xlink:to="hrtx_PurchaseOptionMember_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_SubjectToLimitationsMember" xlink:label="hrtx_SubjectToLimitationsMember" xlink:type="locator"/>
    <label xlink:label="hrtx_SubjectToLimitationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subject To Limitations [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_SubjectToLimitationsMember" xlink:to="hrtx_SubjectToLimitationsMember_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_SubjectToLimitationsMember_lbl0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subject To Limitations [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_SubjectToLimitationsMember" xlink:to="hrtx_SubjectToLimitationsMember_lbl0" xlink:type="arc"/>
    <loc xlink:href="hrtx-20140331.xsd#hrtx_DocumentAndEntityInformationAbstract" xlink:label="hrtx_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
    <label xlink:label="hrtx_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DocumentAndEntityInformationAbstract" xlink:to="hrtx_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc"/>
    <label xlink:label="hrtx_LimitationOnExercisableWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LimitationOnExercisableWarrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_LimitationOnExercisableWarrants" xlink:to="hrtx_LimitationOnExercisableWarrants_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_BeneficialOwnershipAfterConversion_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BeneficialOwnershipAfterConversion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_BeneficialOwnershipAfterConversion" xlink:to="hrtx_BeneficialOwnershipAfterConversion_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DebtInstrumentConversionRatioMultipleOfPrincipal</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionsExercisedNet</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_EffectiveRateOfLiquidatedDamages_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EffectiveRateOfLiquidatedDamages</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_EffectiveRateOfLiquidatedDamages" xlink:to="hrtx_EffectiveRateOfLiquidatedDamages_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ConvertibleDebtIssuableInConnectionWithPrivatePlacement1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:to="hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_PurchaseOptionUnderPrivatePlacement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PurchaseOptionUnderPrivatePlacement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PurchaseOptionUnderPrivatePlacement" xlink:to="hrtx_PurchaseOptionUnderPrivatePlacement_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_DebtInstrumentConversionRatioShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DebtInstrumentConversionRatioShares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioShares" xlink:to="hrtx_DebtInstrumentConversionRatioShares_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_SharesAvailablePerWarrantExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SharesAvailablePerWarrantExercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_SharesAvailablePerWarrantExercised" xlink:to="hrtx_SharesAvailablePerWarrantExercised_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NotesAuthorizedUnderPrivatePlacementInitialClosing</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:to="hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes_lbl1" xlink:type="arc"/>
    <label xlink:label="hrtx_PrivatePlacementCappedPenatly_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PrivatePlacementCappedPenatly</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacementCappedPenatly" xlink:to="hrtx_PrivatePlacementCappedPenatly_lbl1" xlink:type="arc"/>
    <label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <label xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_BasisOfAccounting_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:type="arc"/>
    <label xlink:label="us-gaap_OperatingExpenses_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:type="arc"/>
    <label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_UseOfEstimates_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_AssetsCurrent_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockholdersEquity_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <label xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_InterestExpense_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <label xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <label xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_PaidInKindInterest_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <label xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:type="arc"/>
    <label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <label xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <label xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_Assets_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xlink:type="arc"/>
    <label xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <label xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <label xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc"/>
    <label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Capital Securities, Net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl0" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <label xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc"/>
  </labelLink>

</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>hrtx-20140331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue May 06 22:49:29 UTC 2014 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedBalanceSheet" roleURI="http://herontx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedIncomeStatement" roleURI="http://herontx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_ConsolidatedCashFlow" roleURI="http://herontx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note1Business" roleURI="http://herontx.com/role/Note1Business"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note2BasisofPresentation" roleURI="http://herontx.com/role/Note2BasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note3AccountingPolicies" roleURI="http://herontx.com/role/Note3AccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note4ConvertibleNotestoRelatedParties" roleURI="http://herontx.com/role/Note4ConvertibleNotestoRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note5StockholdersEquity" roleURI="http://herontx.com/role/Note5StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note6IncomeTaxes" roleURI="http://herontx.com/role/Note6IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_AccountingPoliciesByPolicy" roleURI="http://herontx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note3AccountingPoliciesTables" roleURI="http://herontx.com/role/Note3AccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note5StockholdersEquityTables" roleURI="http://herontx.com/role/Note5StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_EquityExcludedFromCalculationofDilutedEarningsPerShareTable" roleURI="http://herontx.com/role/EquityExcludedFromCalculationofDilutedEarningsPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_StockbasedCompensationExpenseTable" roleURI="http://herontx.com/role/StockbasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_OptionValuationAssumptionsTable" roleURI="http://herontx.com/role/OptionValuationAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_OptionSummaryTable" roleURI="http://herontx.com/role/OptionSummaryTable"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note1BusinessDetails" roleURI="http://herontx.com/role/Note1BusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note3AccountingPoliciesDetails" roleURI="http://herontx.com/role/Note3AccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note4ConvertibleNotestoRelatedPartiesDetails" roleURI="http://herontx.com/role/Note4ConvertibleNotestoRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#hrtx_r_Note5StockholdersEquityDetails" roleURI="http://herontx.com/role/Note5StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="hrtx-20140331.xsd#DocumentAndEntityInformation" roleURI="http://herontx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAssetsAbstract" xlink:href="hrtx-20140331.xsd#hrtx_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentLiabilitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="CurrentLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="ConvertibleNotesPayableRelatedPartiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="OperatingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_OperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="OperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract" xlink:to="ChangesInOperatingAssetsAndLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="InvestingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_InvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="InvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingActivitiesAbstract" xlink:href="hrtx-20140331.xsd#hrtx_FinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="FinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note1Business">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note2BasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note3AccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note4ConvertibleNotestoRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note5StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note6IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiquidityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiquidityDisclosureTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note3AccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note5StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/EquityExcludedFromCalculationofDilutedEarningsPerShareTable">
    <loc xlink:type="locator" xlink:label="EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" xlink:href="hrtx-20140331.xsd#hrtx_EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityExcludedFromCalculationOfDilutedEarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/StockbasedCompensationExpenseTable">
    <loc xlink:type="locator" xlink:label="StockBasedCompensationExpenseAbstract" xlink:href="hrtx-20140331.xsd#hrtx_StockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="2.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0"/>
<!-- [WMV4][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTqBhR1cOw37qdfT/PN3Se6viq8MEgNf1gK37o5+ZijZsLc4+wNvBpwajV6eaQx1qjwa9+whSMP+kLc8NsgnKtqDc2PLzk2yBherwevrarle1sr1GHzC4E6g8ls9RpTpiP/M3Z1PM7a4k/ich6+p8LJcOvYMgwt9LOJ9tmuD2OzD5RsUjKe+NJtJg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" xlink:href="hrtx-20140331.xsd#hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/OptionValuationAssumptionsTable">
    <loc xlink:type="locator" xlink:label="OptionValuationAssumptionsAbstract" xlink:href="hrtx-20140331.xsd#hrtx_OptionValuationAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionValuationAssumptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionValuationAssumptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/OptionSummaryTable">
    <loc xlink:type="locator" xlink:label="OptionSummaryAbstract" xlink:href="hrtx-20140331.xsd#hrtx_OptionSummaryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionSummaryAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note1BusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="Note1BusinessDetailsTable" xlink:href="hrtx-20140331.xsd#hrtx_Note1BusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note1BusinessDetailsLineItems" xlink:href="hrtx-20140331.xsd#hrtx_Note1BusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="Note1BusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessDetailsTable" xlink:to="Note1BusinessDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note1BusinessDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note3AccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note4ConvertibleNotestoRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:href="hrtx-20140331.xsd#hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:href="hrtx-20140331.xsd#hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="Note4ConvertibleNotestoRelatedPartiesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtSecurityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtSecurityAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="InitialClosingAmountMember" xlink:href="hrtx-20140331.xsd#hrtx_InitialClosingAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="InitialClosingAmountMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOptionMember" xlink:href="hrtx-20140331.xsd#hrtx_PurchaseOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="PurchaseOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecurityAxis" xlink:to="us-gaap_MajorTypesOfDebtSecuritiesDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_NotesPayableOtherPayablesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="InCaseOfDebtConversionMember" xlink:href="hrtx-20140331.xsd#hrtx_InCaseOfDebtConversionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="InCaseOfDebtConversionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmountMember" xlink:href="hrtx-20140331.xsd#hrtx_PrincipalAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PrincipalAmountMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsTable" xlink:to="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="ConvertibleDebtIssuableInConnectionWithPrivatePlacement1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesAuthorizedUnderPrivatePlacementInitialClosing" xlink:href="hrtx-20140331.xsd#hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="NotesAuthorizedUnderPrivatePlacementInitialClosing" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOptionUnderPrivatePlacement" xlink:href="hrtx-20140331.xsd#hrtx_PurchaseOptionUnderPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="PurchaseOptionUnderPrivatePlacement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConversionRatioShares" xlink:href="hrtx-20140331.xsd#hrtx_DebtInstrumentConversionRatioShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="DebtInstrumentConversionRatioShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:href="hrtx-20140331.xsd#hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="DebtInstrumentConversionRatioMultipleOfPrincipal" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialOwnershipAfterConversion" xlink:href="hrtx-20140331.xsd#hrtx_BeneficialOwnershipAfterConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="BeneficialOwnershipAfterConversion" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:href="hrtx-20140331.xsd#hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:href="hrtx-20140331.xsd#hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_PaidInKindInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableRelatedPartiesCurrent" xlink:href="hrtx-20140331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="ConvertibleNotesPayableRelatedPartiesCurrent" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note4ConvertibleNotestoRelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/Note5StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="Note5StockholdersEquityDetailsTable" xlink:href="hrtx-20140331.xsd#hrtx_Note5StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="Note5StockholdersEquityDetailsLineItems" xlink:href="hrtx-20140331.xsd#hrtx_Note5StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="Note5StockholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacement2011Member" xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacement2011Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="PrivatePlacement2011Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacement2012Member" xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacement2012Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="PrivatePlacement2012Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsTable" xlink:to="dei_LegalEntityAxis" order="4.0"/>
    <loc xlink:type="locator" xlink:label="JefferiesLLCMember" xlink:href="hrtx-20140331.xsd#hrtx_JefferiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JefferiesLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsTable" xlink:to="Note5StockholdersEquityDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesAvailablePerWarrantExercised" xlink:href="hrtx-20140331.xsd#hrtx_SharesAvailablePerWarrantExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="SharesAvailablePerWarrantExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" xlink:href="hrtx-20140331.xsd#hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LimitationOnExercisableWarrants" xlink:href="hrtx-20140331.xsd#hrtx_LimitationOnExercisableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="LimitationOnExercisableWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveRateOfLiquidatedDamages" xlink:href="hrtx-20140331.xsd#hrtx_EffectiveRateOfLiquidatedDamages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="EffectiveRateOfLiquidatedDamages" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementCappedPenatly" xlink:href="hrtx-20140331.xsd#hrtx_PrivatePlacementCappedPenatly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="PrivatePlacementCappedPenatly" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:href="hrtx-20140331.xsd#hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercisedNet" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Note5StockholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://herontx.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="hrtx-20140331.xsd#hrtx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="6.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" order="7.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="8.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="9.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="14.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="15.0"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"GC=:&K@$``#P/```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,EUU/@S`4AN]-_`^DMP9*
M4><T8[OPXU*7.']`I8=!!FW3=G/[]Q;V$;/@EL4EGAL::,]Y'\[%"^]@M*RK
M8`'&EDJFA$4Q"4!F2I1RFI*/R4O8)X%U7`I>*0DI68$EH^'EQ6"RTF`#7RUM
M2@KG]`.E-BN@YC92&J3?R96IN?.W9DHUSV9\"C2)XQ[-E'0@7>B:'F0X>(*<
MSRL7/"_]XS6)@<J2X'%]L-%*"=>Z*C/N/"E=2+&G$FX4(E_9GK%%J>V5QR"T
M4Z'9^5U@4_?F1V-*`<&8&_?*:X]!EQ7]4F;VJ=0L.MRD@U+E>9F!4-F\]A.(
MK#;`A2T`7%U%[1K5O)1;[@/Z[6%+VX6=&:1YO[;QB1P)$HYK)!PW2#AND7#T
MD'#<(>'H(^&X1\+!8BP@6!R58;%4AL53&19395A<E6&Q58;%5QD68V58G#7!
MXJS)?SFK\]D$:'O].T+;YLC/L76K"NR9/VCKIL>4"VY`O#OC4]S9`7[V/L3A
M,\[8*&U]VC-P^A2V<:ZI#K5O!,:5L`MT7<%HI^B3XNF">\D,FBPJ0'1HTS;[
M#K\!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O
M+G)E;',@H@0"**```@``````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ
M;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].
MP[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4
M_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7<E.4]AK\>4"T\U<%J"`=[!ZH^^CSY
MLK<T36]X+^9]8I=.C$">$SO+=N5#9@NIS]NHFD++28,5\YS3$<G[(F,#GB;:
M7$_T_[8X<2)+B=!(X/,\WXIS0.OK@2Z?:*GXO<X\XJ>$X4UD^&'!Q0]47P``
M`/__`P!02P,$%``&``@````A`#B30&6&`0``V0T``!H`"`%X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<R"B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````+R7RVK#,!!%]X7^@]&^D4=YESC9E$*V;?H!PI[8)K9D)/61
MOZ\PP6D@3#=F-@9)>'0Y=S0:;78_;9-\H?.U-9F`22H2-+DM:E-FXN/P^K02
MB0_:%+JQ!C-Q1B]VV\>'S1LV.L2??%5W/HE1C,]$%4+W+*7/*VRUG]@.35PY
M6M?J$(>NE)W.3[I$J=)T(=W?&&)[$S/9%YEP^R+N?SAW<>?_8]OCL<[QQ>:?
M+9IP9POY;=W)5X@A!M6NQ)")8<K+?F4UB8J%O"\&ILQJ8$K*X88#)!UN."0;
M!<Q6*:"L6C*K65)B0#&K`47*X88#)!UN.#2;!;=5"\HJ%>\'UG*L4DH.]QDG
MCSBW4Z11P(Z&9*-F8^:-K[3#XCVXV*7X&/ARE=],4VDS'U/,T$!<A0Q3EYYB
M3HD!;C5`RE&CWN(^G)O8,5XMZL<D#NX*`W2%63/G"JPI.J,>HR%-K_X,4Y?,
MG5%BN-&09(`;#9!LU*A=1(CO*;RZU`]E_QVJKKQYD&U_`0``__\#`%!+`P04
M``8`"````"$`OB`;*:\"``"9!P``#P```'AL+W=O<FMB;V]K+GAM;)25RV[;
M,!!%]P7Z#X+VC5Z.\T#L($\TFS1HTF1)T-+8(D*1*DG5]M]G1,/VV*&+=B53
M-`_OW+FD+BX7C8S^@+%"JU&<':5Q!*K4E5"S4?SKY?[;:1Q9QU7%I58PBI=@
MX\OQUR\7<VW>)UJ_1PA0=A37SK7G26++&AINCW0+"F>FVC3<X=#,$ML:X)6M
M`5PCDSQ-ATG#A8I7A'/S+PP]G8H2;G79-:#<"F)`<H?R;2U:&X\OID+"ZZJB
MB+?M(V]0]T+&D>36W57"036*CW&HY[#SPG3M=2<DSIX5:1$GXTV13R:J8,H[
MZ5ZPO#4=_<H'>3[L_]E;\2I@;K>+^F&T>!.JTO/^KVCM<C,J4,#<3[V)RM4X
MGZ;IYMUW$+/:K5\B/B%\[R#NXY^1\N6M'6%7JF)WR@FW9`]JY;[0V,+>]0>L
M+(LC<R[PAWFHLEXXI=QH58&R4+%K+KDJ@3WWZRR[Z8P!0LES@LD/8YX==^B7
M0H2>LA\M&.X(IB`4[W=8S"[EAMN:W1/*@%`&^UH>M0.6L>O."@76DF4YW?TX
MN"Y''ZSPVI\,6*S#!XU"Z.8^"+0$OWG!KLI2=]@3-6-/6HI2X!G:=B3'KF]:
M<A+4,6#8&3RD3DPDL)YJF=/LYTY+A@1S&L0<LV>GR_=:RPJ/![O[W6%,J)(3
M@C@+(H:8JE(WP%[X8K<*O"<V563I_N*`!6RR7-FQ9%3#&>5\2NAA1U'1A'`*
M/&U;/9\BZCE!/_8Y.P?F4T@]9QLO=@N."TG;6]"CDH7S&8Q(SZ(%T;AFX;P>
MY&`1/I?^!J!!R<*9/1@X"BIH]K-P<L,6[U5&#T#V']'M':*"LIWLA`-\4!"V
M:6-1?U5OPH.#O6OR+^%!1=BG+8BF)_=I3OPD7M\EER5^5_I'WQ:_2[+^JHX_
M````__\#`%!+`P04``8`"````"$`4KP#[%`$``#4#P``&````'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;)1778^J2!!]WV3_`^%]A.93C7HS.IG=F^Q--IO=
M>Y\16R4#M*%QG/GW6TVU2+7*X`L*'$Z?^NBJKMFWCR*WWGDE,U'.;39R;8N7
MJ=ADY6YN__?OZ]/8MF2=E)LD%R6?VY]<VM\6O_\V.XGJ3>XYKRU@*.7<WM?U
M8>HX,MWS(I$C<>`EO-F*JDAJN*UVCCQ4/-DT'Q6YX[ENY!1)5MK(,*V&<(CM
M-DOYBTB/!2]K)*EXGM2@7^ZS@SRS%>D0NB*IWHZ'IU04!Z!89WE6?S:DME6D
MT^^[4E3).@>[/UB0I&?NYN:*OLC22DBQK4=`YZ#0:YLGSL0!IL5LDX$%RNU6
MQ;=S^YE-5YYK.XM9XZ"?&3_)SG]+[L7ICRK;_)65'+P-<5(16`OQIJ#?-^H1
M?.Q<??W:1.#ORMKP;7+,ZW_$Z4^>[?8UA#L$BY1AT\WG"Y<I>!1H1EZHF%*1
M@P"X6D6F4@,\DGPTOZ=L4^_GMA^-PMCU&<"M-9?U:Z8H;2L]REH4OQ#$-!62
M>)K$!_7ZO3>4Q$%!C7TO29TL9I4X69`TL*0\)"H%V12(SX:AC-;4>Y:"B8KD
M6;',[=BVP`@)X7E?1-[,>0>/IAJRO(8PBEB=$2H0H*Z5"'9W)=[V^5F)`BLE
M*@9*VA(?`'<KS5"VND:$%PA1`@X:KD2!YS:0MPN'$VKQ$B'CQF%/+`[]L>NZ
M%+.B&&\2^ET,D1=0>2J6/J1ZO\/41X#KR(Q\*F&)$+A>+*&(51^"2(1L'^Y!
M!:8>C`*Z\!(A8>-!QH*N:YKPK[J`&%Y?W$MT18_H4F!#5VCH0@CJ\B;1I+LP
M"NLBV-@/NP@B#7;5<)<IL"$M,J0A1+O,OZ&,`N[[3#4WHW1\G6[J(R/=8D,@
M0OK2K0]!?#>A$OMW@@(;OAL;TA""OGMBD7<CX;H0!B7^7L8QV)E=]_5K:]!4
M7'!)9:QT&J.3SKM53`B$^:J47%B(YYBJQIWH?B$/:W>WV`5&>5\VC'-;.\]S
M&>LNCIN"8%C0LV&9JMK#]6&-[^J+S&+<,+;Z('2,5%HM$(FT$?$D(D90#ZK*
M/5PAUOFNPO@2&AU@Q.C%:6YI>001]%05IDKV<'58X(FZJ_@BID\=0?2J>ZA/
MJ).8L7/C2P?7OD,,*+C;Q#0-&A"IK7$)`(WL0]V"7;>+V.RP&H-+3\(;QP""
M8'#\OZ?-:!?##@'LNF_$9JO5F#Z-W<X1]8DT6L<7Q07+/4D^L]\RQ.CD8\&8
MKJYW!P'%\9B4;QKBASH'NVX=L=EV-085QIXW)JU!"^PVCQ!VK\K"M@41@3#M
M/+!_&S1M'['9=C4&3Z-A',3D2((""28(P8QK@3A$X9!1\&K'5SS/I96*HQJ0
M/#BJM4_;X>W94P=VX_D2AKIF`G+:%S!3'9(=_Y%4NZR45LZW0.F.8MC<%4YE
M>%.+0S/:K$4-TU3S=P_3,X>!P!T!>"M$?;Y1XT8[CR_^!P``__\#`%!+`P04
M``8`"````"$`+)ZZ2]8"``#`!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6R4E5UOVC`4AN\G[3]8OB=?-`00H2ITW2IMTC3MX]HX3F(UCB/;E/;?
M[S@F*0DK8EP`ME^_?LXYSLGJ]D54Z)DIS66=XM`+,&(UE1FOBQ3_^ODPF6.D
M#:DS4LF:I?B5:7R[_OAA=9#J29>,&00.M4YQ:4RS]'U-2R:(]F3#:EC)I1+$
MP%`5OFX4(UF[251^%`0S7Q!>8^>P5-=XR#SGE-U+NA>L-LY$L8H8X-<E;W3G
M)N@U=H*HIWTSH5(T8+'C%3>OK2E&@BX?BUHJLJL@[I?PAM#.NQV<V0M.E=0R
M-Q[8^0[T/.:%O_#!:;W*.$1@TXX4RU-\%RZW"?;7JS8_OSD[Z)/_2)?R\%GQ
M["NO&20;RF0+L)/RR4H?,SL%F_VSW0]M`;XKE+&<["OS0QZ^,%Z4!JH=0T`V
MKF7V>L\TA82"C1?%UHG*"@#@&PEN;P8DA+RTOP>>F3+%TYD7)\$T!#G:,6T>
MN+7$B.ZUD>*/$X5'*V<2'4VF0']<CZXU\1U0&]\],62]4O*`X,[`D;HA]@:&
M2S#N`G,8?:CO10HA6I,[ZY+B!",(0D-UGM=1,EOYSY!2>M1LSC7A4+'M%+82
M@-<S0N"GC/].>H=BQ1;%%L&R;=P$>+^QC<X]5\11+QF00(9.26RVIG"9+A/9
M3:`[!4B2WM]!.LW-B28>*K:7%`-&,#EEO,QFQ2F&!/3)">/1R1NGB>=M70,O
M>,M-R[X=K$,/7`P_GR9O&P:@</.O![7B,>@XB4[3@8[R]\[B@&CV/T16/"::
M#P_=.,V1*/3BZ7!].UZ/;GK!``R>K.M39<5CL$7OZ^Z;TT#E^KI'R0@>^JGU
M>4_C^%S'=!U%,%6P+:LJC:C<VVX8P97I9_M&?1?9AW,TOX$&WK8[OU^`!MJ0
M@GTCJN"U1A7+P3+P$JBD<BW8#8QLVCZVDP9:9_NWA#<E@X<_\$"<2VFZ@6TM
M_;MW_1<``/__`P!02P,$%``&``@````A`..I@V\V`P``1@H``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3DN>&ULG%;;CMHP$'VOU'^P_+ZY00@@8+6PVK92
M*U55+\\F<8BU21S99MG]^XYM"(GI!M07(,R9DS-G)ADO[E^K$KU0(1FOESCT
M`HQHG?*,U;LE_O7SZ6Z*D52DSDC):[K$;U3B^]7'#XL#%\^RH%0A8*CE$A=*
M-7/?EVE!*R(]WM`:(CD7%5%P*7:^;`0EF4FJ2C\*@HE?$59CRS`7MW#P/&<I
M?>3IOJ*ULB2"ED2!?EFP1I[8JO06NHJ(YWUSE_*J`8HM*YEZ,Z085>G\RZ[F
M@FQ+J/LU')/TQ&TN+N@KE@HN>:X\H/.MT,N:9_[,!Z;5(F-0@;8="9HO\4,X
MWX0A]E<+8]!O1@^R\QO)@A\^"99]934%MZ%/N@-;SI\U]$NF_X)D_R+[R73@
MNT`9S<F^5#_XX3-ENT)!NV.H2!<VS]X>J4S!4:#QHE@SI;P$`?")*J9'`QPA
MK^;[P#)5+/%HXL5),`H!CK94JB>F*3%*]U+QZH\%F8I:DNA(,@+UQWAT*XEO
M!9GZ'HDBJX7@!P1#`[>4#=$C&,Z!^%28E=&6^EZE4*(F>=`LA@N*D-">EU64
M!`O_!2Q-CYBUQ208M9BPC]B<$+H3(*_5"(6[&D?0PG^;?Y*DD_J28N=^ZTM(
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MZU4=PFRT_]ICQ%H?(\Q!H`W`%F_(CGXC8L=JB4J:0VK@)?#V$/8<8"\4;\RV
MV7(%^]O\+."\1F$[!AZ`<\[5Z4+OM_8$N/H+``#__P,`4$L#!!0`!@`(````
M(0`[1:RK?0D``.)#```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)S<
M77.B3!H&X/.MVO]@>3XJ!$VTDKPUR/<W6^^[>VP,2:Q128F9S/S[[:;!V`],
MWR9SD$PZ%P_0W&F@46__^K7;#GX6AVI3[N^&VF@R'!3[=?FXV3_?#?_YV_EV
M,QQ4Q]7^<;4M]\7=\'=1#?^Z__>_;M_+PX_JI2B.`U9A7]T-7X['U\5X7*U?
MBMVJ&I6OQ9[]YJD\[%9']N/A>5R]'HK58[W0;CO6)Y/9>+?:[(>BPN)P28WR
MZ6FS+JQR_;8K]D=1Y%!L5T>V_=7+YK5JJ^W6EY3;K0X_WEZ_K<O=*ROQL-EN
MCK_KHL/!;KWPG_?E8?6P9?O]2S-6Z[9V_4.G_&ZS/I15^70<L7)CL:'=?9Z/
MYV-6Z?[V<</V@'?[X%`\W0V_:XM<GP['][=U!_UW4[Q79_\?5"_ENWO8/$:;
M?<%ZFQTG?@0>RO('I_XC;V(+CSM+._41R`Z#Q^)I];8]_J=\]XK-\\N1'>XI
MVR.^8XO'WU91K5F/LC(CL1GK<LLV@'T=[#8\&JQ'5K_J[^^;Q^/+W?!J-II>
M3ZXTQ@</175T-KSD<+!^JX[E[G\":7RC3D7TI@C[WA319B/]9JI-9Y^H<M54
M8=_;*OJG-\5HBK#O;1%M=#.=&K.;Z\MWB,FZ5]CWILH7>F76%&%_:FV1+VS*
MO*FB\6B(SM>-D69,/M.UVNDP7Y^J7%V^,6,1FCJ#UNJXNK\]E.\#]H?-RE:O
M*SY,:`N-E6[3)[)RRN.?XL@BQ*M\YV7NAFQYEK2*_0W]O->OYK?CGRSWZ\:8
M7:/)8MD*GDQ>UJ(--FUP1`/[^K%B39?+NEU#5NRU9155_-:T&Q?TE)U/Y56'
M/48645?H=`?BKB$[D'2%;DSD-:6M:7<@:QO.]MH@A?/6L(7&+#*GW+"!0LI-
M_VC5QH-K'H]VU6;;<+9J>6N773$EQ]7J$FU^+9>QA6%[<<I'QSA=HVLDO&Z/
MD=?D]0C#D(W?9V:R";JFL\5AUY"^B7J$=B6O*>X:VL5)E^C&C5PF[3&T^[(>
M0^OD?>:C`Z7TL1.,E#X^:EVQX56=0KZ4E$+:L*0-%FVP1<-YGG2#]+W3-=J<
M=)I[@?$N,/X%)KC`A%VC3\C?0-1C#)JI"TQR@4DO,%F?(0-PKC92J-@%AQ0J
M=9BXEL)$&Y:TP:(-MF@05V+\?.>T#1^CE4Y[V+W`>'V&](S?9\CH&;2F';?#
MMD&Q@5%KVH5BVI#0AI0V9+0A/VN0#AJ[OI,.VF4C`5^*C1AG9P7=(&DWA6'K
M/9TY2`\NH;"@L*%PH'"A\*#PH0B@"*&(H(BA2*!(H<B@R%5""B"[1_A"`/E2
M=T-VQCN%B]UUR^=54QA5`*&PH+"A<*!PH?"@\*$(6E'?79#."MM??G0H^6N-
MH(BA2*!(H<B@R%5"RAZ[WY*RISYC<4TR-R7=:`JCRAP4EA#3^B[P>CJI_\G1
MML^)UA":?P>NR87"@\*'(H`BA"*"(H8B@2*%(H,B5PDI?'S^D<X<X&MPOA0-
M(;GG-(51A1`*"PH;"D<($>2;OAR[YT*;W!CTDMD[!U.MYT_!/Q<WLQX1"*'H
MCA"*"(H8B@2*%(H,BEPEI/RQ:;4OY(\O1?-'[M],810=OH3"@L*&PA%"Y$_7
M10+E@=2%13PH?"@"*$(H(BAB*!(H4B@R*'*5D!+()W2_$,%Z,9I!<A]M-D@5
M0DPL3&Q,G(;<U&=TC5VHLG\DA[B*)U6YZAT+93+O65&`5Q1B$F$28Y)@DF*2
M89(KB1Q)/E][?E967Q+RIPJ=X?!CSJV>A#<;I(RBJ*,@%JYB8^*<"+\)F(S(
M-;Y[^O4?;P,\3'Q,`DQ"3"),8DP23%),,DQR)9%CR.=RSV/(IV4,=D\-XBBF
M@*7;XBDYQJ8FD")K2TPL3&Q,'$Q<3#Q,?$P"3$),(DQB3!),TH;,ZY/*U8@\
M!<EPA5Q)Y#CR6>#S.((8BDEC.89D`TU-(&4,(;%P%1L3!Q,7$P\3'Y,`DQ"3
M"),8DZ0A4W'E,A_-Q25%?5W!OES9W\BE?XJ+9ICD2B(GD^7G,\GDG%XZDDE[
M4Q-(F4Q(+%S%QL3!Q,7$P\3'),`DQ"1J2).IR6A"9B]B7"/!),4DD[=$&QES
M^5\GW;FRJ)Q+/O_]B1%33)?+(R9YY&GR%S6Q\"IS"8F%J]B8.)BXF'B8^)@$
MF(281`WYR"4Y8<6X1H))BDG6V1+R9"U7UI!CR*?"SV/(KR-G\$&_)F;0Y3B2
MK3`;I(RC:B:^>842)#9>D8.)BXF'B8])@$G8$#$SI1G&A+[6*,)%8DP23%),
M,DQR)9$3R>?':2+QM#=_:1T]<<_()(K9(&4B5=/S32(AL?&*'$S<$ZGOQ>4)
M(>_TRS_>B?L-$2F:7O?-;P:X3(A)A$F,28))BDF&2:XD<AKY;/D7TB@FV:7Q
M<4:N8TQ--1-?1VW9$'$$^YY=6+B(C8F#B8N)AXF/28!)B$F$2=R0/W=N@HND
MF&28Y$HB!Y)/GG\AD&+.70XDN3<S-=7$?!-(2"Q<Q<;$P<3%Q,/$QR3`),0D
MPB3&),$DQ23#)&^(F#[2SF>"I3SJ7WM$4R]&[K-G]!%-@U2G:TPL3&Q,'$Q<
M3+R&-&?DB7AAAGQB]W&9`),0DPB3&),$DQ23#)-<2>1,TF<TE[UF4>]Y5C.C
MSVH:I,PD?E:#J]B8.)BXF'B8^`T1LWQDUB'`RX>81)C$F"28I)ADF.1*(H>1
MG7,[)VQ\AZWSQ>@`29_4-$@,)WK].B]Y,%DV0A%7"Q,;$P<3%Q,/$Q^3`),0
MDPB3&),$DQ23#)-<2>1$TH<U%PZ//0]M9F0.S-0%$HF<3_DM)TWDN:A?ZR`#
MJRFAB*R-B8.)BXF'B8])@$F(281)C$F"28I)ADFN)'(>V:'^R@C)%Z,C)'U4
MHPLDSES&U.AYQ<NR,8K`69C8F#B8N)AXF/B8!)B$F$28Q)@DF*289)CD2B)G
MDCZ>N6Q>G+^5NY-)<L%D-N@\;_J,3)XO>Q`Y^UN8V)@XF+B8>)CXF`28A)A$
MF,28))BDF&28\(\^X)DYC\/'D1:A%!]M(-Y6OBL.S\6RV&ZKP;I\XQ];<,U>
MX7%J/7VDPG>#OQF8M)O:@KT'O-MN:0OVSN]NNZ<MV-NRN^VFOC#[ZB_U!7M7
M7M=;^H*].8^UCT\;Q#YAX77U7,2KP_-F7PVVQ1/;E<F(?P+!07Q&@_CA6+[6
M;Z)_*(_LLQ7J_[ZPS](HV+OYV*3$</!4EL?V![Z"TZ=SW/\?``#__P,`4$L#
M!!0`!@`(````(0"BTK$MA0<``&HN```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;)R:6W/B.!.&[[=J_P/%_0`RAP`5LC7@\Z%J:^L[7#M@$M<`IFQG
M,O/OMV7)#)(9O21S@:'SZ+6D;K7E'CW^]>-XZ'W/RBHO3JL^&XSZO>RT+7;Y
MZ675_^]_W"_S?J^JT],N/12G;-7_F57]OY[^_./QO2B_5:]95O=(X52M^J]U
M?5X.A]7V-3NFU:`X9R?ZR[XHCVE-/\N7874NLW37-#H>AM9H-!L>T_S4%PK+
M\AZ-8K_/MYE=;-^.V:D6(F5V2&OJ?_6:GZM6[;B]1^Z8EM_>SE^VQ?%,$L_Y
M(:]_-J+]WG&[#%Y.19D^'VC</]@DW;;:S8^._#'?ED55[.L!R0U%1[MC7@P7
M0U)Z>MSE-`(^[;TRVZ_Z7]DRL5A_^/383-#_\NR]NOK>JUZ+=Z_,=W%^RFBV
MR4_<`\]%\8VCP8Z;J/&PT]IM//!WV=ME^_3M4/]3O/M9_O):D[NG-"(^L.7N
MIYU56YI1DAE84ZZT+0[4`?KL'7,>&C0CZ8_F^I[OZM=5?SP;3!]&8T9X[SFK
M:C?GDOW>]JVJB^/_!=2,Z")B21&Z2A$V'4RLZ</\(RICJ3+YI6)]N"O4Z68\
M=&V[8@VL^91-9Q\8T$RJT+6=E=%@/IU.9O.'^Z?E0:K05:I8T\$#&RW&'Q"A
MA2H<1"YH^_)Q#['61?Q+VYG)@$U&'YD6UKJ(?VE59G=[>BABKPEE.ZW3I\>R
M>.]1?J"A5>>49QNVY-)M$(N0NX3U[Z*:PIFK?.4RJS[--@5L14OQ^Y/%V./P
M.RV?K636@J'/"\,64Y79='4T%;LE^'KBMW9:V=;@ZH2G&_RVR55/U'X$7<)B
MELJ$74;K:]02;==B85"G29--6H8:#<E)%T]1]"B>NIUF6H=PFCNDO?6Z-?P:
ML\7&ZH@V-QB5L+O$5.N_TT7&VKRX`J&!7B+!8A/U3MX=C'^#456"&P1;J$QX
M@U&)Z`:A]S>^@TG,C.)M6HJ*M_FZ'-,CRNQUWDKQNF[8Z`9;-SBZP14&U5O:
MNO5N,3-U%OU;S(/*!'<PX1U,=`<3=QFVF*O]2;J,98TNC.(Q>G8J'C-[BM.*
MIW3#1C?8NL'1#:XPB`T"SXV>;O!;P_7*T\8<M$R;.D+=$.F&6#<D5P9EDN@)
MKDS2?6'-6U'X7^<+2\LI:\'0?2\Y18O1#21L2#B0<"'A0<*'1`")$!(1)&)(
M)"9"<3QMYS[A>-YJU:>T>7&J96G/F[5@3(Z'A`T)!Q(N)#Q(^)`((!%"(A+$
MO-FF3:8C_N^2TIH]50PU$A.A.)XV.Y]P/&^E.U[;K:P%8W(\)&Q(.)!P!3$5
MTSF^,9T>U/`A$4`BA$0$B1@2B8E0',_+'/J;!=[!\%:ZX[6MX5HP)L=#PH:$
M`PD7$EY+\!>BT6"D[XC:/_]*;]HS*X!$"(D($C$D$A.A>'VA>=V\"^*T[FUM
M"M:",7D;$C8D'$BXD/`@X4,B$,1,))/)F&F;LQ`J1)"((9&8",7=C%Y)/K'*
MFV:ZX[75L9:0R?,8L3'B8,3%B(<1'R,!1D*,1!B))2(>6U0KU+8`B5%"C0%>
ML?AXIF>BT*%N[K3WP;6$C#$@=`R(C54<C+@8\3#B8R3`2(B1"",Q1A*)R#"Y
MWBFJ,<!+&]<Q8,[[O!3:2?Q:JEM+R.#8#49LC#@8<3'B8<3'2""1J=B=+P:+
M1;.A;#_&SA?M_2?$HA%&8HPD1D2-!EXVN8X&_IH_H7=%$!6BVJ)F!*U:M^9%
M:@H=8U1`Q,8J#D9<C'@8\3$2W$"LL9:QPQN0MI>*,!)C)#$B:B"0FSX3"+R9
MMCW0B\AK)B"1F<:W7F,W$C'$BHT1!R,N1CR,^!@),!)B),)(C)'$B*AAP,M$
MU_D`Y`%155+RP%A+>VO^/ZTH#T#$QBH.1ER,>!CQ,1)@))2(6!8/?%FHM9T(
M:\0828R(ZGQ>*KIV_GTU7R8J3&H0Z"4@"1D6^$8BOYT/&VLX&'$QXF'$QTB`
MD5`B,C,N)I,;06"JWXD:(+Y18D34(.!EHT\$@:@VJ4&@EX.8J235C&4C$1D$
M#YWYL%6`=0`'W\3%B(<1'R,!1D*,1!B),9(8$34$>`WI$R$@2D]J"&C[FC4S
MU:=D"`A$A``;\VVUFAAM*=(2!&B$@V_C8L3#B(^1`",A1B*,Q!A)C(@:!+RR
M=!T$8"<@"E&J\SMU(E.U2CI?(-*U;-;-B#:#*HY$I,J(:B9ZA+A8Q<.(CY$`
M(Z%$#(..L$J,D<2(*.ZW]'*AV?T-KK\'Z"4B"9GV`!BQ,>)@Q,6(AQ%?(J($
M,.4/(SW.`JP2ZBKSCDJ$56*,)$9$=?_G*H76C4KA6*\62<@8!KA2B%4<C+@8
M\3#B2T2LWR9E=<,`CBC$-XHP$F.$'[7]_0N9"`-QE%:</SQFY4NVR0Z'JK<M
MWO@Q61[O%^OE"._7"3_#IMDW;$D'`;MVERWIM%_7'M-1X%OVM;5<W]2WEG3^
MIJMC6TLZAM.U.]:23N.0?7CI*)WT/:<O69*6+_FIZAVR/0UQ-.#'3TMQ5EC\
MJ(MS<PKSN:CIC&_S]97.=&=T?&<T('A?%'7[@]_@<DK\Z5\```#__P,`4$L#
M!!0`!@`(````(0`4%S**BP,``,0,```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;)276V_B.A2%WT<Z_R'*>Q,<2`((&`VI>F:D&>GHZ%R>36+`:A)'
ML5O:?S_;WB$7IZ4I#X3@Y<7G97O';+Z^%+GSS&K)1;EUB3=S'5:F(N/E:>O^
M^\_#W=)UI*)E1G-1LJW[RJ3[=??'E\U%U(_RS)ARP*&46_>L5+7V?9F>64&E
M)RI60LM1U`55<%N??%G5C&:F4Y'[P6P6^07EI8L.ZWJ*AS@>><KN1?I4L%*A
M2<URJH!?GGDEKVY%.L6NH/7C4W67BJ("BP//N7HUIJY3I.L?IU+4])##N%_(
M@J97;W,SLB]X6@LICLH#.Q]!QV->^2L?G':;C,,(=.Q.S8Y;]QM9)R1T_=W&
M!/0?9Q?9^^S(L[C\6?/L)R\9I`WSI&?@(,2CEO[(]%?0V1_U?C`S\%?M9.Q(
MGW+UM[A\9_QT5C#=(8Q(#VR=O=XSF4*B8.,%!B,5.0#`NU-PO30@$?IBKA>>
MJ?/6G4=>&,_F!.3.@4GUP+6EZZ1/4HGB?Q01#=6:!(T)7!L3$G[:9-Z8P/5J
M$GF+((R7$U!\')9)Z9XJNMO4XN+`T@-P65&]D,D:G'4\<PCY[7A@2+K/-]W)
M=`6UA#E]W@7Q:N,_PSRDC68_UI"A(ADK@N6LU?@`V%)"<)^GU)V&E*&%L!]+
M@A;`##49*^:=R8`1TNLSWDY0BR%IU^D27':^YJ?WJ%GT-*$%=TLQ8`.3Z6Q:
MO'5AX#TV*Y8]:FZQH2(TJR.:AU&+/@"#/30=3(N'8"2:M[X8&FIN@:%B9<"6
M7@#UN/=Z!S,:8D[;);K3$#=8VKBHZ>,&R\5P2,E;FFXE#.*,AYRWUZ`6#_E(
MU(T?XT0-AK7R5M8F3["YC_\.F'Z<]LK,;3`M_@@,-;B\2#"S<DVP>0+8ZC-@
M6FR#Q</9VJ-F89;771!W>6`]N39WFZM3#*:20!6>'IE1?X36B'`V(X]8Z$G3
M/B$U8CTV;L^G45MP<5?I<:4UHB8X8A7#I&W^.#A=LB>O-8(%OE_MR)@-11@<
MB;VY50Z3QF5*<KIF3Z?#"M^G"Y;6C^\)BG`OQ$%L[X6F?0H<:#X!I]76M([J
M,4'1M=R&HS6'[?#>/FW>VQ#6LV):$=9G/0MR7(4;41]B7(;?%-FL>`[%$U9%
M3^P7K4^\E$[.CC"^F1<#3HVG4+Q1HC)GE(-0<'HT'\_P;X'!,6OF@?@HA+K>
MZ'-N^_]C]QL``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X
M;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;
MQ&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR
M&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+
M&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$Q
MS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*
MZ@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*
MWDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@
MWP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P
M&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]
MATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(N
MCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.
M'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY
M.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-Q
MOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D
M`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB
M[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9
ME^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(
MP5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N
M\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$
M6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G
M]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO.
M.UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1
M%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.
MCALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'D
MN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAF
MG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL
M+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,
M,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!
M\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A
M*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1
M[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:
M`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KI
MWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04
M\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9
M`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$W
MU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WY
MGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F
M\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`
M"````"$`BK7X9,0+```<:0``#0```'AL+W-T>6QE<RYX;6S47?MOXM@5_KU2
M_P?+TU:[4C.`,0&R(:N!Q.U(TW2UDZJ5NE5EC$F\\8/:9B;95?_WGG/].A?\
MN`;#31MU!PSWG.\\[G?/?6!??__BN<H7.XR<P)^I@_=]5;%]*U@Y_N-,_=N#
M<3%1E2@V_97I!KX]4U_M2/W^YK>_N8[B5]?^_&3;L0(B_&BF/L7QYJK7BZPG
MVS.C]\'&]N&3=1!Z9@QOP\=>M`EM<Q5A(\_M:?W^9<\S'5]-)%QYEH@0SPR?
MMYL+*_`V9NPL'=>)7YDL5?&LJX^/?A":2Q>@O@QTT\IDLS=[XCW'"H,H6,?O
M05PO6*\=R]Y'.>U->R#IYMK?>H871XH5;/UXIFKY)27YY.-JIEZJ2F+R(E@!
MB#_\9QO$W_TN^>?=']^]Z__[V^_^^:.]^M=/W^Q_]M.W:B]30V1"#.IEON_7
MBH6/$\F]U(*;ZW7@$T-``7/0U;,??/4-_`R2`<S#K]U<1[\H7TP7K@P0GA6X
M0:C$$&6PCUWQ3<].OK$P76<9.OBUM>DY[FMR6<,++#'2[WD.A`DO]A(-Y]6S
M1#2931.$P=DTQ"O4)@],,O%BO4WFSR4V<;I&S;J.\1^GBUE1;U=GNO;S8L^'
MQ^C*8T7TA(_+F6H8P"&#?A_=2@-V(F7311_TG4W9Y>ALE@V-H3'NU#(N%_?C
MA@J'1I>N;%!H?!C?GLV=W2NKLBZEX7/U`.QPW7K1@:Y;T[_'!OZ=(T_./*"=
M)F),*D?ZK.L5W/C@>':DW-M?E1\#S_31L7108]_FQF0N\;H7#Z5G_,%U'OVD
M4(BV&ZA%K=#9Q`@M3XSN%9>)SL>4_21O[3<NK[N'W]YO71J'27%B`ZO$G\N,
MKO6<+M]8=XV@'SNNF\]-AB.LWN'*S35,DV([]`UXHZ2O'UXW4+O[,*/#7M9+
MOM?P[<?0?!UHK((5:Q`%KK-"%(\+-F-(/;JXO#,6=TPO02:*HD*H82S&)Q!Z
M-Y\NND>ZF$Z[%JH9\->QT`\C_.M8J`'_6W3FTW3,UKL"F<M38@=G^/WWX^ET
M.AE<3B:3J3X<Z#IS\C+-:,=?V2\V3OH[<],^@A$@F`XGTTL-@/3U"5-U5@1#
M`#`>C2:CP533X?^L2#@]@JY].E)E1Y4@D!15@D!25-DDL]<!\Z<]!=;;)/=5
M@D!25`D"25$==\S`8^E1)0@D194@D!15MC3:85^%96;)?94@D!15@D!25#LK
M/E,&GDJ/*D$@*:H$P;FCFDVK%G=W!ELHVZ_,.JN/4UU8Q+?7Q6:-,$]=!N$*
M%GFR7;3!$.:(R;6;:]=>QS`C#9W')_PW#C;PWV40Q[`]=W.]<LS'P#==>-G+
M6F3_UK2$#4S8JYRI\9-C/8,R;GTL\4VBXE0:<M;3<3:AC_7^6!]IE\F$K2/5
MGKURMMZ^=;GNTKP$-Z)OFPTG/O1S)6DZ%&NT/8Q"&C[!%BS4+-*"#2`GLI00
M;-&%C<5^A:B-I(68C:2!H(VDA:B-T'7*.E?FR56PA;WSW0`;QJ3?3Y:&1?74
M"R3`2S*F'`1IL^_/QB8E'FULT]96X)>]OC'7\(]5QR66-K38M[.A08F5#2U$
M;>3S)HLN)SQ?ND!Z+D&RXV_NZX?!`$5)PPS/#@FF_(2K^<FFE3#=E9O;*+[$
MZL8V'9F^X]UVIJ>C*0S.ENVZGW&X_,<Z'Z%AT>OF^F5-#J3`*2$\L8'G7?`E
MK"RG+Y/1.'D#/JQJI%4V4LS-QGV]WWI+.S38T2&F@EW%%>SBW9R5$<5[MHOD
MV6S93DW$_!`&L6W%[&@3VX*IPC.LP#-(!8G@.4:_7J$?_"3LCV/TP[)0:1#!
M+U+U0W()Z^\R'_`05YK4$`*:U'5XND0`D_\,`01!!@*8J&8((#UE((!)588`
M$K1``'!JLN*8?C`@;`8Y4*@$_:=2"1R36<FI/*&55?0+^FNL-#CZ/<K-A&\A
MT0LWPYL:`$>IK*)8611#P@X]K7`!O*EQ@0&C;C=#WJ"*\Z4YA)`N8"@\`C10
MYY'NLI)P+N@L`-1[9-YA'4*2`JE(-@2`(P4""<1`TO@[H!@DC<`T&R0-P10"
M-P:?L4_02'`CI"0,@$=*KRCJA`$W8IS1#02"+(8DV:#)HDB*019'%J'09%$D
M@2"+(6DD9%$DQ2"+(TDH9%$D@0`>D<*0-!*R*))BD,6112B&LBB20)#%D"02
MPQ-39(\NFR:+J&3]=#0]:/U4>5DW+J0.JB9-$/>L>3)[2F:.$`LVER)3:?R9
MGXDG\''M5'D*0N<7F&3BS_TLN&"'*OX\-'8L>N5K:&X>[!>8BB:[0B_KZK5>
M0)*M;^PF(X^P$E.A'];75:6-\L[]<P26XQW1:#FNJS2NR^\D!K^VW9@@C1C8
MPH)L$.CK%$/G*=!1%\&>*]M-,$A*QT!"=7P/H;'Y>1O%SOJU)6'`F"U&5P8$
M#_FO!:$>A@B#E&Y&@(.XPHHGT',A.CY,1[#HH.L`'8.EZ]`TDBOI+!JD7I87
MP]WY5UUB&&S%]+R)>PJ`C<XBHR&NF`@ZJWP\Y/O6`2YD9SE:<I$XZ')X=3OP
M-'MV9\YO+GM.`/#@[*G'\D:SIQ[T<=ES8N[!8U-\OU'P=U?)X`L9WJN;?%2.
M%KB]4I?F\W17IQ5-[D^8VD]8JH8WN/?*FP1\?#'0V!/)H%<9SX9P5LXMCR\8
M"4D#B#=0GM'"X&T@.FG4]OFAD11(R$Y1F-"<.G;8YXB[B;3XLD28PAH[8%4A
MU0"N_5@H#+E+%W/C%^XWUXT+YW9Q`[C_1Q<W4#7O82'B3BB@9B+7IF*H)(<3
MI<:1J0QW9,AG-IVS_0'<6E6_-$2],LZ-Y`2"U]E2'XT=1TX-V@_(N1)BS[.,
MW?RLOBZ5B[35""G1D;"6W`15(]L\7/XW#98'C359A=\F*ZL1GK*D;X60+@9P
M(T[W_:8]I=!Z=GCB9-Q'EW?JY$<\M9/-,W;J@Q)1:IA;.)*+^#GRL8ED6BP?
MEJ^EM-@D."2R'#ZNBS2Q(#_R'<2))2-A*W]R>$]$.&\.4+M=[*Z+*EIS[E->
MD[,TB-CZ3>U(::<\!B&^:X>=+:M%\:60C\JG<*WJ87;\!`Z<D)_O\3_>RX^G
M*'@G2+AS=?_WRH7RP4*NR8L07*59;AT7;M&!YT[PZ)`%6ZB!-T\NIH<]ZF3E
MDV<-69O(@HQI*PLD)!-QK)^H+!AEV\H"]8FL(5A+9,$O&UO+@OE6*@L/^Q4V
MZI"#;7%!DU06[_N1H._ULCBR8[$%+C19!!>55<01R9G(`I/;RBKB"(&CLL#D
MMK**.`)"(DL')6UE%7&$*%!9D&YM9>5QU"%P1-9(T/>7I7'D<Q7/L(G@HK**
M./*Y.A3,52JKB".?JVAR6UQ%'$$J\9<.'[255<21YPE=D">HC44<>=^/!'V_
MRZA\QFN"&9](*6('KXB/<,5:Q$>)E")J?)8/!;,\D5+$B\]O73"_$RE%I$`>
ML4B'#\0MRF,TY+VK"WIW;JXRUN43!L<9$1CPC`-KZ\*S)P)\<@4[HXF;<\0@
M/)$O).G)MIZ5!?SD/A?$]P<<1D4$W;UL7-,WXR!\5?!<9BZ.#_I(4-R?@B#W
M$2\!"RT10'^&YWS`(T04\$OB(3Z'\4Q>&S%Y7^#=@S_2:B,&6B=H^/S#V5,;
M,=`Z$<.3*M9/(F(^^IMM'B&>2W'H%A'QR?&?[16?.;R'L487D71O;^/0S/./
M[U*:H&/N\48-N0R>(I);7V=WE4CKSWNX+T/F1#PO2OH.UM`BP/^ZC8D;L141
M@@L((D(>G!CN=I-U8DX$PA(2$<!9Z5S$#J,(ROB[&?K86[BNNY.C%185)\^A
M^E^]%#?M8'Z/\4DX['8>^7P`'+6RU^;6C1_R#V=J\?HO[#Y2D$SIMWYPO@0Q
M$S%3B]>?\`9=T(MAJ@AT\RF"FS[!O\HV=&;JKW?S\?3VSM`N)OWYY$(?VJ.+
MZ6A^>S'2%_/;6V/:U_J+_X++\+%!5_#<F2,>R\,>'P1GSP?Z5>3"PWO"U-@4
M_.?BVDPE;Q+X;&T98,,9DLR(7I0_UNCF?P```/__`P!02P,$%``&``@````A
M`&*3L*9S+@``H9,``!0```!X;"]S:&%R9613=')I;F=S+GAM;.2=W6X<R97G
M[Q?8=T@(,B0!),4/42UYNS5@DU(W[6Z)%MGN-1I[D:Q*DFE55=*55:+H*V.P
M;[!7"^P`C;F>I^A]DWZ2_?W/B8C,RJPBJ;;:WL7.>#QB56;$B1/GXW\^(NKS
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MSZ'MZ:M1WOOVP5D^JGLDQ*D@>0JYA^SNA^SWQ75W[`>;_,^SK6>;.SO=K^(0
M8>%OB\MJ.H,\",]G\[K[^(,_%;W/PA!_K$;SR2R?7L.]$?K3>_5UU?THO&G/
M9_OP^+R:]HG?&PP*!N3KH0^]8ICOB]%H_=VDNH+K15ZCG</LL*[GQ;3[0A*,
MHV):5A+=Y5N<GFO+PRMTK[^X9;K3?3W,MGR`/_0$:;]B/R<UJ_@R'^6308$4
M82_J[&$4TS#@=Y-\/BQASZ/LX7?'!]G]1]T%'TZRDXMJ7J.G]1IF9534=5;-
M+HKI55D767U9#,JSLF\:#HI!,@T[W4$C%7E=0]5O>U_G]47WLZ-I<9F7PZSX
M@$FL40@9#J,C&P0)]-&Z+YY4,P3\YF>.IAC:*990@Q9_F9>74J>U;%+,NL.]
MT=(S#/CY^JR8CK.;)EW^75S\J,Q/RU$Y*XL^!Q!<F>XZN\RO\]-13WWY?CIG
M>R,WNE0B`#BB6<FKV:2:P:XP4#:KLFDQ,HVXS'FB8%=99E:=94-,EV;M#K;(
MP1;9W0?-8EU4HR$Z_+___>=__8^?__N_&SMGU_T]=B-7R\AUQ]D;(I,X(_9-
M>[Y>3K)!?EFRC[TG!WBSN2]G6)R5@W(%]3;/<M*Z8_IR6\LTJ?B(`1KMDR4L
M)$JHS%GV!AG+M2[T\&,5K_@P*"YG&6KK#B$;YK/\8_2Q[:I[^A@HPW9'@>KM
MU]NBQJ4-+HP9P^)],:I,2;K<^ZJ8L,J1/98/Q^7$G/*L?-^38>>S%`^FM*;N
MCOA-A<4YFU;C+#P+`[O/'$Y0Q@(8%>CO?O\:"1\Q3O?S+_.Z'/B2RM%<;D*Z
MH"<SZ,IJ^=[L(?)W4(U&^;3U:<]0!C\]E]65P%;CR[FMZ_2N<_@(O8%7B=,^
M5C)[-:JN[B1.>\,_S^N9RZ+9@$$U&>!MFP7SJ18_T+"V"D!A9#G;`Q8KWR^W
M5@<%F'10FFS[QH\%!?YJ'W19;D9B':;`)S$):^XOKMBZO=989J6*T]E*4[5_
MD4_.L79L0"-8;H:-L)96]R3\!@^SW)!+J&[G5G?]1W.TB-6;2;A<ZGBZK_0G
M*C'OM4E7LRW=MW!J@Z(8!MVYRJ>&C8L/Q72`Y^ZIPN+C9N[@H<P52K7BG408
MZWA?$B!DI]?963D!<DBC5].F%X?%@$@&#&'FO>_Q3;[S678*L)],-!XV%*T$
M=G67&A\%!Z]^Z#5^,-O*UK,OYW4Y`<9T1SG`_Z'Z<U3^I/@PR[X<X9MNB$3B
M.-E!40^FI?-*"$)6Q;87D:JQ_B[?/S2#]H*:K8V??HS_&X?MDO=U,64O3H`?
M^66!:1G@N0\GH*R'BMZ*Z>@ZV]LXVLB.,%IC?(.^`]:!5[*?__:_""HN\\GU
MVL]_^S?]>57$?\UK?22R^;B:3_GK40;YN6.[?`0LNK0A!S8KMEUJRUCLH+D!
M;0T",)P/I`^388EO0KS%Y?.L%(A!RJ=E80C_R[(:7+"0"HH%#RZKT37_#`9A
M.)V?,^P(=T$T<(ECU]HV6#44+?]2M`Z+NCP7:,>&E6,)8Y%IW<)J@5DBXDSV
M#B$J)W\N!C/AJL[*:LDOAM&P$\3S_MA=3UA?S4>(Y!A3BER&@9@76\K(TVQV
M5?(/N8YA?BUJ%M^;H(_Z=/%5-L[>AYLLFN##1ZJRJZ)X5V\LRL%40?R;.1"4
M+$`<OF$[\>)WQR=OOO&7>%C_.>*_M*2]$5S*WN>C+^[5<XATJ;WWF&#_K_[Q
MUJ;^&E0CK87%DZ78TB?35V0!_)&3<LSFOBZNLK?5.)_HV[-\7+((&]@>?VQ3
MSEZ<?-NCX]>92>F3W]:7^0""\45U,7U?W'O1T@P/[O(ZVSMZM;NS^6A-8G-:
M2$*#%+,S<G@2&T9XC]K*]"$M^0!@D"DA8^%&?GD-($78>8'H"51DRO.^&N,<
M&>ZAE.WP]1]-CS3B)>IO$'!.4#8]K_30*4-EXXJ_417M_S2[*,\O^!<\GU7G
MQ018TI[2YEA.'^J27T.,)K4E+)NP-=>*&3:R-Y*\,^/`N$+`AX7%)Y`/Q37F
M/2O.SE`<,VTH^@`Q;].XYB28[9!TZK6!.&0V>4I":R;;:F$&W)W,W2YJ2AR!
M81-I.D!.FU--3"^BDIFV[JY_?;(#*V;Y>25@F>67INRKMBZP9AW$B,,1@]:R
MNF*%C,\>E@.G@-#2#;6BR@S(EQO%"H\&!!=3PEYV)1L7>F,$2BJ&&T'/9"UF
M>0FDE^#TZ#O'Y^)L9[+<LF0A5!$\086A?:E=O)-17,NN+DKA\9%!0*9/ILX,
MY4C&&;+,VBA#*#*#D)]A7V6AZNRJ1!`Q]>P5UK">GR+L^:0@X`_&#24(YE<O
MK<NLL:9SVZ*VV1U@<UU[HCSB-'SKQ?>-[*L6*ZY0Q)K,S$"(6U+M1@N%='DI
M9Y*`*T0.&=#>X%Y/>13K?'EQ#60O<SCN&!+.YEA*$C@@(J2DK"]X$CQ:30T,
MU/E9$2/[,R+$?'`=3"I6,64Z^;?E8/M&Y'"2?<NB2;0^A^4%\&;$^-KM:EJ"
M3!`(&<,#>:Z]R\M1%"K9@=<'>V8&:@RYM,'%E3=::[8=T'#?;1QO9*\JDDIR
MQCY>*X!BG1KRE0]IBI+Q!XPB3\4[F3S\J,!4O2WJ2TE\]DTQ(RRRR31!8#)$
ML;<L2M$<R:?-#:!"=DQX68Q/>9R/MFVE\'U^BE73)DE<]6*+<*C$BK8&V@EO
M#0HD1135;`)+6458E&"V&7.@)!)O($7P1\:"T!&6V?*"VVVYSWPXA#S%$&B0
MS';5,#?8L&:Y&]GWA=0Z9H$0JJMJ:CLBZ?&A-!E<@FUA2NV"8A)0#:-'9MC.
M-T.+`7?R<=/STR_NO7JE=.JF.=E?Z%+'Y$/N-"%K^7O=MS*32W1E]@)V*E<J
MH8*1HZ$T-4,;+O`-\"JP1PP4UV&1GB1]`./1405H[-'IO!R9C]"70$I0('H]
MXO&S:4XF?SXP=S$I!FRTDL.,W#Q6_C4)=!C?](?]E*A"W9I2<W,2$"VUPWYH
M,M2F@ZIF+PY-$"SMM-;>;W-^>JG9<Q-S+2RJ-80A*%JN'ASEIY@V)0&2@VEI
MS1F)A.K*)%O(F)@$V6?5T328,HKQ-@LZP+=2P%RX'N'<R08C/I4?JF?S(9(L
M"QZ(TSPB`9/9`C#1(!M`@%D)'V`D4571<C/X@)63[G+<^4RJOL_#<D>W[%9J
M:PV1C[,&JGG(=8NEP;Y3DP`S7Y8]&;%F*RIU]FFUF18DQN0763O`R&;%X&("
MFCV_7@-0!(_9$D^3%3AFOK@;P&B+S<>LR<L3TCGR.2TK(K&AY59#]+(8@9!?
MM;A6;AA)EU_,`5/$Q3)77C>0C0)(FV6ZR/'&2'98OKVP!<=Z:E[^>D@=L7A?
MO@]E%KBL_RAL^(?"=6G0/WS18+/>G/_054N-2<,C(53]5,$,)H<X4^*Y0IX%
MD)+UP*ZB<H(>BFG1ISR`-'>%"1@BT7DMIST8,>?D',5F3A(K4@&^6+0;CI?)
MP$\R`CW,MM48M4D"O=-J)"N.M1[E8Z"]`44<@TDS)4<SUD&D)=S3XH)4GX`G
MD'@LB\=`%W-&AN`/I6+.<[D'9X:%V394&]79ISVF)"4TFPS<LZ$%"1DYE/]`
M5O.I5DDVL<`6W,!8(AO9HS:XQ8)".$%]H]&NQS5![_1:%M02U`:I87][8\#\
MLQ(^A&@^0A&L'T&VWC2#G?Q`")=Z!(9%NKFW_0K4B(V`>Z6^-/-\"ART,9.?
M:&7KM6,AP2!&^,9[8J65N4G`6E2T@Y3`AU9F)JG.W9#T:XQ;!)D[/0_'5`1,
M8ZTC^%,CH+R$_1Z;UB1>+(Q9CT:6=V2WVU*-]$]`Y&FT?'I>)#?.>V4!$T@E
M$N.ND^T[-V<J,2=WIJ_!#((;04RC1`9W7O0MU#)K\:G@GB0^\?B?8I3!%!:V
MHM\QIW<G@CX5!Q"!.\V'&OV=>'=%$FG!`-\E72G)\VQX$E>$*1^!>\GJQ!R*
M8[5I8?8Z!>0&",A[RB@JV,)0"NDJ$3\.!16TW:"16;D($!,^W(H`"Z--J&`0
M/MLSP.V!G6&S#UC@F8+K[5T>&XW8W!Z3,7@?F3'\5%L>^AG^63"$[2.Y1ZH*
M(%O7E0I;`#?#V68S0F4)3V:^\4H)*P6ZF"&>8W=DT2T:.6P'%<O>'>?3=V26
MZIRV"AP$`RUNS_V=C:V,+-S_91NTW1.693;P5]-(5X#MI:$I+/]=3FH1`YZB
M*.IM9*P\B3&A-\R==:]8(I7[>E61Y:6E/@5?PO`__;BUL_;3CVD2UVMFR;.M
M=307U<L4ADT)VFJP&6@.MX-#K9I.+J%^M7IYM4WIG;?A#:N29L=ZSS)(#X\Q
M%*]5P=I]M)'M`6W(8<X`$!8(6IE:0$"5A]K_&GL#B6&HTZ*0)*H"#($L<UJ<
M*?MFDKID2I^A70/$OR+B,@FMGA+-&.J*&)C6LAI))COCAJ8]^[G8Z/P2,5*7
M942XD#6]B-_0TEC2&=+K\XJH$URK5B#22-0Y2"@!:>`Z/'%(K;*^=!JJ)\4Y
MGT&%U6_/+(/::3&PYZXBGH5]_583[>C][=VG&T^B$<5@Z$//K<7&R(WL8&Y(
M#UGQ7LEM&YP_'0,UL5\./]2NQ!AGDI4IFSBT(=65Y&G,QP3YI.9G3:&5S?%P
M/#F>><CLVO(8K&-5MG9V&YI3_X_R7M8L-@`9,:8\$--'#LK_/R3E86)89T]L
M#2:-2]9LV.Z""I53,"$LT$CP:_>SC>1SJ'IV-YF]/!5$8V\2VK==92MCTBXT
M`RD$JN?*Z:J^DLA56M!S*DV_B!!R)8.P^U^2=U[++JHKJ1LK55&O/%-Z-P!H
MDH*6"V(O$HZ.2#!E'#6>2C=6H69<.M0D:F*4O'N*`DS-/;L5?3B<\#2$,>H*
M"V]E!2UBFJNQKDV`]SX9-!@K_RY9D*MHT>B/)!Y(=MJP_S)B:"1$$+LFS63+
M5<@TG\2PL3H5NFXSM2GF*U-*.^6EUTW)*X_9=JP9VFNM@+80D7=**M`I#*9&
MM3(]2@H$\R32FL:`3GYG]L)LW+:J],N*Z%UI20^%ACG%4S?5V;?;=?:[3'""
M;6+97O#6Z#"+"%5F5"[?FRP#DY`5HI/8\-487A<,WH"U&FLZ-"WSTHLW^FED
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MMT7K[$(P'T>O1GH"=:8P#_'3C[@(AQ"6*!<'X]PJJ,<,,K8P,#..;`8K*%O*
MHVHZSPS\!?R#()B"BH!K<N^:6"NF,=="<)O<,))G:1MQ/@T]PQ32P*98QOA*
M;/7?P9JK>@ZH@&&X48IXZL_35%$[&@EL-B]X1R->/2)KU``H,U=(\B<0'E_&
MPC;!-3?6Q@!R77.U8JKZB`2,`/=>=4+Z6;W$5`94JX@>Q]YK#ZD*W92MQ&PN
MD=.6LIE>8,?O;"^DG)H:3L`/_C6E$0`P5\U'%#YE4_&F6!`H_?-\0C,>PI]J
MAS=R/8IAE`*V*^YH$H*=J+HVA^C8=YOW\]_^)TT3$Q#U"#-P25^?$NDP80P`
MWES_?1+R,S_XL&221FR\=IJH/I8:XF99KU;_\H,#=4T]!HQHA;)PQR_WS<#Q
MIP.KS_Q,R7+?L8/OD'UBJR7N1Q5I46;XO'.P9<DC-[1Z';<`Y=(W;^CMVFGY
MG"7O=@G[#J%!;E]BLQ2C=P@G)EY1ISYASY#4"$$T1J/22[71A4EB+V1INV)&
M.'CONF58I1?C_!VH/9)E.V85-NM[J__Q:;$LMY#,E(9U(YD(=M1Q5@]Q'"Y8
MRUH]GVMH$86Q>1`X64Z=)<!M('ZD_N#WT/I30AN@\U!RA.4/`]JSK3$-EA7T
M/M'.PLZ!;AH>(;%D<LBP>]./`$<K^P[E%9L=YY45BJ6]&6$3CBPX)WN'AKEL
MEG\(I%MLMJ2+UJA1_K9/22M@U,)IR%/3FE8N,E4K#3OI:%@-;H;#8P^):@?T
MY*O"0%0`DI.5&)13.O`Q\8S%VO11]%$PSZ,229A]`UU`=CY'E*2;?YX/S]U-
MYZ>$CSX@?:J64!='66S:R"[?>1K7)/PJWR'K*)=)H,-';)9'<]!#0,RF0)U@
MRTQF+!(H_SDL$2(,.GLGEC-"]&2PL-E(7[`_'$0AL0M_($6S<"%VZZ&F*2$^
M>^'MJ3#:_O$2],[B&*:CVU979RB#(89D0EEV9($O%EI-O\XP!X^B6Q:TH5KG
M`LQ^$,=8F[$8:&=V8)<R4RTD@L#A5RQ`$UX/-)D$-9%;)V*S7;C_V?;&3A/R
MSCKQKCT3/4PR_M(]G192V#VZ-F?-WEFF@"IREXH`%:Q/3DMB]]Z@6J?YY)UA
MZ+D<>8/"R)BJ'\^W*==^6'TJ/V>Y5K5:`KTEJYQ1+$>&P+;TTD)^(^)/!#6%
MO=F31SVO\S*?JE.E;@YG=$VZHA02O_&Y)DDC[_;RZ-B\&YI!+D?]9C)"`.(A
MI7E#;")T`A)3_D)?Z.^K0MT6Q7"=VO&4TEPVF5M=A=T&EUA.26D@]*>5EHE`
M0,I?T;PC(9+>19ESA-\9P@[P)-DX",<DH%KAMS"0'9OX9/3*'K57T)[^AL4`
M1-%@*C>2`FL\%I?45UC/IRHKJI6;)KZ+"J0.>E&<3T+6#8SU`T;F@SIH$K3G
MO?T=LY:27&WJ[!&3N)$9K*[\`&H0\,A;Z`KZUD[YM?3.M$9O6.-C#"N$^+22
M%G72:&R=L5W;<$5=5<\0HX2<&AMC#Z!I/6G],K38Q<P6$WG.3$6S(&.2$],\
M%Q0U<%OLPQH".<M0;0OG0V&3>U&U-9U=_82<E=GOL<GD,<EQ6E&C<J=A_0L,
MNXH@FX1AN;Z2=R=L1-._XXF00($A]I82?OHEW[;<J-P+)KYH@LUHB)^8H"GW
M:`>;9`%JQ+I^U#D0(Z3YXL3\Q;<>N;[48&[;_EFEF=[LI[]>2TQ*XJ9)6R[]
MN&T@V@+N#S=)Z^_]W,V"(>X^HW@'#.9&YT:+TA*K)8.@IK''XI"+!P",#[_!
M9RPY4=9NQT""[5&Y%SOY$5N5")/-]%CU1)HO:P76H#0F]);'7B9'3+3WULKK
M*?MIH))WL4CJ0_,/%J"BPZQ)-5FG5:^-T>3EH:>UE*3$-Y@EA?3V%JE3TO]T
M?8#DL$(Z?9+>%U4BJD$=GBWQJ%,-SW&%MJ(^<5V6OR65`M1L!W4ZV4)T;J!C
M&;P;>I[,<S90`X05C_-A.&H%S3I90WJ"D94""MV]34!+!K<U!3EQY0<,":F-
MNZE[<`Z&[1"V5TP2,6_',C=Q(7[*(:PRM8;&5!7IN8_7*D$](<3>;Z$E?6A1
MPML00AWYR>(NOPY4M6B=LEI]R4/OR1OBZR<;OXB8PXFC/Z7`J,K@#^&XI?^L
M5I#3$9VR$T<13.\E0"EA1`/(?@EP&_XTH`F#YY=R]?>?-'4.B=8Q9SIXQT9%
M1OO\$Q@T3@H.&@J7%%AVK5468M@$O5=6;F(,8^)CR6;(0LZ(:6R&WK:>((.^
MBT(@]&W/E0<%U-$!KN!.+:J*KCRM*X&*T;7[/]D#\4#_7]\NXG0S:7`+&5N$
MY9ZR\XE/E:.T_#5!CK*.3W]CY<R<W-.8UC0_")^%U*940Z?".:L*4_EGJQ@2
M$ND*H"WC)T-@<Q#GN[K9T0.EEYPM`H,6+$T),QI66'`E/$9\0S592:=M)*55
M-:(ZZ*?=XT"^%`66L4B#(8/T*!K2]<!GUHBBJPG4R"IRNO%]-$NYN3VX9:-@
M:`I93&KK`/J]THQ%;/R*@F5J2QX=;JUM[VYZI=C3U*J#76?WO547KK1XB-6T
M1(2A/VD(VS.<MY,`MJ(8T0$^B>>L&5QJ$$@T*^<KYT.Q@1.6,IXR@3#@C($S
MZL(2H*8R7,]ABH^@;*#G%YQ)P?"=4BE1`=#$4SWIB(+.RA,IL8KG&\^?_T;_
MD$RV?*=\1>+,1O:RX?WB1JH5$`%7%($<J((5_FT10S.W^LU)MU^4ERUJ23R1
M6),271&BLU@E*G0\$`;,%538\1TO_0%E3V%)ZC&8HW&C[.F6'])Q[J3FNR"T
M/EI/0O9LY0F\6(;?S)N%VE(:O"OY*R5_/(N`4JN>K)8ZBSUUE(<CO+A.5]PD
MM!O9=Y=H@_ZNJ(;KPAL&@1S89(Y>_P8]Y%0_NN^V]\XH3*.Z\]*?26BB\LS-
MJV"*B.+=^)C1U>'RI+R$/2Y_GW<RO-_'LSJ(?;@;R%Y+<4J3/B?#K%WQQQ!$
M&7?DG"1-MM.RXD&['@(V4CM#A-U+&A@>.0\\.DS+=0NSBB*&1L@X<X:V->+`
M8G\WQ^1M<P1)[LK'B%Z).H_[?SDG(`X'1W/<AO8)YJQ@:CP1YKH8!4_'HJ,*
MK"#14%2+5UI8R_@&'K50;%HY[)!4\[<.=5F+7%2)5$5>TA%PP@2VP](MJT]+
MW,AV#`E'VOIVQB%"_!838.N$",O).I.MH^G,&`0W-3F$K!*Y&4;A2PT:V4#J
MY\/BV+^BX73-\+Z/QM9A#V39S!,FFF794`;V&)Z,*DB&C_JH#M87:90[H6\C
M*#6)@-IJ(;'J1?69]^4P^8^[1V`]OC*8Y3,2:3K)BX$/=L9YOY1]#$('D#HV
MSGTX%/.O,N&BSR&G6G"L6R418N<;P@,A'ZBZLQ6.E,-9F#?USNB%6T-;EJZ4
MN2TP>"I9ITNXE#H>[W^V:^=1)"#A=IEULM$X.?Z/IG8_NA.XH;6W?&&HC$;;
M[2MLV-GT8W16O((&ST3=:65&G8)VU0+"TD+Y`D9CMXWK[EG-P+$6^7JMLKO^
MSVS]6N[]S\SA+Z9F82)?W3H+PJ/=3KD6+6-QV4OFWMIYWDR^M;.I/Q9GOZ,_
MTVR#A5+!@M@L6_?6VM;3)SZAN]Z0OYQ:S!B$_?[NVM;F,Z.Q!8$2C-2T01^:
MG!8E)IG-Q<4SWOV=M>=/;$;KMM&[]W<WMG[Z,73<M@2K`U0]M6K8KE">EGVT
M,,^BP:S=;[8:\/48:;*\2^AFN8L`7!]D+RVH_[SC/)<]8RN_J4BJG$AG7'^G
M'?/=$,GM6J5T@3ZP\%(*+3N5+KXSF!!:5LQ_*?U!?M>[L7QM_Q^DK)8WL/_\
MM__1+\XJ;_8K'B=;@H;2+K2R:"^3PXT]NS)PF#D__4BKKN4OA=[WU7JJEDX/
M8!8V6+YKX%DJ/6HMOGST]:I>7MDWOG=WC[?\9?VZ#L)LLC"YQEVR<O075&)6
M6*TR!`2BTK)]05N$/](!;/HJGGM7T`XE2\QW\*31P"V9H0TA\CDIW2F'!LB#
MI6BP'>\X.0#,N4IFEBK86MO%#LL6ZZ0FK'$?:7_Y(#UK(AC*<1E/?QRI_*88
MMVM&#@5<.;JCI\V.D9H;9L\V-E/UL*%13%F@4]!:R;N(<<2`^]O;&\_2RP_U
M==_#;VULIT=`.@D^65\KJ957#&SQMDV>HG\LK6RTEUDK4'7*O^C(5*@!B3LQ
M79!M$APT"U@@7N&V0M'";EN2J?=0B8[^IQR&+4*?M@M1JB]YC,91Z&%HFPX#
M6-5=XH7/5^LG\J*``%%Q27G:&2>UAOGT;#-+]FP)UVI0D:'IM025L$2_-;43
M&5D0K^"<J+5!Q2(@?Y^7G'`F,M*0XE<(E((#7<$.VP-K';B$]L26\%)</PUA
M2CDIL!S"(;ZU#$#X6F1#,F8]AG^+WRK2)O/"6UJI^>0XD;$'OG62$_%K6T<D
M0CNL==TY0;$PRJ?(3JS@(:NW!7O6VK,+P+NPUT.[`\D">!BAW!*=$.0;*"A;
MM7.@X^/<R+LDV9%6KGR'&5UQ.@61VFGN5Q7"M$D=\HG;R_,:ZC`-.T,8BI!X
MMT<PMU;>G$L*G,G(<\*0.2D/NV)DXID2KS_V;,^;3CALEL5[RU9*M*4Z-.,-
ML;Z^#KPW%]'\*9EJI8S<I"1Q]H4$3>^(M"OF"C430EX>[N_-S^?DV?"#,IV6
M#59FMN)^$TXN8+<1TE\<PJ<XO&7K-'IL`^=J%EJ9W7G<PHA.G)\D*;86M`0&
MD<)4T-ED1:*0'WH[5Y/QDR?26MN=)NE.MXX^W7J^`R90&!/0@/+D\35/E9]8
M44=PWDR'ZB:MVX/4-"-QON!N,$9!PCDR0`+,@01>1Q\2\``B-8Z$W5J*%KBQ
M9#VV]"Q2XE&3I1ZB`R$KP]"=I(PJ4I\Z)>/[2:X`3ZF#A]9.:_Y&*](]O;'=
MGTYFB_3?%05%"N1[A6`JT\(%392&X67C`&3R=96!ZDPNA:2OLX>F6[;3"*;?
M5*HRX*-8*=1$KLH*96Z6X^4$F88'0[>@`^36H[V.;*^Q4L0TRN_0S)>/[;Z1
MY0D/[FCW(@,I(HP6TF9V*XYDB7AXJE`Z;R)BQM**/&.3L$#R\/K.T!&?+!:'
M.$,%"H0JR\6']TFUZHH]YGX*-3U;%XX.V83MYBU'QMTT;QNH!$\4O=-0:K:V
M^60S(IEV>K?G,%V4K`4W+#>HM@NTL!Y[8AGL=A9$9`J3)<@E!2:>?K+Y/!H4
M/EDPI=(]"@9ZRP!*0GO!#>^3KL:;?50B"(.!H"7X=G]SXVD"A))AFR@R)B8\
MZX3QZB592'9T^XYX5XG:>(>2X5V"_C1]X]M[>->DHB]/][FAB6)-@HR6+]&E
M`OAC]J:+D#O9GEUAU)AP6(&7=<@T/L*(:?,"7EX$]8J\EP>:N.7@MK;=;_DU
M4K_4,2-+;$G@EW;-@>8O=*@IO,J>FD_=_N>8Q-L,F84E*516SF+5+2R?ZK!U
M-'9WFI0]^74.V1OP5,^^6C!R\U%;&[L=XRSKDI_C4`6!FBALP?+.)^Y!\.0I
M`+XH=(1"D07EQ#NM\_]1YKZXQ<,\;SP,HM5*Q&"O=NS8!;#<4G_9&U(S:O-9
M5'Z[)ZM_B0?>P/AM-6BVTJ"1H@/9J-2$2Q$?L,414P)+:E1>_D3#E1)H=3@L
M&K!G+=-]@^T,SB)-K,-/P9X"F0>X5U].*Q`G"]&RJHL-%^Z;;S.MG]V>BMC9
M>/XI3.L)DI^6H*AAG`]-`Q([I1O!51IL:4#;<D2E%,(K->8?K],(^+:=!GA=
M\<L-.SOK6\\W=W=U56K8*J:]G!;O2T>%W;,\E%#ERI>'-(Z.U2]360\XA5UN
MH.6LHX`$U3857=H1FAOY?ZBJ1O;>:=)?S0Z*?1,[SZ"\C"F5QQD*Z*VPDYVJ
M-E>_N\Y&.5>_1YY'^(TB$!_]`1OJ9]L..>99SK@NVGY.X<OY-9I!U)2IB!T;
M_?#Y,8S9"W&9Q*G5`+4B%GMDTW,/K)5E/2^A<Z7-A")/-3D26H+CT=G4%M$!
M:<+UDF&-S1U6K"T=];S3CGPJBYTLR(+INA,)?[]08+];>MR*':E/%F.N-/#F
M_T2C6;ESCFR3*HB[T#J:U#YKU/KXH[;8DFX(E2)"+F&EZUS&.[0T*63&RHKF
M!9I"I-8^!FZGQTY#\W4,M%I$A<!GT2T%5V3GDC@>Z!F67ELE9LP#LMOCHT7?
MLKWEI>#&KRQ$)IZ,]0;,MN?2<F/P8#%CNQ>X@\Y71#-Z;9&6^\]WK>S8"P"-
M!^O>IB`#'W\OP46R:30^@:IN<SIGNL:Y:@&86Q&YY,`8*[%#<"F=NZK(GHZ*
M/C&E-\00.X:0"!N?KG\9&K=*+VDSJJXY^.R[>#0/!Y(H%OBYSI?'1WYR/<4\
MEABQ,RZ1*M5[]--.-_>JSU[<[[+#V<:),ZP.NYK8EM;KC8MFD^)A!<!*F+<G
M8X>IFY8AP1.R:W9.@`$$$^QL3@K1NL3L68S9#=:1(U)-LO@=47C2NIU#DN)H
M1,AV4-'@J]+.PI(4IQ$=C3PEHP[CR;JR7JH=M_<]-B+FQ/)#;AF@95M&.1A?
M<GZ:"S&2F.%O'$=XS_?"?'1Z3FI<M%U5<@M9UM]V"FZ/M\\HDCN;6Z/.P&IV
MWGB-T]`A/*M4G!4X$*(]1P&!&ML:73Z.L"5&0*[2?NW]-698CTEJ4&=9VQN[
M/_VH%A,\3ZK^:ZV]@U3QAS5"PDKDJNVUS<>%^9R9/;65.B;*T^(TH]TFD#IL
M+.`+S=^V(0)F>LS_L.-\S8&F+RFTO5L_'I#;0:?#:QK+4^BZY7W4`*G&'/16
MV3KOV3GWP:\+N!+W/D_RVQ7OMV7];OU,)PM3UXB:3[J/_:;[P8%.N!5HTG5)
MA-;]]H\5`JT?R.K=]_/2;F5&5L`XI!]M6WN'')9M@*5XEVW`H@7J:(9V0[8J
M=@^?MG^0Q/9/UPU&_!@SG1^W:51ZL2/]46PN+HVP]MRZ_!!OD0"R?4OJ4V8H
MA6.(N5$C?ORRUB)6*HND_[*47(\>9(Z?-10O%CF6C,E2/6CDT,],M=R2>&NJ
M%8591TCXF2%.M-[5J_?D]-@K%_K9IN9T4U>ZOH\'*/=@K0Y01GBA)-^@)[N]
MQ]^F&\KWA8P@6VF+$_6O/?R3[$Q/(+\,UVH`F%*W@S<[=&G[R@US]^-(84]3
M'FY_MMM]N#<]2D/E&#2.R,!;V=AXFJL!$0^W>K\EV"([&0#E-Y]T9WRM7KFG
M]!>I-X.RP(D.JW<?:KZ[VT&0%<_?T$1$*;QYJ4_`@2XA$A]*IY(C]>$L@W&F
MA4BM4)$\C9?0N=R'\K,NEXMGP6DUI_UQQD^U\`L/Z=:=U&/L4*@UUV+36KQ1
M4U3(9+HOM*Z8I`!FWCQWU9Y4912A%;MTT'PB@JQ*SP'A(7_K%)+%97:_AHKJ
MI->&BFJD<\$U/8`^^Y$/JZ+XM4/L8O#/4&5%L$"^)(<PH"9#1]1.EIN^>+N=
MTO)J!),K&$NLYPVIC:/"HU97UH*N&MFIF`=>83+[]89%OQ]J4?"&5:6:YPU#
MYB$B4JDM4=7>YR5H;*G=BD>HP.K*:<4(J[6;'"&V<__1:;>^XOJ6^91+..=@
M,_!/2Y!"Q$1=GAM!9[$+UTN'9'94?QR5[W2"C<_LU(!6SAC-=:)6/[=+7Y37
MU(8"_[B$0JDU";3W`,VHFNS=1GG[`$*+2+I#*"AJ=YK;`_)L=_,W3EMYH1^J
MP./X;^@DRFSK6$!S-!]'$F]7"$U:)N0M(32<N0`CM8;0_TSD`E.+93?62!ZA
M3]*W9GW.@'#!1JDV]UN;CK>%W>:QN.6F^VRBN`6>)[Y&?Q1P(;"%"18M8D^(
MVB<#PSTTUN)BE](0T\3+:7K&NGL)S)K?8W.=_1!>O<$`[NM0E'AC_U![)WJ'
MPH)\P\MW&"3=M;A@IF^?_'MM/6;"#F;]6G='=)W*RWBSPA'=)N;]/V:I,H7=
M@[,?\[Y^_:6]T0OG,S]J(#G0%=<790]/9(K[J()8@$X^FBC0Q3V*]A:4ZO1'
M*WO'Q4JN#];LI_7R(S^QAZK//&[0,[-_@XR9KU_52WPG6IOL`+_5I5X%V[>0
MH!"),<^QIMM.J_!+32SR;1,$L]WZ#>9]75=Y!Z+;K&K/=A3.Y^TI+.8'U"R=
M$X*@M>R/*;K::]V1<SN+5LW665N$N[</:#QO_WYA]O"`W]0K=7G=P^4_WKSS
M-/M6G0TK?KY]\\9ON<$E_8)SN/"W`8H@V(TL-NMV]9$EZG2=,_*';^VZN=Y/
M'MZTG!^^T7WOAZ"MNO>>C1KZ9F/WNG69QYVS2W/Y+3([&VD=#&\E[%TBWXIW
MNBXD*<!#M#C]FC`XD6.%LYYE/EKX5<U#1"*>K_TF_2;T@<XYNP6V7RUNZ>(:
M/Q8UZY)R@\4&*^S'8PZ2Q%Y@8FQ<:31N$Y`[OKT>>O!U19M;DE>Z[V\_W%<3
M#N,=Q$M)>N:XNV`_<\"-B6:$5DG()S-G-TF3QXHT+=FZNH1^[[<W9*M(="'S
M.Y%MUUM6=]4[QO.['J&_7<>W;E1BNH0WTK'![NJX_0@-YP`.H*@7]QW:3P^-
MLGU0E:*&/3\$LVI5*;U[RZ9J]5R5Y*>YU[(WX,!I_!,COL)8'$Z$9LS)&9M;
MRKWJ%?K.5R^.&%]WK1*QW[*L7[I9-UFPGM"8%5$WJ9993;@"U/3B>S720JDU
MD:46^]Y&.4?WFK;_[ZQYNO<BHQ.KL.2PHUUIZ.[@BF&ZK]E^J,HXG7M7V+?Q
M3K*#)3G`SM,]*XT1;[(W_L^>";Y]C&_C;ZZ`%])6=PG_,AT=S]ZDX]M[=A"]
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M;.P;+)R,6V.LNU0[9I9#D`[Y14MN;.++0I!7F3W1$Y_]$74=B7?$+>30W^JB
MP+84MB`*`$Z=-Z20P@N6W[<W>F.'*,F&;Z@T\.L!F/+M!YR?7I;[#D9]+QT>
M8DUQSI1Y[^6U8\);-ES*IU^P]U\A6XLOUU0AL^2Y?!KD-]6:[45-IHO3S>(%
M$JV?UI[O68O&2O.3R)$ZBX@CE[J[]M(RMHJZ"34*>N>P]*D%_<!;T+OO]&5]
MGS(PNW&$%I)=[3YOM"Z)C]MLT4ZVG^M$MJ^I"P=XUC=%,L'>8-';A]4Q3_1%
M%C+?)`"+0T3QC#-RD_WMPN-*(>,D8=">VE+;KS9-TKU-;42VKU@66+7UJCUF
M?R1="X*.V8B_F!QY[[]O-U.&HN$B3(S&8DF8N;@'SI`P2+/W-R[](Y(VR)JW
M(&1[5^HV$.!IDCK\0>;[-8UNUS1/M%(Z-\G!KSX[F^D9)>5Z`U%"XEU5?+!M
M-^K75+O(<Y!>Z3[`PN[DQL-9_&5R$.#1JLS.1_#BCNFSVX+D0.2@O8NJ/U$/
MZB[_XYIEVA)W@P*#;"FKTL"MQ,H!!?%1=6G=HY%3JP#*5^#\*6&/WMMK_:`V
MUOJV5^^^C\&L+DT6=MEST[,W7*_PX*E+77>XCR;RV+K"*#\L3QIRSN4FE!BH
MCX.LOL//K'-/-3ZBD-Y=Z(-G0>VV=G?L8JR5#^SZQ5G-]X_K>O;B_P@```#_
M_P,`4$L#!!0`!@`(````(0#";;*S1`,``!0*```8````>&PO=V]R:W-H965T
M<R]S:&5E=#,N>&ULE)9=;]HP%(;O)^T_1+DOP0E)``%52=6MTB9-TSZN3>(0
MJTD<V::T_W['-H38E([>`,%OWCSGPSY9W+XTM?=,N*"L7?IH-/8]TN:LH.UV
MZ?_^]7`S]3TA<5O@FK5DZ;\2X=^N/G]:[!E_$A4AT@.'5BS]2LIN'@0BKTB#
MQ8AUI(65DO$&2[CDVT!TG.!"W]3403@>)T&#:>L;ASF_QH.5)<W)/<MW#6FE
M,>&DQA+X144[<71K\FOL&LR?=MU-SIH.+#:TIO)5F_I>D\\?MRWC>%-#W"]H
M@O.CM[XXLV]HSIE@I1R!76!`SV.>!;,`G%:+@D($*NT>)^72OT/S#"$_6"UT
M@OY0LA>#WYZHV/X+I\4WVA+(-M1)56##V).2/A;J+[@Y.+O[05?@!_<*4N)=
M+7^R_5="MY6$<L<0D0IL7KS>$Y%#1L%F%,;**6<U`,"GUU#5&I`1_**_][20
MU=*/DE&<CB,$<F]#A'R@RM+W\IV0K/EK1#JBWB0\F$1`?U@/KS4)#)".[QY+
MO%IPMO>@:>"1HL.J!=$<C(^!&8P^U$N10HC*Y$ZY:"\(0D!YGE?Q>!$\0T;S
M@V1M)*GO]1)D*[*C0A4"Z'I$B-M%C*"";^?^2*1N<HB<YZW/):%#=*Z(3Q*+
M$5(W9'R?38FA`P:IB"/[R6LCF0PEMB)[3V&A@<GU:$J\]"'NODKQQ'[PVDBF
MNLH(I:F3UFRXGJ+)J0\L*FC[ZZF4V*&*'2HCB4WOQ;$+92TGZ$(5DX]`*;$#
ME3A01F*@4!J%I\?J;9-9ZV%ZJ;E@TUR?*R5VL%('RT@,ULU;7+;@,I@:;X/#
MX_VN5V(';.J`&<E$%_$F1$XZ,WMY?*JQU5FSCT`IL0,U<Z",Q/0[9"N.'.K,
M%H2SP6:VP!`<6L-TJ;/V_P>9OLM&3$Y[2O?1^J"9F<2-1ZFS9S-7,#UM'QOQ
MC7%P!:(YN8>G1G(JS@'1:$S3A5$R=8L+XUN5XK!9XG!P[AA$,YS-\&H(WY*,
MU+7P<K93@Q=![/V_YJ5@K5X*]%CO%V`F=WA+OF.^I:WP:E+"K9`O.!ZXF>KF
M0K).#X\-DS"-]<\*WKX(S+KQ",0E8_)XH<95_SZW^@<``/__`P!02P,$%``&
M``@````A`)(TTYAB!```Q0\``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX
M;6R45TV/HS@0O:^T_P%Q[X#Y)DHR&FCU[D@[TFJU.W,FQ$E0`XXPZ73_^RU3
M;K!-3SJYA$`]/UY5N:KPZLMK4ULOM.,5:]<V6;BV1=N2[:KVL+;_^_?I(;$M
MWA?MKJA92]?V&^7VE\WOOZTNK'OF1TI["QA:OK:/?7]:.@XOC[0I^(*=:`N6
M/>N:HH?;[N#P4T>+W;"HJ1W/=2.G*:K61H9E=PL'V^^KDCZR\MS0MD>2CM9%
M#_KYL3KQ=[:FO(6N*;KG\^FA9,T)*+957?5O`ZEM->7RVZ%E7;&MP>]7$A3E
M._=P,Z-OJK)CG.W[!=`Y*'3N<^JD#C!M5KL*/!!AMSJZ7]M?R3+W7-O9K(8`
M_:CHA2O_+7YDES^Z:O=7U5*(-N1)9&#+V+.`?MN)1[#8F:U^&C+P=V?MZ+XX
MU_T_[/(GK0[''M(=@D?"L>7N[9'R$B(*-`LO%$PEJT$`_%I-);8&1*1X':Z7
M:M<?U[8?+<+8]0G`K2WE_5,E*&VK//.>-3\11"05DGB2!*Z2A'AWD_B2!*X3
MB9>$)(P^E^*@6T.4'HN^V*PZ=K%@ZX%P?BK$1B9+8!;A\2'('X<'XB+6?!6+
MAJ6`YI#3EXV7KIP72$,I(1E"8MN:(#HBGR-\,D(<D#=JA+#=KU$LTC7Z[D@_
MN)$A)!Y2)?S*E0>:``B,*N!Z<`08@JAX[GO&BQ$2*)!01^37$)HT(+E=F@"O
M;?!R3(KOZR_.$)(,20WC(#:%J?;8\Y)X7*_)@MI09=VVK<0B0UXPTF/*$!+B
MGO,B([`YFH/!'/G)N%C3%NG:KF=3@`U-1D@RA*"F,(W]*22#YERUQU[J3>LU
M65`K:LBNRQ)@0U8T>HNA0H@,5>H9YEPS)\D424V4&(-*>[@N2H`-448L,H1@
M@HA9D/FOK)JD]!Y)`FQ(FG8%Q@DA&*?(BU.C(G+5'H>IDEY-%H&N>7NH!K31
M)68M5#"N;:BXL5RGK8-;2])\#-'E&8W^>B8)-F>U4P1F]Y08#)P?N6;<-#OQ
MHJF4=6&BZ=Z\Q0BV:$W8-#4PH1(C=WY$C#V8:_8`1OE8.+HPT8,58;?U,(*=
M6Q,XU984B!@42(@2&9E5S>[^JF$0T8L5@9^D%#NW)FSR7`I##`J+_61*F12F
MVJ,TG1S3(V=T_T^$8=,&G\=M'A@OSL07VV>E<`VBR[MK`)#Y!`B,,LPD!MN:
MYQN%G!OF:3_JLNX:`&0^`0*CQ6<2(RN4D#`V>E^N(]Q81>CB[AH$9#X)@LEK
MN=<0@^(>O#`*W)DZ'>(G23PU(5W>74.!S*="8+P[DQB4%X:!.TNJ.A>B)%4V
MA28-#C=:E=[61H95^N`*#`69Q."WVD>32P-\-+KPU(3G@89V!YK3NN96R<[B
M1.3!9]3X%$]K&5G"5S.<DHSGN3C%B>?.:(!#U*DXT.]%=ZA:;M5T#Y3N(H8R
M[?`8AC<].PV?Z5O6P_%I^'N$XS*%[W%W`>`]8_W[C7C!>`#?_`\``/__`P!0
M2P,$%``&``@````A`-<`S#[&`P``F@T``!@```!X;"]W;W)K<VAE971S+W-H
M965T,2YX;6R4EUUOHS@4AN]7FO^`?%_`Y*N)0D8-57='VI%6.Q][[8"36`7,
M8*=I__T<8P+8;KKD)@G)R^O'Y\.<K#^_%KGW0FO!>!DC[(?(HV7*,U8>8O3C
M^]/=/?*$)&5&<E[2&+U1@3YO/OVQ/O/Z61PIE1XXE")&1RFK51"(]$@+(GQ>
MT1)^V?.Z(!(NZT,@JIJ2K+FIR(,H#.=!05B)M,.J'N/!]WN6TD>>G@I:2FU2
MTYQ(X!='5HF+6Y&.L2M(_7RJ[E)>5&"Q8SF3;XTI\HIT]>50\IKL<MCW*YZ2
M].+=7#CV!4MK+OA>^F`7:%!WS\M@&8#39ITQV($*NU?3?8P>\"K!<Q1LUDV`
M?C)Z%H//GCCR\Y\UR_YF)85H0YXDV7VC.4TES2!SR%,9V7'^K&[]`E^%L(AH
M!&H1\>NRS$.D5@FZ98:?+TL^-6G[I_8RNB>G7/[+SW]1=CA*6&D&85#16&5O
MCU2DD`98RX]FRC7E.5C`JU<P54\01O*JZ5@FCS&:S/W9(IQ@D'L[*N034Y;(
M2T]"\N(_+<*ME3:)6A-X/[<FH7\_FTWG]XOQ+I/6!=Y;%QSY>!K._Y\DT+MJ
M`O9()-FL:W[VH%R!6U1$%3]>@>_[48%P*.V#$L=H`7F+D8#4O&S"=?`"P4];
MQ58KX+538%.17!0J?\#0@4!HQH,HL0)1Z5)D6_W%<-W(6M=53#J%`0)1&(*H
M>IE`J7X<&743Z`;[GG;NFE`KI@/%S%0D'RD,0C`9$GY,IL0Q@MUW&9F;ZVZU
M8DBV,!6)J^C9#3*HY?%D2FR2W9OK;K5B2+8T%8FKN$(VOX5,B4TR;!>ZE@S1
ML%WIKN0*&S34,&KC*D[=9#%:);_5DB%C#]`49:(5LZ:5H\DRQ--EGWLCL^H9
M.OJ<4&*+K6\VW0Y:,F3#5L<DKJ3'-]B6M[`IL<76VVHV+3'8K)Y)7$EO8K!A
M.#K&!ZY16W1]0C1=JS'PK,9)WM%<XU/G\>C$8GUZ#T\3;+7DMM4,^2*K>Y)W
M--?XU+D]GD^?\D.^R&K++=8:@\_JG.0=S34^=6J/Y]-GO,%G=P9VGP-N_%S-
M-3[8YPU\2FW67V2UY19KS;PY-*9X$5D%D+2"88"OP=WTO%!3FPW7&[?-X3X0
M(KMW6Y\Q?#<]-6#T=?B<YG4?"I'3O*ZFWZ8^7/3DJP>Y@M8'FM`\%U[*3VJ2
MQ9":[MMN-&]GYNX'&'(K<J!?27U@I?!RNH=;0U_-H[4>D_6%Y%4S)NZXA/&V
M^7B$_T`4QJ[0!_&><WFY4$-=]Z]J\QL``/__`P!02P,$%``&``@````A`,R2
MN5`9`P``-0H``!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULE%9;;YLP
M&'V?M/]@^;U<<U>2JDG5K=(F3=,NSPX8L`H8V4[3_OM]Q@G!9'73EP3P\?'Y
MSC'^6-Z^5"5ZID(R7J]PZ`48T3KA*:OS%?[]Z^%FAI%4I$Y)R6NZPJ]4XMOU
MYT_+`Q=/LJ!4(6"HY0H72C4+WY=)02LB/=[0&D8R+BJBX%;DOFP$)6D[J2K]
M*`@F?D58C0W#0ES#P;.,)?2>)_N*ULJ0"%H2!?IEP1IY8JN2:^@J(I[VS4W"
MJP8H=JQDZK4EQ:A*%H]YS079E5#W2S@BR8F[O;F@KU@BN.29\H#.-T(O:Y[[
M<Q^8ULN4007:=B1HML)WX6(;AMA?+UN#_C!ZD+UK)`M^^")8^HW5%-R&G'0"
M.\Z?-/0QU8]@LG\Q^Z%-X(=`*<W(OE0_^>$K97FA(.XQ5*0+6Z2O]U0FX"C0
M>-%8,R6\!`'PBRJFMP8X0E[:_P-+5;'"\<0;3X,X!#C:4:D>F*;$*-E+Q:N_
M!M16U)%$1Y(8U!_'HVM)?".HK>^>*+)>"GY`L&E@2=D0O07#!1"?"C,RNE+?
MJA1*U"1WFJ7E@B(DQ/.\CH+QTG\&2Y,C9F,P4XPZ3&@CMB>$3@+D=1JA\*'&
M&"+\O_DG27J2+2D.[/4VEY#(1FPO$>,SQ-((WO4UNK5I\`H#>6=%%$SLI3<&
M,^IA!H9N70A+&Y#TM>F,1V]NWI-_>A)LT][Z43`=:#08ET87PM((>OH:W?YI
M\-"_V4";P8S;S3B-IK$]O.T/CT:3\U:T5$T^HDJ#AZKF]K(;@W$YYD)8VN!-
MZCMV7:IZTGNI&HQ+HPMA:=3]KW>ZN%/5X*%_PU0-QJ0:SZ+A*]$?'@5OO:OS
MCZC2X(&J<'B0&(S+,1?"<BR$@ZUOV76QMK/>R_4(<LET0FR=@\;ACA9Z\X6+
MP3#;(\B$.XEGPW#M\2`\GYA&F>G>IKM55.1T2\M2HH3O=6<.X23HGIJOAHW^
M:FC[?C<`3;LA.?U.1,YJB4J:P=3`F\)Q(4S;-S>*-VUSV7$%[;J]+.#SC$(S
M##P`9YRKTXUN9]T'W_H?````__\#`%!+`P04``8`"````"$`:QM54JL#``!]
M#```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R4EUUOHS@4AN]7FO^`
MN"_?!(*2C)H`NR/-2*/5SLRU`TYB%3#"3M/^^SW&@8*I0M*+$$X?O_B\QSXX
MJZ]O9:&]XH816JUUV[!T#5<9S4EU7.N__DN?0EUC'%4Y*FB%U_H[9OK7S9>_
M5A?:O+`3QEP#A8JM]1/G=62:+#OA$C&#UKB"_QQH4R(.M\W19'6#4=X.*@O3
ML:R%62)2Z5(A:N[1H(<#R7!,LW.)*RY%&EP@#O-G)U*S3JW,[I$K4?-RKI\R
M6M8@L2<%X>^MJ*Z56?3M6-$&[0O(^\WV4-9IMS<3^9)D#67TP`V0,^5$ISDO
MS:4)2IM53B`#8;O6X,-:?[:C--3-S:KUYS?!%S;XKK$3O?S=D/P[J3"8#642
M!=A3^B+0;[D(P6!S,CIM"_"ST7)\0.>"_TLO_V!R/'&HM@\)B;RB_#W&+`-#
M0<9P?*&4T0(F`)]:2<3*`$/06WN]D)R?UKJ[,/S`<FW`M3UF/"5"4M>R,^.T
M_",A^RHE19RK"%RO(O;"\!P_"!]1<:\J<.U47".PK:4;W#\5[RH"UT[$>3@?
M>%QK"EP_1)S0M_W%`ZXLKBIPO:HXGF%[UAT:IJQ26_08<;19-?2BP4:".K`:
MB6UI1Z#[>96AO()]%O!:#W0-"LA@9;YN[*6[,E]A.6579BL9^!PPWIC9=8Q8
M/4(X5@.)&DB[P%#6[V5-R*9/"1;-_2D)6*34367;!3X>Y-K]<]K9[J:(,R;B
M*>$K2#)%[.5B+)-*!E(?>!GTS"AI6./W)RW@4=)J8*<&8C60J(%4!L:3#3^?
M+.RE^R<K8&@B(Q.6O6Y;D:UDX+,WZF-MR)K-$O$LD<P2Z2UB5"YH!$,'1)-U
MH57?WGYBT%J'1=%G":]&Q0G)P#QZ1G5BEHAGB6262#M"-`GG8Y(C$Z#?/&Z"
M&*2:H&S0K63"MD,].6X8!A;\C9W:C2%_X5GA!(HE=,/.9)9(;Q$C/Z"Q/NZ'
M&*3ZH?2:K61\V;%=WQ-NJ'9(YD:F\2R1S!+I+6+DA3A-#MY+]VT0,4CU0GT_
M24:NC<!QVJ6AK(PAX@=>X$_<BH>(YX/.!$F&B._ZUF*"P#%.S/=SSZ4;\I@F
MW]@E;HYXAXN":1D]BR.8J&@?[4^'SZYXFRGQK1-M/XOOG`B:_92/G0AZ_C2>
M.!&T?HB;_0/@]%>C(_Z!FB.IF%;@`TS-,L09JY'G1WG#:=V>-_:4P[FO_7J"
M8SZ&`X!E`'R@E'<WX@']#X?-_P```/__`P!02P,$%``&``@````A`/ZWQ!#&
M`P``7`X``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R45]N.FS`0?:_4
M?T"\;PCD2I1DE>UJVY5:J:IZ>7;`2:P%C&QGL_OWG;$)BX$D\!*%83S'9V9\
M/"SOW]+$>:5",IZM7'\P=!V:13QFV7[E_OG]=#=W':E(%I.$9W3EOE/IWJ\_
M?UJ>N'B1!TJ5`Q$RN7(/2N4+SY/1@:9$#GA.,WBSXR(E"A[%WI.YH"36B]+$
M"X;#J9<2EKDFPD)TB<%W.Q;11QX=4YHI$T30A"C8OSRP7)ZCI5&7<"D1+\?\
M+N)I#B&V+&'J70=UG31:/.\S+L@V`=YO_IA$Y]CZH1$^99'@DN_4`,)Y9J--
MSJ$7>A!IO8P9,,"T.X+N5N[&7SP$,]=;+W6"_C)ZDI7_CCSPTU?!XN\LHY!M
MJ!-68,OY"[H^QVB"Q5YC]9.NP$_AQ'1'CHGZQ4_?*-L?%)1[`HR0V")^?Z0R
M@HQ"F$$PP4@13V`#\.ND#%L#,D+>5FX`P"Q6AY4[F@XFL^'(!W=G2Z5Z8AC2
M=:*C5#S]9YQ\O2D32V_MD2BR7@I^<J#>X"US@MWC+R!P^UY@$^B[0>>5.W,=
M@)&0P-?U;+[T7H%S5+@\&!?X+5W\TL,#S!(8P+H#HS,"8U)P)P_&4(4)VF%&
M?6#0&;):V?PL+,,:8.,RKKA,2@^+'[ATYX?.4($J\GQ8QC7(QJ<#,C1#=V1T
MULAE:@M+-;?S"S6<]D%"9QO)6,:Z/ZNM`0U6)6#.R6@P@YU=[T]<:$,4%FB7
MLA_G%SH%9;;S24!G&\E8FF1".RR2&8W!^3H37&7'+RP6DU'9(E;K^2!-W:EH
M;QNK,#7)^'B\*TG2I9F%J%<W".F5-10,!B:+TO@")3SP%>#KV<.0M?05IA9*
M>*(KD9'2=#RX3<@H`9S9\N3@^6T0NB`/?B]]T-ZU[)WU`.#MZN,!KA'R@WF7
M&N'*&DIALFHTO5"C7G+@-_6@,+74J$41@A`2<*,-FGK@MPG"[`*?7HK@-R6A
M,+7P:1$%/[PI"GY3%<XFJSX?=[+5&$$O6=#>=C,4IB:?H$T6QF"\7A^]K`;1
MI@D?=[#-IY<F!$U-*$PM?&J:<(-&4PF"P@1LRGLG_+C0;1J]E"`PQ[XJ.X6I
MA4:;$G0H2U,&4-_KRA9>&`J"7C*@O6L]<&DN@.&\J6R3+H.!7EE#:5&"L#X:
MF%G>#,PI%7OZA2:)=")^Q#D]@!&XM);?$)L`;X2Z?;S8P"90J\LW,-OG9$]_
M$+%GF702NH.80SWF"/-U8!X4SV'K,.%S!5.]_GN`KS@*<_`0[ZD=Y^K\@`#E
M=^'Z/P```/__`P!02P,$%``&``@````A`)[DZ8>.`@``A`8``!@```!X;"]W
M;W)K<VAE971S+W-H965T-BYX;6R455UOFS`4?9^T_V#YO1@(20H*J=)5W2JM
MTC3MX]DQ!JQBC&RG:?_]KG%BT;6;Z(O!E^-S[J?97#W)#CUR;83J2YQ$,4:\
M9ZH2?5/BGS]N+RXQ,I;V%>U4STO\S`V^VG[\L#DJ_6!:SBT"AMZ4N+5V*`@Q
MK.62FD@-O(<OM=*26MCJAIA!<UJ-AV1'TCA>$4E%CSU#H>=PJ+H6C-\H=I"\
MMYY$\XY:\-^T8C!G-LGFT$FJ'P[#!5-R`(J]Z(1]'DDQDJRX:WJEZ;Z#N)^2
MC+(S][AY12\%T\JHVD9`1[RCKV/.24Z`:;NI!$3@THXTKTN\2XKK-2;;S9B?
M7X(?S>0=F58=/VM1?14]AV1#F5P!]DH]..A=Y4QPF+PZ?3L6X)M&%:_IH;/?
MU?$+%TUKH=I+",C%553/-]PP2"C01.G2,3'5@0.P(BE<9T!"Z-/X/(K*MB5.
M\RA+E^O+!/!HSXV]%8X3(W8P5LG?'I6<N#Q+>F*!YXEEL8J6ZW@Q@X1XC\8`
M;ZBEVXU61P1-`Y)FH*X%DP*(WXX(0G'8G0.7>(T1^&J@"H_;?+$ACY`Y=H)<
M>PBL`9($!`'-(`QB\X4=V`F[U#I/KKUA*I.^+;-XCXP#EQC6X/PZ#[1>V$.R
M"609$"_B`\C\^!P8*C!5SK/`ZY4]9H8R=-1\90<>E4-J3Y9I;O-_Q+AZCY(#
MOU3REFP<O6EK0(--`W#3EL5Y!/#_MZ<[]U+A9(%N"17-5R&OOEY^ZOU02*X;
M_HEWG4%,'=Q$I]#FP1HNFUWJG/[;GA6[L45)^`"7P$`;?D]U(WJ#.EX#91RM
M(<?:7R-^8]4`CL--H"Q,__C:PFW/H=7C","U4O:\`6$2_A_;/P```/__`P!0
M2P,$%``&``@````A`"QD&.?Y"```R2P``!@```!X;"]W;W)K<VAE971S+W-H
M965T-RYX;6RLFE]OJSH6Q=]'FN\0Y?TV@?QI&K6]:@!CHQEI='5GYCDGH4UT
MDE`%>GK.MY]MC,';B^DI5^>E:7[>WK"7C5DXW/_^_7P:?<NOY;&X/(R#F^EX
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M'U\.%0WW@BK2A:WW/^*\W)&BE.8F7.A,N^)$)T!_1^>CGAJDR/;[PSBD`Q_W
MU>%A/%O>+&ZGLX#"1U_RLA)'G7(\VKV557'^KPD*FE0FR:Q),F^3A-,NR0<=
MZ1#UT>FS.7HPO5DM%O/EZI;8!SV734^:QTW/3Q[RKNE(GP,/&=#@U&>K__G4
M02=&['KLXFVU?;R_%N\CNB!(SO)UJR^O8*VSV5$S!;?C^/^&D<9/9WG2:1[&
MM^,1C5!)<^_;X]WM_>0;39==$[+!D(!'1#9"SPV=-?9!X@/A@]0'T@?*!YD#
M)J1**PU-Q%\AC4ZCI;%5;2SHM`H](6R$[1+[(/&!\$'J`^D#Y8/,`4P(NJA^
MA1`Z#5W4[AQ9\<(W)B1TY]&"AT1M2"L.D`2(`)("D4`4D,PE3"-:<'Z%1CH-
M78ITF.Y"NN,*;$S,AR*U(:U(0!(@`D@*1`)10#*7,)%H(64B]=\:[)JBHVLM
M;!$;0T)::5MU@NF4RQ.U0;9;#"0!(H"D0"00!21S":N=;A,#:M?1O'9#:-1M
M61&0&$@"1`!)@4@@"DCF$E8H7;P#"M71O%!#O$'V;Q5MD%4C!I(`$4!2(!*(
M`I*YA-6NO:Q[-_UX@NMH7KLA[B`#B8$D0`20%(@$HH!D+F&%DF=AA6K;L*`;
MZ4#;H--P!0P)Z<.YQ/W[8QO4CCZ0!(@`D@*10!20S"5,%.V?F"H?#W\=SJMO
MD#L!$,6($D0"48I((E*(,H9XS=H]?7[*!\9LT0W.#MVF0=X%/_-6]2[*=HP1
M)8@$HA211*0090QQ&;1W&B"#L5I,!H/8T`.*`T`)(H$H1201*4090[QF;8;<
MFO4B$"YNZ!8X<!G0?L=;!QKD+01S?U8T?NRNG4YQU]%.E`210)0BDH@4HHPA
MKI!V0JY"/UD0C'&B?/;4-X'KI>J'H@A1C"A!)!"EB"0BA2ACB->L'="`FHUA
M8C6W'LJ]!_C/`7IK@>8,+1M6K!A1@D@@2A%)1`I1QA"70?NC`3(8.\5D<!U6
M,_2`X@!0@D@@2A%)1`I1QA"O6?LBMV:](,Q6>KMG\(I@+!;3HW%==/MUK,'2
M7Q':J&Y:`$H"0`)1BD@B4H@RAKA$VE&Y$OUD13`&C,G@>K)F6@"*`T`)(H$H
M1201*4090[QF;9C<FO_Z?<)8+R9'Z\;<6>'M/45!&]7-"D`)1@E$*2*)2"'*
M&&(*A<.,8QW.C6.#7/>`*$:4(!*(4D02D4*4,<1K'F8<0S2.#?(L@K>E%'51
M[=`C2A`)1"DBB4@ARACB,FA#YUX<'R\(H?%_[A70(#;TX!)CC$H0"40I(HE(
M(<H8XC7W&<=@<:,WVJO#<?=U4]`*3P/>H\6,-I?K5>\I1--HT;SU!!&BN$'Z
MKN3<2+Q=MJ2+LO-&($H1240*4=8@\E&4GJOCFT:]7`Y7![UDV"!7'4!Q$Q4N
MZUW\<!IXGCOI`CIA($V*!Y-=1_W[`&7VGO%4%V`S9RP-ETG[OP$7C@[WULP&
MF1^C]`\.D9X3.JI#,:($D4"4(I*(%**,(5ZS-GL#:C;>D"T6#:*/;NX'_A8J
M#7XM0[?9&"-*+%K5,^4VO/7&4]B`[NDLM:C++!$IBTSF^7SI;?]E-J#.S"72
MSFZ`1,8(,HD:;TCW9$<B[PPB6F[KQP_S\V/]:Q6BQ**PEFBV"KVG&&$#ND>^
MU*(NLT2D+#*9Y].%MT>6V8`Z,Y=(>T-7HMJ/+6N;WK/BTG1LEUSC*IE:C=&D
M%<!1RSN92&_NZ.NJ&_8846*1&?;E;`5J-6G<"069I4W3'4Q9U&2>!MYC0V8#
M>B:4]HFN6C^1R-A*)E'C-+OSB;1GT0^O'8H1)8@$HA211*0090RQ&3(;YD?K
M<+ZV-DC+ZDP+;X&(NBB[X,>($D0"48I((E*(,H:X#,,LZ@PM:H.<<8X0Q8@2
M1`)1BD@B4H@RAGC-OA_]RP]K,[2J#=**.[/",QA1%]7-"I.+.EJ48)1`E"*2
MB!2BC"&ND.]>/UX09FA3&\1FA8ER4(Q1"2*!*$4D$2E$&4.\9FWP/K\(SAH_
MV-W5-@WR%@1O@8^Z*#O.,:($D4"4(I*(%**,(2[#,,\Y0\_9(&><(T0QH@21
M0)0BDH@4HHPA7K/V@@.&OK&.[M`;Y%WUWATXHE?3]"W1N<1C1`DB@2A%)!$I
M1/K]N.XDC`SF?3?SSM0YO[[D47XZE:-=\:;?92/='N];;%ZTV\R6]DT[:)E2
M2[V(08M^.Z^V?-`24DNH%SYHF5%++32TS*FE?LZ#E@6UU(\W?DNP6NM-O)[C
M!'?44CLCOT](]=`63T^?D.JA78^^%JJ']@;Z6N@X9$IZ6@+J0S]$];60!L9L
M^><6D`;F\1I:2`/SB`<M-'*TO]UWG%MJJ>V:WX>Z]/:@#KWQ)'.ORE1\?^VD
M,?W^VG=.I#'])(DMM,6QUIL.?2WSM7Z"QQ9Z/*<^?2WTXNA3O_9T^)Y,&SW`
M?5Q/UQ[^-%\_T86'I[2A$>P[H0V-7SV%)^U8T(NDK]N7_)_;Z\OQ4HY.^3-=
MG--Z1^EJ7D4U7ZKBE8PJO4Y:5/0*:?WO@5X9SNGAG]X3'8^>BZ*R7^B$)NU+
MR(__`P``__\#`%!+`P04``8`"````"$`VT>%4M8"``#)!P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6R45=MNXC`0?5]I_\'R>W$NA$`$5(70W4J[
MTFJUEV>3.,1J$D>V*>W?[]BF@9!56UYP,CESF#-S,IG?/M<5>F)2<=$LL#_R
M,&)-)G+>[!;X]Z_[FRE&2M,FIY5HV`*_,(5OEY\_S0]"/JJ2,8V`H5$+7&K=
M)H2HK&0U52/1L@:>%$+65,.MW!'52D9SFU17)/"\":DI;[!C2.1'.$11\(RE
M(MO7K-&.1+**:JA?E;Q5KVQU]A&ZFLK'?7N3B;H%BBVON'ZQI!C56?*P:X2D
MVPIT/_MCFKURVYL!?<TS*90H]`CHB"MTJ'E&9@28EO.<@P+3=B19L<!W?K(9
M8[*<V_[\X>R@SJZ1*L7AB^3Y-]XP:#:,R0Q@*\2C@3[D)@3)9)!];P?P0Z*<
M%71?Z9_B\)7Q7:EAVA$(,KJ2_"5E*H.&`LTHB`Q3)BHH`'Y1S8TSH"'TV9X'
MGNMR@</)*(J]T`<XVC*E[[FAQ"C;*RWJOP[D'ZD<27`D@?-(X@=7DX1'$CA/
M),$T\J/)%:6,CRQPGEBNU0/*;5/@/)%\M!3B.FP'EE)-EW,I#@A>`NBA:JEY
MI?P$F,VD0ICW_R<%(S(Y=R;)I@):@;N>EH$WGI,GL$1VQ*P<)L;HA.DCUD-$
MZ/<AZ1`2!7W(9@CQ9Y,.0T!FIQ6<<+U6D]37&GH=O6W'RD%BZS[3G_5E(+T,
M;,X"O1+!9^<EOCT&`X9QG;5X-KTHS4'`=]T4HCYB_2XB?1>Q>0O1DP>%G,O[
MF-M,T@)#QSH-@1?V5:P<9FJ]&,7C^%+E^?,X"*9Q/S\]?SZ.`-%_#LO2U'#D
M#R/OTF%N%;HWJV9RQ]:LJA3*Q-ZLN3'4U47=!E[Y"?@&5M]%?.TG8)]A//43
M<-$POH%-;N.D(X)-VM(=^T[ECC<*5:R`$KQ1#*^W=+O8W6C16F-OA88=:B]+
M^&0R<+`W`G`AA'Z]@3\FW4=X^0\``/__`P!02P,$%``&``@````A`$%$\G)=
M`P``2PL``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R45MMNVS`,?1^P
M?S#TWMARTMP0ITA7="NP`<.PR[-BRXE0VS(DI6G_?J24.';LM,Y+$-/4.3PD
M17-Q]YIGW@M76L@B(G00$(\7L4Q$L8G(G]^/-U/B:<.*A&6RX!%YXYK<+3]_
M6NRE>M9;SHT'"(6.R-:8<N[[.M[RG.F!+'D!;U*I<F;@46U\72K.$GLHS_PP
M",9^SD1!',)<]<&0:2IB_B#C7<X+XT`4SYB!^/56E/J(EL=]X'*FGG?E32SS
M$B#6(A/FS8(2+X_G3YM"*K;.0/<K';'XB&T?6O"YB)74,C4#@/-=H&W-,W_F
M`])RD0A0@&GW%$\CLJ+S>SHC_G)A$_17\+VN_??T5NZ_*I%\%P6';$.=L`)K
M*9_1]2E!$QSV6Z<?;05^*B_A*=MEYI?<?^-BLS50[EM0A,+FR=L#US%D%&`&
MX2TBQ3*#`.#7RP6V!F2$O48D!&*1F&U$AN/![2084G#WUER;1X&0Q(MWVLC\
MGW.B-BB'94-[8(8M%TKN/:@W>.N28??0.0`?8W((5927@H3H$&2%*!&9$`_X
M-63V94GI9.&_0#;B@\^]\X'?DT_EX4,T54@01CVD[O0<F=$9F3%=&,J],]1I
MPFZ:X34TZ`SYK@=/IQ6N8W8^HYK/;>71$`@N_06B,Q2G23VK@!VU<^I!#8W2
MGQJ=+7657&<9UK-+PZ`*IJ%R?`T5.C>IG&5DF[?>'=!D=078L),)7I@+]^C8
M*'BNR7"P0,.<.C*DW6)P!M>NR?L]B<Y-*F=IBYDU8>WM"Z<]U.#!)L7!TE1S
MH?4IS*[^<JQWD^Q@:@NB>,MKB;**QC"F/BJ//7A&@EA@:DH:=A<(O>K$[U?(
M>I^Q(4!$.B3AO3Z3U*OC\,Z>%>EH:DH:79!TU9R@U:"H;NO!U"$)[_&9)#J%
MIO@@:^[Z@X@3Q<$$9VN7Z,+<HU>-!.M]5J-+0X%V3(5A,!Y,/NZ[]ERP8*V^
M&U\HTE63@;9'P\'44:2NX1"$?32UIP/L-1UWZ?2)=I/;K2YN/\BYVO`O/,NT
M%\L=KB4A?-@K:[4RK4+LAG/[:+YRJY1?O8%5IF0;_H.IC2BTE_$4,`,K1[EE
MR#T864+R8:&1!I88^W<+2RN'CWN`<R25TAP?@-FOUN#E?P```/__`P!02P,$
M%``&``@````A`$(&L'*O`@``5@<``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3`N>&ULE%5=;YLP%'V?M/]@^;T8R`<-"JG25=TF;=(T[>/9,0:L8HQLIVG_
M_:YQ0J&)5OJ2A)OC<^ZY]_JROGF2-7KDV@C59#@*0HQXPU0NFC+#OW_=7UUC
M9"QM<EJKAF?XF1M\L_GX87U0^L%4G%L$#(W)<&5MFQ)B6,4E-8%J>0/_%$I+
M:N%1E\2TFM.\.R1K$H?ADD@J&NP94CV%0Q6%8/Q.L;WDC?4DFM?40OZF$JTY
ML4DVA4Y2_;!OKYB2+5#L1"WL<T>*D63IU[)1FNYJ\/T4S2D[<7</9_12,*V,
M*FP`=,0G>NYY158$F#;K7(`#5W:D>9'A;93>KC#9K+OZ_!'\8`:_D:G4X;,6
M^3?1<"@VM,DU8*?4@X-^S5T(#I.ST_==`WYHE/."[FO[4QV^<%%6%KJ]`$/.
M5YH_WW'#H*!`$\0+Q\14#0G`)Y+"3084A#YUWP>1VRK#LSB(YN$2T&C'C;T7
MCA$CMC=6R;\>$QV9/$=\Y(#O$\<R6"3A+'J;A/A\.GMWU-+-6JL#@I$!2=-2
M-X!1"L27_8`1A]TZ<(83C"!7`SUXW$3);$T>H7#LB+GU&/A\P?0(`J*],JA-
M5W9@I^PJZU*Y]8&A3'Q99O8>&0>&U@R33^8]KU?VF/D`L^@1(X,`F6[0@:$'
M8^D78B_M01.D8:BF2SMP)]T7]Q@95C=*EI==+M\CY<!C*1^9=Y=O.!TP9$,'
M_K[-@@12^_^,NH-CB6,$)N9E))/DLANWKB=?!P<>2_G(N9O5F+9SDZS<JGC#
MC3LXECA&QFZN7[GQ>\Q?=,EUR3_QNC:(J;W;43%<W3[:K\]M[)KP.CY/M]U:
M)?T?L-9:6O+O5)>B,:CF!5"&76>T7XS^P:H6,H?MIBQLM.YG!>\O#K<W#,!X
MH90]/8`PZ=^(FW\```#__P,`4$L#!!0`!@`(````(0!2E=GQ9PD``($I```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*R:6W/BN!*`W[=J_P/%^P(V
M-K<*V0KXSJ5.;>WN>2;@)-0`3F%G,O/O3\M26U(W8<F>S,,0/O?%;K5:+>&[
MWW\<#ZWO^;G<%Z=IV^GTVJW\M"UV^]/SM/W7G]%OHW:KK#:GW>90G/)I^V=>
MMG^___67N_?B_*U\R?.J!19.Y;3]4E6ODVZWW+[DQTW9*5[S$UQY*L['305?
MS\_=\O6<;W:UTO'0=7N]0?>XV9_:TL+D?(N-XNEIO\V#8OMVS$^5-'+.#YL*
M[K]\V;^6:.VXO<7<<7/^]O;ZV[8XOH*)Q_UA7_VLC;9;Q^TD?3X5Y\WC`9[[
MA^-MMFB[_L+,'_?;<U$63U4'S'7EC?)G'G?'7;!T?[?;PQ.(L+?.^=.T_>!,
MUNZ@W;V_JP/T]SY_+XV_6^5+\1Z?][OE_I1#M&&<Q`@\%L4W(9KN!`+E+M..
MZA'XS[FURY\V;X?JC^(]R??/+Q4,MP]/)!YLLOL9Y.46(@IF.JXO+&V+`]P`
M_-\Z[D5J0$0V/Z9M%QSO=]7+M-T?=/QAK^^`>.LQ+ZMH+TRV6]NWLBJ._Y5"
MCC(EC7C*"'PJ(U['<_WAJ#9R11%<U-[A4RDZ?>W]BN)`*<*G4G2UWHUW#5.@
M=@Z?C0W'ZPW$@U]Q/59J\(EJOO9]1=&!P:T=BC]056O>>-<.C)2T8@R9T[GA
MQIT^:L(?RK](%7[+79DD=<X%FVIS?W<NWELPD2$-RM>-*`O.Q('1QFR3)IK\
M^RC](.^$E0=A9MH>MEN0627,F>_WSFA\U_T.>;Y5,K,+,K;$'"5$4@NS`04A
M!1$%,04)!2D%&04+"I84K"A8&Z`+H6WB"T/Z%?$59D1\,3(S!#K@+@DF2J!*
M0$%(041!3$%"04I!1L&"@B4%*PK6!K"""5G^%<$49J`JFLGJTF25,JZ9T3X)
M<"/21)B1D)&(D9B1A)&4D8R1!2-+1E:,K$UB!1N*P5<$6YB!X@)N=&D8]^Q0
MSJ30U6@W(DVT&0D9B1B)&4D821G)&%DPLF1DQ<C:)%:TH6I?B'9G"+QZV6^_
MS0JY9E_H`OI0;V45%D;J6&.,9HIX3>&8,Q)((M9(/4(],A_"1@A-1XS$C"2,
MI(QDDL#:`Y:MD$`G\/^'1!BQ0Z*($1)&`DF@RQ,KF=MS/#M?P^9Z$PUF(V8D
M:;24U;YM-6VNH]7,M&'%!NJ2%9L+:0$#BGDAI.T@*"+[1['4SAD)&`D9B1B)
M&4D821G)3&(]J-C5F/W)]0<5TO:#*@*!;)+;)Z,Y5S)Z=0T:HK4<;V0/5ZB$
M1K+=<0=D`8[4]7$S]^+&+`YPTI`KCE(IU'=E-GID:F:F'RMVT,]:L9.]W2=K
MBC!BAU02%UI>'5*Z-BH9N:FH6SE)^OTF&J$BGHS?L#>TXQLI&UHC9E839C6U
MK?JC@6TU,ZU:T1(]/`M7O23=7']K$W:P%'*A\#?1<N@0SE'12$&%^E`>#46:
M@RBE*M5X0)(C0LM&%B+2SA(T<]59BE+2F3/JDU'/T'+MS`ZNZ(_->4QS\<_B
M%0+WC]L,V69#-X$S:.9(Y.I4FW,4<!1R%'$4<Y1PE'*46<B.A6AO:2S<@=C-
M?V*M%[M&,C$5ZD,QU2GCDUYKCHIZ^`-4O#K\(4K)@M?K.&3]BM"RF6OJ+K6S
M!,U<=9:B5..,5-?,<F;'5[2T-+Z.K^O>C;DF.V/2N3IV.9F)RS`,5UM7+8-9
M&W`4<A1Q%'.4<)1RE'&TX&C)T8JCM87LV(L&]UKL;^ICQ4$$S6V)^E"^C=PF
M&3A7BEY]PJ:.$*2B!Q^&(FD!0E3476'$4<Q1PE'*489(GOR9YP/BN.8+`B:L
MD(5'(B,4\]K7M&V@`)'H%2]VNEH`<S="I(,<<Y0@:BR3L4JU`%K.$%T(D^B$
MS;RZW@<ZJG$VUPF%S$[0\<D*-D=%7:\"CD*%L".S2T*$"G:JDCXD1BGM*>$H
MM3W!H6#/^D>J4886/G)MSU71='\BIJI'-V,JD=4*.C[IX^:.DM(K=,!1J)#G
MU)E(%JT(%:QC!)_%E'E*4%$[3Z]ZRE#A(T]V"$7O_8D0JE;=#*%"=EJ2-F_N
M*"F=+`%'H4(J+1V?S+@(53[*CKI@QBBE?24<I=27VR$E-4.EC[S9@02ISP12
MB)-Z)Q')1=(.SQTEI=,AX"A4R),[+I)E$2KH48P1:;,)1RF:%0<VW^^)V0P5
M:K-6<,0S6<'YEX?TM9TZ:L92.":-U4Q)7>UHM`S6[H"CD*.(HYBCA*.4HXRC
M!4=+CE8<K2UD!_^?=BXW=32P/:$)JY"Q&L\Y"A!9[0L]:@BU%(Y'A,A8I3E*
M$-GF2>%(M12:SQ!I\PN.EHAL\Z12K+04FE\CXIV`2W=/USN!6MRN%`IY5LD=
MT$X`%749##@*$<EMRJ!/EZ0(!8P]$2)M.='(F)GTP"E54JJ^CSHN_#)O_*,%
M!8UJUPM$VO62HQ7U0X\_UZC#]_FNV`[=OB#6XF1TY(;*@Z5<]^L#\FQSI0AI
M@BD3<!0BDG7<<7LDL2,4,$HY(FTYT<BX)3XZZL:ELW%G3-:>#,UH9PM$VMF2
MHY5"WJAYV+4E9=<KF&N?&0$A3D9`(@^62F,$:%<G3K2$HDZE@*-0(4A9TQ9I
M;R(EY9M'B@X]RHJY^40CPSP?&7FK:MX,.@YYE@S-F#.%/=X2I?03KQ3R]?BM
M+2E[9+YDJR=.B>B`J:V>-66&I(6>*T5KRDA%\U!62?G6@`W)/B-"*:M)Y@,F
MS1L>$WT35P=,/9":M\-.GS0I&=HQYQ+SMD0I/3PKO'.]T5];4O:(B3VC6<WH
MJ>5M:[^P0J:81/82-"0/.8??G]@4DPA.A;'NA4JJ+T]EA^Z0%3EE1F=WS"TG
M&ET=&>5?CLP(WG6Q-[\9FM'.%HCTO%ERM%*H6=P\$@WQSE4=#6/1D>]0R?=9
MCOGY.9_GAT/9VA9OXOTH:*CO[QJL7MYR>Y,'L`31(U>@[X7WNNI^@UR!'FPB
M.BRN`^W31#1'_`IT/A/1U_`K\/K8@WN!S^"ULDOR,Q=NZY)\?P*_W5^P[TT>
MX&R47YAY$_CYF?,'IP\:=53I@_L3^+V6:P2#"?P"RGDRF,!OF)P'CC<1IV*7
MKOB3$$Y]^!4X/P*=2U?@R!4B53]ZM[EA>`'N=?.<KS;GY_VI;!WR)TB`7GWD
M>Y:OT,DOE?J9X;&HX-4WR!%XXPE>=<SA%]!>!PK(4U%4^`5NJMN\/'G_/P``
M`/__`P!02P,$%``&``@````A`-QQFQM5!```3@\``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3(N>&ULK)==CZ)(%(;O-]G_0+@?^1!1B3I1`8'L)IO-S.XU
MC:62!LI0V!__?DY1@%0=9]*3]$W;/)QZJ?/6J:_5U[>RT%Y(S7):K75K8NH:
MJ3)ZS*OS6O_^+?RRT#76I-4Q+6A%UOH[8?K7S9]_K%YI_<PNA#0:*%1LK5^:
MYNH9!LLNI$S9A%Y)!6].M"[3!A[KL\&N-4F/;:.R,&S3=(TRS2M=*'CU1S3H
MZ91GQ*?9K215(T1J4J0-])]=\BOKU<KL(W)E6C_?KE\R6EY!XBDO\N:]%=6U
M,O/B<T7K]*F`O-\L)\UZ[?8!R9=Y5E-&3\T$Y`S149SSTE@:H+19'7/(@-NN
MU>2TUK>6EUBF;FQ6K4'_Y>25C?[7V(6^'NK\^%=>$7`;QHF/P!.ESSPT/G($
MC0W4.FQ'X)]:.Y)3>BN:?^EK1/+SI8'AGD%&/#'O^.X3EH&C(#.Q9UPIHP5T
M`/YJ9<Y+`QQ)W]:Z#1_.C\UEK4_=R6QN3BT(UYX(:\*<2^I:=F,-+?\7058G
M)40@LA6!WT[$F2QF,\==S#\NLNQ$X/>W10R156N2GS;I9E735PTJ#_K-KBFO
M8\N#8=!Z>T0R@V$_\PN,XBI;+K/6Y[H&5C`8Y)>-M9BOC!<8F*R+V3V(D2/V
M?00?!2[KJR!00:B"@PHB%<0J2$;``%L&;V#(/\,;+L.]Z;/:]>!NEJT8T4?T
M37P5!"H(57!00:2"6`7)"$A&3#_'""X#TV=4),N%G/A.A-CC0IK)(?LA9#`'
MD0"1$)$#(A$B,2+)F$@>.9_C$9>!N0B?&<TDU241]$N7AI#!)40"1$)$#HA$
MB,2()&,BN02KW8,I->&K8'/)L^<=%6OI@]5Y"LN*6&RX2.M1G]NN(\XPQ_:(
M^(+P1?ONK+F4BRL8@GKI$)$#(A$B,2*)(%;;1<D2]S,LX2*R)1T968*(+XCM
MM@NV;5J.XL;P?G`#:1P0B896?!L`U:FL&@_O>]5DK"%Y`^N`5"X/R@(&M*\+
M'BV;T!&QK_,=98^(CTB`2(C(`9$(D1B19$RD1/EI<[P-_SI1'BTGVA$P\E[<
MEBD;O^^"[CN1CTC0D45;$G-[K@Q>V+U?#C/M@#0B1&))U7%<2^Y9,E:5?(&S
MSF_XPJ-E7P2QX6`S\D7Y^KX+$D>V]MR!2-`1N_5ENK"572GLWD_OOB"-")%8
M4G7,F7(.2,:JDB_\J"89P\]MMLN/L#\YV?:3I&TIF]0A&U;MD4M*7_9]PU'Y
M8!3T2!20.UVH1O4!HPKJT5TYPBCN4:=L6JY21'U`JRS<$K<"<>`M27TF>U(4
M3,OHC9_XES"8`Q6W$7_FP=H-"Y/*72]P'_#(]6`]P_%PJ]G:#_B.WW8><=N#
MTQ?6V4T].')@OG6\+>2+7^P<#W9?X,:0`=QFKNF9_)W6Y[QB6D%.D+O9[KFU
MN`^)AX9>H2[@3D,;N,>T_U[@WDI@V30G4%<G2IO^@7]@N`EO?@```/__`P!0
M2P,$%``&``@````A`'8.%DU_$0``$F8``!@```!X;"]W;W)K<VAE971S+W-H
M965T.2YX;6RLW5M3V\BVP/'W4W6^`\7[!GPE4$EV!>M^JU.G]MG[F8"34`.8
MPLYDYMN?U5*WNU?_%8*IS,-`?NINV4M+4B])-N__^=?#_=&?Z^?MW>;QP_'D
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MR3LP83]Z7G_Y</QI<MDM+XY//[[O`_3ON_6/;?#[T?;;YD?^?'?;W#VN)=JR
MG<P6^+S9_&&:EK>&I/,I>F?]%OB?YZ/;]9?K[_>[_]W\*-9W7[_M9',OY!V9
M-W9Y^W>RWMY(1&68D^G"C'2SN9<7(/\_>K@SJ2$1N?[KP_%45GQWN_OVX7BV
M/%F<G\TFTOSH\WJ[R^[,D,='-]^WN\W#?X9&$SO4,,C,#B(_[2#3Q<ED?K8T
M8[S0;V[[R4_;[^7VLK1_L?+3MI\L3LXG9Q>S\Y<[+FU'^6D[GK_XPF1IOR+Y
M>=`;DKVJ[R<_7_6&+FQ[^6G;A]%_(7(3291^3>:75[VEB=O2$[^I7[>5)F[S
MFE_LNB;3UVS?B=O`YA?;\\5UG@[9V2=[<KV[_OC^>?/C2(X@\N*W3]?F>#2Y
M-(.Y-!]"M$_\G^6])+P9Y9,9YL.Q;%5)Z:WLK']^G$S?O3_]4W:P&]OF:J2-
M;K%R+<S>9(9-8DACR&+(8RAB*&.H8JAC:&)H8^@".)70[N,K.?$[XFN&,?%U
MD;ERX`,^C8+I6K@N20QI#%D,>0Q%#&4,50QU#$T,;0Q=`"J8LIO\CF":8>1P
MK)+U0D?O:F@S#3-ZH9NL]DWV$8:DD`R20PI(":D@-:2!M)`N%!5L.1C\CF";
M8>3@(JOQAX;9F0[EU=#HQ6COF^RC#4DA&22'%)`24D%J2`-I(5TH*MIRFE71
M'I]FN,.M:=T'U07C:I"%_`C"/-%A7NT;N6X))(5DD!Q20$I(!:DA#:2%=*&H
M&,HDY(`8FM8ZAH-(%KKPK"`))(5DD!Q20$I(!:DA#:2%=*&H@,G1[8"`F=8Z
M8(,L9/P@Z>+ST+Z1BVH"22$9)(<4D!)206I(`VDA72@JAJ;>"R=0+^^XIK6.
MX2!ATD$22`K)(#FD@)20"E)#&D@+Z4)1`9,IN0J8F7'*W%7VZ@/GG&8@'<M!
MIO(CR,=9=!#<-]KG(R2%9)`<4D!*2`6I(0VDA72AJ/":ND7%]^6$[)OK*%H*
M4Y*4D%)21LI)!:DD5:2:U)!:4J=(Q\_,Y%^_0YOJ+\I"2]%A<1ZEH6^UST-2
M2LI(.:D@E:2*5),:4DOJ%.F0FOG\`2$=IO\R9721N3*EM419I20H8:N4E)%R
M4D$J216I)C6DEM0ITO$S<_0P?N:0N9#$._"`:2;A<:[:Z;\<3H)#9ESIV(YR
M8'5;)"&EI(R4DPI22:I(-:DAM:1.D8ZUF:&'L?[%X7.8T,MX+C)7YBI*G*N@
MA*U24D;*206I)%6DFM206E*G2,?/S,[#^+TU5X=9O@KL0-'I?1D?5_>MW!9)
MS&5;LT5\^J:DC)23"E))JD@UJ2&UI$Z1CK69V(>Q_D6N#G6`"FE8&O27W%83
M4$)*21DI)Q6DDE21:E)#:DF=(AT_,ZD/X_?FJ>AD*`]4:`>*LO4\SM9]*Y^M
MH-0.'R1P1LI)!:DD5:2:U)!:4J=(1]M4!&&T?Y&M0P&A0AK6%#9;0<D$E)(R
M4DXJ2"6I(M6DAM22.D4Z?F;*?T#\A@I!Q6^@:&(:7:9?3?:M?$J"4K;*2#FI
M()6DBE23&E)+ZA2ID$X/JY7ZYKI6LA1.3$D)*25EI)Q4D$I21:I)#:DE=8IT
M_`ZKE::LE2Q%1\GH8OS*M]JG)"DE9:2<5)!*4D6J20VI)76*=$@/JY6FK)4L
MJ91DK<16*2DCY:2"5)(J4DUJ2"VI4Z3C-U8KO>GRTI35DB6=K?/H9L;*M_+9
MNB^S'*5LE9%R4D$J216I)C6DEM0ITM$^K%J:LEJRI+*5U1);I:2,E),*4DFJ
M2#6I(;6D3I&.GZE,7G].-T]]1`6\)7U.G\<W?GPKEW\)*25EI)Q4D$I21:I)
M#:DE=8IT2`\KBJ8LBBRIE&11Q%8I*2/EI()4DBI236I(+:E3I.-GRH\P)=]<
M%$D`D:W[VB:XW#2/[QC9CD&YDY!24D;*206I)%6DFM206E*G2$?;%"MAM%\N
MBJ9#;1-.ZBW)*MRNO2(EI)24D7)202I)%:DF-:26U"G2\3.521@_DZVS=^:1
MO$.OCIJS>GQP'2@ZW\<WE&Q'E:[[CFZCI&R5D7)202I)%:DF-:26U"E2X9X=
M5C#US77!9"E,5U)"2DD9*2<5I))4D6I20VI)G2(=O\,*IAD+)DL+.9#Z"_;S
M^.:2;^7R+R&EI(R4DPI22:I(-:DAM:1.D0[I8073C`63)962+)C8*B5EI)Q4
MD$I21:I)#:DE=8IT_.*"Z>4ST(Q5D263]4%*QO>0?"N?DL-8TM%1RE89*2<5
MI))4D6I20VI)G2(=TL.JHAFK(DLJ)5D5L55*RD@YJ2"5I(I4DQI22^H4Z?@=
M5A7-6!59TH_#S>-;1;Z5R[^$E)(R4DXJ2"6I(M6DAM22.D4ZI(=513-61994
M2K(J8JN4E)%R4D$J216I)C6DEM0ITO&+JZ)?'"59^LQ&2Y_X?I!OY5-RW]%1
MRE89*2<5I))4D6I20VI)G2(=TL-*GQE+'TLJ)8=6`25LE9(R4DXJ2"6I(M6D
MAM22.D4Z?F.EC_G8CAP.=]_N;OZXVLCI6&:0(ZDZDX]H#!_<F+'J<33?GY97
MI,22*;3\6?\LNG*?^E8N>3-23BI():FR)(\CR/`J.O.X4C&%X<'1Z4?1!8RC
M(#JDQ))<9C&?A9F>3:(9>NH;[`/#87)2X3O:D:-RM/0-W,B5&D:'Z;""9,Z"
MQ-'P&3CSJ9T5*2&EI(R4DPI22:H4Z?=\6,4P9\7@2,Y_^]Q?1%MXY1KY"S.)
M)]]O,H]NP*:NU3O[.:IE='TL<PW\\RRY([^RPM,+*RMM*ZD/^G2:1SMPY4;I
MUZ7#&!<.;]O#6$_,!S*W'7UTXW+"-1H^+]E_6,R2S,M=XJ>.YD,HS\^B\VWF
MAO%]<D=^Y,(-XUN5CNS(BW?1Y+)RP_1]=.#B\J"_PBIG^=<?M><L&2R9>PW[
MJ$WBS;ER'7V>));,W#'HB*0<UB@SI#Y/+I91HF1NY#`I[:OT*RM>M;+2M1I6
M-GDWB[9^I5:F@VN*@?B"8'C<_]?FZ6=G13F7N=/BW`P3'?@'DENW+KU6ME5`
M"2DE9:2<5)!*4J5(QR*>]/>)MNPOCAZ0:ZP%Y@.9N9U/F45\']2VDB>"7,`2
MU_$7N6:''PZ`9R>3Z!27N9'#7+.OTJ^L>-7*2M=JO[+H:%NIE>GXFIGY;\BU
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MP$4T<^2#G),*1_N1HVU5^@9NY,K12)C,A#Z<\/SB4&?G_[YLNEI8DME:D`?1
M]'[E6OG)7$)*+;G253]9G[D..E6C*BUWK?R:"E*IUS0YF9RI_Z+)0^5&^-FJ
M];X:%RR_B"D+$W.70PY_JEZ>+*)*=^5:^?(E(:66Y.*)R<1H1I^Y#I+4P=9#
M3.WK\6LJ7$=/Y8MKJER'GZU)A]#,_0](2ULJA&EI2:=E5`.OS$-VYCSCDR4A
MI99L6DX6T1Z7N2X_RX[^NFSN6OEU%:0R7M?T)#JD5J[3S]:F`QD7-+_(118N
MYKD$YF)TK6#E6OET2$BI);D"97(QRK+,=?!;,7?DARU(I1O67`/'L)7KP,LV
MB[@J^45P6'KT(^A/L9(24DK*2#FI()6DBE23&E)+ZA3IY)(45'OIFZNZA1DI
M.L\.I*?0R^CXM;(=@P<.$E)*RD@YJ2"5I(I4DQI22^H4J6@O#ZM*^N8ZI);"
M*30I(:6DC)23"E))JD@UJ2&UI$Z1CM]A)<B2)8BE*"6CN<+*MW+SKX24DC)2
M3BI():DBU:2&U)(Z13JD<57R\@%TR?+#DDK)H55`"5NEI(R4DPI22:I(-:DA
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MC%]9[<BOK"&UEN3BLM\_PNI/;P%3/AVP?]AJR[^HJ^5`YEILL`7B2M>V"LLT
M4FI)4C8<*RKY,MO*7*H,UAC%+^?PA:>@([?,\(;L?K,\F43OI7+#A'N*C4NX
MIX!:]\+]]NO<6'U'O67BNN]-UPN7+`<MZ5WF/)Z6VU9JEQG&"N_EVU;F(I[?
M%.?1?"ISK=2%@_AF=<XU%IZ"X;G!AM=E=Z7)^<DLNDQ?N7%\VM:._+9H2*TE
MN7CD]Z5A;4-@]!:+B]&W;3'6J,N!]"GH/'J3*]M*[6)#1WF,P+W\U+:RSPR<
M3\]QD+/K]]F=<^3"TXM;QJY_.**^DZ_:UA<$*S>,7UGM*-R5[$ORU-I6^Y-;
M_'FUS@TS<M(9JWD/?QI!ON<\+G@M!?/>%2DAI:2,E),*4DFJ2#6I(;4D\_7N
M_<6DX(`U?%W[\`W6#^OGK^O5^OY^>W2S^6Z^BEW*N8_O]SQ\3_S5XMVEN2HA
M68DE%[*DWVCQDN69?+E\/\/#$O.U\_V.C"5363(=6\]2UB/O9>05S):7YJ'C
ML27GLJ1_X_%Z9O)^Y*G0D3YSZ2.'VK$ETF<X2<>CS>6UR?ETI,],8C!<*8G[
MS"0&\H&<L3X2`]E/QI;,9$E_3,1H<UG2'_2P9"%+^N-)O&0J?>1)IY'U3*6/
MW*T>6R*QEN<QQY9(W(8=">N1N,F'#\?Z2-SD&8*1)1/I(]_B,K9$^LB7D8PL
MF4JLY?K]V!*)]7#\QVN36,OW((SUD5C+9_9'EDRDCWS/W-@2Z3/4@/%Z)A+K
MX0%;+)%8R[=3C8TFL9;O71I;(K$>3AOQ:-)EM(=T&,UI"?-HE"7(HS&>2(SE
M:Q_'7I/$6+Z]D$NDQKTT%2R72'EZ:8I/+I'*\M+4C5PB?['BTWCL9?4C[:_,
M!AYSLRN-^*?YY:?QPXQLP=&=1;;?V.:39[LOS=/6?`OR7/.E>7292^2YY$OS
MZ#&7)(OII;D;.[9$PBMW&[E$[EM*G[$E5PO9C#(=9Y^KA6Q&N2<N2T[WN25_
MD>/I^NNZO7[^>O>X/;I??Y'3Q%G_C/SS\#<]AG_L[%.!GS<[^5L<4I7+7T*0
MO[VREL>9S\Q7TW[9;';N'V8%^[_F\O'_!0```/__`P!02P,$%``&``@````A
M`#*H:[Q5"0``?"X``!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULK)K;
M;N,X$H;O%]AW,'P_L279CF,D&5@'2A1F@,%B#]=N1TF,MJW`<CK=;S]%4119
M_+7N=J-O<OA8+)(_R5*)XOWO7P_[T9?JU.SJX\,XN)F.1]5Q6S_MCB\/X__\
M6_RV'(^:\^;XM-G7Q^IA_*UJQK\__O,?]Q_UZ7/S6E7G$7DX-@_CU_/Y;369
M--O7ZK!I;NJWZD@ES_7IL#G3OZ>72?-VJC9/;:7#?A).IXO)8;,[CK6'U>E'
M?-3/S[MME=;;]T-U/&LGIVJ_.5/_F]?=6V.\';8_XNZP.7U^?_MM6Q_>R,6G
MW7YW_M8Z'8\.VY5\.=:GS:<]C?MK,-MLC>_V'W!_V&U/=5,_GV_(W41W%,=\
M-[F;D*?'^Z<=C4#)/CI5SP_C=;`JH\5X\GC?"O3?7?71.'^/FM?Z(S_MGO[8
M'2M2F^9)S<"GNOZL3.630E1Y`K5%.P-_G49/U?/F?7_^5_U15+N7US--]YQ&
MI`:V>OJ65LV6%"4W-^%<>=K6>^H`_1P==FIID"*;KP_CD!K>/9U?'\;1XF9^
M.XT",A]]JIJSV"F7X]'VO3G7A_]IHZ!SI9U$G9-9[R2<6B<7*E(3;>OTNVL]
MF-XLY_/98GE+[$+-15>3UG%7\P>;O.LJTN\KFPQH<MK>JC]^J-&)%KN=NW1S
MWCS>G^J/$6T(DK-YVZCM%:R4-S-K>L#]//Z_::3Y4U[6RLW#^'8\HAEJ:.U]
M>0QN[^XG7VB];#N;>,"&6R3&0BT.Y3;U0>8#X8/<!X4/I`]*!TQ(EEX;6HF_
M0AOE1FEC1A4;8,4*/2&,A:F2^B#S@?!![H/"!]('I0.8$+2K?H40R@WM:F>1
MW"WYP&-M$KH+:<Y-DMZD%P=(!D0`R8$40"20TB5,(XHXOT(CY8;V(C5C=])R
MRB6(M=%%E7J37B4@&1`!)`=2`)%`2I<PE2B4,I6&'PXFJBCK5@PSB%B3D&*M
ME6<:<'F2WLA42X%D0`20'$@!1`(I7<+&3@^**\:NK/G8-:%9-\-*@*1`,B`"
M2`ZD`"*!E"YA`Z7=RP:JGBES"K)7/E.4&ZZ`)B$],)W9]V-G;V1D2H%D0`20
M'$@!1`(I7<)$46GN+WC0*C<0'[P-$&NCB_&A-^E5`I(!$4!R(`40":1T"5.)
MII:I=#D^*&N^0C3QXD/DQ8?>J!\[D`R(`)(#*8!((*5+V-A5^G7%X%MS/OH.
MN2$"48HH0R00Y8@*1!)1R1`?L\J]_&T1SF\HB%X9+0*=Q=&3T\QJW"$O7LR\
MU6"M3,44489((,H1%8@DHI(AKI!*RGR%U'O5M?KHY,[+++S@&0?:ZF+HL#96
ML+Z:01E:"40YH@*11%0RQ`53*9HKV.48H@3Q@DB'^+I9^E'$6IDQIX@R1`)1
MCJA`)!&5#'$95`[FRO"S;W8ZEU,-V8?NTMM$<=!G?-;*3]RMC16LKV90AE8"
M48ZH0"01E0QQP53BY@KVG76C\SS2Q70]5KN2EI+W]`$9>BM3,;45#<H0"40Y
MH@*11%0RQ&50:=T5,N@LD,G@)H;M>WP2`$H198@$HAQ1@4@B*AGB8U99FSMF
MM5>BI3JGNCK,Z@20Z='GA'9O!-.%_QCJK<P:2`-`&2*!*$=4()*(2H:X1"IE
M<R7ZSN[0&1Z3P4WZNF4!*`T`98@$HAQ1@4@B*AGB8U:IFCMFM2Q^+CG121^3
MH\L#Z9>-J]-;?U7T5G95`,H"0`)1CJA`)!&5##&%PNM2UM:<IZP=<E-61"FB
M#)%`E",J$$E$)4-\S'[*>GDGA)B7=HCG%U/O*"RQ5OW4(\H0"40YH@*11%0R
MQ&7P\]+OR-"GGV8T<0A)8X(H190A$HAR1`4BB:ADB(_93RUU3G6COA"<7W?;
MSW%->YDF?$"+B$[%]5EYB!FG0;,^F4@0I1U23R4G9'C'[)FU,DH+1#FB`I%$
M5':(\BARS]49SCBO5:?/-TWWX[!#KCJ`TLXJ7+2?'\)IX.6HF34PG@5ZSA$5
MMJ+ZL$&>O5<!:0V,YY*YX3*I_,]]J@PL%IKB?K4H<R]F=DA_15,?2A*U)I25
M12FB#)%`E",J$$E$)4-\S-<EE32',.8.T2^[]@/O8#PQ%>T9:8HH,VC9KI3;
M\-:;3V$,[OKMF!MD/1>(I$':\VRV\$[F2F/0>N82J63OBF6A<T,WHU`O[>KU
M@Y[)CD1>#Q)CI;^;ME_9$&4&A:U$T3+TWF*$,;"O/[E!UG.!2!JD/<^F<^\(
MHC0&K6<ND<H-78G:?&S1ING?V40ZJV1J=8DF!1)'+:\SB7J74_O*3GN**#-(
M3_LB6H):G1MW08'GPKBQC4F#.L_3P'MM*(W!P()22:&OEGKON_+@2*4I.@`Y
M0ODCC#LK-7F]G)X*B;4Q83)%E"$2B')$!2*)J&2(+:_HNF2V->>!N4-J3GH1
M`O]ID5BK7@9$&2*!*$=4()*(2H:X#-?EMQ'FMQVBM6`&F"!*$66(!*(<48%(
M(BH9XF/VD]F??M.+,,_MD%+<615>=I)8*R-:BBA#)!#EB`I$$E')$%=H./6]
M.II$??+KB+'THEK<65V,)M;&"J:=.PLO0RN!*$=4()*(2H:X8"I#=</OY2=4
MU"6T]GD:=\B+)GY0M596!NV+*AJ4H95`E",J$$E$)4-<!I687B%#E\>Z,FCD
M3&H2`4H198@$HAQ1@4@B*AGB8[XNVZ5+>7ZVVR$O9'B[)+%69IY31!DB@2A'
M5""2B-250M5[ZBIU0LN@KPCJ:V:'ZO12)=5^WXRV];NZ_C>;4D[9X^YN8A2M
MUN2)7'@E%`KHVF*['*!D1B7M.R&4S*FD?16"DH6Y!.F7A-.5.O09Z$%(%R?I
M'&2H)*22<*!D'=[1>(9**%&B.FVVYO<@HAYH&:%$7=T<[$%$/1AL9QV$J[7.
M=WUO5*(^GPV,)R"M!^NL@]EJK>,)>*-9T(<!4$*SH%](H81F@4[CAWIP2R5M
MW@!UEE321C0H(47IB'+`&S4SV`HU,M3&>DF2#<I,;0\V32T/-AS05-)'[X$N
M!325@VW0Z<Y*G;=@'3K96*G#"RRADPFJ,U1"EWW7PU-,S0]XBM5*'N)J]PWP
M-:V'(0EC6@U#_8EI+;0;<M+/'MW]?=N\5']N3B^[8S/:5\\4'*;M:=%)WQ[6
M_YSK-\JRZ09P?:9;O^V?KW3+NZ)C#[K:.QX]U_79_$,23?I[XX]_`P``__\#
M`%!+`P04``8`"````"$`N]43.C(!``!``@``$0`(`61O8U!R;W!S+V-O<F4N
M>&UL(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````G)%=
M2\,P%(;O!?]#R7V;?FPBH<U`95<.!">*=S$YZX)-&I)HVW]OUG5UHE=>AO?-
MD^><E*M>-=$G6"=;7:$L25$$FK="ZKI"3]MU?(TBYYD6K&DU5&@`AU;T\J+D
MAO#6PH-M#5@OP46!I!WAID)[[PW!V/$]*.:2T-`AW+56,1^.ML:&\7=6`\[3
M]`HK\$PPS_`!&)N9B":DX#/2?-AF!`B.H0$%VCN<)1G^[GJPROUY84S.FDKZ
MP829)MUSMN#'<&[W3L[%KNN2KA@U@G^&7S;WC^.HL=2'77%`]+"?ACF_":O<
M21`W`^W?;!,YMR_Q[ZP4?+0CW`+S(*+P'CG:G9+GXO9NNT8T3[-%G"[C+-_F
M*5D69%&\EOC4FN[3&:@F@7\33P`Z>O_\<_H%``#__P,`4$L#!!0`!@`(````
M(0#:G#TT;@(``.X&```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````)R57V_:,!#`WR?M.T1Y;P.T
MJR9D4K6T52=M*QJT>[2,<R%6@YWY#@3]]+LD`\*6(*UOCN_?[^Y\%W&]6>;!
M&CP:9T=A_[P7!F"U2XQ=C,+GV</9YS!`4C91N;,P"K>`X77\\8.8>%>`)P,8
ML`N+HS`C*H91A#J#I<)S%EN6I,XO%?&G7T0N38V&.Z=72[`4#7J]JP@V!#:!
MY*S8.PQKC\,UO==IXG3)AR^S;<'`L;@IBMQH19QE_,UH[]"E%-QO-.0B:@H%
MTTU!K[RA;=P34?-33+7*8<R.XU3E""(Z7(A'4&71)LIXC,6:AFO0Y'R`YHW+
M-@B#N4(H<4;A6GFC+#%6J59_5.>\0/+Q3^=?,0,@%!$KU)?5L:G;/)O+>-"O
M-/ATK%EZJ$E8<,PX,Y0#/J43Y:D-N=]DKBAJXAIHUT5Y8Q-Y;XGK);_8NMO&
M-<GW.8P=-]HB)/)6Y<IJD-,J33E>><_5W"N6=:FC'$RFI`C*9X/2I?*)WYZB
M_S(9*\SD0ZO)=T<@^_)VA<8"'I5]3U+I#)@<344P\8!,4SVI;J<7\D9KM^+R
MV(6<.'Z#/##=ZI>2$^9I)#//098A49*3/]J+4R%]DE-R^C5S><)3+.]_K;@3
MW1&NN$G:+4'.U*:#I(58SK<U_59VNV[-E>/,NTU:X4^;'-HD[X"4R4^4LYV(
MS;J).DWJ^?HSC,>OHK-K)VS:,S^)UFGRGC"#[A)TQKEHVAPMEK]6R5=C7_&Y
MF+D[GMG=KCR^%--,>4AXB^SDAPOQR&O2YZ63<:;L`I*=SK^"<K._U+^ON']Y
MWKOH\=)NW(GH\*.*?P,``/__`P!02P$"+0`4``8`"````"$`IXW6AJX!```\
M#P``$P``````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M
M`!0`!@`(````(0"U53`C]0```$P"```+`````````````````.<#``!?<F5L
M<R\N<F5L<U!+`0(M`!0`!@`(````(0`XDT!EA@$``-D-```:````````````
M``````T'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(M`!0`!@`(
M````(0"^(!LIKP(``)D'```/`````````````````-,)``!X;"]W;W)K8F]O
M:RYX;6Q02P$"+0`4``8`"````"$`4KP#[%`$``#4#P``&```````````````
M``"O#```>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`BT`%``&``@````A
M`"R>NDO6`@``P`<``!D`````````````````-1$``'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`XZF#;S8#``!&"@``&0``````
M``````````!"%```>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`
M!@`(````(0`[1:RK?0D``.)#```9`````````````````*\7``!X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`*+2L2V%!P``:BX`
M`!D`````````````````8R$``'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"+0`4``8`"````"$`%!<RBHL#``#$#```&0`````````````````?*0``
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(````(0#[8J5M
ME`8``*<;```3`````````````````.$L``!X;"]T:&5M92]T:&5M93$N>&UL
M4$L!`BT`%``&``@````A`(JU^&3$"P``'&D```T`````````````````IC,`
M`'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`8I.PIG,N``"ADP``%```
M``````````````"5/P``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`
M"````"$`PFVRLT0#```4"@``&``````````````````Z;@``>&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A`)(TTYAB!```Q0\``!@`
M````````````````M'$``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M
M`!0`!@`(````(0#7`,P^Q@,``)H-```8`````````````````$QV``!X;"]W
M;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`S)*Y4!D#```U
M"@``&0````````````````!(>@``>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;%!+`0(M`!0`!@`(````(0!K&U52JP,``'T,```9`````````````````)A]
M``!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`/ZW
MQ!#&`P``7`X``!@`````````````````>H$``'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+`0(M`!0`!@`(````(0">Y.F'C@(``(0&```8````````````
M`````':%``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4``8`"```
M`"$`+&08Y_D(``#)+```&``````````````````ZB```>&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`-M'A5+6`@``R0<``!D`````
M````````````:9$``'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4
M``8`"````"$`043R<ET#``!+"P``&`````````````````!VE```>&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&``@````A`$(&L'*O`@``5@<`
M`!D`````````````````"9@``'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"+0`4``8`"````"$`4I79\6<)``"!*0``&0````````````````#OF@``
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(````(0#<<9L;
M500``$X/```9`````````````````(VD``!X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L!`BT`%``&``@````A`'8.%DU_$0``$F8``!@`````````````
M````&:D``'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````
M(0`RJ&N\50D``'PN```9`````````````````,ZZ``!X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L!`BT`%``&``@````A`+O5$SHR`0``0`(``!$`````
M````````````6L0``&1O8U!R;W!S+V-O<F4N>&UL4$L!`BT`%``&``@````A
M`-J</31N`@``[@8``!``````````````````P\8``&1O8U!R;W!S+V%P<"YX
8;6Q02P4&`````!X`'@`$"```9\H`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>12
<FILENAME>0001193125-14-194964-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-14-194964-xbrl.zip
M4$L#!!0````(`(&%K$0V;`-@@E4``$4(!``1`!P`:')T>"TR,#$T,#,S,2YX
M;6Q55`D``Y(R<5.2,G%3=7@+``$$)0X```0Y`0``[%UI<^,VTO[^5NU_P'I3
MJ4F5=9"4+,N><97&1^+$8WMM3X[WRQ1$0A(VO$*0MK6_?KL!4N(A6I1$G_%4
M*I9(L+O1_?2!)DA]_&>C07YD+@MHR"PRG!)^^"%T?B`-<N@Y_K7)R:D;PEDS
MY+<,CKFW+(#O<'X2AOY>JW5W=]<T8:@P><"$%P4F$WB`-!H'!/_]X_\^(I/#
M@"&+/7(3,?*%3DE[A^CZ7J>_I_?)UYM#HK>UCKH(KK@?!C:Y=VQ7?-I*,<+#
M32\8M_1VVVAQ5X34-=F6&KF'9_F*XZWY!>G!.RUU,AEJL=PXP<SFV+MMP0D8
MKQF-MM8PM&1X)!IC2OW9)2,JAI)T?&+!)39W_WQ`=CP]I(*E.(13GXF%+.29
M!3SN[0<X_'X&+)*1DR"\GXV=L,!SPWNT*A+MM(TY22Z\CJ[U'M*Z&I%<$&-E
M=L$B[,SES2OESI"$M7Z_WY)G9T/%HG$@@-;Z_<O9M3EA#FW,`)`@DY"/2&1/
MR/-7;$0DT3U4X*<MP1W?1HW+8Y.`C8`'**:1**%Y+ZRMUH$B9(*.V'U(N/5I
MRVQ_&XB+D:%]H0$.5@QQ&`QD;LC#Z<'L`!SB%AX<<7`L*0K+3";!VN'I+UL'
M;?BWJ^T"^X^M^65I^JTY@^20SP+N65F64A?A`8K7:!N`DH^MY-B,TOPZ-<=6
M/,F$4G;26CSI(V8B]E[VI(V&IM<Q:?W;2>`YVL_414W>>"_9YC#1(#R",!Q;
M78/_/K;F1PE)CV:NE1JK$)(<6U-91EI9QEQ9+Q$K&649*RC+J$E9G8P[Z2]0
M12EWTFMRIVXF<+Y$7&1B2#V!<T=.6M\=^"\U<F2S1:>A[VX\Z5XN<&I&_/$;
M5)Z.YUZ'GOGG%^8,6;!U\%3J0+]G8X?-IR6/J6)PC]W[-C=YJ*0B%H>!@GON
MIZVXKMN[#L'A\?+COR*0$VMHSX6O8G#/Q=9!,JPPPX^MA2SF0D#D2>1ZNIBO
M-31CXS"VF[:SAC'_Y=8'&65I*\7\./QMJ*Q^637Q38+EP@\!;J_-*09`TN)V
MA$O(:V9&`0\Y$\?WIAU9S,()HY]$X#IPV<7HF`8N=\?BD@77$QJPS]/%!+(N
M5=!/J4N1YW6J6FH#K5U622T&RCM27@)2GJ.*U+32D/(;#0)(X"F4O,-D#I.,
M=AZ`R%N()GII-'G'R`O$R+/$$:,TCL1=83ZTV1$;AG-EO1<J"S"S1%OE*'H#
M<:93&F?>,?0*,?0L<2CN$+55LT3[=NZ%3%S2*05E7(03%L2?7QURKB=>$-ZP
MP$&3WDQ]EK7YDGD^HLU3S1\-FS]&>_-;!3LY*YZZ@%]J']J>`'<8.%Z4+CI>
MAP%3KCA5ML.[17OE4WO4BN$QK-;+6>TR"LP)%2RWW'S5YEHTI\=<(3Z&G9*>
M6Y3TW-KQQ_=H^;09$BRZ4S5#RK%H_4TS9-Q$C)T4K9_XZ\+.^FLQ^,MNK4O?
MK6[I3AV6UMNEEKX,N&MRG]JO-Y6>0A`,(J21CLZ+YO663:S:=_KNSY&M;*SW
MXX]/EFC7U%5/WB6LIBL8V]]<5Z5[,=[3WMMO+NA&=L_5N\V?<F%8UQXRO9.S
MXJE[B,7X".>NVAYB5I97,/'KL'!V<I^G7UW^5\2.F#`#+I<AF>5DN4*6V_H=
M=R6XZY;FCG<$OB/PY64[U4";;YJZ-IE+@<)EP&ZY%PE[>L5\T!ZS7N]*+YE3
M[O[]DID^4;-FMC]JT\C3RUIR*PV>%U+:/\:TRWM4L,:[!01<VM24,,"#<;A=
MW,!X=<`^M*D`F\MY9!>W)1.O@.FWU4MY\JZ9WH][V^\H_/NB,-N+WZFC%V^T
M*^/J%:U('Q-"+\IZ6B%+73-?[EAXM^.3[)E<)1<8C7:_CEQ@)(W$0L_UW>I/
M9O7>"A5`+>UCHWR'VP.U0'Z#Y#L$UA/DX1J@XD;+U[^N-SKK@/"]('VC!>GS
MX[%;NF7S/16^V8=&C)UT`:2CU>./BZRN_UVCD/YWC$+Z"J69'%L''N.-AQ50
M^*9C3W7`U;&(GEEOTT7T;CZ:/+2(?K=C_3ED%9^M;1$=;T,\]V[CRJ$=?RPF
MBF\_L]$(J#-Q=G;X:NU?=[RN(H3%^-X9&U/[6"HI!;NB2I\H01@-;97GYK4Z
MP-9)NJSO$'NC$,N^NDFKH[G;*7\T^HH)1@-S,@!8LEMF>[[4_KT/2F&OK-=S
MZIJ>PV80.O-,.M_0D0RJ,.&WW';IE#\!_0Z%YX/"L[QVJ[P-K%Z4:8-B!I;#
M72["@.)CFGDPO):T4@D.E2;]MM^/T"E_;OD=$L\/B6>)$L6^:.:U5D]D[L=7
MU]KOM8I<KG05"2OM``ZC(@K80?Q>V+VOUT<?6\E!,J>'UZ>^I\E=LD#@P_(B
M5<%;_!8TE)DU7G(>.?AN8R^W`W6I$'.$YJEDZ1\QUP,72,XMXB%?2[RG!%XP
MTSF7/*V9KN=S6Z*;F59RNBX1X6%B/HS)O/$E2PU/%W56))>L3:C`B@+_X"+F
MEMIR_1(>TB"8<G?\*[4C1O#B*WS/+H*&Q)"2!PJOU"46,[E#;?%IJP%.U^UU
M>EUPEX^ME3@>U"]H_C6X.4%[NK[;JT/0RX#YE%MQT`4"<@OT0`@6BL,H"(#(
M!OK4]1T](V4%=K7+N$25.\;N.B)F)*Q+7]U^S\B:-<=W/:Y+P=37NY6Y7@8>
MA.UP>FG#JAG4@VB3Q?TYVP@J?7TG9X=R/@M"P[IB+=&-OKN;1_!*8J7`<^ZY
MYL8(T8QV1IR%].N08XE>UI5##=E``3MZKV\L`.O!RHR6>46WO]`7"XQ,$Q\B
M3AXAV3P(&#OMW`07<B@&H94%669C?:>SIB!!Q*PS3H?<EF\4JB&3[&B]O"R+
MF13SQUKR+-%-IU<TTC)Y9+LS]=:E])-'5\R&RMBZA&*Z%GUI6FR[E9D>/(*P
MRX#6CO//NL(F1J@5<CUC-PO_$MMN(L*RVJ3?UU<7(=7!W[0@UHU^MLK,D=Z0
M^[+DFPO`%;@/+(MCKX':EU#$X4.&/@^IO4DXUK1N+ULBEC`I9(;595FB$*/=
M6U.6*Q92[C(K>54<A*O(B:1'';$1=E8V4%%#[T*TR<JUG.$"ZVTFY1+E-71C
M5RZ:-I52`G#BV18+A+J7MDG)W^VTLSY6)'^P"?]E(6:WW^FNQC\5A*``KE4;
MQ>IN&;-BNM]$O)5KPM7%>_#.R$.RE?](3"'W]WI:#N8/\"S4;VM+6/[++'D]
M:IV\'SXL8$:^)9WC6G38[7:S*ES"]*`V$2LKL;NCZ1N(>.%C-Q*"7GSZP;52
M=>SU##TK58%/T256$J6R?C2]UUU?%'4/X\P3]>BE\8!BYJPVEJ>R<AH/:.<A
M>>0/^3%1:[S2M6SG)\>C$)]6D*&R/N#82C*<L[!^A'1SK<@,DWP4K"S!*ICH
M=XWJ$A1>.TP%-S&"XXN'F961:7ZW90WUZ"!;N]GKS.5:POHQ)*VD1B7I;G=M
M27]C?#R!XP-8`M,Q.X_P=N?%2%YZ$86X5<D"<J436%_):L&ULYOUQ?7D.7B"
M257/`UV]VZE_4D?,#X"/NK,-*=?Q@I#_5WZMJ8K+"OT`OSR(UA2M>OG6KBY9
M=N42>P"S</<A!-;ZU*7W=W++J(6\"H%\=9&J`V_7Z*XC$D3<@,$H6(3(OZ=N
M?$\*EJ0L"-CB>U/U@&Y'[^3RX#JRY`%9_XQ62&K=WI/,*-<<KP?4>JXB6,IV
M0;MB(U&K@]W(W1&J3=1<6[V>8@N?P5LN;HYU)1"L(&YUY79Z%91;D#9?+^+F
M@,O`PWT@UN?I5XA#I^ZLZA_@KW/7J&'P.ZU03%:48`$TZA&_>MCH]7>T3:3/
MWIRF4^QGB!MO8/X5\8"5WD6NIWF1C7C5N>=O]=<B=F6==W+I<A6Y*X'EU+V%
M)=TC8#VG\.KL'T?PZBC/JWPER0L;,$S&+(&LXS<M'-^SP.1U]7-P89+;B5'*
M<-$FHOGHU(_WB>02JZ:>4ZF("YDNZBLL,L`)=ZEKUH_<?K?0<:C(OB)R5Q2\
M.AARFEY?\,4;YR[ESM1\FJTI,W9V<]*O(D/5S8:KSV"%Y-C+W1I?=0+U;I;,
M_\AY/AU"D-NI(.[C[^K,_S!Y/@%V>WH58)0*BD_9J0?LKMA8]O_=\)PZK"I2
M#WXZOKHX)S?P9W!Y_/7F]/!ZFYR>'S9)Z^BX];%51C]5K^&0(\^4/[F`+]NM
MS%IK-_ZM.*0OS\XMWO-PPH5)[3\8#8[5CO+*3!K)5O2'J!WDE9G:=R"7\"+5
M)%K2I<K_*GO*XJ?G)VJ#A=;I]]*Z?8A=5A\#4).%JCJQZ;BR$D;`GBF&&0('
M!10=PIF`VJ>NQ>Y_8=/*'-*/')12.RBB-K:(>A4OS!8?(8E$9;9_X,;T9=1R
M6%5#?_5L6)G28'K";194YWCNI1GFJ"SD)$\=`LK&7E!=H;"Z8S8N-*!.D132
M;#,D"^#]C=GV+ZYWYUY#\/5<R(I"1"Q8<XHEU`Z*SC]WJQ,X4EVE^/]L',A1
M*N6ETLUJW/ZM+>*5HG2P*+"I\ZL&'SWU,%DIM4)V_!P)[C(ATJ]1=RWL34-@
MN83H`!1D'_$&9/AL0]"H+-#W=KCO$Q%.;?;I^[\B+]R_.?[]IC$X._WQ?(_\
M)X*2?S3=)V>GY\>-GXY/?_SI9H]H3;V[3[X,KGX\A3%M/U07XL,>ZM/EX&J@
MZ;M=]>W[,9Q+GE!!?B.0+</RY.+\IG$R^')Z]L<>N>$.%(CG[(Y<>0YUM]6!
M;2)`1:-](L=>G_[_,<@Q8XTLD/(0/VC-[ZGC[_]+VVGO5_V4:!B)M(8)N19*
M*L6?/;PB#_LS?D$K^?A82NREE#B3XC'U^!,+/)?<3"#4^"P*N0G70/W6)!]&
M7N"PP)Z20?.R22XA+SE4G?N!?`@GC"A][D(!LX_=;>I.MV>'M/WTZ3M6=B82
MZ1.0\=(GO2A(G?V!<$$H$3[>>;##*?&E2*:4FMK@`U(&R+=R.PEF:C_PK,@,
MB8FIU`)?@Z4(_IHBX:'`DW[`&49O\IE[Y@04X<&,8Y:=77V?^)X]A4.-(;;P
MB15$8R!O\UL&U_@V#5%'3=`>2+;X),IL,<''$#A)Z!'N`-M;1E!_X5SI*,P(
M@CKQ1H2[_V%F*-NTV1D*,I3Y0^Z5A4G`]0X9@:LG\Q1PB(;$`022(8L)`5_/
M-8%R0,([#A]\?(233E&:['4N4S)F+P4`R.N9G!<D`$7)(W>,_2F:6<=Y)J_I
M/[777$0!L1FUB@C;)M=?KV\NSI"WB+(3EH8#0S:H#8#8(X@J&P(1XDS(/9U[
M),!-SX"A?3+TPM!S]DC3,)@S9WWS1:H7:,OISMWT3TS2A`HRN#SI&NT?MA%[
M0X9(B5T"[#E"XP'V_``.N?+&%T".FA%F-<"3IT`Y;7`7Y@47N#02C$K/O/4<
M+H'W(>WYI^>_9IP4.?@P!5RV0*ELL6#LX44PG0EQ/$O6-`BJ@$SX>`*?F,-"
M;\Q<<(.T")+G8GG!S>@4A$/FI0Q3O$HX-,F%*UT..3@>>(W%9"]=MG>)X!;`
M?C1BZ"$P"FQL8AF5HK"M1)"!"?&`EYFH,1P/,CM0?P:,6%!C``ZY&]%D"B&L
MC$.L!9HR^#*D$3L;2X>`;N.G&P-4$=*QAQN\"/5E!%FBFH;G"A9*Z0#-'@P$
M^F!3KA[,!ICYJI``R0$T((R4&+?:FY%-`U`DZ(PXS)*Q%4-#,T:V+#8H=X7D
M7I!O#$M$#KPQK2`VU=Y:X$T@G)<&W4J1=IO<3;@Y(=2VO3N1B9_R`AMA+N(0
MYH"(:JNOU-0L*(R`)L8_0>XX(!(2"A@-%"VB(7@!=9D7B=@`H*@XN.-%#0R:
M,+DQRP=U$^RA;)$`T\>?@D6-H@&:Y,>43N[`0\'M57A%R6*M#ID"#CY&B[)9
M"%PT$M2`0Q@ZQ(0W%1R2'ZA>J0G(48C#MMU@`N'"Q02.!LST`@NY"SIBH7(D
MP#%8TIR^A(#=UK5&^\FKQ<>A?.J2+X`+O=WN`SP9P2QN22QX`1]S%YP'B1XA
M/@<^OM)`.6`ZAIX?#3(A5$!FQ4BB7!THI&`B08ODOS:OF^3$\RQI7D4_M0DT
MQ^(DRT(&'0('`6NPF@,:!$LXFT$:N&+"Q^A!SE@8`JZ3.!,+<(X7X:0#\$3<
M1->$FI!<,S]4;X?`?IS4!$`W&D+&D&4$N#Y>F)H(2+V=(63$5YF,WTJ)!.`8
MIE8F6!(-9F\XL.`*W-]C$PR\W)6%'DZO6-]0RP+QT(4@&N'\O+FRXWPPGVZ3
M_,8P1)+X(4?PRSLOD!9"!U2DXH(,'5BQE$YW#\5JB-0392S0Y$)L'EZ<75SM
MD7_).R`I7W&XU<AX\.,A&U>,S0*OQ5^>J?#K&T]=^`$2L,I"*P(&;`OC-`EP
M<YG,.W-L2\!P-9)1K,\@0H^9+"2&$;>M&#"X;''PWA`@C[NC@.*OUYJR:G#!
M%83`3"ES3#*,_W>&H)B^#`6>2K`@W384@2)R,A$$LD>H/+Y96.H^E_&Z3VV\
M4^FMLM#>3CMELII*.::,16C")!;#</!F-"P.M.F0V;*JF554J=`V\K!`F:TS
MO1`#%!@AL8:,F.A>D@L$*C@;RI!W*>L&@YBP+)"%EP@C:ZJ"_HSXTHH88#$K
MB%4\15D>KK:WL0[,34?%5]<K%GE8\,9UJ$HEVC:$J81K+#4,4@%P%G;-.)3+
M<A#K0E(,,L^'QR?OO>`J$DHUEJV$0V9.7,_VQF`3K!>E$5*!17HY6FU1>P,A
M*VO#;2S3!=A*11SN,1C,95-!5=K9$A:6G?)F(=;1<`76LQ0&C&3]K%[:(Q,C
M3$RFPPF]39M37J`!`E!9'.<&!K[EMYXTHCR@FCN9TU`/I\XC:/!FL06@=%41
M(]T2,C=.N41'B+*9AP&\J:JQ<**8U.."7>7TV6H!USL"JP_3CC`0`_B!YUBI
M%4YD?4LMHGRH*&!1X4(0E_M?<#JX$@H\6W5M1C9U'*H6#8F&J"V\E)KP4\`F
M^/8L/.GB?2%):!(!91#XGIMJ5HDRY/0EJ72%OU@I,\/*N`6EOR2-RP.@'-]+
M@)(Q"G"6#N!N^T'%`JK09],HB5=D:90H;`AR2^7M2=6/DLLK["^E#`,+P9"#
M'N*^45)3X6N^H%*.`_`\5L9KZ+))JI"HW$!)@W.%%1]SI:1^%$`5IA)L$DNM
M^7-FDK1J9:$B4H32SC1;9*$4LWB07L(6FX'/E5US[-8(6\^U?#H''"4K!Z.0
M$4';XX`ZJ?PKVPC<EYTSN<@%-<EU?B,)8DE;,^7A0,D%X6;4:#!FL[0/UW$V
MD@T03X0-$05C"1AT^2:YQ-/X@JU@FKALXIUQOF2KU?#HO5F8/)Y^DPX,[D&*
M>]\KR8HM^"<2=>5V$%I3[OV90P`,1&VHLB'&)XT[52\%3.:#6?-'QA\@Y,JC
M0$S5U9X/&2YY<(*K(BV.+`J2LQI-2XH<2`JP)I-U#!G(9*M6P+(^N@>XR`ZD
MWH5AM@UD5U)_;5UDV43>GQ/6TDWDI[*PCYOC+%C:"%RA>*;R<1G)I>-Y:F<M
MF$@FVSMLBV(+(#+CDG&VV,E4\HNN=6CP)X,I4!N824)9>WQG-#6HBEZ01?3G
ML(B"N%YUF?^BNP%&6WN&!>7/U(TP,\R6<^8$*TZ5IES<B24KHL(]5(P[I?=>
MCV7L0C#'Y.>WKB%%SK_,F*I@)Q.FUH!P!O&(8`T;0*024!"'22WEI?8QF7+7
M$6@%=Q"DFX57\95R0Q*YQNLS_<D/UQ!-\4T]I/L#!#VH+R>PT(`J3JY8<0.3
MC)EXHS'^YLC'0%0A.V0,O1=-G:P]1K9LDTVPQU=@K3@H*3VUFW9[=AL4ZWS7
M"^-^VYW:%"PRTYQ[/Y1MROO3W,>H9J4__%HFQ(L`N/[4`)_MLCCC?T4<`NZT
M?,O$,^FD\PPM0(ECKEYZ!]4'!'V.=U=P79$\'$)L3X@8EBX;J]1D4C$A(WGS
M2D:%>#369FJI%J\:P3_FKZ61RW!3N?!W>G>GV4E*";S9"P=5!]W0ME4WA1Q%
M<CV%#SS)0[HD/JNNY\M1"H`/5<=[A,$A`"^U)$FFWIL"U[6@?++8,(32*=Y8
M+9+&^ZS\BN)[:7)Z>#LYFVHUHSN7>1NT(:>";7*\H0KR""S5L0Z+L+R?Z^2#
MB..,(*H*D^%FP9RWE>JL6`(7/KNR7_%=M]><55[%+/=(3C/?<?0R6JU&^\E;
M6[]AG(=5E=SJ$C<K_M?>MS`W;B-;_Q5^4\E7,Q59$4D]K&375?;8DW4R,_;:
M3K+96[=2-`G9S%"DA@_;RJ^_:``D08JD*(D/6&*J=LMC2V2CT3C=:'0?A!R4
MX>&)SMBQ3`\'\'`\27*'H1W`\0Q-!7`6@3?X#LPX'G1H?3WIT7D&P.[1-YDS
M,`:V_]<BKJQD2A4V;]')#SP/,@'WZ`$RI]`;&KZ/U!9$.0D^!Q\=Y-/,'+'`
M9VQGT2F3JYE>4@`Z7++SF,-1,B(M3AD?B=="X":R%M&VE^UC\3;F<A9FJ@,[
MS'HY][`;XI4:+5YR8J7K:$&K"WSDSCT8.TF`/&.)R4!`O'L42LB<--2#2`0-
M9L@EHFE1BT5Y]QA7NF]>YIANY%@E7P*PH&74X+0IKR`PU=_`@^2X<IN05">K
M)B>IJDE993]F7%#(U70/H,JSB$JK6*3"IJI+!I%7LX^._7"'Y^H<(S'I#B!V
M<HOPDB+Z7T-Y>\R/3>99Y_E^A!'T]!+BA+R.IHT$RFCI9)/+VH)I#-IVX:HZ
M2%:/-1A4*=N4KH(*`7?X%9(;E+7C;N3&-V)P!(5AC5:`TAX-#:,\S;G;!G3W
M&R$($A?`+JK@MR04^&FB`9[E&B0\H55"L<5BMX$?LH"\P@.EWX(-!8%4+DEA
MDW>3"S&\Q-[JI]/3ZY5Z.<A;N^:<D]"T25**.!D2&H9E'W!Y%1P0$_>$<?D#
M),*@DX9\[!02$1C7Y0&8R`UZ8+D_Z?;H/SAT(J."<J<E.$NTE`P'=D\L30K'
M%5'Y0UH`*&'#(2U)WD1^X7XIP7C(&,*P,E/-)&-#BF(6V`M3QQF?I?3(B^FF
MC,[*6W9X13S6#,L("3HXR\0A!,GF0N\[1JUW])0+HRV4*D;GY2"/)LTTTY46
MW#+A)IN-V.A+43LW.0ZVHHPA8EE##/W^HR<A&R)=$G;&BQ''G\G-.''$H-%0
M%M-:1J>J3U&M8?@F6JY+G6UT5#H+W;'T%6_]?3C080(MD>:"("`L!G#BBQ+"
ML`W`W2/BS/Y>LX@A>X\(>PG\PO"K8?BL8KUX5"U8D:3XANQ.X)7A*LI<.W3[
M009!2U_O`_R3@RTDQZA"(-C$N.AP$M-(:BLA>",*"9,+4%B'+01NTZ350*1J
M@KPIW-B'$2CY'O](J*1B1T$9=LR)VV-%/J7Q):P8H$D*F%:$A?$>G<`R:(RE
M$=3`C_DKL,FZCA=[H?9G*:O`G\LU"C4R^!"A6,5^"$7RY$=/.K5MO*@DVCX%
MD2*`2^.;)@QFOT2#FY'NG*PQQM9+2^XBI<5!"%'^Q0O-R,&(YWC3F:Z,N[UX
MG\!C)RQ)F]#EU-#X-RF"X&+H=$"UVL)Z&V<GXH]=.W"W$O)$ZB!2Y<:KN:)(
M3-TB$N.BV%"=!?U$;85BC1=913K]E9[@7V#I(1,DHG(:3XLP5Q8F&$A70;'_
MH*X!_`\DY`C(D9"+N4F/+TG!CF6N?2&E(E3EM!`1B@%IWGSS<VI)8YEQ$K6`
M7X"\(?.XD.HC7%D]R8I9B'KDY,'F:V"!>;5'_N4BEM.,/#[3`:PC4E9#B<#@
ML]PS2=($/6E6`&>PD'N(QTAB"/S_K,T$$)$_^/<?'0]%[X68($P$^2XIRF.A
M)/F.,\=AG_;"1"=G#NP(6N?XVX@T]Z3"/RT)=Q`"`W=-!*$7R4;:B9F@N2H_
MS)*%70LN:;)E'%T&ZRK035</YG"@H8,>^0@2*X\F8VF8\XBH`FA\3;)L?P7&
M`PM%[IV`SJ3.R`0DT"CB)C*M=RIF&-1"K&+2&BN-Q%$TB4UB50^K0H>).M7]
M@,3J5$"(;@T3+OR50$DN+08*XTN/-U8Z8/IA9@J1NL@&PZ:),J_@N+(U*&F\
M!2W"6:"*(/-&?N!((PH`MQTE*8WG!7Y'T0:1[$-8#:Q%3K/P@@>2([HX6#,0
M:=@"I(UV0`9!G!EDE/6PJP=O_LG2L)-[1%;D"M.`XFE@U8!&=#R2.)0@,_?-
M1.FK\6_\U/$&[?!(Q[V`L]`,"QM+:QFVD9'33MM9D8)MUD@7'JENPSM?#%[W
MFOTES&XDDB&6IA.&)**YJ-!1>\##);XF(TD"VCK%&S,KL2>65\YJN6QT=,(C
M#=^MELZU9*7MA:$A=;!TC;5.F$`$R^PIC8>3A)(7.BBH8N*:`GX/=W%]FVX4
MQQY89^>G]^"!GLRHXP(.(.%T-FR*>&;DP$<:90>6;$(/3`,36B)!2%D25051
M&3ZI?^V1%0#N-80;+KZ+'Y&$A9#U&$M/),811E"IO+1$.?OU!8.1#`3G0J2>
M+@@;FTC#*H[7EJP28X[P>`V:-\'0N'`\Q+)!G/))PB15N1'5:/#2D8\0L+&6
M[%@@7=[A(C[7%_43Q%]/@!UKP"$=M>G4!R<=:9W@IN'Y$9'/F&Y8$@*MGO`!
M#+)I@&II"3:^:3ECG:G/Z<('+39-L"#B6\)Z<)9=B[6>E3'C]CE0GQ2=\_82
MUEF=`7%IR=@:R+*+K"$:48PT86=NPBZ>PP0>%L4\RC.1]IQ8X_$H;&WCQB=Z
MO,QT33O%8Y2J?G+73>RZE'XRU")9Q;?D,4[@X=]X[W[8L-J)CG]E:B\_GU]\
MOH-Y>_E1^OWR_.Y?H,;!MTRON\Q!;`%W9Q]E=<@\-5Z5+E8<^Q/;W4LZLBQO
MH4$,EO&7!90DI/^294F^N_+6/@[N;ISG?DZHS[YG)%3#%#$9[Z:''Z7?+F[N
M+M^??@R7D.\LDF)P<E!)[C,*=NXS/DW^X!LY?\D>CUS;</*UW@<6BOYY3@A;
MZZC/KF[.+VZ.SJ[N[JX^1>DD25Z\2)YCF<:/$H]N.C@'-UX$ZH;*H@AX]/'B
M`UE.?D7JT^9^I#V,(+!(;/;9<6:90*B,?!P/1[H-C*MR[DL;V9"LS]ERAK+@
M:G]J5XS2KF+NB"/Y1!W)!3B2/%4U($SDPG::KET6._#$!'/LAJ'IX?KT_/SR
M\T_1'V7>V;6!B;ZKF5;MH$A_[V:4$16XR9R*[LY-UFH2"G.3N=H7UDV*X"45
MZB653"^94&E#OF#8KB^(J@2*<NV<I1P*\"HA\+:QS-H'E]<7@PL$+MDA>!O@
M,FH=7-0.7`K`1<2H+E>FPJ@N?W\9B;\S&J[1JDJQZRQ_H34HBK><WS<ARG2]
M*(!)"4G:T@DU^K/\W6_SMJ**8ROUBU+65E1Q;$6MQE8*@3#A1$[?__+3S=6O
MG\^/PLHR74=H-ELC<%X4GZ&#S&.2W/?&OHN&*E/P.-MNIK<(>BCAPY;9PYU.
M@=1DSK+JZ"59.%@0S=SRASS\\4_FB2IG;[M%,_D&45?<PD]UOJ%3X*P3P\4=
M.@'J.H?.+QY"S%F(#!&L[X`"XTD_.KVH0$/@/_)"C4E/F:CB&,6.8%B@!.J[
MPA23[3R[VH)]EO[C(!</P8V*_/DK&SK!C3J'OA>XD1=V#GO#L2R.4=2-&VK=
MN+%+,#PC_ZT925[6:8=@F+[W@(/AG)*H^,7-!,._9Y!4-1T'A[;0*JB/6HF#
M!1FZ('%P2AOB^+-181RL]HZ5D3A&49<_&XD6!PNR>-J(@P49NB!QL."XD1\'
M#T:*.$91-VX('0>72@KG%5VN,5P+S8KW;\(%P9N$P71TV\3`PSR'VF0`_+YT
M67]^A)RAK_U,%H\/-UD\%B5(%C;I,RX,DL<]];C*(%G0I,]8M"!9D,5SL,GB
ML2A!LN"XD1<DCWL#>2R.4=2-&ZT$R?1WT"085?O5WA,ZG&2.IX$BQO>)>Z\N
M*<_.VX^.Y[W+JVWDU-1@V^RPKK;938)C3E6,DN@M="2_H]<.TRO9--I3RZCM
M3#MD;#<H][L6MO)3&A-7LSU-CXGF*64/N>.,==KR#$/T2[9C'SG/-D_M0^^K
MX^4KT_\-O(SD6R9I^78L<OOWC-R-&'V?T21R!"941CI`CQMACG#I_4$[]C-J
MG.$F6F,W",J<)9Z5#BY3"O",SHO8@%I25%TD*^6/85#(?AO>T@M45X1UTZ"5
M2H06RUZ2*S3)K;_A7<D\&3"O8D8*0.]P2%P+8<X7>/V%5\EQY%T\YT',_Q91
M71'>J_#2B,W(!3A.\E(,D!ETW;]ZZ&H6\?<)01$Y2EJ^,!2&[:RBCL"0"-81
M&'8$AOM"8!A#2`S@21Q.WX(!M'_D"@;OD2/_(_B^%(O?=]HH>&_#B]@2CG?$
MB!TQ8EEBQ"R`*`4!:=R(KG0[CUR94'#!+XI:%T+])KAV`HOF(CUO(4GD-7()
M1:2`2,]3:#:`]!UM9D>;V=%F=K29'6UF1YO9T69VM)D=;6;'!];19G:TF1UM
M9D>;V=%F=K29G9OL:#/;]Y(=;69'F]G19G:TF1UM9C/@TM%F%H&+B%%=1YM9
MA2@=;69'F]G19G:TF:LZZ&@S.]K,]2M%U+:^CC:SZX3N:#.+E=!U0N?BQB%V
M0G>TF1UM9D>;N=YP.]K,CC;S%7'`=;29;?LSP>GO.MI,L>)@019/1YO9X49'
MF]G19G:TF1UM9FR'>YDL[F@SVP^2A4WZ=+29'6UF1YO9T69VM)FOFS8SYD]8
MPXEP0KX>,^;P'(:4C9)^04`J!9ZTLX&ZR2V8.J7D['1LG1U;YV9LG;'9<(PV
M)9?H23COT>+&D\JQ'";X&85=Y*-&J&ZB1;XM56A;Z[PC"]V5+#1KB6VZ4%:7
MVJW^B(S`0E>S4_R0D,SA%NG`%&8B[^*%4@O`DGH?TPI<S=+N>KO%N+=D`:F$
M8,<54%#.VW$%=%P!'5=`QQ70<05T7`$Y+6^=F^RX`EYG.V_'%=!Q!:RQDXXK
MH`.7CBN@XPKHN`+6`E7'%=!Q!71<`1U70/6VTG$%B%<96CYVZ;@"]JZ6J>,*
MZ,H_.ZZ`8B5TY9^YN'&(Y9\=5T#'%=!Q!:PWW(XKH.,*>$6-KQU70-O^3/">
MWXXK0*PX6)#%TW$%=+C1<05T7`$=5T#'%1#;X5XFBSNN@/:#9&&3/AU70,<5
MT'$%=%P!'5?`OG`%5-^U>)+JB]SQN:=S:,K$89M)^R#IM?1ODKV1T[S>R#])
M)<`5*03XA.#NZ#>2@71SKEG>/]\<J6].)LI$Q>%CK)%*Y#V16M""/.#5H,9J
M4->K83@<R_6HH04]R+GFP'+AV3I0CY5133IH00E*KC$4*F$X&"G[HP0UUQ+>
MQYN_<W3OQQ)DJV6,0]M]@8EAKF5LJA3LMQM0"HAR;GJZY7C!MNWQ=20W1J.,
M@*:!$OUA7^(F2OI,4A>^(]T@2P/6DFO-!;7G5_%S(4&3Q!631'C3@,8N;>ET
MX9J6A.U`[DG/2"*-&5A%IHWUI4FQC4K7@:L_:AZ23A]<1(@?"#&,)N$'/&&U
M2@M+HX000#X1+$#AWPS[(VEN6A;P39@V?IQMXN^0I^*7K$[26QK''2O*X$?R
MF^C?\H_O^M+OB#!FX,5CX!?[CJ]9\#+\&C5\38_PS@`%C><%0'F#5X'G`P4&
M8<MY1/$?\(?POSWV[OY*0JLE*ZB+IBC7"NX>0_5CB,&?II-SOY2\X!ZR?;ZI
M6=92PO]':$4"/.F>AT"GI@W`1=A*+$)=0?YZK]E?0B83C^83\6P!&+F.)6FA
M^?2E^,7W2'/!YK#M>;ZD^=+X6V`;DC3;#N8]::$M"7O'UP"O7,A.@C$1\A('
MOB8!.P8@)C8';(VV;B[P3QK%>BPR>4=/8APLR$)ZR,$"_UXPPW8]7J*YYF,U
M`*W*)VTI*3V\1!2\1!Z=9X1MMD>^^>A8>&Q>^*#PBT#K\C4P\;<7+L*BAVLB
M_@R6!-A??#P_1"RDZ8_L::'!RY,?/5:@NTK.4A]^BD#4-<ZA*FEJ!?!I;X*#
M-$H(C5_GL^4PDY(+\(?_*O=P?!Q^&L`13&4I?2/WH.</?X`S3IN0_;@!Q5IJ
M]T:`V'*)3(68I`N@!;Q9)+,!P,I$Y$P*_Y(8]XL/U@:$0]BR9OC!TH/Y!"L3
M[_@)%1$>3H"MC3[!(X@9VS*C&;I'-IJ9.EWWSC/!;O2B(X\H8=J?3K\-M<&=
M""0TTY<N8J-.6K^NP0-U%X$WP5K",1/]V7\T/>[=$F$!\Q[-!2>M9)ESTP=T
M>L:."0\63B9,C.9X8`&>ZN='$[_V&3L#0L!TC]C`@=$,R(LL:2Q+AK;TF'8,
M9)EDEIB(]&FKSJ"MM5`7F57N6C@E<QPQ6$!H,"2A`2%O`]S%$:IE$@_Z;/J/
MQ"\8.`(]<EEXI3M/R-9B[.>,^=<%GD'XMZ-C+^,BYH:Q01#".OC90#,ML/ST
M=PL0EY!BP3^CY1'B;^#1?QG8XU#_10(6Q^7PWW3;]?\KV2D<Y,Q,BT0X+GHP
M/9^R>.&W8>T27T+4#@.^O7A/!P@?P]H"S,%(HF'@4KG(BR'26PT;O0'"X8?#
M1^$1-X!1>.W1CI!;/+/^._X,,(E$N1)I0%^H6QI$#O&"PY_Y.<`0HDR)'<GT
M&=>1PV5\9A`1&#"09\VD4XDG)6<RYQJ&2_P_BG;AFVP&37Z^B(2%D-,5I6.+
MX@:FHZR1,]S`_UX"*]N3:80P08D,GTT/`T:<@&P1+1K?0<2>$^([F!=8RW@O
M;!@$"2+8GB$:4!$J/#`7TS["RCO"#@.KE:%"%)H;&K&X,PUH)1WZT,BJ9N9+
M\MDU^E\*.W2GP;V1.BD2J48R@X-$,&KXAN5@D;&QP*]")XXE@G!/F@4,,24#
M;]I)D`H*P3L;((8S)*I$%KYBX\>O9MY]AG=8TI-F!2B)@)GJ(V/$N'V/'NCC
M,.K]'1HVY0D$_L"D(!BZW?`#"Z9O>7"TA/@<:VF>>&]?.J>4I$1'A(!I3@F8
M$!`PK3B1%84#]"^PEEY,'&X#=>@WDQ&9*]#'0C.-(VPE7TR8*_P_O'NPPJUI
M*`,WI?>:!8,/0P`ZPEB=\5)/C3A'AK[T@4'DVI$1Z2`_U(N'!LR/M@=ZQ$Z1
MZ(@*30#)H"8+HTR_>T+&#P_\9D+LML=-A;7LD3^M?0N_^-G,:_R>9]7Z4G+(
MZC061%8'JY*L^,N6(*_Q[7)V@$08>S77):XC8XEFZ;@GCX=4L=1D39Y,EWW[
MFU%/'AR3N<C:VG(8$`?B/<D"?[ABY]^HO>EP2(W[,GQ\7XY=5Q@PY&ZBJ8AD
M[X$,&A62#0.A+Y7&_6$ZYLC8,Z4,I\!LXKQI3H:3RYH_NO[+#ZGT["7@(?[Y
MTL9_L.FN_W<<.UW3C-5UF+"2XX1PX!GI;/#HSU/O:J8.3A>0+I7_)(JXIAF)
M*_#_[.>L'/#HS<EP1,JO_O']3A*>),9)1#@-_$?'-?]&QJ_@L])?N<1#PINH
M]UAE8))%(QRG1IC\*DTZYPQ.Y0>WN5@GW*#"L)">PF5^N7`4D]0HDL];E5]Y
M<S+H#\9,]A)O/UG-NE_:.-(,X(^?(+PQ_>4Y`'M2L&.6>0\@\R[?.>J`_;C6
ME$X@Z70T&!T-E.1:R'[O27(U)#_X/HI>;L`5W(;Q;N%)"#LW9BH%T4/MTII!
MLFM85>WEYP]O3F0<C#'EEI#DI+SHG[!?-Q=P)'\=X52!82B#W$%$W\^S\0$>
M1FS?FTJ5'--9E-BX"O,:IY""B)\3CV*!42X]%]N;$3>@(3'ZZ73*AK1>J!7D
MP?N>:T($?^IY#OXF]@0`61E/PA\#IB?M`7V$I`V)0#@`C/<-E:R5Z[%\'@-1
MM5*>)+T,,7UBMC=L.XD,'"W>D*UW&LM71ER\YA1Z.*\<XYTSU8$R93^FT5=-
MN9:=Q%HM1;C&`?BE_0L.OR_#>+-HF>4>,&YBGWC!39+GR*M29)R5)U?FKS:+
M>9%Q'H8_!9(/J..(SD,+Q5G[IG1Y3RCU!0W5X?OTO)>ZUC@T+])M[MEM2M9)
M0M:RKSZI7F(U[P@]+;%<A<3\GZYF8;`(LW'MHCE0IE6@7+PE2I[EKWOI:O'"
M+F*6U:BL#K84,QV@\LN6'9VSD_/W)'=;#`=J<E5M"`(RWAIE1LUKA<JLCHA7
M[`<<S*6K0"J7?H2W;`6H$<NP"KH[(=F.8JMX=[@;V&VEZV%*:.RI(!`GMAK'
M(53B37=?(WDPJ&0F>!,,X$U7LPMR:4W\$:\P?E-&N?ZQR@&399,_X#+#()/Z
MC_]W="3]S^^??AO^[__\1U\$+W_8HZGQ]^3IX8^E_>MY\/S3Q)U.?E'^^O5N
MZ5F3)_WO@?6S?_SK^X_7QA__M=21_9_[J_?GE\N?[KZ>/=[(^M6S.OEJS.Z^
MO_ZLWJ+QD_GU^-/%P^>9_/"+.G%&W_W7_.N_WD=]^-WSYZ>SQ;/VUV]CI/W[
M1?[ZU[,V_>[Y\?;3]7=?/NK'G[T'^Q?_Z[FN7'_\^XNR/(,,/'IR-=="LN?*
M/_WK[_?#B_'#L>5-;Q9W"_/Z^T_J?^7K3Q-M^.5[4W\<?[<X_OBS?O7TQZ>'
M9W_Z\>IG<W3_;_\[?:E^_?JO!]/29M=_.=?__N<__U=Z?WMS=)1QE0EL>]A9
M%%4?S)*()5B3QL_2HRJL$7<FPIV.\+KCBATDJL?<FJQVLHN3QH]?X<EF0H^G
M>%$:%%]\1SK%BU>W:&8-;KIR%PX]ZDIICCPC3;B*-2W37Y(_9YS]Q=\5;29&
M3<_$173@A!=LH+E+"1+\T7&X-J='`9#>?`^0"O<QT7.HQ+R0<@UZE1M\%/M0
M4JOP+^3BO\&YD+9``9Y3+!'^7C\\IV3E&IHD'\T<]T@92"Z;+0_F:7WY!9S,
MD9>QE\-S,R:<'NN3S/03K?J"QWK<(H73I5NT\(F[B1>R/.W%_X`XM"^=>N3,
M&LY=PMQTQAOY(S4M2A9R">-$@0T1#^]C`QVQ&^_D'MZ1D;0Y),6QJNAY#?D7
M?8@@1Q.3QD]C5\$#T@822V1*428S"RM$J7B9-'Z@<PE5"C:*BV`];/C2<7]0
MXC"#'#-#Q6EXUDO.612E?QQ]^2TK2$V?_O05OC0V6:[ZCIX^DKI`\O*H2M&@
MR\?$81P6P/7B@EC'AA-%TKD`JR+\@C3HC_(6%ZE#E-`+<G73(V>IM![G&[4_
M'I`"3/)%"B;/(4T2+02:`QDY'0M[`"G1!)A!+PO3C:H_.,A((L8X]5RHG(1Z
M+28.K5&A59XVG'PZ;D\R9_EE,:1&CM3$\=4"Y*3_2<-A'8@7EKVP*AF&4CGJ
M,=GIC!1`V5*D)O:E4.X>+96%S2<K=2,%=NS/O96:H^1?H9!-(]5G,%)R;A>^
M**?V+Y*#%V+C^K_$4ZHH_LO1(1X]>1^]\I,6[VG17!L(KC(D)^)8$5`3NX#-
MO!Y8FANM_*A`-[.F,-*`3JH<$%R!ZL:51##CZ,$!":THO5M0/@BE56R&3%(+
MH7WAM`>&2*V!*AO;>72NKDEC^<C`XV)/I+>EME6\VPYX'S>^W;A*E9@1`*^@
M?HZ#!79_;3F4H':1C11;EM"=!@]X3J1A6$/W.R)ERLZ]93Z0I;-+65Q4V\:Y
M%'@Z&1&`!;*LDHI(U<[%_@*K&R,%O_ZHGGWL;U@B&1;T38!?*0^'H<1<\\FI
M3ERH/%5Q"`Z5%"SXYOM%PJ\G6T8B"*7UIG#7*EG$X"W#$4O/CPY\!`!DAFW'
M9'$\AC@Z:-.C%Q@#EA`?D]!.QOB2`^HQS4&U6/C*1QA%JO`1;DVNNNR1SJ_I
MAY6+WFKI(M2"P*+13%)H]@6A1=$3(:5AVH$3>.#ZXZH\XN<X0(?N!@X"WI)5
M1W0$!HX="F4??Q?>:TUZ,>C-UL_K+#Q;-++VF6=)?'>!?\<<9&SEEHD5;)"/
M&-I<8S=19U3>R?T![48A)6"1"P^?E.C8P%J&VBXM+M%B$M/]3A241:$6_(T$
MZ2MM5#WLT18+P#$_:G9:(%NS?!(NC+%4Y4MIZBQ8K@_<-RLOY`-@%B/$L20L
MP\%P$*-27.BY$GC1M>*QR)S#LKAY*:O*D+0/(#_18`:U6\/!-#<`Q[B`8SOX
M%@ETHUT$LU;H!L51T4:%EBI9!M&VX)M!?QQM-**(.AQJ"!\>YZ52E_.TWQ)W
MW'CN)W,CK;RNC?1Q&^VD-!;#NHHWTJ.^7&8C35!N%1^_D?'^E=N+]MB2@]6`
MUUQZZYW:9(\&7!M$SD9<Y>3+V(@+$5@/E.D1?^MW(W$UBSL5&G@J.T76%&*X
MTGP:9F\9$4?I2&E,9:LUALF-7-;%&R1]DSE%26J^6.M13)$PNOIF.3/:&:6B
M'=(I\X`]WP.)3S)#F,!VHY*C<)H?D<7:B"M10WU:6!-I35<BK?Q_M(CWTU:.
M^E:\I"HQ.DF:\K_"B\L-Z2+7><IVL%4=-(RMV$]^=IXH@$4!6Y)Y@6TA(4D%
MGHZ+._'Z`P=%]HBLV94Y6HX1(>GBCKD(L,`#LY@S>C&<_3"OC,%-Q]^A4\DY
MY^/^()$GY@D:J##K'/1D?:9<[4\W<=!M69'<L!6!YXRFY)GD5`V4,`]N!Y'8
MI,8.+\<]XG]\<-RY='ND2F]O^,]\=OJ2JJI'\G0P&@W>1?W6T*_EHB>3>E0:
M)22"`=*,ENG0:78$>$0<TET4>-AC+!86XQA9>12-&3;R)PX/0@VX51@HI(DX
MG\AH,.PE5;-T#QU"WI>E9&G/7J2=,,C`D\=EMOZ-7;,Y,_'OH4K']`/6R'86
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MDYC+B%:F(]*MF0Y+MI[3K6O_AH,L/MD&"O^(V1_1WGW0$[*]K`JUMG,JPT'C
M:<4[<AYM6<XS2>82G^@%\[D&)5`>-<"C>Z(XG5-<U.8]6[-"XLSM2FNZ%+*S
MP*E5XO97^,3%?&$Y2Q36:45<;]<6WHGPAVP7M]?7_`%;G`X@!U<>[/=#::$<
M[L%QE]);DAS'H2%^E??NA\U6!M-2V@`N/Y]??";\P]RM]X/!;OS6:3L!@N*A
MPNY!ENZ!GL%E?V)0B3V\97D+0GZ6\9<%T`ZD_Y)E;^F[Z_%;0UKDG&U])MES
MI=S>OE/`MYPL+(T."^Y73H<VI*NN9P3YRJ6L[.<%W.1UC?3LZN;\XN;H[.KN
M[NI3Y!\E>?$"VWG3^%'BD4XG^8':B;K+:`RHRD.%89P"\[?99\<9'B<<?CZ*
MAV/;"L0GN3/7B+/+=VHE+D2I53''[2KFCOBH3]1'78"/RE-5`\)$\>-.T[7+
M\H9JR6`NV8Z-XLN.PC_*X,0:1S[*ME\S]-'?YUQ(E2>;TKF\^B9>82ZOX!J?
MSN6E-$9<GI+I\O(N^ZD/V>5!N\@.^XH"'#TL&%5"&&UA.;4$'%VLO"%P9,?*
M+0"'W#IPJ!UPI(%#P/@KI^LUU'/FA&UUA5>N`!1JSG(#P>I?2*XH:_*%``UG
M5=^EF/\Z:FWI`38PA[G&5-<<-OA",H=5WVNW=@[5JN:P$!RVOBV8$WF8HYH,
MO,Y,ZV]W8?"F6>!J+@PN[\-W.K60"R"JR=.Z&^0ADE6!\P,#/2'+6:P<RE?M
MTT6ZX)(W\]=X)W"EUS@FE+%R2S"OBF^VW@1L=<>GK`BCEO35P.G5*_>4L7((
M]M%=#YP+(:_K>N":(23O/MS#AI"BZ$\93E=UL)<&TN)5P64CY!GY;\U(1CER
M[A`AT_=F1LA-1\5-Q<0YE3SQBYN)B7]"-G+#^EAC;MJL</H)95<\<396=5P<
M&D&K3FW40%R\-C,LKG)6XN3&=5/.'Z;5M9,_'$_ZZK?5Z3`=5"<#ZLE@TEC^
MN'H[J\M[CC:+P&N/0@59CO4'X*\=J]0.JW;%JKP]C=P;'8\[K,K%JI*1OKBI
M\'$.L*P)]&GY_V9Y<)%SW]NW,\C'.4NGR0C_=EV)/FWNHNUWS@)!]`_T<?2O
M7NU%AX)FM\:M;014[$`,)[BW4*E4CR"H-ZXKAUY"2Z\[1S9>FV97>M/QM`E/
MJ^9X6F%M3JQ=@4C`U<*NX%4#5_69^P,!KJ+DOMP[5D<=<.4"E\A;A%)G`7FM
M3)MD49H]/RPWK,QB/E%DRZK[$T6VU1)!423+KB841;JLPD-19,NJ411%MM5R
M1E$DRZY\%#?;D]=\^?JR/>F6N&:2/0K?JE!QLB>?EVV^T`C)OW2O>:9.*QM-
M*P#:!*`FLQS/B]G.4KF<PTCD''>)G`WUU25RMM7<ND3.H"^K&8KJMD2@O"Z7
MDX==72YG,^SJ<CE;8E=1+@=CE])A5R%VM9'.H;\#QBGX-?RK?AHR)?MDN+XP
M]Y10Y*4I]<@%-X2$-$5H-QSUAQ'_+M!]$UY?(/S6G0>;W-V8.`D%6EZ>;0P;
MY1'P@P)7)<]PQC@J)>U9<PU/>H#+)V+24,L*J<4S&6S)9;')]RXLS88KELJ(
M]XR'`PR8F@%3QZZ:FP5^X(;W99++8+#41`WD[S-DPM_9+4XA`2"<[.KT_K7H
MC5ALN'!HY:T.7"BFA9?<X.$I_5%LLDND`8,J)=2E-PY)SPBP#QE'&OZJ]H`D
M4"2A8*;/((3U<$%3WK$T5:X@',E#);DMKL[62Y_?)Z8NFEUR3YQFNM*3!K2\
M>&8(=3]ER*.6*;&[O>@_X-H@*?#"*UG.+`VK_U9_=,C-O/1K\"PZ"7/'0%;,
M81PS`*Y,K^9YP9SR\KTVFKPA@[%F:?*&XVUH\E9S%.VVCC:24E&SV%V;7G_P
M)L)X>\5;>=%M`)RSWBFCTM1^@[/(#+Z4])@.ARVEI,I*D@MNM&9VX4Q1:^5,
MV6C='":374F[R2!3J7JM%1X:Y$G6&I7=VEXL\2FI2DU]%IU=A[)K5%:2SRX#
M2FI"V?P#A590=@W%W>$!;";-W9XC2A>W;8HHZXGNFD.4_#1_6XA2Q'UWP(C2
M6LBV?9U'/(H\*UN3="A#<-5X&J+\PMPI":@.\_&@R:5Y8WI?CF9`4A[=U>UJ
M_DJG_GY7=G"6_!HYK*H:^FHG?L5#?XWGF;R"UC;5]`>K.M@;XAE>$]N35WTK
MD'XJQ8S715I5*6;4.?1]P(S"?I:^?%"8L0U952G,V"7*+:B_CD=0`XUK2#>P
MMU%NSGV4\8N;B7+/S2?30+8A+4UD&<G@MO;`MD7N$LYX6PEL!1FZ((%MI:PL
M\K0_&E4'SYG$K,E:O8IC6Z&H5GA%"!+;"K)VVHAM!1FZ(+&M^+!1T)!V:+`A
M9'A;*HE;`P?KOB=QASE%>O&+FPEO?W,LS8<KZI>9Y9*<`>UETK8)@E5AARY(
M;"MJ`F:5&S6]4.61BGV4,'91GR($B6L%63<'F[/-8C'M(&,%,@ISMB.E/Q3'
M+NJ&#"%CVE(IVRWI1@\Y93LLV,PU&=->D)8R9$B6.4/26](7]BY=EG`8N=LF
M>$.%';H@\6VE29@*,7H]T^?X`+(O&[)V'LSB.=CD;08#YQ[@ABQ/JD:.7)ZS
M0X*-5B[0HK]KEF5AF,W(UEQ4E]5Y[N5UGB\"5W_4/$275XH;`;YS<7M]+6D^
M^?D>/9BV#?WDX==M+*TSFV$)8ZJ`S;K5^])IYE/(NSP)/2%W*7GF"_ZT[3\2
MLH1/VI(PIGUVGM#\'LL92@,!;%_ZX%#)_4<HN65?0S90Y2>I*,A#H%P^XJ2`
M_[.=+'FP^"[515)C$9U$BOF`L[\&:0]&!1WMS1E?3#O`N`*"^5QSS;^9%1(*
MB=`:--TWGX!A8U9VUM)T!<G%+B1CP32D(&B4L6`ZV(:QH&L-+>WD.`5WK:&;
MJTRTUM!Q'I5JLP@:V<HM<']ZTEL3^&"<P,/>BF5GLCJ[*D[3B-K6Q1O0OC>*
MKN)+URBZ*;X(U"@ZGHJ%+[^'G%"GC!/JX@6YNHDCVVO7U%&'-(UR?@B&-,,.
M:39$FJ$X2#,9"(XT-VBNF221\!Y+XN)-8*!9TAURY]+;/^)3J`Y]>/2I<TG6
M5/D8CR+O=&E-TG?M-05LWSX:M4"G5WXQ;\^E-ZGQ>H+2"_E,LS1;1Y`&_%FS
M`\U=2BP9T_AA<8OE/9PQ'UHQ)#]T00Z+Q:ILXA6T]K"XIXZVOX!9\,HF7A&"
MG1<+LGY>85%D?292$^__/D!(47'D<5_9C=3_%9E(0\?'KQ%%\KKE]WOH!#/J
M'/H^H,>P$#WDX6&AQ[!N]*BIRCH>R9;T;[G[Y[!:*'G-GWS<P#U_;='23_CN
MR[:VTC_1:I&5&H9]KK+FK/C0JJSYH0NR<1:KRII7T-HNPIXR4,6QB_H4(=C&
M69#U\PH+K>LSD58WSF)#2-'&>=J?3C.TL)<F(MC&>9NFODJAXZSA[7*;`Z9W
MOS>U20[/J@53`KED/J&#O9YS=G-]`>FU"#?7QQ)OR?6XX<WU^[VEY4M6V]K2
MAF5C37,^"I&.;(?S49"A"[*C%343F\GWF-#06V4RRM#"'F9B=Z%\K`L]CT6X
MI[)YO@5!P*,[!T\C:7<.GH6?1=OY<5^>'!9^"K.=WX9WLE+H:'H[W^:`A=G.
MMZF$%K;S;0Y7H.U\J1/J+;EMNQ-J+B#-:V5L=CN_,%UD$'*$F>/.D)EQ7GT8
MQ]5-D-ZN;7L25SFKV_^F=?.ZCZLR>7,3Z0%YIWN+-NAM(AP8K^=P:T.BW4:P
M.Z\]JP+L+IT\."A8[DH!<JB&NU*`4@3#D[ZJ=-B:BZTE,PU[?*0Z.K2Z@5'#
MB8:U>[\V5+":9JA^TBM$CS94E)F:$+?08$N&\K6%!ON:A>#UU586@FLY3]+_
M-1WQ"G%:U@0[>?9F6\6;;<,)[BU4ZNBH)>W47HA00CNO^ZQM/<?YI*=,MJ^^
MK\#C"7HRMR$ONNAGW)4"5G>\GT.4WAWO9Y*CIXSDN#_:[7A__U%'E%VZ2*AS
MB&WQXZXMO@S:%+?%#W<CU=A_M"G91U]I*H#^+N,.AW]\'WA'#YJV^.$6&.4?
M'<M`KG?Q-3#]Y6?'1^>FIUN.%[CH#KWX9Q;^S`E]Z#_"+[YWYG/')E^G;,NG
M@?_H`%4]7(%@^C=H]L\W'OG+&TG'FT[\(/([71G_>>I=S63U9\V&;>F?MSJR
M-==TKEWT9#J!9RUOT,)Q?61\(I<4O)$,I)MSS?+^^>;R\X<W)_)HP/Z+!U(@
MSTFHIRJ$GR2%7Y%M,MI),O*Q2\\+D'$>P"4*U^0.!?I%;+SD3]XZ(8___.`Z
M<_GG`&24[QQUP'[\\]HUGS0?75N:CN;(]N&75,M_<G*NZOUH].;D.#VR<L)F
MJ-_2/*S$WS476OJOW!N`Q,\!O/-J=HMT_"S?1-Y[S;*0<;9DG_/8!]>.?DJF
MJ)HQ*\IQ>CIW$_Y$6E''M;8$L?!#(X5"`N>]X_%C#3RCF6F6E=2(B^0[H4-Y
M=/V7'YAU/V&X`\S!QL`&'[6Y-&^W9$T.^J-_?%]2Q!#GR,?#WQ)6YU/XX`-Y
M>SBI=\XUN]*$/CC\%_D\?OBO>+B)&<2_RQRY.BAML_SHE#<G:G\\8(.K0MK$
M\#^:<]/7X+*1*YL]'+06/B\>V0)[BO2(Y)6YO$4+N#*FY-B&,&^#Z73*1K=&
MF.2\S68(;D=!-_@]5[./)O9L!O[1.-?FV@-:([D22FY1R94I^[&DY"J17(ZF
M98TP)Q(O>OH5[[7%`F&[L37?6C8A=V1.A9*DPP%B46?8F`RX/PG9'IDIS@C/
MEO%'&*"</FNN\1G/)[G/AD8?E[;GNP&!F[*HH:ILW-0C8TN3/VDNB2P*4(/9
M35Z$,1P.AKRGJW%X)[7$`.IP&ZVLQU)Y<#P<3'>/`:Y=!P?LA@="AA[E:L:]
MO\CSU3"X`39^SN6MDZYX0"FG4NC%U1$_%C4>2UF@!)\]3KOL`F%6EFXEYC;F
MP4>!4;`?LT:AE(U%1G)%(2?]`/UBZ._([\JY9QKUEQE3RCW+./9(XTB6&&5!
MX#>X@BYC4C+LJJ89&8S*34E2T@K#WIH&IJ9-K6S8NUNP<9P>3%&8E&%C+-@8
M-1UL5"/W=+M@HQ+$FM(1?':>&.X.V(^KMO+GSXC<:8B\CQ_?YVR.TQ!<%JF2
M(],LQ.QM<Y0:AIN(;<>!\>JXGQA#CCA9JWDG?U[M7(PFZ4W[-OY\6WBJ=BSJ
M="-8XE=WH062/]+0-`Y%/R-_W18]+_!:"105DJ4+]]W;B))>]OPD9GZG,%E2
M1G`<!$Y'Q[F6D_G2%<]],5]8SA*A6^0^X363O77`^X(GY&%<)KL$O#7W-8O_
M.TSG9\?_`V'Q=>?!3J8F5X?'EG[6H,"*AJ-ARHQJD[(Y?5`;^N"X[%?P.;GL
MK)]<*W^,/S6@CTPI,P)4_1$9`<!M*4E.+<O1:39DEGX7@8(H<5]:(>1<INW[
M7I7PG*3J^U[3U9'IU[9^X:OO%--XB']+6C2"?.5F7,;8T$B%O"2MC,8*[F+,
MJS8M+F_=Y7JTP21WYNILUHJM(K*%=%MMB7K66A53ZPVXZQ5S1^[^_D3O_KZ`
MN[_S5-6`,%'9\4[355L%0?6WT959QQD7858/?84-`7FRY;;1=BYO]XE7,NXW
M[UQ>L<9*7F_>#+++M=X(NAY,H\Z-;!P]+!A5LFXNWV_@Z&+E#8%C_;WE#0&'
MW#IPJ!UPI(%#P/@K5<>?UG/FA&U5DIPK`.O6+KIQN^(7TF[I!E](>I.K[G/+
M?QWK\RWJ"JMG#G.-J:XY;/"%9`ZK;HQ:.X=%;38B=&O'(F])"_]7X/GF;+D!
M,_P40)CE@2>;IH&KZ><N[\.CX6WEQ`L@JLFF[AOD(9)5`6XY`STARUG`,6#2
MK5?LTX5JV.',_#42QU?;7\(K8Z6#FU?%875(\FHI<27:>'L2HU=D'X)=B282
MA!QRD_4*A'1-UED04A3]*</IJ@[VTD`:8E#?)4(N8%J.1[(ETW)1A)Q-MCQM
M@VNYJ9@XJ<768N*?D(U<S2(AL6;,3=OTL)U"\6LZV55[7-PBN2=GW!WG<I%R
M#I)S>3SIJ]]6I\-T4)T,J">#26/Y8]%907FMB<5R),ARK#\`?^U8I798M2M6
MY>UIY-[H>-QA52Y6U<V-5'LJO"[B4@&B_$URW]M3F<HBW(]*&BZ.[J'X7=*Y
MZG<)O<#/2#)MW0H,_%?3EIP%@NC??@C_ZM5>="AH=FM?.4_K0KT,%M1J$F![
MRGW*:VY=FEWI3<?3)CRM^AIXP7C-B;4K$`FX6M@5O&K@JCYS?R#`57C)2>]8
M'77`E0M<(F\12IT%Y+4R;9)%:?;\L-RP,HOY1)$MJ^Y/%-E62P1%D2R[FE`4
MZ;(*#T61+:M&41395LL919$LN_)1W&Q/7O/EZ\OVI%OBFDGV*'RK0L7)GMSD
MSN5\H>F^Y-C2O>:9.JUL-*W`1X9D(U^R',^3%@A;"#`@I'(YAY'(.>X2.1OJ
MJTOD;*NY=8F<05]6,Q35;8E`>5TN)P^[NES.9MC5Y7*VQ*ZB7`[&KL;NIWBE
MV-5&.H?^+KR?@J,=K(L+:Y5VBWT7&=F/OF#GC`7,:T,YEXLX;-HYM8WSN&6'
M/3.#[D\%\OVQDN!I*R=@FBJO@F$IN;3$6PQ+&4ZW&E75@\JG"F?%I'A,IXE2
MTN+9F@PFV\U6]?,US)VO[88V(HRF(@RM%'4CL;+I>#LSJT%H-6\Z5A1]K(YV
M$YHP;-+=])5]!GMI6)ET)_T9^1_Q/AJ#(2,?A6>:]KEC69KK;40O6VH:%*#U
ME55&^[F34,V/L-2<T1$J%8]PU?5EWR?`4Y`"PS9U@)X7S.GO[L";OE+NQR$K
MVJJ<^S&5<4R_=1OJQ]6\6[OMT(VD"=5!SN:DR9HP>),)/[!5\`.)(LWP3S5R
MG#2UA^8L,H,#*#VFPV$`*JFRDH29&ZV977B`U%IY@#9:-X?)SEC2;C((@JI>
M:X4'87F2M4;/N+:_4'R:M5)3GT71V*'L&I65Y&C,@)*:4#;_D*P5E%U#VWAX
M`)M)W;CGB-+%;9LBRGKRQN80)?_HJBU$*>)S/&!$:2UDV[YV*1Y%GI6M23J4
M(6UK/`U1?F'N1$"A#O/QH,FE>6-Z7XYF0+QO`LP@SY=<S5]AG]CO:B7.DE\C
M+UM50U]EEZAXZ*_QC)Y7T-I&L?Y@50=[0Z;$:V)[0K9O!=)/I9CQNHC8*L6,
M.H>^#YA1V*/5EP\*,[8A8"N%&;M$N04]!?$(:J`F#BDT]C;*33:HM1;EGIM/
MIH%L0UJ:R#*2P6WM@6V+?#R<\;82V`HR=$$"VTJ9AN1I?S2J#IXSR8:3]:<5
MQ[9"T0?QBA`DMA5D[;01VPHR=$%B6_%AHZ#)\M!@0\CPME02MP9>X7U/X@YS
MBO3B%S<3WO[F6)IO6J:_3.5M#R-IVP1IL+!#%R2V%34!L\KWFUZH\DC%/DH8
MNZA/$8+$M8*LFX/-V68Q\W:0L0(9A3G;D=(?BF,7=4.&D#%MJ93MEA2ZAYRR
M'19LYIJ,::%'3`<>%<N<(>GM$FFN]RY=EG`8N=LFN'"%';H@\6VE29@*,7H]
M>^WX`+(O&S+1'LSB.=CD;0:K[![@ABQ/JD:.7.Z^0X*-5BZ%H[\K8@ZIHGWZ
MA+TO[L[.YA]Q7<U^0/"2LV7V>S]HI@OO0]R[H'KT@XO0):L=O=%\KDU]$;AH
MFP9\%=K3!PK')U"[T"<B*:E4#S]5DBSOB9+"<#^LU*C2D@9U65*6T$(I:0-+
MVCLEQ8<BE=F2W!^I=:LI*786O4;+RBIK4UA9RE`(9=VO?^O])F^]0^Y<+LU+
M<CW^(Z6%6N1)TV<U-?)\<VAMY!D!5.*=NH^AR%^^9IZ9:4@<4S7/3#H+FW[M
M-D0S74=_Z;T)I^"NHW]SE8G6T3_.8W4/7]MP_RT!1$]Z:]J2_^@$GF8;+*F>
MU9!;<79=U&Y<WH#VO;]_%5^Z_OY-\46@_O[Q5"Q\^1U!(A091Z=/R-4>D'3Q
M@ES=])!T[9HZZI"F4:HFP9!FV"'-AD@S%`=I)@/!D>8&S373AJMSWV-)7$WW
M`\V28(,HO?TC+A[HT(='GSJ79$T%Z_$H\HH"UIS5K;TQB6W<1Z,66%#++^;M
M*5`G-=Z45'HAGVF69NM(TGSI9\T.-'<IR3TI8AQKLL:GQ:I,SI@/K8:='[H@
M-3YB%:3R"EI;X]-31V-Q[*(^10A6YB/(^GF%M>SUF4A-5Q#M`X04U;0?]Y7=
M[A=Z12;24-7/:T21/)*3_1XZP8PZA[X/Z#$L1`]Y>%CH,:P;/6IJCHE'LB5K
M9^[^.2SR3-XX+!\W<.5P6[>)3/BF^;:VTC^YFNVC%*M1A@+VJ3F&L^)#:X[A
MAR[(QEFLYAA>06N;OWO*0!7'+NI3A&`;9T'6SROLCZG/1%K=.(L-(44;YVE_
M.LW0PEZ:B&`;YVUZL2N%CK.&M\MM#IC`0ZT#SCJK%DP)``9)'>SUG-/U?E9P
M5T%C6]I21\);4O2N/1(^I"TM7[+:UI8V+!MKFJI7B'1D.U2]@@Q=D!VMJ)G8
M3)K>A(;>*I-1AA;V,!.["U-O7>AY+,+UPLW3Y`@"'MTY>!I)NW/P+/PLVLZ/
M^_+DL/!3F.W\-G3!E4)'T]OY-@<LS':^326TL)UO<[@";>=+G5!O24G>G5!S
M`6E>*V.SV_F%Z2)#TFQ#FCGN#)D9Y]6'<5S=!%?YVK8G<96SNOUO6C>O^[@J
MD^X\D1Z0=[IN;H/>)D*"\7H.MS;D1V\$N_/:LRK`[M+)@X."Y:X4((<AOBL%
M*,4+/^FK2H>MN=A:,M.PQT>JHT.K&Q@UG&A8N_=K0P6K:8;J)[U"]&A#19FI
M"7$+#;:\6&)MH<&^9B%X?;65A>!:SC]IKOXHJ=D=YX=Q6M;$I1+9FVT5;[8-
M)[BW4*FCHY:T4WLA0@GMO.ZSMO574TQZRF3[ZOL*/)Z@)W,;7F<A^AEWI8#5
M'>_GW&_1'>]GWFF1,I+C_FBWX_W]1QU1=NDBH<XAML6/N[;X,FA3W!8_W(U4
M8__1IF0??:6I`/J[<E?OK&>./PE?M_L5#>Q:GZO`]WS-!I;VS\'\'KGQA0P>
M87!.7<DP_//4NYJI\CG2\7Y6X2]B.%+?G(S5T;B:^SWRY*M5!2'5(V-Z#'L#
M"*-LK)C`,ZZ1NZEZE#<G0'Q3BVJ*Y*[RJHJU;XZH,3EF3"#&5%)J&JU<Y4`U
M!E<Y'/\QDL\KN,UA>V&KNC.&24!8$[Q+&QN-Z1@_N8[GK5EEI6Z)@?4F*P.U
MTO66(>OF]WIY&[UDYT572EMX^4'[[`::JFX4JQJ$B]4N/2]`QGG@8@NDSZ"<
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M>I+O8$GQJO%07SH/$/P[P)]R?;R`R%CPHG"=@*PR\E!8JYJ]_/_:PO%^Q`\C
M@U["]QZ0C4`4:1:`&P31R`5Z;`PP'+RF//0UP,.SEOB]FH7UPP3,U6Y/TO`3
M+8N,FT"$I%F6\TQ.^1\U4"+6(/(@TV-ZC\CH2W>QG&09FS8H#(L(L``C*WJD
M]H`_X/F2B:<@DHJ?;$]R9JG:@GX6@T'C2^*XZ24!>C:QFK'-895H=FPZ_#1B
M0S&)CAV;6!#W)Q=A2[&E.1XVGD9^S6@^^:REN0]X:B5MCFT0?H5_;WK2W,'V
M99E?$#8C_#M;LAT?YO<>K,D#`6#;MH!Y#0P3/WM)GN8B"SUI\!R8SL!_=%QL
MNWWI=)WDSR8V%GA'4DASAJV$V*"%/(]*HDFCP;=4-O/1P:$_ULP]@M43248,
MU`7C?4+4>FTP31]K&R.`_@C^CZSGQ'J#;.BQ(D]^A`P&)P0(>H^7W@P,%F,"
M-N%SI",(J>(4*C-4E:Q"C8)"#Z-"Z/;@=;H5&&0!YKZ7/.'4MN'.E1N$\<R'
M.<61[SQ^DSPX^B5:=&Q.(KV'R+2@NR)DPPL+EU+16HI#B2)''H9)__C^Y=ZU
M:#[@_P!02P,$%`````@`@86L1-U&4RKF!@``RCL``!4`'`!H<G1X+3(P,30P
M,S,Q7V-A;"YX;6Q55`D``Y(R<5.2,G%3=7@+``$$)0X```0Y`0``W5M;4]LX
M%'[?F?T/WO1E=QC7N0`A#'0F))2EY.(F0`N=3D>Q3Q*!;Y'D7/CU*SD.FXN=
M.,'&T+XT<61]1]]W='2.)$[^DF7I`BP@B($N=282KOS-S'\D6:K8IM/6L'1I
M,?ZKQO`0^#-K"(1_Y[_W&7..%64T&GW4>%.J80+4=HD&5#R09/F3)/[]^<>)
M`*D0$!#'TK4+4AU-I.RAE,\?[Y>.\R7IYKHBY;.Y_>E+_`T#6X\=1$$:FX9%
M3S-S8.,.,3[:I*?DL]F",FN8F;8\'HL'"^U'!:]UKE0J*=ZOSTTI#FK(N\TI
MW^NUMM8'$\G8H@Q9F@"@^)AZ#VNVAABVK0AV2:$MQ#=YUDP6C^1<7B[D/HZI
MGODT94Z23HAM0`NZDF?Z,9LX<)JAV'0,89'WK$^@RRTA;"P+#K.%:1\?Q)-?
MY!?7C-H&U@7[9\@08VGW`5A&$EW?M"Z?1]$'8EML+-13Q&]*Z*O*3-JX#;RT
M.#BT&?]L@K6MC<MO<S/C-[&":/^S88^VM.WY->633YR&#,TU/$>J<1L6K(,Q
M`TL'?6:?Z&X'G9[=B,,9MK8`80@GMLD,P4`=,$XS+I5["#F_RI0"HQ67$$^&
M!9:F5GC>W$6TX[FT_QYW[5Q!`8/1V1/!9T'.YGS/_A`,,.=06YLJF"U;'L'G
M`Q</D<%[I&56081,L-6[18:[+'0L0X@&[`W-']B<Y&6R.$9$M)F-_.."WJNQ
MPV^A4-<TO=YDS%U^]GZ7V.8&)9F]-7\VT8&<9G(9:02XUV?BHS_!MI9,)>`@
MK)^/';`H</`FXTZ=N,]%@57FY\R;U"L2>;Y:^26U7A8.DHL#<YZ4'N=!9`?3
MNCP)=N95);;#$ZJ)RH,VXU**">B(M:L!"<V`-7B+`WE;.JPG*MS;=Y-E;D8U
M;$M++B(%`[W5R1!"B\]^887]G;BO8=3!!F88DEP*`E!>XC!E3;-=OFJJ:((Z
M!B29-P4CI9UEA*NV$$U#:(HSM^`8Q`7]==PH'"SU/"*R(F%LQ91">"64OW&`
MN>@-F\',`5I@B)I%121<I^":;*L.9R77FU1B!WY"`^Z.T:O-;.VQ;QN\5RH6
M5C9)8JX$H+RH[+--T[:\3I.K\)8QTEV9PW5:J.=6B(D[:RWK.A:F(D/EA<BE
M54$.9LA(),"&0*6?JT83(Y2JL.BZDR`M8`A;H)\C8O&*G?*H[IJN%SNJT,4:
M3F3QBX":<N2-IE$4]A++<7DM\SKA=R/F&THAUY(R+]V:O"4DF7PO(PMJ%1(S
MO-UD96D[^5.2F\S+&^V[QJVF(PZ>^)SS-[,2V6%:!=E]XK:``E=>[)=680B&
M[>U!^!TG$V/7`4[#JW>^]N-;_7;_YX_OFN..[ZR#DOY4'/;N)M9-U1U=%$FI
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MMC!EPKXA).BRFR#3C<61%-K(6LS;ZPU@TY!:LVDB,7`1X$5;HS/^DC4X"";E
M9#)0I(7MT2!J0FNOG=CW+F,`37+%689(?2-K(^\KI*S.3GFAX'W=9.GYY/\%
MLXYS(+I1B3W$W(BSR0T56=BSQY7%_1POP4PH>D1%W]VU4XV!*?GUEIK.._T2
M77'NH%?!(:#A*1M\"31MPO"3]S4)7=;!I5V3ODRCM43&?6;9[B,"9XC;)V[N
M\4"8F&`A2.];JS#ZXMYKGW>"9K<*'5;%U#L54PF8V#634&PSZ'L/AQ%H]97<
MCR-$\M!+@#M+%:;_7UI+1YO)9&:;0-^[BA%H]54\2$S%I>/05Q-R&3?=,CD!
M'5>(]:4\C*F(7@7U;\I5H0N$0/"-N=?1-Y(EZ=>WL4H>C7W?"8JKM5J<A=*E
M->0%8EJ%4A#Z[D/DH5#L%])KNZP-7$P@]&Y<(C<(HZ._T81PC2\LW#C<@N;5
MZDO>?54*,?LSMI"EI>7"0>@O<&%B:P`Z_<SU^H8(06+[&XB&$SH"6HOW9I.F
M-8HO78U=0V:\U_;_1_+.)YN.&!F=P>E):Q<,^CL)&$+KFI/?F/Y>1@6";7UY
M%4_D4M4V^"GG1+MPM;1+%SFGVG#N]QL-/W`%WG`AZC<:?F!8"-MG"CVO.'G^
M&U.OU7]02P,$%`````@`@86L1'\5R1"\&P``/)X!`!4`'`!H<G1X+3(P,30P
M,S,Q7V1E9BYX;6Q55`D``Y(R<5.2,G%3=7@+``$$)0X```0Y`0``[5U;<]LX
MLGX_5><_>+,OY]24Q[&=FU.3K9)E.\<3V]+Z,IF9K:TIF(1D)!2I`*1MY=<?
M@!=)I$`2A-"$F-6\C".)Z&9_0*/1Z,LO?]O=W?F(?4Q1B-V=^]D.Z?]/./G?
MG=V=?C"9WCADY]P/^;=.2!XQ_\Q_Q)3_FW__$(;3]WM[3T]//SO\I\PA%+,@
MH@YFXH.=W=U_[(C__ON_?A%$^A0+$N]W;B.\<XEF.R_?[!P<O']U]/[@:.?N
MMK]S\'+_5?(0?\(C_M=[Q/#.\\3SV8<72\2>[ZGW<T#'>P<O7Q[N93]\D?SR
M_;/X(/?[I\/XU_M'1T=[\;?SGS(B^R$?=G_O]\N+&^<!3]`N\5F(?$<08.0]
MBS^\"!P4DL!7X&NG]!?B7[O9SW;%1[O[![N'^S\_,W?.(O^-&\[)+`_P>B_Y
M\D4LL)V=7VC@X6L\VHG?\7TXF^(/+QB93#W!>OS9`\4C/A8-GW>%L%\>)L3^
M+C[YB_[%P66!1UP!TS'RQ$O?/&`<OM@10]]=G\_Y>,`T\,-G`?.>^&ZO]-&]
M;`Z89O#<Y\3Q3<C_GF"_*8_%ISF;YEGL(_9PY@5/#7F;/[9G#-FK(,3[QQ$C
M/F9,@9W\[V,,S3%R<(P88<%HR-4%EWV\D!1YDCYJ=(H)*H<]QPDB/R3^>,A!
M<0A6E9GL2</2>Y6J8'+O8?%O%@;7V!/S9HCXI\JLUH]C;$V(X5_?A('S]2'P
M7$S9Z;>(A#-%1F5/&I;IFT0=W*)G9?'E'DEFH!E^5F?0\2S^2T5>%0^;Y+%D
MJM\B/I?66"KI\\;7LV0&-6*U_'FCK"8CGSX[7N1B]XP&DS[RG,B+M5PP.B%>
MQ%?G*:(^EQD;8GKS@"B..5%XD75&-_J:L3"%R>,*`Q/[+.;@]%G\J?PV"H,8
M97HP%>/_AKPH)M1C+)K$'S%5CNM&,+D^$UHWT62"Z*P9@[F'#*O9N45Q@D-$
MO,:&2/:86;M(HHB:\5<Q@%E.:[?L9GPK#]>&0F[&>L4`!D1^$CB1.!7T?/>4
MPQK.SOU10">JAFKEXYE1A:BCS*#\`)F=_\3)\77,MTLX6<:I[+IXA"*/'XI2
M,LO\SL<@?KC'']E+?[.W^GA+S`831'QM7I.GE]0G!+</?`CJ1/=X=TZY&<.R
M`9;7%8B(8]'L3O#D'M.&\LT]NM@'(-A$GM>,.?'`@B4^68E/Q.*ZX,1S;.'G
M$/O<VLD8$T]K^#`R4IR8%S@Y"IYP!`4T(^"A>^Q]>!&QW3%"T[_F_@7.&3[G
M?S*IB.(7'2%V'[]M^C"7U?[A'O9"EGTBE-3A[LO]U$7T]PHJ2S-+G^G4<`!D
M>&%EI)PNL.S1/,\<^XR5=!JHS9/TF1&W=U5P"8-R0024[S8?7KSDOXUG\'N'
MSQ\^Q4Z]^%=\%>!QXHK*OO<";J!^>!'2*/>6FGC<.-A'E`2]9P([CW*$TCW`
M.#A2C5H)5FX^2H'*2V@5KR(>NHBD9.Y\-L4.&1'LGJ1[&``JI<1R;V`6G-7-
MN1(9V<S,`50NL'J0S$+TU\O608)&*+/U8"`2`DM!VJ]:27HX\6,P#EGOGH7B
MA@D"F@(%L,VF8&SI;SM%D9@7?GP2ZT>4BD-*%0#R,YS\2;")7B]7^3L(F5:]
MJ<KVH#>IQ04./_R)_XFSZ2/R.'G6"_N(TAGQQ\()!&)8J1'>^P?8ME&.5?V<
M6UX#BA)4@%`+P"'%4T3<U)W(&1F$_+20L)V^`P1\*F0A-WU3Z"F)KU:MK;&?
M`&(D0V/#X9`+_L"X63RD`3?IP]F0'YUCYQ=?N5.QW5UAH.520<\2,O5;DIJT
MX"RNI;5X%?@.W$J1$]I(,Z%&-@HK9@UE!:>E-EO8V=NGTCTT+=T+@NZ)1\1%
M!E]>JQ<&D(<.9=IVMO-F!Q)U0=8N%.UCRC(/&F<5V>,6%T?3J5D\RDBE46L,
MZ^FHY&Z3#=%,N-\@+2LY)>NGE8JIEU-G)8*".J-P>GP`=XD[6&Q*B-D_CZCC
M4R8OLT>1A+?"U7HZ*_+WZW+`2A19DP%M.+D:0*(AH7H3;%T;`7#UE"Z;30:I
M2D0*)ION75>;5EJU7=8EXT!%?BI'2CUW9S"9!'Y,&LZS6:1A$:!FD*Q*!\[Q
MW'/=6!#(&R+BGOM]-"4A\D`L@A)2EOTNS;`IE5?]6M'"YUK$J/F+*%MNDT23
M*-[P3KBD'`*BYA2HVKT5:P*9B@BA_#6R%(8V=J5N+2J9E.H-!A`7CPW7CIT#
MJPGCH5Z:*E<'25#>7CXJ;^D;D'"]8CJ?IK-C&Z^WC=?;QNMMX_6V\7K;>+UM
MO)X,I\%4%(K@AG<:W`$:NE=.K`O79A6B@HE]N<8,\[<0@5,G^!%[01Q.D%*'
M.5A6$;1YIJR=IODC9:7<@#1>4G/%XT1[[H1+1_`G2JP`XE5'TJ)/36GN+H-6
M*SZH>[>5J=6*YK-[JFR,CD1(8.[G.:WD$'@1,%A(ELAL?C"Y5#C*Q_C&6,2E
MHC"#W'2*)+I@"JR(I=8?IB7]*QS"KH$\`>M>2171%V22"OZ5<2U4+)PA"A4Y
M0E\F=34@T*@C:?6*3`6;6IFE:+TV;'I]QF3\P`GT'KER'..K2+S(8!3S,(A"
M4>[-Y7RU`*$F)YN_[^B*.$7\S<9YF.=%V=8);MAZE[?>Y:UW>>M=WGJ7M][E
MK7?9SX?,SH^J/5%JN'FH?]7S5KTGU?M+_;O#>?.W!T;5`Z.Y;,D8[Y[[)6*A
MX(7=!M>8FPX.\3`G+8C>!OP/86_><4)G`5UW81@CMNFKR)Q450*<]9;<"9Y2
MKE&3&I"^VYL$-"3?T])RYA=@%3E[F36FI__R^JT4,)P1F/HO\O5(08P+.:4?
M$\PRL8)=)BQ/E\'H!-^')X3%B5U#BB<DFD!`6D_49KH()+X*XC9_69$DP3P@
M?XS9N;_@.,E8]EWM7--F0UIPSX+AJ252N$V6&W`4<ZUQ@I/_G_MI29(3/,*4
M8GEI$IC;*BU.["7P:2V+_%V7GNSALF)6.2KDZK8#?)&HU11``)A7A`JV24MI
M%Y)[6\.T2->66@>"=$6L0)FXZ;8SI,$C<;%[/!,;T/++S/<?(#^%*G6KA^`F
M,[_@U%"6KMDZ$O'<//<?,5O#@U'U_*8[)2K?724<0;,8%YJE)E[/^181BDOK
M34&LIP;4-Q@_'5G6ARP8U8^2V=6B?I11MXIG\UFOH"6E,C9\4Q6KBC/B(WX8
MTU:35<]O\#*K?W?EJ!"=FH4.QBX3_9`^(TJ1"&O%U"%`@;V5]#IQ/U(ML12I
MM\9M_F6R<6IJTJZ(9;1!PK/JB78.LA+9I;B],XY;B4Z5+/<6]RT9=;O[ENKL
M5MBNI**%RH:0%VH>8DH"MWA8@0"X$?W-#YML)LX4U"/SV^*V@CD,DF45S/=K
M;R3;B'?-=_W5]>2(&QS^#A'%MYS\,?_Q5\@DT2IR^GKM>-YRD#F43-/+Y+C[
M\"#7?7A.%.+=-+BPFPZC@/WR(M&1LO(]05LK1MJ36GOB_1BK)T%PT1<39'&L
M$+&Z+32=^JLB4G,IM#6M9:W,=;>$U:%`._Z44]/-K+LA8Y^,B".<2*MMJR&W
M`$7*MML=U`*<B^I1E.9F+8C:=KFZ5:>RL)=$>X!J>SDE?46?'Q!T(921LCSS
MJ\'+!R:6R$KQ;-[6/)?T5M96_*M#"0KMUO3-431:FUB,W-+L5R>^485Q96A7
MUXHLE:EJZ&Y;R^1-DB5PBYX3PTAW6LV':6<+J"*GOP](1@5=#I7T+.\("H`6
MHFXJ1+=!>\.JJ78\B_^:K3/].W\TN&-X,#IE(9EP4Q#D$J-`P:87NYF=7Q1-
MRY<0\=P$54-JA*VZ)9HAIBA)F/IU%X23=+D-T-(F4DFO4P?J:LD!16P6J[>T
ML-[J2-KL=]<(L%K9P>5&B$0JBA]$NO@C3HR/A'H;^E*5MMU;C(8Z4UF@8,6G
MKO#3$L_<;N-_.O$=)6L-V\8\=$K#-I>P6NTJB][\N(`*T[^IZKSE?N,\8#?R
MN(W:XP.[H@057\$WV(EH'#5S^NQX$9>R",H1BSP*TSS%HO:&]?R8Y[)#!BD$
M1DH)#A:]K>LNS!_*Z3K'_W0R]8(9YMC31^)@>69XSXN'BV>`2&T=^^0[=I/X
MJ7[`0N"[.C!F-ZL_4ZU7%PXTL`)1&<<+%M-<@MX3HNYR3*:(W$KX9BR:))_%
M2[:EN66$0^MQR_ISR@Q","X,&9>YJ9Z$Y,[LS!<%3KJJ:)J)6\TCTH8)D+QG
MSHI!GB/ZV?&Q@U%:%W7%F(D3K/4M]_5,J0O(\J7&>%NCS9\QFQ.L9*I9#B$W
M@]*JJZ8G(<RIP52M5TM+]7@F'P"J:"PDN_9+SX+HA5PY)$BTH6[?Y#2OT`3#
ME<&MI0GHXE`JAMO"NJV?.,L8@%6^JR,-4V)7;0+`3X&J:KL;-@?42O?J>YR2
MP]=ESL`W[F3*$;'KQU14>ROA;GDY`3DTTLQL.#3R!&S?Y6A@49"00K$JS>O6
M>="X"`!><`<'31U)F[?D&D#52K#V-&_#\NY-Q"W'!MK8*6-6H\@`CWZ&8%.M
M7=>&CRC>->Z+OJVTC.*:KB`S#GI0CY!I%@U<$ABZUH!W#YED%#`FI]1)!#0]
M02^KS+F,U@C%7Q0I2+F%\OA4D8.SSS5\-@!K=C6,OT3L9DLJUI"$\[I4$X2S
M*)0\+@KS7@$OX$9$E51A/"7UH-GUDIC$#:8[44:ZL@LRW'%.A:S=>%DE1:3<
M<1W8,U+3.!P.1S7"MLL+-P-249AP[3J2_1J[\NT<L`VU(F7+CK$6[&=5"!3U
M\B]_V]W=^=?GR]]>_?M?OSO3Z/D/__61^_WMX_B/F7]W$CU]?$N/WGXZ^')W
M.V/>VT?G^TOOU_#=7?]BZ/[QIW?XVO_]?M`_.9]]O/UV_'"][PR>#M]^<T>W
M>\.KPQO\YI%\>W=Y.KX:[8\_';X-7O_T)_GR)[MP7OWT=/5X/'U"7WY[@]$_
MG_>_?7E"1S\]/=Q<#G_Z>N&\NV)C_U/X[<0Y&%Y\_WHP.^;G]"?\2!'U\#ZC
M^Q__[WO_U>F;\3N/'5U/;Z=DN'=Y^.?^\/(M>O5UCS@/;WZ:OKOXU1D\_G$Y
M?@J/+@:_/DR^_O/EX/3FR\VI^S`Z>N=\W3^*>A\^_'NG?W.]NZO96^Q\,D5.
M./`+O773!A\<5@[/)/!CN`A?VYZ'Z-S_45@J)>6XUZ)@T?T(N!Q,B%ZYU4T;
M7J?DFJ(TE$XGYS=M=5@V;L-NC[7#Z#MZY/-"W!>,XXWQ>"8/0CQ#A,:%_9;8
MN2;LZQG%^)P?_REFX377E2!.'W"F[;484Y\S]<W#C,((<[`WRKC8@!VNA$Z(
MJ!+KNYV8?U*F_Z/GGQQ&H"AF",9_"T10JT?"6:=F8(%M:XVY-F@*%I%4,%OT
MI^'*O=<J\_=-F+_%=+(/-OM@N+7CW5EWV@$AIY(9WZZ-?!--)HC.YF:QKDV<
MCJ-A!A>?;%WQIXDW@RAD(?)=XH^O(K`X,.-,VFK95@F[$35>C@M4(ITY3C]C
M,G[@Z[[WB"D:XZP5PI#RD_N&SZM*UFWV?;0QXZIQ!',-:^]!M6]PC860^>=]
MOAL(`4;($YO3P4:9%6N\AG5[0W6"M@TO3*1A[5IC-8OMHPAD9>=^XJ/<.+UI
MD'W;+@`3FM,DF@K&L)5M//\.'VG`0(*/(-C\C]B>I?B`E:>*`UC/^8D.NR<1
M%95?8K(QAZRU9FX:7'1B(]00;FUM*CO[V+R/8&>WLF9OT(GIU3*HM:T^K>QG
M9P$=81)&?$F))K+/4T+C$>8OM8F[6SW3/X(YM3YR"CU+-W/2;9QZ!'VA'T);
MPD)>V\6US<IV\TZ")SA$Q$N;)#1WCLO&6@G!J7225X^@UZM;-J8LH4>=H_:S
M;-3%.X]PJGAM`QDOFJ>+-%PUJ:4D%E[@Q\TV@5)>J@F"W1#7YKRHS<O\V:%2
M=,JM%ING'>;IP:6LR`F!7?@H9:HH3=A<M7"YM&""CZ3$8%)32L&QFY%B!A_5
M7!3=(NXBCE2<[B'K"!2)6$U.J-09A8+L1>$`Q>E)"Q;&G]Y,/1(FE0O$A+L6
M5AQ,V$E3'FSZ-Y5M#7T)`U6XN1;,^HM*C#W'B291W/WQA(O0(2"E'A2H6@M(
M:XREB@BA0LF&-'`P=IFH_R!\I<AW\&!T$?AC<;,GRHK$76^F)$3>4ET2#(*J
M/C/V_#6-T5Y#XK676@:;1/7"/J)TQN=C''8&LHTJ$>X0M(J2K+U.LMS_0M\M
M,4]]ZWH'C.V:@&V<5K8F-J/U1&U#Z^45HN<A4R71W)_7?&0=?T5C<LU<@,U&
M!3/URAV#VOCE'(8-A;>V(U%+%R[5EIM!>0Y7:%BK:;S>Q"ZV-<_+#>:P?8F^
M!/26_Y`-1ODZ@'#>PUJ:MLL,ETW:98#J!0=6&[B.-(Q;40TUNSY&$\!!%O1]
M"&B8'=0$"V!W*5)"/X!:+)$@5,)F@1B<2BPCU=*:JKI6J9JSE=`TT8-&`8+1
M?U406;U761,@Q1L5;>MOX4P^GMWYY%N$3S!S*(E#,R!-PGK"%BLIFK44%60,
MU*XZ3QVV/44I+<LU$AO-\G+HFO65,(H6C,:LQ,N^H6@4,M@:B=M@'/.6I%*0
M3FT^_#9&9QNCLXW1:3%&1RC@<Y_Q8>(H7T#[L4`%\BC6LKE8E)]"BIH!K."-
M0RFM#3`.Y?.U')6&'<:,8@-G"I:B8]\4U`=(2==I5!L58D!>GP]$_''2/D4:
MDEA22K3\<8MU0E7O&A:%/RND8'I=Q`2'$74>$,,53=?D`I<^:+=\>&-IRU\>
MR!4>[UU#-!/;U"!\P#3]&["!5QU)BRNCQM.\K(AJ!0?D.MC&1MN,C4X6*"6^
M0Z;(:[P?R)^T..'K+,.%4I*_L_D[A73#Z0L%.,I[>1IMO!4#6*Y:7^>J7=IV
MJZ1@6+_$%`O-"./(5OXW9R3P?>P((7TFX0.?#(_\J#/TD!.?4HNA_W),M`>W
M5<#.3(B0ODP![-GX%7I1R/<Y4?;]SN<4BI3SUIX2M!K#6LQW-A?ZU524RB7P
MUS&7I9QH6,_R<3J/FY*P5-S.)L[[ERB,@V1.@(I&5U#KK%95D:3Q8D\QZWF*
MA>RLI"21TCI3&:?SZTQ)6+6EF@"`NHR\D$Q%T\2Y4;L^:K)!;><B`F,HE6-M
M@2,=.(^Q'Z?0(6_PY',.'LBT-PI%OYF,(24`%8:QFF^X/EXJ@E*H!Z1G6!('
M)U5<>HP%G`?.MS!L)3SQGSE\/J$QOB`3DC2K+KZ[JMUIF&IG=T4H%)2*[C0]
M9<[;1+%K/"9,])QQSP)ZC1E:/1EIS8QU:71?=Z\MY13Y(],W7D-$W'/_$_'=
MK-L0A.4KH=)I3*NDESD*(,+4%MO_G8\F`>?SNVC3P^+T0?@CBXSH#X&C@FPS
M6$W?^603)VU>*3@Y?7:\R$TN]P0;\68`@:XR[2Z??YH+.H.ZTC.DE\6]1"=Q
M)6<3;$CQA$03")3KB?X0:UA!MAFP%9ZDM=STR]>0^1?H1Y2J.OX:#=CQ,U(S
MX67X57J23.RN9\C!R=T:_*:Z1*N[8-:+,<.NRKMD`+GEEXC;#PU&R87UXB<M
MQ$8J<?$C;*HZPL]F0I5;JM7B%*]72W\9J"-;/NJ*1&NO\U3&TJ\M6SYZLQ(3
M=>-8J3?;`(;<;6*M4*S7H+UQL(\H"<#377*$[.=+*TY7:5Y+7F90C>E2(G<^
MFV*'C`@_1\(E29<2:R>*6"6Q1393<_"4"ZQMB(#2I*M`VHC<%FV(MCE^W=%^
ME5E]`.AMT_JV:7W;M+YUFIFE+/8]Q-A@%"]]<,VW0@S0D&A'[ZV*#Z:[YC(=
M.&4GH;(!%7'JIFHN,T`B)[#"8*O$8-1<"2P;H>+T0`$H^N5B\M<%'B/OU`]K
MBQ\R[/P\#A[W^$,)#/R/HO1E`W;+2I.*I#[DM;'8D^'KU)*JS'.CV3&T*N92
M)M?\.YO/CRG2J-(LNI*UHT(:"A>R7M8VR6X3&I!\1J*SG#R_S@@">0*6T\*4
MY5\0B^'M,LOVRR5$</GM-TMS+'O<8JYCN:F\G.58^M[&K<4RB@?K2?J@JY(^
M4)_1:[I@AQ0_DB!BWNP:3P,:8A=.Q]32M*KT:^\-9`[9<O$!I0/_BD<C3`EF
M%Q?]!HM#\I@E'5]F#,^7@^P-MUV]-J:K5\,;77U9`U7Y6#+9DH#P1=XJL&6[
M0LYN)R!-("OE!^/8BXF)9'&ND2,J^K3$61T)^2O\%'\%Y)55HMSE-:D@5\/N
MD()IE-KP`WHM&EYGD4N+TD!]Y'G8/9ZEOV/I#T'P7I>ECDZ$M9&HSS'63(^)
M^Z9G]G/67:X?,!CX*^EU%-MJ&=8G'3<W4=-MX9&S)KRM7*FD$R;K85_<:.4F
MJ\(P5B-V=4+;5$2CD#:L@TI&@9\V'=P31,?Q:3-;S+=!5@TB83+[5_Q[SNB=
MO]+Y5(Z;$4(=6VP&)0R3D[Q(:QWX*9]B`F:L*0%;-X;-?&$=O&IE4IOOJ[,,
M^>'6"<DCYL<<T2:5<%[=N#,NFJ"Q8D9O[2"=.EDHRL5T#J[4]]9'TREVA]A'
MH3?3<COF1^C<#E4CD/KT6LVN.5PA'G-=Z`JG/_892N0TUZ''L\5/4HNF]X2H
M>\47;UR\:"73H<S8,-1X!Y#?3BW>=A"$2O^5]ZY><G&`G#)JB7;,^FD@397D
MWK61+-C4,$?%*GH_`'ZK,E1(WUU#^;/$#Y79PO%G8)I;2LQR0N`Z>E<N/,!\
MW1+/8=S[VH9#MD"XFSNHFDP5,GGU($6B?%G,!/PB+*/5)7.Y7G#*J;8-_6M5
M;OOXR\2@6AA05UC-=:,W<L=VNW5DF"%:Z9U9WX"1,@!MQ<B)=@S<!M+,L*QP
M[V@F]TRF7C##^`;31ZX/Y">C*W'?S4+LQH<@=AN$R%O^7OCG^?O_@<-K[`1C
M'^I^&H[9+NIR0.BRZ5;EO]JP^9;HQ+A,7OR1^!U($$S+;]!-2[]MF+-8COH(
MMC8JA9P$3M(,RW>3Z+%S?Q3025(S3"<A(QMP:9P5\>NG$52.WGQK603-)>4K
MQ=%<=,M8GU'IJ#94MRHF^?R'HCA,M^!:YDHT03(W,^+1+%R9-95S_NW-9ZL+
M&FF)L3/"'.3]@1$]]=WJ-@"JTBX=V6+T:Q/IETO&<//TQ9):"?`;1"$+D>^N
M=D#1UC>5-#H"C8JTP!()A]&]1YPS+T`5-?*:8;(\9`?TDD0.*ITNF@N\QSER
MXWIZ'C*P`/+#6?%4-A5U00*U,6/Z(E[J=F]0TLNC=L&TD8O#=#N))1W&25'D
MG7-K_/D3+H8]Z"OYPK!VCEV::KTH$N-A64NTDCT^22#BVX:H&Q`9.(-4CMX)
MQ5,M'[/M&!;T?@N\R`\1G9T1CY_030%1'+9+RV%%)`K!6+KBCTGTN8T[#J@Q
M790?M%,69D$>"@T.="7_&7O>)S]X\F\P8H&/W?B"I"(5M!D&9<-W"HU2&2F$
M*.F['A(7G;%3L7S8;BBD$I$H=0W0!V!Q`#_CGQAT$!8'[L2^7"H5TR7^5XEE
MSFH`$):'[L(QH4(P2J$_5:[[7_8$J7O$<"R(_P=02P,$%`````@`@86L1(0'
M?,GY.```0^$"`!4`'`!H<G1X+3(P,30P,S,Q7VQA8BYX;6Q55`D``Y(R<5.2
M,G%3=7@+``$$)0X```0Y`0``[7WK<]PVLN_WK=K_`<=[ZZQ=D6S+>3IWDU-C
M2<Y1(DM:24XV<6UM421&8LPA)B1'TN2OOWCP-4.`>)!H2KG9#QM9(KN;OVX`
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ML>Q!2G;OQ;_>'5^$-W@1[,8I`RQD#/+XZYS_\IB$0<%1ULJ%E$^P?^U6C^VR
M7^WNO=K]=._Y?1X]^1;1__WU+PC](R,)/L=SQ/[[_OQ(R?+U"_;$BQ1?,Y`O
MJ1G@X^`*)U1NQN3KFPS/Y2\G6;;Q+I/E-9-E[PLFR]^4)(OUDMI0'B^6"7[R
M8JC(XTIK)&C"'CJF3Y3/,;H].N5L2PMJT<7W!4XCW%(:(TU"V:=P@O,@O^)4
M5_GN=1`L*?6]3U_@I,BKW^RRW^R^W"O-X6_EK_]S4=!O6^"T.)V_C5-JEG&0
MG)$\9L8XN\H+-D`KX?C'??/$Y57Q70FS<I(QP*J/8B3=R?\GN:I58@1U5X?5
MW,+',)6!36TXW7U_\>3;6@)$YJB6`55"H`^5&/_^AZ#\;4M;[-^SK%)9D(4:
M^<HG7H2$3@W+8G=#U'E&%H[`$W=$!4!4L):%>S/$69[C(M>8G/RACG$96-<F
M)5L[*A0S5X\QS2XN#B\O6H8"8BH*P(@)$-OJ=T+UI;_A*1"5CL('BNQ+*;2J
M8945]VRP?/;RTW*HL-_\9W^5970(]PX7_8,6\[&:&,"H*?FB@#/^&F:>-8"/
MF.*R-8A<8?8XC+8@EJ]J#QYO^=#RO6CM!_G-+(W8?PY_6\6W04*%RV?%?I!E
M:[I+^C%(5EBQEEF]VUWB#&9C(PY^72C&NS8C@%G9#E0R`"NC*7P4(SO+\#*(
MH\/[)4YS3(4\+6YP)H9`.1X4)F;QIL3`#"S,@(%?^RH%0%A(D*,@C1!A0J!P
M8UZ#-$(;V(DSF)L3'8!OWF]KQE9E[$8Z&E!!BB"Q\S(NV2LJ@P'T)GN,P]`,
M?,]$9(FS8GU&T2NH@;*9<LDVE"=8/07I7W&TDC[2OF<=P9G/-KABNX-27$!O
M\(SP)?:@09I5:YX[H5_<.\WT/NL099+2\VL]G"5*2'J]2W=$BTGFFWX8B04^
M$P2)>E>@`;8@"("M-].M,^H%9C+-'L?!59S$18QS.BM=%"3\>$.2"&<YFZ&*
MM28P:/NZF[MKR@4@,')\-'MS='QT>71X@68G!^CB\G3_A_\]/3XX/+_X[[_=
M4Y1?_U]T^,_W1Y<_@X;%K!5!AL$K]X+'4:''H(N%^A0!F3^0+E6Q&Z?`:)NQ
M/CK:\[1CB%1"$3!.FC3<)PB6]J%)K&!R"ILJ:`+$3MNP3QQ`':Z#:4*ILS`D
MJ[3(SX)U<)5@3;"A]V&G8*F<I-^=0,43+0538%^P'T1B@PU<-)3*DJUPU+)=
MK:GT/^_F"BK)>K<8QK:.=T*&-?5($DM\S$*8BN5>9(S%U!Y/2($KVSS'"4O6
M.0LRM6DXOV^3:&#-Q-9P(A*N6."&YXT9&]!1&B8KEL"'Z,:^"7FF$4KK[3U:
MDHP1S7=06!Y_H%MV_D&WK"P5AKUY%20LAPWE-Q@7***?P_X2H+LL+@J<HB4U
MG3C'J"!L<J-_2.GW[Z`XI;80),D:18S<G&7\D12C-0[H#QFZPFM"96$<6)R*
M?AOE':[#!*-XSF,F.-M!=S=Q>$-E2^GS="B$-_0+Z:"84P(!RI<XC.<Q_7>P
M8+,6DXNQH']<D(Q*C.EG<HM$3RE<<<C%"<EB05*4,T?UV0X*BE(&GNA3?K-P
M8)^#[*?<;90,M#W5JC^2B?OTQAI1N+G5ZRJSPDP(1'_%)>+!6J;8*,[YX@;I
M+4.J5>G-@<5S^M=GNX79;H<_U0E2:SL`Z]*9K<TVB[+O[%/+.)]#9,\DTW3"
M0%Z;>1WYP5P*H!V\!;;$%C3SQ<2,KL?5HT\1$^SI?6AEHK5@G_M67+3>A"C%
M8PXC>IN4YR2GEN\(.V25D!$S+&`C/%'$4\V#Y"R(HZ-T/UC&=-54[=O[GW;-
M+)%3];QIKYDBEN"S&Z=T[\+Y`@?T=9@2*Z`@'85S7`1QBJ/#($OIEC"?A73S
MN^(N[P&>QV&L<AC,7W2Y1:"G[CT<5/%#D6`(.P%9P$M<88-=K+HKJ+$K.G!N
MZA($V[CD:M]G>G_'S,^9:F;2'70Z)BP,.LO0$0>SJ]9&F,<8'Y"=&2O`XE![
MFA.1HS0D"UQ?[M/LH#5/.\Y="JI^5S_!%#77-*?;I>E0)590@29?5F'V,N]<
M=P53^[S;>9J2+$`(IN9='ZM]#>R8ZT$EEE#9YD7U$O48=9%@+QO&CTH'MOE,
M(^V0<DPYL4M,!_@6)X1G=9?B*3='!N^X[8MZ"/M=%"K6W-^(&N;0^R(39(D#
M8K"[(5'!):%2S:)%G,;,R%G!EGZ[,GS+(;"GH>S7M$KFW+*"#?:@*;:FZ!(G
MV$!#@IUIU-3I&+0]ZE`#VP^1SFHWZ0IGM+)-LZFIQ1#N\C')M;;1?=)EZ9*0
M\SNK,`Z(*:JR#I+F4[F?$@AEIB&'!G9EXM7#<*[Q<!1/N>U1MH@9FT5/52J#
M/:[@64T8L&Z,"CYB!`K@#>437&@G"NDSCO&.#5H`RP?EAQ+*"G*YD.-%#$"`
MW/=49PAG.+NX"3+\)LCCD'G1<;*BHTUA"X9O.7BH&LI^UQ+.3.Q\!#N>Y<8,
M!]&Y&^5,(/0T3M$!29(@:_WV&73$S%0#Q`E:4"_V)QQ?WU`!9K=T?;S&)ZO%
M%<Y.YUS&TU7!RV-2N<TL<Q@Q%X_'C:/GTGN,>8Y6.35A=EQ.%LL5]YNO3"U<
M4'@&NC,;J#LRIDZ@3TWKTH*LA,[;A-SI`LDFKSB?I*I)`Y:,9+P19SY5D3HC
MC.45(GN!&W11L]Y&S%CM7^U-38/'K:(`.J*@!PY!S?YKT,N")J`2.ZPLRD6:
MD`4Y<VC!#SU$QU9#?VU)BYV,1^`[NYB'N8VQO@`KG^=FT:^KO&"S:7Y)SC$3
M-4XPY<;X7!+Z`YMCWU,7YRW)+"?%L6G;SZ!C20!1>K<15=P$*H5M7$?Z6_9S
MR!9L[G.RJV1D\EEZ="T3C\JSG?_'E,%GE>$1C6>2->91&)%=9>11MBP'>$F5
M&?.`.SL86[!+K[]OW*;=6BH-WG`ZC^JAZW>WTF8L3C5;K"%#C2;($FO`X&RI
M"D?AB#4WP6G>9T;]#SM9D)RD[ZTN"3_NLE8C$8_/5%PE)Q4@6]U^5(D-6(#5
M+%JF>SH_P%?%07D?^2S#BWBU4-B0\7NN]V1T]#W?:VBQYY>TJ0"2F]H05V:,
M@2:.Z`TK>L5+'^1':;.^BM+H:61:",N)@G5Q+"LN$`6SA$`LN-QRU;A,?"64
M%]+R7AG`31ED,,J6];:L^?BL^F"A2?A:>M.H=9H27D=IF&&ZKAY@\=^CM"QI
M?H#G.,NPO+2Y,G-C"#&7<S`WCHY9(*K>9VZU[CNE9('N/`S1$!D3>>C<HVUY
MMRJD&=NTXCWW6SC]]"&";>J:=M,8I0KB7OOKP0TRN44JV%9=-1M;4[SJD.9B
M0A[&VN3U\":S-17$.G/KP0YT$2_#=F<9N8TC'+U9LP!>V_6HXW?J-#M+`DXA
M#W,V0.EY^O@O=(J5@R;(4("-0B?RO>Q1>HMS\R,P@\?M3[5ZB`+,9C7WR4Z<
M3$`E=EC9G@MIR'K<24KAG^3,9D0U3'"R0IVF\E1H%OZVBC.L;#JC6$+L"3@M
M(>9L0%+]S^CO;P*VL2-S5C]5TF((V)EVT`,9"B^<F2H6.,EXLO-T>@B,Z>E(
MV$SBZ<226?.!>#I]FM![.AJ`!W@Z9?=M4T_'X'%[3Z>'*("G4W.?S-,Q`978
M867KZ6C(>O1TI/!/XNF,J(8I/)V,A!A'^5OZ03\%61:P*_LX"V/U56:35QS#
M?WVDO3=$Y)S%/=8[P1OABCFTVV(",;''#3+RUY:)9UJ<\E+T>268ZOJ0\7LC
MV)B4/J2A\7)B59'^AV!M_8@K3$X+(Z3=*7PAR=1KYQ3W$!C3*9:P@72*EZ4X
MZ&J-YI(U%O;VMH,J]%ZQ!F&XM5?>L?T,9S&)MB/L"EMU(>%RLFS#!\A<HY(=
MOUU)Y0*>-)V0)\,1M7#1^UG-Z.`0K7'JHMI6_OJ2BWI1!%EAF;C$YIF@0%?X
M.D[9=6@>+>+4(#-VC5`QUUP?G+:E[(PY[-DK[#"U#.I5ZL(L5Z.CJ`G'VIBJ
MVNM7E9_T_3@/$Y*O,GR)[XLWE,E'S85C@S?<TO?5=#VG[]>,$>.,..OIVL6:
MX$NL88-S*-ZL\CC%>7Z`\S"+E^7E`G;%/C^=GU$]5,W6:GD5AN9.R*TND3T_
M@`A?)11J2<4/,[A<;"YL2X8^-!8,;;<#U$7&4@+@Q%F*5&8XT6E<9<6JYYPF
MR0XU"!.L+*WA.JF=*0$EAC@!WDNI^9^1)`[5!Q3F+S@DF:F)@O3E9?92,9ZH
M*+$!K-T^O1J\0-/)+N+K-)['(3OQ[4BG6TCM7G8M%F/$!*(37",(DEJ@=.J"
MN%IGIP8R!%O(6&=U,4MXH;K=0^_#CO=^921]7_F]*E!KXR#=+8#<^.V%D]B@
M!'EGO"V+;OK2/.TX7RFH`DQ0'=N134C@MM,[`1F`!3GC=%O&L!Z^UCU/92^Y
M;1W[:0-<("]Y_QT)[HBQG\C7,L2YMPN5"CW`_9U<*/-9R_I]!\?>F`=P`]Y-
M,]1-=4#[1GN%:$W4;DKT?L>)+/!E<&_LBAF\X>2/]=`%:61%.6M=,Z![35I\
M.PVMM+#!>6D2@723GLDK[I<RE:1![I1(;6NJO:01T/W&-;D7]S['I_/#O(@7
M0:',@Y$_Y)(]L$D)P&0H0Q8UK5GNB!C$&GTH_RM?#`&L1P$J,0$+]HJX(D&!
MXZ>;C*S>=5KIC#A`5&'AI^-I)$HEMT0Q-+DI<U44ZM`GJ:A1AELBCV,J4$2]
M0?,ETN05QR6RCS2`%=;L-U;(J><Z([R)/8A3-N<PF_\,WQJA.0?\C%=)@*@(
MHD>!V50W04<.@QG.`D_0/24K[)?A&YSF\2T6+J00S7`!MGS=+?9FR@5B'6Z+
M@H0L#\?KLU8'&08R8+#N!-^U#L8RDM(?0]Z!(;<Q6%<RCNNU+3L`"Z8B;1R:
M;@CUD+Q)9U61<?`'/>X(;W"T2NB.;$9%Y0U[Z"B\P.$JXQ<'#N_#9!7AB-V"
MV><M?LJ2F=OKBC9F[8V16SG>T<6!B(.70O.$J9;8J)$;58*+ZU<MT7F\H./:
MH`^7K'J6:KA!Q,[]&0:!TC=@&>OZ.PX7RX2L,?V&[#8.L;QD\BSAXX)_":O_
M?IW&O^-(7,+8)WFAS^_QS<\EW.9-*.`Q7$F/2O'%D"P+=K>_8`<UW\!>;+X"
MB<]`_#LT@QEV-/NR%^F@]F@'L$')YI.:;RBKM,SN@BQJWT1EESO$A^7Y:B%^
MQPW`?%"/R<0UN6]488!'<'O`ED(C+O4.XG*C4O`=5(N.6K+W#EC0T3JJ(4B'
MZ-C:G<9+5LPLXJ+MVGGTF1,;ME[:<)QP*&VM?:5X#\E7=5*=9ES8J<1X79(7
M.!*9)AMN;Y"$JZ3JB"#:E6Y[OWTUD,:A:%\F:1A?B("R2%BJ=V9O^<ZLD9%9
M?RFE9(<&D5\WIO[(Z&JQ+=HTG+/'ND[#C`$\&?QA6L8$=:3D88.38($/R"*(
M59VD3%]S"F+IB'N^@B6/0.T@)@#Z($0`WX`:`T[<<)PBU#,T9-73[\`/D\%;
MP3&$\9P:[RT6^W@#L*KF#?[T"KD)'"C[<9SBHP(O5-F(8Y,?<46Q%V*2E<=^
MO#%Y$1<8]LKPV*K6KF7#-#BUEV4L_6S!3ES]#+!-VBYAF%$$\+RJ,48YPJ5,
MP"O1N!H:;U!TD1\8?.%1ST[,IVJAU1-CL7K1/I1B1![JPI<D%H@.MQK7^M[Y
MVN%-7&&TC7`8,_`8R-#I:)I0A6>%31!X$!EQ%W1NXNE#Q^419F_4P>@=ER6L
MES#(#;R:-ZJ8RT(-8->D=!AW[DD98#?5B?-(A^A&T08/O!ROU_L0"2[TX"F%
MY/'GC>AC$9[T#9B:/,X7Z`(3GKBX+#\CB^)WF(X_-&7A"I!K)YXL@(!H%G8Y
M+67$D?P32I]2%:*P>MDQRF[&!&*7UQH/87L'@;=V>5#A!SOTR1!(#0/7BC:<
MBR7=CYRFK!)E.$NC\L3T!%.G,F=1"\I\05(N3$P=S"0)LCJ8(0LKC$+0XK+?
M<*:VYAF1<+6HZKN:[SFXB(B:Y!43DM^#CLK#^107**&"LH+AS'RIJ"AGHCV'
M;0<ZBNK(V#I1V+<O4_#9<M34!KCRT=,X1:6`S6^?`49`'IA!*'H$V$YY(D54
MEB':%RXU?\O&&S4D#;"""B'DN<5`L7M;G(D3?BKC&:0<CY-&GV*`:^?Y59!R
M>'L.6LGW!ZPQW#6/KKU9R_/-WP9QQIMBM+[G/,X_OLTP/DKI$,1Y<4X].54`
M"XJOVZ5&W]+YW3`SCKMSRA+%)4^44:;@H2@P'9.)5`>8PS;F9[%M5$B=CX.8
MM3M+(ZAQVL=W^G$JD\YW4QO!":UCG("VM()3JZ^AJ=/6(Q^:/Q*6Q9W$Q1IZ
M<,HY.]V6\B^>W_'9\(+.)`54K.\!JE;8!)[NE?[CKFP^[A)GB[V^T>F5H>-!
MK3>Y/!\#E:Q0$L\Q>KK&098_`U\T_2IT>S!Z5Y/9(6M?*.EBM5@$V5H?/5(\
M:!OMEA*#"Q&5C$&.#0W`(Z:HV,61E>3\AWI*IO`EP<=`VSI(.ZT'6M8+.%T5
M>1&D49Q>GZP65S@;V]_4\7%IJS"V++93B'-78Y$:#IMCYT]S8[B/)BHQ#UQ[
M%<>A\;5U'^5M`_G3/DP4\DCBYMUO^0G'US?4-YO=XBRXQH?W.`OC')]E<3CZ
MQM^-N^LM5!@IP2;N2HC=4@I4B8&X'(\FO.YH!'Y&LJEFC?W7"62$6!0LC.]/
MVQM;K_#>O,O&7_N!YYC=D*"_WR<IW[*L@H1%!%Z-'<$:+@EP:,M=X.E6GUHD
MU)(),:&FF`PF,I,Q`F;C*%\>27MPMCK)6F5DJG]:*I3J02L^ZI;K7+->?T>?
M+/*C5-Q.\+%9&E\"/\D,X\D)$"[GPH`7/IA"US:^J1\5/H)<!^GW?9>17'59
MSB.GB<(9$HG\'IA*AN"#&(,#-#?B/E"C#O!6Z4=YOL+1P2IC?4[$)H''@=N%
MG:L9(%(-&F="`UJJ6_$SMOC7PN)3?,VN@]FM/34W\);J;MAO][!V1A2R]?K0
MI:[Z@$E=.R<A!L0FP&2%J,;<&64/9'WQH_0QW3QG53ZD`:[YQK<DF^.X6%$+
MFJ71X?TRSCB%^IL].7[&?&$SSDVE`UH@*5\<\2N8<R'1X_,3S14]HM=HI;_'
MLR_3?M8$A]2CR.1IK?8I.LC2W3?^_PAC'_I4<32-0U8]XNT#V/>2E'Y.;R&\
MWF==NE/+Z'G.'Q<-(VJ>W7)W$!6`>G$D%@`-*P-P0@J\]V:5QRG.\P-<!'$B
M+3AG]K#=+-M/TZ\1,+9H#^VBBC5Z6C)_UJW8YCO96(\KL4'+R-TP-X=C13DS
M\Q>L:T'T4IW0,(YARYM;(-QG(%+D8%-96,#JAB01=5'$A,;DY+^]6"9QL4]2
MNASF=)T\9ZNE\B:5(QG70+\E.Z@ZSJ5(?T?E2L:DJMHC<L%V4",:XK)!AV9<
M%;4=`75$WSI)\)R-E+3ID30+P]6"-5#"T0&>QV%L?^G%0;N5%$UKA:<M05`I
MR3-@9>JQD:G/$E&X+?)91D*,HYP5J6<!]H`"<#H_)NDU2Y`XP%<%==SW@V5<
M!$FK=Q%6=4$83,\I_N3,%6"2JF0374,JZ5@A3B;?+J6X0$Q"ONTL940;_:YP
M`1V$&JY%,K)RI"-";1#[07[#J>8W;+:\#1(6?YX5^T&6K>D`Y#=!&?U7GK7/
M)"@U2W]HR;*#@@)5XO!*3ACT;HL10C)UVD,+N'E_%_Q*LDO*+S^=,\MJ[*EW
M'V_ZFM/DI"/NUX/GW!%GSWL_LIFFU=-HBMV^,=K$#43(`#/)BFH68]+U6IGF
M:><$'"E5WXU\*--F[=KA!C91IP0=K,0**\@,%R9%X[AKFWWJ'G>I1J.BZ;G$
M$YN%&K8]/3T![$<+*[&#"_;*)9/H*,V+C-<?-K*AOL==;4A&$\"&&K;3VU`O
MK,0.KH$-P%ALX#-AIT5\E6#V[[P@YYCO.,^"C"^<!O%M)R).`4XK3@!!S\_0
M+FJ)Q,-*.2H(*J5"I5A]D7*86+F;CL@8V`\_;3%EK0V[.Q.R=+O<&3Y0HY5%
M\1^6X?;']P?I84BAIQ9?/J6ST`;]^2BE?TAQR,ZY?XJ+F[.,[I$+?)8$(3\R
MWP[GCT++MER4*S^`>%G;?L4:7PI'%WO4B(>8?*@4$#42@IU$#589&5$7@_I]
M\%$S6Q5T<\0:WKQ/(YQM<SM*Z68[2/83DL?IM6H2=J/B>$YNQPS`<L5LVTB%
MN%A=&T6E9*@4#7C:=502&07Z`:?Q9Q3VFR#'(K=(RE=FEQ:O.1BB`76(,X92
M"E16BU,8'MC<:(,Y<4,2+LBWN5][%Q0L\+@^4!<@UK_@D!JF)@I@7YV]=L4?
M';0KZ(-OM*78*K?:*M"&[6(V>6R=PXL;2K)IR>(UAVG)@#J\V73R,'9$S\*<
M=S42/T(=YUOK@+@A.V"]Z^7T;I44\9+U&:639!K&RR"QMK(>&BZ;8EM>#\(`
M*[G8V5@M&6B'-6<5&5FD!O<A^]\W..6I*T%R>I=2EC?Q<C8O6,NN2@*919J_
M91U&U),&,+E&"%1+@;@8+>L#]/@M\"9..`Z.`<8A%I<!9GE.*-<"1VR_*Y&"
M/A92$P^N\7&\B$6SQ>WHCV)KZH>);=AE=$%@=K6LNW#9*KB1&MVQ`(S4W!O)
M42/Z3C<R"1PI]V0#!$*Y@P(\K2:*^3F^CG/6MREZ2[)SG`?=2)/)D!J)I(N?
M,9`U2`B3MVLMG=M&1D2%1$)*63"S&[F?R"\>2[ED?(T!YI*=!7%TE/X0IU'5
MZ$RQWU<_Z)C2TR4($4.B3'?C=)>Q115?X&/T'B2)*3S0"3R-Z_T^#1:$VNWO
MK/]6'I)5)R!I_9ZC`6GI3Q$S:HF!*CF@$YO-@5=&D31H0II?9?YE`W@FY^%]
MF*Q8"<29$'*C(?F6E=B^[G9KW)0+@$E6HJ!2EITR>;&6![4%@@QK6JN"#`/8
MMBQKFXY(P*UL_RS#BWBU@+@0U!:BSF6NY$!/2TF`FJ$;(R-3F1V<YDT^ML^3
MN?MT%JS9>?)F4L3^*LO*$Y4]SVK;O.3`%"><VU:]5KC+Q3;@])W4VR$[94KH
MVR#$U-Y,G9'NX\-30AN:4_@=C#L2[$%OV&AQ5;H8<KRF-**VY?,F,Z=S<0NU
M>415LM2=D)N_8<]O"J-LR;6#A&1L9BSO,+>$@UW-!BA+:<VV*C#U308G3UGY
M*Q$)N:@2C]@PF2UB-A!7R6QQBL(F_L-CJ<LR7V-92?D<]"#J022TN3H];EE)
M`!8@?)V@20I;\=R<CJZI08BDL%"(]WQCX)=?_U^[N^C#3^]^_.S?'_X5+E?W
M/Z>?OXY^__+V^N=U^OY@=??=E]GK+W]X]>O[RW6>?'D;_OXR^;[XZOW^\5GT
M\R_)IY^G_[HZW3\X6G]W^=N;F_.]\/3NTR]_B^:7+\Y./KW`7]S&OWWU[O#Z
M9+YW_<.G7Y+//_DE_O67_#C\[).[D]LWR[O@UQ^_P,$_[_=^^_4N>/W)W<W%
MN[-//AZ'7YWDU^D/Q6\'X:NSX]\_OEJ_N<'9';[-@BS!>WFV]]W__K[_V>$7
MUU\E^>OSY>4R/GOQ[M-?]L[>?1E\]O%%'-Y\\<GRJ^/OP]/;G]]=WQ6OCT^_
M?_>O=S_,E[]^.?OA_I_?__[Y5[_\FO[ZV3^_^>;?:/_B?'<7++M^DFPYQ2@8
M)Q<-P.CK?#0B\M$4-O_\CY"0YJ8KPS02B`FJ=CYR<5ZQI/_Z/WL[+U^^9+]<
M5FD#[!\IM6;81<ECBHX'Q2FR+0"T>'F#T:*5R]*H;97318=Y&T$2LHHC;"=>
MT*?3;;V'8MFF3_-*%?P9-GO!C=))4F%T_5\&)9M`S+7-87O`]XQ<<Z)4$+HC
MJR1"5[6LR1J1.QX\8P^%9+$,TO7?<T2:6`S[+3N]S%EMH>>0QX[>4E7TW5`A
M\S5@G$Z6LR$:5:%@*V>C,0=F#&7.QK(QHZ25LQ&V-C!;L\&?21M:#5M';@>?
MDX/L:<7\(%:-K,ENF).,_I-G-TAVMWV6]/]A0L,T;<>H^0;4U-^G^1*'\3S&
M47_%$MWSCH6D560]%RTIV;*CZ)JQM&(`2-D2+;;$$C'`W)C]A"XJIW->?[#7
M@M0/.J8V=`GZ-1K.CSE,HJ+D%/62>C`DIL#8SS(Y#I]?D]L7$8Z%7=`?MLV!
M_NH_AVG![M3(C$#U9XNTV6T2GHMA<T[`=8R4*)'^SQ]\Y_?S;E%1DYH@AJ\Y
MWNK54`<HHO`YVD72RK*35_HP19ZXX3FP4K::T[&N>(?%JT[%90SH/Q##.IZL
M&H>-#LP,3(HM:*7MTD_G59*YL]Y$XE7^BOX-IR*0/70!$](9^_K292,![!FS
M"<3$&CG`HH]]S0A/\!W_D[*!J]7+0TJU:YE`%6A'0A(D1"DO$E56R,H;WXDG
MH*X#.:K"M!VE%%_(37ZY$?@I8&UZBM/LG+78J3(OFKJI^T&2X.C-NGPN+Q]4
M&>Y(5(?M^ERY0TRQU3ZQY(W851_&O)W>TRJ\*T1%5^OJA;Q^`WH@C*7:[F9T
M#'U!#IVRA56UC:ZJE>^37#DN3%YQO@:D)@UR(4BP;X(?=?%Z+@*_G79`DB3(
M<N"D:R/0B3V2@[;4I7=R2UU?MK.B:T)IUJK^U)9O6>]\]*0A7(#2V:RD8.M_
M/4="-\NU19PX(3GL1OQ&#[Q6J[UJCKPD56**D*KZ%W^>2O8^C:5UL,:DZW)M
M=PS^@/V;$>>+6H+N-"OU)4%UBE/EQ]:_$"\R,V<BMV=)GEK#GP>:+\=7//&D
MS2&%2)K#V-.TE(N-TDH4V6`P?,6VOH.&+(#Y-A*@TQ2U9*B-%^[4U11D8H_>
MH(7Z<#YG9[.W^#PH6">:^+=5'/%63,$BN);7.S!]QRHX9$098LZK1&!5D3`Z
MG:-&"E2*`9KU9XPV<0!Q8&WU[1S0_6"YQ-$93H,B6<M,Q^@%:^>NERI(6ZOM
MJJ9"`E2*`+C`F0%,;($#C50[=UH^H;,E3U#NW*E1;3L@63K%RGT*!K7CV;UB
MPJ'V![1]21;W:3]7?@7BG[&#Z(?LEJ5<NS?"=L"W3:`6,T;[<4M#@#L[D/?"
M:QUQJ*),IN^YAIIT]"=ME-@^OE)%G4#"3L9:T+8_5$!KG(,NH[X5D[#/!QVL
MM.VXSJ0QPAYD='KJ11+>+\C%65.U=^:_ZUO4^YYWS-A4D86+(`KF.ZWP"O]#
M)[Z2`\97S%'?7M5T6`+F<BI.,WFU#L?C;/F[;LZ@"8>)C[*Y,.V3;.4B->&Y
MMD(G^F-M-=2`.1<!N[?%!32:!36/NY0T4=&$L+U`7.HK\W=L9T`(F],!3NR`
M'!BCZ4W0X'\4VX-F.]#M:#Z<D,LIB1/#Q[&I+07?:7F'U'"K.12PR_D(FB5C
MJ<NV$%O;2Y72AW?ZQ<I8RM'$)A[*1DV*DFX#H(<6=!=PN%@F9(WQ!<YNZ8PI
MCXN<L%MF>8$C/M[R2U($2?OO+-OAA!0_X^(<A^0Z[<F"]<[/90'V)A3$"4LI
M.RJ%1ZKYE,?^Q!>(>3/?V9QOV0>P`GIHC0O4?,.4H\V_M1!@*X`MM>;MD\1B
MQ*^E\E^QY[;;3TXKA%LT`E;6/\+TL%/U;YCS"O3UQT%>8YS(PB#F#JW=6)68
M,<LV`RHJ4]84:<K$!'4F7T'0%4:X=OC8WO-.2`I:)<);0I]SW9"QLJ,@2W6)
MJ()(6=NK(_E%*]/MY?//*R/8.I0![4[QH//9'*L)&:0^P8SW#*,X1RE!&4O$
M9^JOQC>O&%1G0-(_L'_C^P+SBD.!2=DAZJ+B^Q"+>Q+L\;S@*4:MVC/T#VS6
MV9=6)FJ,3UFCZ#$FM;F6BS%)>@*PFK=T$EUE?#GXB/&2*U94A<F$3\*US"-!
M%-PB3E=DE5.+P'76&7-*`A3A/+Y.N4$4\0*CNSA)6#V95<**8PJRI;FD05*L
MF1TD39Y:]$?)4Y.;P]!T,-A*9*P"7:DE/C<L@C4K^L.'/]65=-P3.N7$]!VT
MK!:<)5^21&=&12?CQY9<YNQ2.$<:X4M(EE4_<_24E(<1:$67Q_Q9RU>,Q`D:
MKT(G"N:7U<IV4(K;[F;&[I*G976I,,AO$K9^5(3RYX!YAA.'C">I&+55R[FY
MNO<.,YTK@@F&;UFDUQM2]EP+J%7"C%=T;]WG_"`$^#?HL9LISL0)0-`0]SG.
M,65U,TNC`WR+$[)D\U#9TZ;7V"S>=`LW&3#P:W>5`(CZP:@E0M7'J&M\`+9G
M`SMQ!A,P#Z9TR7MM3?J,8\[E!BV_!E3MYKN3%,@T)4>-&$`!W<ROG`[7L_NX
MKY^)[#&'Q6R;E%\C:*]8:_2!,02=,)3`$3-$8/,NJSUK57FQQR)ZGW4P"RD]
MF-*8$YA%/WK$`A;@Q%R2%9<X6S"3O:2<^PRD[UD7`Y'1\VP@C.5N07F6/1,9
MVVUK@5E-^M$D%C!-,Z.(.RDLPDE2=B7%9&;I>\<IF;&/L.<:F^)"4\.R:T60
MLTXOLK+91X<8;.[`41J2!:Z%.V96P.Y(J6W*X`VG1.T>NGX-2C!&-6=4L9YF
M>C+!EUC#9IMJ;5J]]QA?!XFH,"NQF9XG;&8="1F_)L&9H:J:;\<*?%?S54%&
MM%!,51U3$\U3/#>T$B9,S*YU=U"R_X4M>-D7E^N!!>ZB!6\FG0;).;[%Z:K*
ME#DZO^BU$,.W'%Q=#67?*XM@CDKN=7K64RK`,VDT!6:%,4-[NT>X&8R@4Y!8
M_2Z#^[*H:V_DI?_A`4[+-DD0?X4R1377*5T5):`=+Z4/)\CZNZ6OU.YX8+*)
M4CWO>"5611:V'\5T\1HEG+)=4Q](@#'^,XKE2;#H"];('G&:6]J$_-H$XX08
MJTFVTE+`B!X'N!GC79S&B]6BUX61/N-XLK-!RZ_J2U93G>S(42,&4$">[%0!
MX[,,W\8\^>P<+PEK==EK$J:ON=UKUQ"':H75\$>5`),YML:`2SICF>`(..,$
MX4V<XFP]2R,6,.2'W/WSC_X-)SOKH>MY9JH8\ZR%FO5D,Y4!OL0:-CB+^@Y3
M:8*$BC.+%G12%=FUM]@D0\;J72<K,^+@U]Y*$;BU;0JA3I,!LCT[_,D`6$$K
MF2UQ5JR9=U>T!\F;M>8TU.)-MYV9`0//_G@IP`[B(FQ.@(JC4YA;\<;`$V<X
M`7=SL[2(HSA9L2'1)#(>WH?)*L(1N\?/CNE6Y?6+^6&0I7%ZG5<%1]ZLY01Z
M;!>`HT.0U*-4?@=*F^]&,BUX5`-"L01<8Z"Q7)9ET?1=?[-^G\:_K?`!SL,L
M7FH.I:W>=?)0C#@`).`U,J`6\XG2\<PA)P.0A'-*SMFUS1XSZ_S=)7>F)N(Y
MZ9NQF<`NNA@1S;?#9KRTKLCT1V]4S[F7(6Q3`TF2*FM`3[1E5B.X7310!0S<
MR&>34E/F6;/2R!]T#/9V"0*L(@U#X/06`QB)*3:0(6#6J38_"];L[O5I<8.S
M\N?^>VR&;SFX[!K*_KL1YZCDN(,X_^J?LIML(!9EBC5Q`M'4$Y;7DSR(\S`A
M^2J3.1<]3]BX%Q(RGB>2FA?HL6$?7$0+@V6)A"XAW[41^U!]>+#JKZ,;ME2J
M*BOQJJY5;10*S-[KUU]*IUC;U^Q"@:;4/7MQ=5DOGJO1E-IAY_5,".BYUAIT
MX@:E3>4*0]*^QZV;KAZSLA1CWW+@EPU66!V/^)9SH=_7-^1-7K!>-WNI@FS5
M:M["8AAWT&O9%N`26]!LZQ+IZ'H?RQ8J>6PZ&6O%/DKWZ:QP.M^,YJG'K<GS
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M28GY3NRK_!_U-`I0D+0'0V(*CMT:IB3GO]60'O&'#OE(J]5V;5GZQ%[O4-,\
M[3#>%!2]#[JM3O.,\U2&H`-550E8CI;U*.RA"3`43?7P>!3A;VR^LAJ;KT8?
MFZ\F&YNO'LK8W`:UQR0D:`T>FZ\F'IMR/3P>18PU-LL3L)Z<0>US#J?/,G*>
M!V-U9JE*&_2N^3X$B2$N-F?'*EK>AYL.Z8<-]2@GOQ>KJU]Q6%R2IL.)/)G.
M\&G;)4]-T?/5:<$771+4XCS)DF<`*K%"RV[)ZZ?I>PQ:Z.'Q*&*D)>^@/.MA
MM_5XG;FC=$ZRA:@L>,5ND8;2=M<V[]F.5Q/:GA,>2PG$?4Q1'+`E!/I0B0%K
M/%:@$T<T[4:V0=,JJ[-'.SUIN#_V=E^J<T6=4M[4[=1.[U(Z7][$R]F<3IS-
MV:5GO>@%`/,T]:)T-&,)GS*]1C6];5QU:(B>,V-XMTJ*>)G@TWD=)/2L*UMQ
M0+.4+67K3GY#L+;T<5R[-7G4K9-,H'[IM(VR'%5MTIO/HU9U[`$S%GUT-90K
M1:.2K695S!C8:GJ4TC^DC"5)?XJ+F^TPTIYG5;F*!>JYN`K9T>XH2K!-(1ZI
M':_/\3J"B'^V3=[6DV70?2/`]9YE'VZ;H6<K,)``,C=`+XTF2*C'T"H?I]=3
M$R8QI2,L)("\]ZB7QL[;E6!HI2#Q_NPVB!,VJ=,A60[=VJGR[<QJ!0#;5.I%
MZ?JH=O#9;BKY!>>RY/;O.)(.SLU,2<_:LA<(<'#9"]?1YT#`K89>V?&!6]`Y
M[Y>.,QR])=DYSH.N?]5RP[B4WGW<0=)!>C8#194XO.,IQLZ?H>\+OXCN<V=Y
M3L*8[:(8$TGTJFFWW@0=@8UD='E!=TBC2R^;3CSJTW)/I>U-[]--[N,-EY_0
M)X4V.46-E\6R7I<NP91>3C?-Y#:.</1F_9[Z"D?IVS@-TI#=>&#Q%'Y]ROHL
MU7((XX)=NKM!E2CH:HV>,FE0G#Y#M4"HD0BZ,(PQ5&T5#@3:="675SIZ2TU&
M9`%[UMY6,:@=Q#B7J=*P72!4`,AT8@2689RPTZ&F*7)RB>^+-PD)/WI60JNA
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M.;+I#-8BANTFWZ?!@F0%\X&8AS[%MK(E`JID@"Y6WPN(?INI0]%^<W,1WN!H
MQ3+-Y*;2SE'Z,4A6PL3R?+40O[MDRR;4)K42EK<.54\3HOIA/5G48J.6W'1K
MRR1'DVUPQP5>.CWX4ZV]G;$9*L,W=)**;['8K)^1)`[7XO^A+&A##"3DV$%"
M!O2A_*_<)B",PA0EF;J=$#8^VMDHE=]-:&3V@T_P'?^+[SVG&-]"""2D*)=\
M,=BI1JDHX@&@Q`@K>*2#U1I7LWMO[IL3.DUD07*41OC^!UR?+'2W#/+G["Z;
M*LG!;#H$3\29(LH5PBO0(T@,<;$,)XA-B3"U*H6-_P["_\_+8<MZMK*0).4M
M5G)P9UV&@-+)UL)E/X]*%N<-+UX<Z:P?A'^U&2RN1.MWH29SHO0HFCI+EOJP
M'8?65P,>T0:]DGFJ[;@UMA9KLJF&[.<$W7X^UVSHO^/YRM7N_2<<7]^PXXE;
MG`77>"/-^0&84FYJ2^*K&D/:0=67H?+3:G,3JPITBRDXM3E%@3Q9#5C\\H2D
M0M*JKG@5#7E,,R/]B-VRT$9=V;W^CF:^C,!74(]:&35F:6L%WK9',\HTXCD?
M22`[II'^7;(=ZM\-;5#QW,"V8H48+YC]LAHHHOG^\?+4COCQ_0/*4ZL%>G!Y
M:A*H+/+4=$!;KR2UKVZ4IS%+^+ACY0SF32:&6.U8CD8^Q?;*(CFGD9^]V'Q!
MZ0[Q[)S>>#;H1FQDE?3OU7SJWV4[=T.2"&>Y6*)8LK,X!EXF\?:=ISV(&&DI
MSM\KEX-)5!V/<*%VVNTIN%S@_H<E;,I]FBOT]D<9BEGN=(G9\>G#64YJ@1[<
M<B*!RF(YT0%MNYP<Q\%5G'`Z^ZLLP]Y/IEL,Z0`4+($5T_UFF0(TR-@/'3HW
MQ_GIO,RZ*A-B/"+-^;%5L^&HRFD&@;WS_3+4^T&"3AMJ92_I0@.^;]B.%)ML
M?=&C"R6-HRP?R40N=F(_@=1S?YEEZWN);=;0BB&D5]WY6IGB^B&9<+HX63GU
M^'H@$X.0'O2*P^C8>Q[G$@4[1&<N8KHAF\=A0/G42Q[/6:%N!]C6O!&B[2M4
M8DQX$<H,'JFF[8&UGY!EA3W$55]N''2+OAVNA4[[;,E4C6H>@.E$X8'7>GOD
M9$H>B+_]&67`S\AY5V;(Y)&@S$H0%P-4R2-0;IH"!.DH-`',-M94!\!F=%!'
M<;)BA>LNZFZ5A_=ALJ([YK=4:C;+K\IJKO/#($OI))!70DP1^6R+C!J9424T
M8EBCEMA\M):"-SI_4-DG8ZFA/]KI1=FV#N(V5=C\W:X=&&;O0MQ0[4=&IEL;
M,!U<J])]RR_)+*3+`*6?$;I;*-:L)3<ONTU_NUSXCWA5@J""H%(45,FRPSN;
MTX6:7^2I!()5G3E0,BTZPNSMA+JJJRZ..`[3Z"`HZK6I=<;<^YQ]`J^4'%`U
M_/(HC#)%C"M4`F\_@L00%\O5_SUK^'R8%_$B*+P'0-Z+5N8UNP=T66(3!]G`
M[$'*$G-V#D$',OL/&\RWU*ECMX:Y1K=O%?N^PL).?-A<R7]H2;-3C0+)A6W8
MZ=0&+9G>G-&VU"J=IT.,HYRY3KPD,/VRTWGK`J_O9;'D+US>2@(VWMKWH$%C
M4%I(I`N@%8[V00910P'F<$[PFNI<;N-+95"KH?!8KJ!D]S;.PR#Y&0>9VJ?0
M/>I0FD!%TJ]K47)%@BUB?+ONA?<<.2V<Q!PCVYU>F3>#(WG(N#QN\#T<*R&4
M"5+5R0SDP8P9--+Q:P^JQX%=N:;";L0"^Y;^+I>,;.VSW:%MME_H$`3:,Y0C
MNW2:.&?`\B)Z.(D%3/9KJK063K;"42OI8[+"0DP.U!($>!4VP48VN*TQ=3DN
M\UWTXX%?&QJU1(Q%_L<C./\=I%H?9\7CV9I;G8*-G-`I$FYG19'%5ZN"GU04
MA!KKYIYBD@1;J:;[X;)?7JJ8:'GT5>T*>;XU5+"Y.B]L=M:</:2CV`=#7RA9
M"YM'I["^>G.`\S"+^5"6^(-]C]FZ@C):4)>>6BQ!!J86N^T;4`I,7%P^U@0@
M+V!V;A6WSOX,QH/;^%2YLZ9&0['<C+CCNJ0<>C99[3]W!I/9MHJ1`-I),5;0
M1RX;")'^3[?V'D3W/[H*PA?BKEEOU.&>_+"E#Q'9Z#)&T"WE#%XO/*],6QH=
M*&_,4`DF2#F4#)1>MX+7B/**FU9-D]UK,]2;&\(.P8167()NT,#W3"WV=?9'
ML89.X]*!()_>+("SSL'OJSOS$(KL"4D45?:FK+.W!9%R;-F!Z[T0^$\X27Y(
MR5UZ@8.<I#CB0M3I^RWGSNAYY_+?"KH@1?@8[]V/C#FJN`O;RN!.V\S0)9:0
MV0[_LR".CM(?XC2JMBC>`R9QM!NGNXPEJGA"C^CN5\OC([W8^"_9+\Y9S_&2
ME6%.KR^*H)">EID\;ET4IH\H3*7,\E"\YHT$<RAC,4:6V`'F>@YSI8^-7UG?
MESS'BR!F:<'[A-7\#(M5D%SB;/'JL5ZEZYRQU%^(6I^(V#<"WZV"UZ'RF&5"
M4[(.C^PG09Z?SLLVP:?9.6-:73AJ;B;L!TG"RC94C=3+!WU[KEPZ%OPO^2*2
M(<ZX??VK=?%$B,DLNQ*T?@/<KQV(K,RZQE26]_55M*IE`IP$"UF`M.\QVU,'
M&2V09;1AB1A/:`=7@1XQ0\6I]O]F1YRF.;7_<O_==D(-=_CJ_BH<I`/7$+9A
MC5G>45\H8W':,EL0\FINQ7LKJ1+\\FT;`U4<U0`QI1<YVO3X(TE6:1%DZ[=Q
M@C/UOD/QG&M1_BUR('-DS1,)IO!;#!6(Q!`:E[K\0^KXUC6W'TDFEW$!:$DQ
M<:O"/0\B=VM4[2EW$=/8C_4&PEM_U2H]-BM_Q9[S76K1>Y_=^F+7G.U+F@_[
M8_3?E:I,9N`3&HW]#EE^@PVVUU7/14']'<[IK@D:M+JR1M?Z[@M$[^1.*V2P
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M)]A['I*R'`J3;9>ND`N^VI>;6BY?ZR"7Y2."-G1WQE&:V32*4JQGB7F07_&/
M+^404P5.BKSZS?:<T212TEF*W[9@MQN?R$U-_I#-0:V<DM\YHN95%ID$SAR7
M0D9,H'`Y@1K!`H[IAO.(_KB]:.@?M'0<U`3!#()Q1)PE?+U1-8PRZY!B(W$B
MR\^@CW^L/N6O?Z&_I/]F,>QO__J7_P=02P,$%`````@`@86L1'N78&?>&P``
MSZ4!`!4`'`!H<G1X+3(P,30P,S,Q7W!R92YX;6Q55`D``Y(R<5.2,G%3=7@+
M``$$)0X```0Y`0``[5U;<]NXDG[?JOT/.CDONY7R.+9S<VHR5;)DYSB1+:TO
MD\F<.C5%DY"$A"(5@)2M_/H%>+%("B0!$!#(C.=E'%M"-[YN-!J-1O>O_]C;
MZWT`'D!6`)S>W;H'!_\3+/ZWM]<;^(OEM0U[YUY`_FH'<`7([[P50.3?Y._S
M(%B^V]^_O[__Q28?Q39$`/LAL@&FO^CM[?W6H__]]W_]2HD,$*`DWO5N0M"[
ML-:]%Z][AX?O7AZ_.SSNW=X,>H<O#E[&7R+?<*'W[<["H/>P<#W\_EF&V,,=
M<G_QT6S_\,6+H_WT@\_B3[Y[H+_(??[^*/KTP?'Q\7[TU\>/8LCZ(!GV8/^/
MB]&U/0<+:P]Z.+`\FQ+`\!V.?CGR;2N`OL?!5Z_T$_1?>^G']NBO]@X.]XX.
M?GG`SK/?8N1ZO5^1[X(K,.U%K+\+UDOP_AF&BZ5+.8I^-T=@2CA!P<,>Q?#%
M43S&/^EO_D)_$9EAWX4.1?_$<NE<KN<`!,]Z=.C;J_/'6<P!\KW@@4IOG_YM
MO_2K^ZEH53-X[A'BX#H@/R^`)\IC\=N$3?4L#BP\/W/]>T'>'K^V_YLJX"[]
M`!R<A!AZ`&,.=O*?CV2HCI'#$PM#[$\GQ`H0[*/UP<D3\ZM*58Q2.>K;MA]Z
M`?1F$R(4&P)>S%C?5(S>R\2RPCL7T'_CP+\"+M6;B45^R\UJ_3C*U@0=_M5U
MX-O?YK[K`(1/OX<P6',RROJF8DQ?Q^;@QGK@AB_WE7V%1GA;@T[6T4\\>%5\
M626/):I^8Q%=:K!4DN\K7\\,#1)BM?S[2EF-1SY]L-W0`<X9\A<#R[5#-[)R
M_G0(W9"LSE,+>00S/`'H>FXA$''",9$FHRN=9@0F]60<ZC<"#T<<G#[0'[EG
MPS&(4J;'2SK^[Y8;1H3Z&(>+Z%>8E^.Z$52NSYC6=;A86&@MQF#N2XK-[*-'
M,02!!5UA1R3]FEJ_B&&(Q/BK&$`MI[5;MAC?W,/MPB"+L5XQ@`+(A[X=TE-!
MWW-.B5B#];DW]=&"UU&M_'KJ5"TS'NR(,)-C$SP$P"-6.F64#BMQ]MJ(C1!T
M?3M'PZ4G4Q^E)%SK#KCOGX5X;V99R[\>3T;CZ1GTR)#0<B<^AI'INL,!/>87
M8(RYBTZN4PO?1<?79#ARC#TXV@=N@-/?4,"/]EX<)*?8?PK133"4GU1B$C6R
MO[&?S3@EJ@'.R8]8*[<;*OLYG<DJ:1_E)V`A.^6)_)C3T.T(1O*)_25Q*;Q@
MSYY#]U&YI\05D5.\P"^7K8^(:7C_[."7%\W5Y=H&GH6@WW^`>N60([1AVZ08
M<DN%"7@>'16X)P/>>G@);#B%P!GZ"PMZ6K`O);9QR`R+@*5^.4F4XY5(XT4L
MC39,IEZ?,B8O8?\P85].G8BG#0*L<],J4&@)TEM;1Q;M(B@91>D1IJ<`(>",
M8B!+F8HX"H@'!J)/"B_X08CH;"H%Q'8CV=\T:C'9LZ"8ETS3".0IMS3&3/Q3
M^C_J/J\LEW"(^\'`0FA-#C+TG*K%0^(CG%WM.Y1EI4)FEP\G?/(B=E/IREJ]
M"0)+"SI)1(3P.@[(P2&>63)-'>+E(6MJ8^66+A=V&4='6K8-]C.-,F1)J\WB
M8@OF4,*N^H'ECC(K3W;I^4N`@O6$',6C(`"Q$$NZ(U\"36NN@I[Q`QW/<JO"
M2\$ZDY)B9LU?^IZM;[FQ";74EZE!1W[M-=[P8F;TV<.V2R2=?R*"(P7F3TH.
M(VC=01?2^#%9R]MQ6IT',6[:K3G;5Q[2^*&4-Y+YLX34^2W+IL0ACO5UHVM-
M5(,S9SPF%*H.>I)V,;Z<PA-K34,O.OU&-B6S9[D*Y<Q9SQ*4#)[@"$LH),0V
M$]`KNQ)BAD]K_/(K`VOG![7BM6JB4_F[5;8L2PRER(!FHH]\TA)#1HDSV=2'
MT;CF2A=;:^57A8]"OU/VNFZ7KF:U<]DMYX4'064>IJQX!_YBX7L1B_J"TT4:
MAN]@182WC8\"WT7.<7&<Z+K><B<6=,Z]@;6$9(5K<5M*2!F/>HG)KA0Q%;Z+
MG!"O:#J5MTD()0Y6N`BC?7H(IM"&6JPJ!U73MZLB<N4!T6#(C)62OXN=LFO+
MDX63.G='2Y3-1'3-U$E?A>M3CZ>J:Z4H^W._F/Z9)JUJ2@LM/G>3UKO"0#H]
M[#)2S<X(3QF@;<\`K5$Q_J3/IL@_I7U60?Z4]OF4]MGFM,_QDE8J(%YWDL:C
M-0.TG%AKU*GRIK$"++.W5U<$,#)9FFPW!"O@^E%B2,*EGA-H%4&SJZE6I?-G
MSTKDE%QL28DTKB'B$K[ZS@)ZD$Z!E@S1*-0ZDD;W7"X5STJV%D"#EY9;*KH3
M:VOZY"DL0@9,#0+L:NY/'GF*'?"1C_4*+T.F)4X*WQ:9A<=4<F)4:0E@G1MA
MD40W')DM8"3"-L>QA#PPHZ&3Q@EQER#0NZ+R!(R?W_D$54#%^.UQL?`%+31D
M4WL>U\70(;<ZDNV(!%1*L1:U1*XO=^]F?@9P-B<\]%?$;L_`9;BX`V@\C=@<
MAP$MU>80UG<@9TE.NK`IRH*<J,6KAOOFSN/HCZ79FCXI'T_3H;3&)2KI/072
M?^Y`.H^R/473VQ']?(JF/T73VQA-?SSU]FE97_$W'E7?-QRTJ?9P*B=N].G^
MTWF2_SS9+'%.<*WTG:\A#BBG^,:_`K;OV=`%A#'*THU/?J#;\"T&SIF/FBXL
M9<1:O0K50=H@?:?YDAT"0M*&,:Z>TU_X*(`_DGIRZA=P%3E#XE:]-K)+OQ)=
M-7<ADCY8$A+)%RG5XH"Q*?V$PB[#U(3!3WG*:MQX.@1WP1#BZ#WA!($%#!<Z
M1%Y/U-C.K5/^'%@KR*@6>^\WM[P9P.?>9BKQ:WW/D7X:+3:DD5.N#BF+0MG@
MVJ#YKD[\302()1J"^/_G7E(X:)@PPBP@I"E55H830T]%I99+_I)/#G@)7R!_
M%WA3>,JF2&T*C\]WHR%%HN:>GFK0ARU$C3]?9/)8>+*^,\$7Z1K9/S3)?0M3
M52<_^>M_N@].D+^"#G!.UG1'S$[Z<4/4%,OAI6XX$""R0`J!'VY\&\3M\ED&
M0IIP[JT`;A#JJ?I^JZ,WE1,WZKJ1?2%Q7/OV]Q`B4%J#3L>B%*#>:OG*H"F1
M$%*2CZ72&C,T=8?6F$7=L.#%%PB'36:BK,PFBRE$TEQ`VBA7?;_5B[9RXO)Y
M.2J,,O)M`!Q,>U-]MA"R:`HU0#;4E$9>2:\CUU[5F"7B?&TB*)KE+'I/'?>7
MPBE[6E+MZHEV4*XEZ"7"?6-"N"4&GF%;=KB-LJB;WD9Y%P''[LD$5]WNJ;*/
MP`0@Z#O%$YT.51"BWY+LG<J%+P9H(OZW*HI2//60:(VXRQI)'(O+>1EI#F$&
M!0IJL/%P^]<+PS+_2:1.<4S#UA+V/1;\J9<_,.\D8S[?/5Q^<Z$WNZZ/0P1N
M"`,GY,/?=";+5Y&3C_^>/#8OQ3:"RR1))>IC/L[U,7\DJF-N$ER83MWED'YV
M3<G@K#*/<V<KZS":DY^;4Y-6GS_'*HOEO.G$JV41;1$Q[&.(+I%MD)15]]CM
M&F"T7&ZPSVP/IK5;8#DUZ<<><.;!*;1I:'9K=*W["B=EXWY9O8AS28:<>'9T
M]=0V_I:O#Y@FY,562>L^PJ8DOX7D!]2Z:LI(&5\FU>++)UV7H*5N3>QV43!:
MRC?84K8'HS1V6Y`^1U%IF6`Z\HZ6"C_QEM5J9\F[NJAP*:H*E]1NU]3K^$G6
MC?40[RD-2LZ2,7:SKU21:Y3T61Q5Z[*II&=\F^$0:2'/KP*\+FXXVU[ER3KZ
M:2V]3#I_B+G%8#P]Q0%<$$]4R[UA@8+9ZR"Q$TD1',5*K^K>+U)AK8:-C[#A
MN(R8;#FQ--/C,65R!`EK#O%2=K2!5=(SOH&)";@:.\/YZ<427CM8PW4DC7KR
M8J*M1<]HFC-](HO`''@8KD#L1<4,[L)0\](V?<\D:*RY(94O?:?HR=$EN,_,
MC7B@Y$<[NIS&.],"81XZ9MK%,5:58FO^QB6J0H2;7#UV_LQR;<^!$[K$-^^3
M@1U:WI"8A6M@ARA*T#M]L-V0X$SS_ZCE"(/DX7IQW]`;0U//9:<<;!U24MH6
MP620N_DJ_JEBW8^J<KI8NOX:$#5!*V@#=MV1OAL-%RD++8$P\^`/X,39F@,?
M!YHO7[4Q:SI35CB8KD]L:N]X&RCD9BK)XZS^O86<;%8Y31N,YX=QN(A_%RWO
M'6FA$@Z-.X!-M$^-C,Q&>EBSR2V>^/G!VHQF<7#27>,E!KC:P-%.?)`8D)R_
M9;DV[8A+QO:G27WP+;<KJN$AX:%4DAN7D1-Z!]J0A(J-H:E3JZV"MUH.&U5H
M:\;`2&?I<&6\&3J3J5ED>LYK"@N9-V3E9,T>0%<Y=)WLFLVTT6+W<B4&=4JZ
MJ(M-SMRQ2WD!:-,-;<?L'!'381_]:W`K12L/<J$6O&QOFOBEOC[)Y0D8/U+M
M6&X%>!4MN4S2-$U^W;"A3XQU),U>E.Y6J+7P*^D:S.;ITEH`?=TS:FG^O:QN
MO0@R=^JF+X];[XV,RAJ!F'""^PMZ:]-"=S=AS'!&H.)#JD(M2@6GL)K^3N)-
MD0=W5PRH)>6!I<-*T:A;8;JTZ+!(](AO)!5!(D7W(OIC12H9;>"BJV%#:^!(
M-8MFK)_08M)ZY\<.%C5Z\+$I!Y+0UA7NJ2)GNA".3ANT_4RD!'(E,<#*/N_Z
MCH$\9$T[PASZGI45%Y+%8(N4S#X`#R#+I8V!G`7T(#4HU`O2+C4^PN:K;HN(
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MBDI69MBY@OC;&0+@W"/K'.#@BM@2+8$C[4P;\M#Y%::^/:92&:J(`9O73[J!
MV<1V#2$MLNTYG=!/)M-_7_UDRU!%)]CVZ.?O/DVD<V&P[I2&%M@V<\9LD8H6
MQ:B@1ZWTG1!E?NM.;'M^=R+SNP%H<:!-._5P:RIDVD`M-8E-ODB!F6O=&,'K
M<+&PT#ISC2OAD2>#2#CAQ6]*OR&6M3?)BZ)Q&.#`\ASHS2Y#;:F@RIDT<D:N
ME+F23:!<*/)^<TD/!]/:]AG`V9P8D?X*(&L&TIXV$P3M=CDJ@JP;"^^9T,YJ
M(<K[TBR=W:V[4CO7*T#O0LCO!V1WH5"'EDLWQ,-6^3$-IF'6P>'5XUW+5M[U
M9MMA/688URSA#S3#'9][<<BV=:98(?M&XQLJC+%*4:HJ)V;*?<C/]0/RL99T
M*!UL_OQN`5,X\F7,FK>9C'(#S\FQ%3C#$-%J/[$%II/`.VLJ*L%%^W=>"60E
M*I>5M.XVMFL^]L;M[,8I-H/VZ^&.)2K?$5E):96&!OK,1U,`@Y`(DK9@?UA"
M%(WP./DV[J7U3'?>PVLN-HEFSB6VM9V*V3H[JW5"W3>[>N7=H&UQ"ZSP5FQ7
M3\=;+2'WGUHKF8)IVCHYVT&WY4'WUNMAK='\>RAGG0R5=GWN3-1=H_;N/N[>
M=D7>O6A3I9:^2V(8XMUW,Q^"P((N+9<LUV.RR[V664"P'H2SDR;*ORVQL;(&
M&Y6\M>9G9V3X*;2`EM`%72$/957&DN=C<8T_:B]\CP9E=#UCKB9H1BJU:I^/
MJU8B5I"+;%,7^L:"QFAU5IXJ$C']BIQ'%0N-6HHP%=X3R]6%R)/7]Q:53<AP
MDU-!&92`E5\%+5W1-5O,UNM/A:T3HM]>+UT8Q$7/,('DB@*C)\-6E`=C%Z%<
MNWY]C]TJ>`U7^[^BD_(VU7+[MATNPJ@U^Q!,H0VUN(D<5-NS]58*G`<_9=7U
M)64\0;X-@(-IT2UZ`VMY-AA/1[XWHV<E6MLP:@:YA('E9NK?`2VBEV?&D#\@
MK!(-X%968%]AB]5^,+`06A/ECG+ZM?A^7(2[(G].&)4E5IGNRM8P0M'YEFQ/
MRT9W9^*RM=.Q7F@O,Q6%Z;]QX%^!R%686"C(K23IO9YN+^4][I6&^MB4Y*)\
MO-"(1?_$1A7>-T5(B,<*Q4<V7B6F6OG2,ZZ@K+<BB]+K(G&VUKIBB5LTC,4:
MI)93U@YOP]6HG.&Y1WQ<RQT0Q2!&/*[MRPPEEM3&*?^ZT?!4F5)%E6LJIFSH
MS#\)D3VW,*CHXL'&G_E%T_4?J\!GS]1LE[L+ZZN/;L@'\7B:[R>@+Z1;2].P
M<U@E0W[<%$5&YSX*TA,ZI:?MRHE)J+M[10EP2KIC1`Q-K#6E/0Z(5YW\K+$%
M2AU)LQ<B54J::Q-?!YR24K=;[.@S966DC#N]W"(I!4O1W3D==G._<+*^]>#W
M$`P!MA&,]D&=?F\]88/A.R7N,`>T96UB>)WD`759IGEB0FYRQ0#&UXF0>L8>
M=!4>1LJ`LN>BMUE3*2W#*4.BXJS'3D6NRE,"D3*WCBNQZ&6#WDY/>45/>44=
MD8%(7I'X5G+NX0"%4=JS1A>M0,5H4HT2CZP(6^:YN(P?/4'0L^'2<H7CD^QO
M&@]-LM4JBH^QIZHN+MG@"+/A6K]?Q:1EWJ\J%UP]4"5Q^JZL;\D[M<PK>^$-
ML=#G-4K9(3^3XX?O><"FB'V&P9RLF17A8>):=K1U%%,CV:9!>O#6QP-'K!P8
M>2R57ND+7>'B?AC,?43;$=QZA(DB<_F;'.[[6\%A35VG-!:Y#(2J;F(:7'\Q
M^92X#6./TUEI<H&D*DU1@8]P8071[=%04ZWR"FK=M-`\,"JL^28FXSQ3A63Y
MN%04UQ+E&:>S2Y0+)/DB:@V6:"5G%Z$;P"7MN_9X^F@N2]:@G3C8BDN6B9]$
MA30E3PM.@!>];K#<\;U'1IK#97\:T'9,*<]<LN48IOT15*8H>0!25AI,5'ID
M-M`&<=V</L8^89/,BCKF#+;)QVR*^@R,X`+&Z!>1X76*%5/MY@ZL`7V)8EX*
M#D^9WFOX"LP@IDV;G#,?70%L;1_ZI)2F*8WN;@:-T556\TKVV9D%G7/O$_2<
MM)V7#@>=0:6[,J^"3KZLE(KLQ;QK<NM9"Y_,Y@=MA86C!Q[Z#U\LHMT7-0>P
M#:HS*7DCG.I@TH*5<GSZ8+NA$R<V4W8CR'6H`#?MSA[GQ%%N4-A(T3U-EI\X
M02?5U@D""Q@N=*A"/='N6P,.8%/I-W\D+'U-DDTNS<]Q$"+$&T<5&K"CQT`Q
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M4\J5()\G8/RMGS#N!8"4>%-/#UR4/7`Y;/#`Y9&5@6MA/)Y&BTO[IK!%S&04
MH<F6L(U:\96QZ".77#(GP?%`[*5+V=?;H>]E2I:\>BF=NYGT<P9'A\VD<=AE
M:1RVHU)/EFM]NP:#2GOV[2K!5<'4K!2/`^!?(S"SW%,OJ*W3AH']R\Q?[9,O
MQ:"3'XI8LP;LQ,F`B43^R;4HN!_!E*PC"/!H-!"P,8RO&5/3"OV@H+%F:.Q)
M(^4U9K/.A/`J<FXT(_:]!O_M*9=6MFGORN..A&^]-G[JQV!8EEO7%)WNS)`)
M1<1)H)LW=IIC-UOD##XDEI1V)7AFO<N(*?HP%CC#$-&ZV%$F>,SF);B/_J3I
M<,Q%N;.KFP-490T6&ITLDFC7&%W1;H9I%L"FL.7`<EW@G*R3S^'D@UJ4HBE+
M7=26QF)0]T!2,K,^ZI&9'K[2)B,#'^O1D4IZ752`:@!5O9T4E&ZR4:T(]]0I
M)18L4;RT76]QWV<?V#B&:>,1F"DO'DA4/8$4DE6N@W*FDVUJ*F[\]"%]/(7T
M7]'GR31NO:W&6FQI*B'4I26J!EEC3RLWK_3&7C(5JKDI]UPRKQNCA7DZ3%'6
M8J'LV:+@XIU.Z;NY%2`G/=J9"Y*9.%''-FMAS3@?)M8.TIU#4ST>IIX2%N\(
M!M9R"9P)\*S`74M=D>1'Z,Q&6`.$JK>!DD7`R4Q/ZMN[GQ3;NU\2PQ"5F=G*
M?R[S>!15$M?(;W=6_6[$9_KM(KL98R8\I.6\5$NT2QZ9`)0J7R8V%G?AJ*#G
M9%Q%K^M"W@90X=O#!GL-C@-]J<<?_4[;1L$DULYDHGHSST;.[+/#DM!MU.G1
M1#B\0+B#&SH?H`H?),K)W:*UK")F]:_D,EJ=.0#4HZ;\Q2!_X++J\B7Z8^PG
M;OS"[=[B);%,J9&[M.]*8I<*NW&`J[&7Q>11MZO%)MHEN0M`F<I:09A,,I%^
ML73]-0#7`*V(R6$?&"]I_@0.@!.=#?&-'UAN]N_T;H7@]`4$5\#V9YZN/`9]
MS'9NK]`HMU0G540$6Z:4L0&.ZJQ%OZ*?TY)VM>,9=/#,LFL9IUJM)(ZZDX(+
M0]^.^T1X3IQY>>Y-?;2("T6)6_RJX4KJ+904[>492-3]V.27QO40:7""MKY0
ME5I;&-6,O1<103[IM@A*P[:2=."4F1ORN>8HYT8S<HDI`VX>@R9O<>EH2:VG
M,XAMR_T"+'3J.=6UZWG1+1W9F%LL@W8Y/LV::VZ6R59JZ#@,<&!YSG9S#VE+
M4DFC4_+@P:S9NY0-E4EXYT+[S/6MBJ(^8H+(#MD9B\-`H_#80!C@/N'!B4J2
MN98"+<\/9RA$*@-M`8="VZ@&N&8:GRJ$-SMJ=]P1-BB99)]F[ZD&9&1DN>?$
M2W[X!(II(/(VNS"LJ?-2`RM=!":3MB/O:R<[<ES$A]A[^D8T5/`NLW+T#IF4
M:I0RF3ER%B8>_G??#0D$:'T&77+25(5^<=CNZ?P6,-F$$ZFM,AXW&FY`',^9
MCY29F/R@'?0#"ZADTSV:V?3/P'4_>?Z]=PTL['O`B:Y$*DKEB`%?-GP'15"*
M5#8WH^EY/XZ/*3N:LH?MDK$I`2:;.2%E;-)Q-^?=,_(;!?:];.`.;:REV&0S
M%R0/G/FQTW"P!N2S0W?'@Z^`)YMF4!WI_G6?CGEG81#]\_\!4$L#!!0````(
M`(&%K$28_M6/ZPH``-M8```1`!P`:')T>"TR,#$T,#,S,2YX<V155`D``Y(R
M<5.2,G%3=7@+``$$)0X```0Y`0``[5Q;<^(Z$G[?JOT/6EYV3LTR!,AE2$U2
M14AFEAD2V(3,[=2I4\(6H,26'4D.,+]^6[(-&&P9,JF,=P]Y`EEJ?=V?U-UJ
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M925C`6F(Q4"+CY^H(?7R7K6\I(%#V7V:$M5&HU'13^.N:SV3IE>/!UB`Z8E#
M7,+D>X^[YV2(`T>>E!X"[-`A)79IB4E;SN4MRSJHA`]+IWK9(*26`6;,DUA2
MC\6M4;OO4S;T3N,V:%5(CF,XUV2(M!K'R@0G)4%=WU'K0[>-.1D"!C!Q.3;G
MGPX>O`&,<1?,+>XYQ&RCBL\]'W8$!2,O#!$*6!N=M)MZ7($YB=-90"Y53I]-
M'Y^3%]<'YA2P!#1?*VH]'U$V&;ZX8C`G931%K>=2RL+.BRL%<UJ!DTI64BW5
MNP^*(/7A]KJ=ZI>T2(@0PG.HK7S]&7:43[X9$R)+B-JARG_R/S,[+:^2>.Z%
MY4_!OT+@N8'EI1V-#E+,)DQ`Z(KD("U(H%>M@'/5IP<^U;/1+<.!36&^W]Y5
M5L6F3!J`R"X[U9]7UW0D(.IB'IM<-JLC<R9>H6=E])RA2H*B]8WV-/+:#)K)
MW-:9_*WV.TW3*L%A+9/#>:M`WA!U?965P!A@<T??EO2UL!B_=[Q))F_S#NF*
M)!BK;\B8DHF4T!UCFS%VY4E2/0L$942(!%7))Z=F?B!O1N=46(XG`D[@BQJ-
ME*^,):1RL&-AP4+M#`LJO&%O2>LU0E([Y<:L@U1VE!?4XM3&61:XVRY&HNI-
MR_(")BD;]<"769#[K/&4UB=G"QVFDJ0<WT(6BH6E4+0C*"9H/RH2T(%#U'<A
MO6OBJ)#3PSI57:,K?T1^4G&4RM]^&*QBX;I1(.FA2#Z*)MCM.2.E!S?2L^['
MGF,3+BX>`BIG:R2F]<G9<V]3.3O0R<9"UC]1*"V-HQU%,46'81[>Q].4#99X
MF*)Z@I5&*BO*/X92D!:3GE#L^%!\K$>?LYG^E-PUAFXY'%7W5CE*"5+_4M7<
M4!YZ%3>F)^,[WDSI11]#Z-@HR8AZYF6$U>HVR09Z%8K-H&['G2E,97"7W3.7
MN]I60<M$WHZXM2/P.9&8.H:3<-PAOVA1K><>BM&K2-QN:SW!+69Q9>BZ`6OI
MI8Q,UV@@\/^-//T6]?<OEY_W__C]J^4'TV_LH&'_.'H<?9NQV_-@\N&(-XX^
MU>YN^S/A'#U:/_:<C_+M;:O3L[]]=^H'[.N@VSIOSS[T'\[&UU6K.ZD?/=C#
M?J5W5;\AAX_TX>WEQ>AJ6!U]JA]Y!Z^_T[OOHF/MOYY</9[Y$WSW^9#@_TRK
M#W<3W'@]&=]<]E[?=ZRW5V+$/LF'<ZO6Z_RXK\W.8`5-R"/'W"%5P:L?_OVC
MM7]Q.'KKB,:UW_=IKW)9_U[M71[A_?L*M<:'K_VWG8]6]_';Y6@B&YWNQV^3
MC^^/Y,&X?G0_>,TNG>;GBCMIGIS\@5HWU]&+Y:<NY]`Q7TPM)[")_9Y[;FM!
MBC<\ITX`)\,+S!DL-=$C_&:,.=%N/+'6?T9.;I1)KQGE;@-X'L6=&!=2P-`2
M,E5NBK"A&)QZ28(TO+_`/GJZ$\RM4V2YQ(T'YJZ+]#+5IF6.G("W8]J0269Q
M:^BZ0;A++UME9Y,F_G;T*?JTW=2;;%M=8"),Z+DOINICBA??H'ONIMRNCI7P
MUKI#6<^/E@&@",&.YRR>N[Z:ZS-V`CUI4XC`U4UBG>2\OGGEEO22V$8$AU.C
M^=QH:?*=$\YA]R9P7<QG680F'IMKS;6UBMG6%$:S[0IHV:R=>U:@+@,TF7T!
M*:J<M=G0X^[2RU1CC_RW/&LLQO(0"$2A1+0D\J]#UKM*XDZD;@W;$O<GPW9H
MIJ[O<8G8VK57T]W:\$INQ[.T/,,0]:T<CRNKIG*U5JY7WTR%/;]>MB4,I7AX
MP6T[&/&X)\$P7Z7-`*)!+(\<8>SK@17B2#&755[(FB/:TC+KUYDW,<[J*&6:
MAC)-]?#G@2S?9-X.C,>N#'@V0)1ZF7C3Y1(/4),?K)LANMRL9STI1;<+(9@3
M*9H#(=4-^1(*+WOJR^K'T`9GZ[8DKMJI)82C7B<ER0-U35/W\O7UQ+X>9P<\
M<I6,.HZ*:G%?$<!@*@/U]`/W`C^>A(+XI<B8#BNZI9JI18?B`76H.B$63I4T
M;-GZK!RS>WBFIDZ>M2/!20U=CT'`Y[,T'8?8$:E*A@Y.QH\&X0W4DY+%B4WE
M3ZB^C1K+;BQIC>C^)!LUU3]O%(Q>$SC#OFO:=X&0^L)AW[LFEL<L"E8BLN,)
M:($/Z@[B+43-]QXOM`&>31.3EQIC-B*BS1;C0\_`[&+N^>WP9OJ!-NP?453B
M3>`,7+ZG#+Q+074R@3/H9"RA=[-*Z,51^R?Q&RRC#Z5G&66IXAA@,Y@&/=LN
M)'"RR]1-6`NV>62RR`V"Q4`NQ&9M-\K./8#)YX:,]8=T4^FEV[8*X,^PF7\*
MOREV9U6LBD/^!ACS%(QJ*D73:1569J!)NYL05:M>6!-;'H]A)+>"@=X#2SIE
M@ZPD2@+YJG7@BQ(N?CU19GC9ZVZ;UW&%9'([\,]CB(+QOCWLE0)"YJGQG`QD
M&_R80M9F\(`12R'Z0N6XQ^DCS-%SL*5'5_\W3I#;J63T=*(9R+''Z0]BWS*;
M\-7A;57\Q$[+\6!;C@ILGB<H8W*5O8!;8TB"PN"1*JW`QM@$O4E[O<``&]>%
M^'#E"9!TK7:ZSG-6W89N>^%$;1.41B]A%'`9.)+Z#ND.P71P$/*Q\PR,+[1^
M9LJWUB73+9P11H;4@HW2G3`0,J9^<RA5VAO+7$G2+;6U7I;Z#3`:PR2U2/A/
MY)#A>B`&XHQRGBEB>Z%^>$0ZU*7A6Y?56)5<%[%V+VR2Y]?*Y"&6SD#BFHRH
M`./KLM8U$7@]*IDM]DN\Q\]J8`RKV3>("IF`YL'-.U1DCR]8FKD)T&S'$2Z6
MYB/T5P!@$WW!G$,`OYB"::E0OXCSR]?U!B!-Y;NH$\0)BS35N)%^',D0?2_.
M+<)YXF^Z/\QUR^@\,8K?B2H%5?O34J,G%_*>0Q/3PE]XSBZ+)E,X8_F_/DCF
M`<ST8!?#(=$_#@;)`^0,'0H;1?_`Q#EV(6040+5<A(8EOIH)M[#OPS&3,"R=
MV:]7S0S/X)R49U.G0C!"H+QKF`J$BUL_#$\#8NX'KLAJ=>Z7^*LGX<Y<NXNK
M1,TI??FH`X'6I@!'1`G@<H:>1);-Y(7K.]Z,$*W\W"W!.:'::!Q=$G=`^'R9
MZA^B.[8]%].73C@W@9GM8G3L;3.UP6`;JV&UO;TB:6<$:(H+D#FJH_=0G<@6
MYY'B:&;$E[TJD\63IJO^8Z5(2F6B,X2"CP3B"*=$=#JMXNB2@BJ;EOF!OFB,
MI`/;(B[7]JK50JF3A6X[G6J%UJFV@4Z)XF*!M$G#E1F`;H+!':20?6^1)8OB
MZ&)`9V#&=!.[..]C-T*I>=.7G<.KGJ'2_P502P$"'@,4````"`"!A:Q$-FP#
M8()5``!%"`0`$0`8```````!````I($`````:')T>"TR,#$T,#,S,2YX;6Q5
M5`4``Y(R<5-U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A:Q$W493*N8&
M``#*.P``%0`8```````!````I('-50``:')T>"TR,#$T,#,S,5]C86PN>&UL
M550%``.2,G%3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`@86L1'\5R1"\
M&P``/)X!`!4`&````````0```*2!`ET``&AR='@M,C`Q-#`S,S%?9&5F+GAM
M;%54!0`#DC)Q4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`(&%K$2$!WS)
M^3@``$/A`@`5`!@```````$```"D@0UY``!H<G1X+3(P,30P,S,Q7VQA8BYX
M;6Q55`4``Y(R<5-U>`L``00E#@``!#D!``!02P$"'@,4````"`"!A:Q$>Y=@
M9]X;``#/I0$`%0`8```````!````I(%5L@``:')T>"TR,#$T,#,S,5]P<F4N
M>&UL550%``.2,G%3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`@86L1)C^
MU8_K"@``VU@``!$`&````````0```*2!@LX``&AR='@M,C`Q-#`S,S$N>'-D
M550%``.2,G%3=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``+C9````
!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1371">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>5.&#160;&#160; Stockholders&#8217; Equity</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1373">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><i><b>Amendments to Articles of Incorporation</b></i> <b>&#8211; <i>Reverse Stock Split</i></b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1375">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Effective January 13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc. and to effect a 1-for-20 reverse split of our outstanding common stock. The name change and Reverse Stock Split were approved by our stockholders on September&#160;19,&#160;2013. As a result of the Reverse Stock Split, the total authorized shares of common stock were reduced from 1,500,000,000 to 75,000,000 shares.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1377">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><i><b>2011 Private Placement</b></i></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1379">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In June 2011, we sold 8.0 million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July&#160;1,&#160;2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular
      purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period.</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1381">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On July 29, 2011, we filed a registration statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August 4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (&#8220;Rule 144&#8221;). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise. If we fail to keep the registration statement continuously effective for a designated time
      (with limited exceptions) during the period we are obligated to maintain the registration statement, we may be obligated to pay to the investors liquidated damages in an amount equal to 1.0% per month of such investor&#8217;s pro rata interest in the total purchase price of the 2011 private placement, capped at a total penalty of 6.0%.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">During the three months ended March 31, 2014, one warrant holder exercised 144,040 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 108,409 shares of common stock and no net cash proceeds to the Company. During the three months ended March 31, 2013, we received $0.6 million for cash exercises of these warrants.&#160;</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1385">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><i><b>2012 Private Placement</b></i></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1387">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In July 2012, we sold 5.1 million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1 million in issuance costs).</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1029-0">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On August 24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September 6, 2012. If we fail to keep the registration statement continuously effective for a designated time (with limited exceptions), we may be obligated to pay to each <font style="COLOR: #000000">investor</font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">an amount equal to 1.5% per month of the aggregate purchase price of the unregistered shares held by such <font style="COLOR: #000000">investor</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">, capped at a total penalty of 9.0%.</font></font></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1391">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><i><b>2013 Common Stock Offering</b></i></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1030-0">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In November 2013, we entered into an underwriting agreement, pursuant to which we sold a total of approximately 8.6 million shares of our common stock to the underwriters at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9 million in issuance costs).</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1031-0">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The offering was made pursuant to the Company&#8217;s effective registration statement on Form S-3 (Registration No. 333-190550), which was previously filed with the SEC and was declared effective, and a prospectus supplement filed with the SEC. The <font style="COLOR: #000000">offering</font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">was not registered under any state blue sky laws and was limited to &#8220;Qualified Institutional Buyers&#8221; (as defined in Rule 144A under the Securities Act of 1933, as amended) and certain other institutional and accredited investors, as permitted under applicable law. In the <font style="COLOR: #000000">underwriting agreement</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">, the Company agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of
      1933, as amended, or to contribute to payments that the underwriters may be required to make because of such liabilities.</font></font></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1397">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><i><b>Stock Option Exercises</b></i></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1032-0">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">For the three months ended March 31, 2014, approximately 215,000 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to the Company of approximately $958,000.</font>
    </p><br/><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1403">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Stock-Based Compensation</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1405">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The following table summarizes stock-based compensation expense for the three months ended March&#160;31, 2014 and 2013 related to stock options and Employee Stock Purchase Plan (&#8220;ESPP&#8221;) purchase rights by expense category (in thousands):</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1424" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1424.finRow.1">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1407">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b></b></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1408">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Three Months Ended</b></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1424.finRow.2">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1410">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1411">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1424.finRow.3">
        <td>
          &#160;
        </td>
        <td id="TBL1424.finRow.3.lead.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.symb.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.amt.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.trail.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.lead.B3">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.symb.B3">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.amt.B3">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1424.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1412">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Research and development</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.symb.2">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.amt.2">
          1,262
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.amt.3">
          249
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1415">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">General and administrative</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.amt.2">
          1,707
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.symb.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.amt.3">
          1,586
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1424.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1418">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Stock-based compensation expense included in operating expenses</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.amt.2">
          2,969
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.amt.3">
          1,835
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7">
        <td style="BACKGROUND-COLOR: #ffffff">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.lead.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.symb.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.amt.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.trail.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.lead.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.symb.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.amt.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1424.finRow.8">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1421">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Impact on basic and diluted net loss per share</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.amt.2">
          0.13
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.amt.3">
          0.12
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1426">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">As of March 31, 2014, there was approximately $45.4 million of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of the Company&#8217;s equity compensation plans. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize this compensation cost over a period of 2.5&#160;years, which is the weighted-average vesting period for all stock-based compensation awards.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1428">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option valuation model with the following weighted-average assumptions:</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1446" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1446.finRow.1">
        <td style="TEXT-ALIGN: left; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1430">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><i>Options:</i></font>
          </p>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1431">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1446.finRow.2">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1432">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1433">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1446.finRow.3">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1434">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Risk-free interest rate</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.amt.2">
          2.0
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.trail.2" nowrap="nowrap">
          %
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.amt.3">
          1.1
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.trail.3" nowrap="nowrap">
          %
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1446.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1437">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Dividend yield</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.amt.2">
          0.0
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.trail.2" nowrap="nowrap">
          %
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.amt.3">
          0.0
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.trail.3" nowrap="nowrap">
          %
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1446.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1440">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Volatility</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.amt.2">
          153.0
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.trail.2" nowrap="nowrap">
          %
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.amt.3">
          152.4
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.trail.3" nowrap="nowrap">
          %
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1446.finRow.6">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1443">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Expected life (years)</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.amt.2">
          6
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 117pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.amt.3">
          6
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1448">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company estimates the fair value of each purchase right granted under the ESPP at the beginning of each new offering period using the Black-Scholes option valuation model. A new offering period begins every six months in May and November of each year. For the three months ended March 31, 2014 and 2013, there were no new offering periods or ESPP purchase rights granted.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1450">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The following table summarizes the stock option activity for the three months ended March 31, 2014:</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1490" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1490.finRow.1">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1468">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Shares (in thousands)</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1469">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted-Average Exercise Price</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.lead.D4">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.amt.D4" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1470">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted-Average Remaining Contractual Term (Years)</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.trail.D4">
          <b>&#160;</b>
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1490.finRow.2">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1471">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Balance at January 1, 2014</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.amt.2">
          6,356
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.amt.3">
          8.22
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.lead.4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.amt.4">
          8.14
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1490.finRow.3">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1475">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Granted</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.amt.2">
          1,203
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.amt.3">
          9.99
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.amt.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.trail.B4">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1490.finRow.4">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1478">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Exercised</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.amt.2">
          (275
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.trail.2" nowrap="nowrap">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1480">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.amt.3">
          6.17
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.amt.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.trail.B4">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1490.finRow.5">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1482">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Expired and forfeited</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.amt.2">
          (11
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.trail.2" nowrap="nowrap">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1484">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">)</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.amt.3">
          17.32
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.amt.B4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.trail.B4">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1490.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1486">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Balance at March 31, 2014</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.amt.2">
          7,273
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.amt.3">
          8.57
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.lead.4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.amt.4">
          8.42
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T)A
M;&%N8V5?4VAE971S7T-U<G)E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7U-T871E;65N='-?;V9?3W!E<F%T/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D
M7U-T871E;65N='-?;V9?0V%S:%]&/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F]T95\Q7T)U<VEN97-S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\R7T)A<VES7V]F7U!R97-E
M;G1A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DYO=&5?,U]!8V-O=6YT:6YG7U!O;&EC:65S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`W+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\T7T-O;G9E<G1I8FQE7TYO=&5S
M7W1O7U)E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M3F]T95\U7U-T;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S9?26YC;VUE7U1A>&5S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-C;W5N=&EN9U]0
M;VQI8VEE<U]B>5]0;VQI8WE?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3F]T95\S7T%C8V]U;G1I;F=?4&]L:6-I97-?5&%B/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\U7U-T
M;V-K:&]L9&5R<U]%<75I='E?5&%B/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F]T95\Q7T)U<VEN97-S7T1E=&%I;',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S-?06-C;W5N
M=&EN9U]0;VQI8VEE<U]$970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y.;W1E7S-?06-C;W5N=&EN9U]0;VQI8VEE<U]$970Q/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\T7T-O
M;G9E<G1I8FQE7TYO=&5S7W1O7U)E,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DYO=&5?-5]3=&]C:VAO;&1E<G-?17%U:71Y7T1E
M=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?
M-5]3=&]C:VAO;&1E<G-?17%U:71Y7T1E=#$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S5?4W1O8VMH;VQD97)S7T5Q=6ET
M>5]$970R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M3F]T95\U7U-T;V-K:&]L9&5R<U]%<75I='E?1&5T,SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E
M;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE
M971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I
M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T
M96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0
M<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA
M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G
M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R
M(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,V4Y834S,5\V8S0Y7S0U
M,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3D=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N
M="!!;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^07!R+B`R."P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y
M($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG2$523TX@5$A%4D%0
M155424-3+"!)3D,N("]$12\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE
M87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<M
M+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L.3`Q+#0Y
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B=F86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P,#`X,3@P,S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M0W5R<F5N="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=.;SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE
M<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C
M8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM:VYO=VX@4V5A<V]N960@
M27-S=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3F\\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!9
M96%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B=1,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U
M,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,V4Y
M834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H965T<R]3
M:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%4%%!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#;VYD96YS960@0F%L86YC92!3:&5E=',@*$-U<G)E;G0@4&5R:6]D
M(%5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3<L-#<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W
M,BPR.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(V,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU.2PW,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,BPY,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@X
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@;&]N9RUT97)M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV,BPW.3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PY,S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R
M<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#8P,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C8T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8Q-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S`S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYV97)T:6)L92!N;W1E<R!P87EA8FQE('1O(')E;&%T960@<&%R=&EE
M<RP@;F5T(&]F(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS.#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DY,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=&]C:VAO;&1E<G/B@)D@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L
M('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S$Q+#4W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,P-RPU-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U-BPT,#@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,X+#@W,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!S=&]C:VAO;&1E<G/B@)D@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-2PT,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV."PY-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE
M<R!A;F0@<W1O8VMH;VQD97)SXH"9(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V,BPW.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<U+#DS-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C-E.6$U,S%?-F,T.5\T-3,T
M7SAD.#5?,#4Q8SED,V0T-#DW#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-R]7;W)K
M<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S3T%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;F1E;G-E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO
M;G,@*%5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P
M="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3W!E<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PW-S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<L,30P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PU-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#8Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!E
M>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,S(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(L-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3<L,S(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$R+#<U,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<L
M-3,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,3(L.34S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R
M('-H87)E("AI;B!$;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XW-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N.#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@=7-E9"!I
M;B!C;VUP=71I;F<@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H
M87)E("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,RPV.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PR-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y
M-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,V4Y834S,5\V8S0Y
M7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H965T<R]3:&5E=#`T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%2%!!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYD
M96YS960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A5;F%U9&ET960I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M-RPU,S@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,3(L.34S+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@
M=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@9F]R(&]P
M97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-CDL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,S4L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ871I;VX@;V8@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E
M<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED
M(&5X<&5N<V5S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-C(T+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3<L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(S."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#,S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L,#$Q+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0W,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U
M<V5D(&9O<B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,34L-S$S+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#DV,2PP,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S
M97,@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0S-2PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E
M9"!F;W(@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4W+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T,S4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!W
M87)R86YT(&5X97)C:7-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<W1O8VL@;W!T:6]N(&5X97)C
M:7-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34X+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-3@L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$R
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!D96-R96%S92!I;B!C87-H/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-"PX,3(L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L-S@T+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@
M8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S(L,C@W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4S+#4P-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@96YD(&]F('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-RPT-S4L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T-2PW,C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@
M,2`M($)U<VEN97-S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!497AT($)L;V-K(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)U<VEN97-S($1E<V-R:7!T:6]N(&%N9"!"87-I<R!O9B!0<F5S96YT871I
M;VX@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,C@U/B`-"B`@("`@
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXQ+B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.T)U<VEN97-S/"]B/CPO9F]N=#X@("`@
M#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q
M,C@W/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M)SY(97)O;B!4:&5R87!E=71I8W,L($EN8RX@*&9O<FUE<FQY($$N4"X@4&AA
M<FUA+"!);F,N*2`H=&AE("8C.#(R,#M#;VUP86YY+"8C.#(R,3L@)B,X,C(P
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M<RX\+V9O;G0^(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@
M:60],T1005)!,3(X.3X@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P="<^3W5R(&QE860@<')O9'5C="!C86YD:61A=&4L(%-54U1/
M3#QS=7`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)A<V5L:6YE.R!P;W-I
M=&EO;CH@<F5L871I=F4[(&)O='1O;3H@+C,S96TG/E1-/"]S=7`^("AF;W)M
M97)L>2!K;F]W;B!A<R!!4$8U,S`I+"!I<R!B96EN9R!D979E;&]P960@9F]R
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M>2!O;F4@:6YJ96-T86)L92`U+4A4,R!A;G1A9V]N:7-T(&%P<')O=F5D(&9O
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M9R!L979E;',@=&\@8F4@;6%I;G1A:6YE9"!F;W(@(`T*("`@("`@9FEV92!D
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M9"!O9B!S869E='D@86YD(&5F9FEC86-Y+CPO9F]N=#X@#0H@("`@/"]P/CQB
M<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,#(Q+3`^(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)SY);B!-87D@,C`P.2P@=V4@9FEL960@=&AE
M(&]R:6=I;F%L($YE=R!$<G5G($%P<&QI8V%T:6]N("@F(S@R,C`[3D1!)B,X
M,C(Q.RD@<V5E:VEN9R!A<'!R;W9A;"!F;W(@4U535$],('=I=&@@=&AE(%4N
M4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H)B,X,C(P.T9$028C
M.#(R,3LI+B!4:&4@1D1!(&ES<W5E9"!A($-O;7!L971E(%)E<W!O;G-E($QE
M='1E<B!F;W(@=&AE(%-54U1/3"!.1$$@:6X@36%R8V@@,C`Q,"X@26X@4V5P
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M;G0@<W1Y;&4],T0G0T],3U(Z(",P,#`P,#`G/FUI9"T\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/C(P,30N/"]F;VYT/CPO9F]N=#X\
M+V9O;G0^(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60]
M,T1005)!,3(Y,SX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
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M:6YG(&%P<')O=F%L(&)Y('1H92!&1$$N/"]F;VYT/B`@("`@#0H@("`@/"]P
M/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,CDU/B`@("`-
M"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY);B!A9&1I
M=&EO;BP@=&\@<F5S=6)M:71T:6YG('1H92!355-43TP@3D1!+"!W92!A<F4@
M<V5E:VEN9R!T;R!E>'!A;F0@=&AE(&QA8F5L960@:6YD:6-A=&EO;B!F;W(@
M4U535$],(&9O;&QO=VEN9R!I=',@<&]T96YT:6%L(&%P<')O=F%L+B!);B`R
M,#$T+"!W92!I;FET:6%T960@82!0:&%S92`S(&-L:6YI8V%L('-T=61Y('=I
M=&@@4U535$],(&9O<B!T:&4@<')E=F5N=&EO;B!O9B!D96QA>65D($-)3E8@
M:6X@<&%T:65N=',@<F5C96EV:6YG(&AI9VAL>2!E;65T;V=E;FEC(&-H96UO
M=&AE<F%P>2P@86X@:6YD:6-A=&EO;B!F;W(@=VAI8V@@;F\@-2U(5#,@86YT
M86=O;FES="!I<R!A<'!R;W9E9"X@5&AE(#$L,#`P('!A=&EE;G0@<W1U9'D@
M:7,@97AP96-T960@=&\@8F4@8V]M<&QE=&5D(&EN(&QA=&4@,C`Q-"X\+V9O
M;G0^("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS
M1%!!4D$Q,CDW/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)SY/=7(@8V]R92!":6]C:')O;F]M97(@=&5C:&YO;&]G>2P@;VX@
M=VAI8V@@4U535$],(&%N9"!O=7(@;W1H97(@<')O9'5C="!C86YD:61A=&5S
M(&%R92!B87-E9"P@8V]N<VES=',@;V8@8FEO97)O9&EB;&4@<&]L>6UE<G,@
M9&5S:6=N960@=&\@<F5L96%S92!D<G5G<R!O=F5R(&$@9&5F:6YE9"!P97)I
M;V0@;V8@=&EM92X@5V4@:&%V92!C;VUP;&5T960@;W9E<B`Q,#`@/&D^:6X@
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M(&-A;F1I9&%T97,@8F%S960@;VX@;W5R("`-"B`@("`@('!R;W!R:65T87)Y
M(&1E;&EV97)Y('!L871F;W)M+CPO9F]N=#X@("`@(`T*("`@(#PO<#X\8G(O
M/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XZ(#!P="<^("`@("`-"B`@("`@(#QF;VYT('-T>6QE
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M<R!I;F1I8V%T92`\9F]N="!S='EL93TS1"=#3TQ/4CH@(S`P,#`P,"<^=&AA
M=#PO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/F9O<FUU
M;&%T:6]N<R!U<VEN9R`\9F]N="!S='EL93TS1"=#3TQ/4CH@(S`P,#`P,"<^
M;W5R/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
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M;B!M:60M,C`Q-"X@07,@;V8@,C`Q,BP@87!P<F]X:6UA=&5L>2`R-2!M:6QL
M:6]N/&9O;G0@<W1Y;&4],T0G0T],3U(Z(",P,#`P,#`G/CQS=7`@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)A<V5L:6YE.R!P;W-I=&EO;CH@<F5L871I
M=F4[(&)O='1O;3HN,S-E;3LG/C$\+W-U<#X\+V9O;G0^(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)SYP<F]C961U<F5S(&%S<V]C:6%T960@=VET
M:"!P;W-T+6]P97)A=&EV92!P86EN('=E<F4@8V]N9'5C=&5D(&EN('1H92!5
M+E,N($EN(&%D9&ET:6]N+"!P;W-T+6]P97)A=&EV92!P86EN(&UA<FME="!S
M86QE<R!W97)E(&%P<')O>&EM871E;'D@)#,N,2!B:6QL:6]N/&9O;G0@<W1Y
M;&4],T0G0T],3U(Z(",P,#`P,#`G/CQS=7`@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)A<V5L:6YE.R!P;W-I=&EO;CH@<F5L871I=F4[(&)O='1O;3HN
M,S-E;3LG/C(\+W-U<#X\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)SYI;B`R,#$R+CPO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9F]N=#X\
M+V9O;G0^/"]F;VYT/B`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P
M<'0G(&ED/3-$4$%203$S,#$^("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0G/DEN($IA;G5A<GD@,C`Q-"P@=V4@8VAA;F=E9"!O
M=7(@;F%M92!F<F]M($$N4"X@4&AA<FUA+"!);F,N('1O($AE<F]N(%1H97)A
M<&5U=&EC<RP@26YC+B!%9F9E8W1I=F4@2F%N=6%R>28C,38P.S$S+"8C,38P
M.S(P,30L('=E(&5F9F5C=&5D(&$@,2UF;W(M,C`@<F5V97)S92!S<&QI="!O
M9B!O=7(@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K("@F(S@R,C`[4F5V97)S
M92!3=&]C:R!3<&QI="8C.#(R,3LI("A3964@3F]T92`U*2X@06QL(&AI<W1O
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M;G0^(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!,3,P,CX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<^/&(^3&EQ=6ED:71Y/"]B/CPO9F]N=#X@("`-"B`@("`\+W`^/&)R
M+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,#0^("`@(`T*("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E=E(&AA=F4@:6YC
M=7)R960@<VEG;FEF:6-A;G0@;W!E<F%T:6YG(&QO<W-E<R!A;F0@;F5G871I
M=F4@8V%S:"!F;&]W<R!F<F]M(&]P97)A=&EO;G,@86YD('=E(&AA=F4@86X@
M86-C=6UU;&%T960@9&5F:6-I="!O9B`D,C4V+C0@;6EL;&EO;B!A<R!O9B!-
M87)C:"`S,2P@,C`Q-"X@1'5R:6YG(#(P,3$L(#(P,3(@86YD(#(P,3,L('=E
M(&-O;7!L971E9"!A('1O=&%L(&]F(&9O=7(@<F]U;F1S(&]F(&5Q=6ET>2!A
M;F0O;W(@9&5B="!F:6YA;F-I;F=S+"!W:&EC:"!P<F]V:61E9"!U<R!W:71H
M(&-A<V@@;V8@87!P<F]X:6UA=&5L>2`D,3,U+C0@;6EL;&EO;BP@;F5T(&]F
M(&ES<W5A;F-E(&-O<W1S+"!T;R!F=6YD(&]P97)A=&EO;G,@*'-E92!.;W1E
M<R`T(&%N9"`U*2X@07,@;V8@36%R8V@@,S$L(#(P,30L('=E(&AA9"!C87-H
M(&]N(&AA;F0@;V8@)#4W+C4@;6EL;&EO;BX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X@("`@(`T*("`@(#PO
M<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,P-SX@("`@
M#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^5V4@8F5L
M:65V92!T:&%T(&]U<B!C=7)R96YT('=O<FMI;F<@8V%P:71A;"!I<R!S=69F
M:6-I96YT('1O(&9U;F0@97-S96YT:6%L(&]P97)A=&EO;G,@:6YT;R`R,#$U
M.R!P<F]V:61E9"P@:&]W979E<BP@=&AA="!I9B!W92!P=7)S=64@861D:71I
M;VYA;"!C;&EN:6-A;"!S='5D:65S('!R:6]R('1O(#(P,34@;W(@8F5G:6X@
M<')E<&%R871I;VYS(&9O<B!P;W1E;G1I86P@8V]M;65R8VEA;&EZ871I;VX@
M;V8@4U535$],+"!W92!W:6QL(&YE960@=&\@<F%I<V4@861D:71I;VYA;"!C
M87!I=&%L+B!792!M87D@<F5Q=6ER92!A9&1I=&EO;F%L(&-A<&ET86P@=&\@
M9G5N9"!O=7(@9&5V96QO<&UE;G0@<&EP96QI;F4@<')O9W)A;7,N($EF('=E
M(&%R92!U;F%B;&4@=&\@;V)T86EN('-U9F9I8VEE;G0@9FEN86YC:6YG(&]N
M(&%C8V5P=&%B;&4@=&5R;7,@;W(@;W1H97)W:7-E+"!W92!M87D@8F4@<F5Q
M=6ER960@=&\@<F5D=6-E(&]R(&1E9F5R(&]U<B!A8W1I=FET:65S+CPO9F]N
M=#X@#0H@("`@/"]P/CQB<B\^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO
M=&4@,B`M($)A<VES(&]F(%!R97-E;G1A=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@5&5X
M="!";&]C:R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!!8V-O=6YT:6YG(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-
M05)'24XZ(#!P="<@:60],T1005)!,3,P.3X@("`-"B`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXR+B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.T)A<VES(&]F(%!R97-E;G1A=&EO;CPO8CX\+V9O;G0^
M("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03$S,3$^("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M('1H92!I;G-T<G5C=&EO;G,@=&\@1F]R;2`Q,"U1(&%N9"!!<G1I8VQE(#$P
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M<G,@;W(@=&AE('EE87(@96YD:6YG($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30N
M(%1H92!C;VYD96YS960@8F%L86YC92!S:&5E="!A="!$96-E;6)E<B`S,2P@
M,C`Q,R!H87,@8F5E;B!D97)I=F5D(&9R;VT@=&AE(&%U9&ET960@9FEN86YC
M:6%L('-T871E;65N=',@87,@;V8@=&AA="!D871E+"!B=70@9&]E<R!N;W0@
M:6YC;'5D92!A;&P@;V8@=&AE(`T*("`@("`@:6YF;W)M871I;VX@86YD(&1I
M<V-L;W-U<F5S(')E<75I<F5D(&)Y($=!05`N(%1H92!P<F5S96YT871I;VX@
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M>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$S(&EN8VQU9&5D(&EN
M('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E<&]R="!O;B!&;W)M/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LQ,"U+
M(&9O<B!T:&4@9FES8V%L('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,@
M9FEL960@=VET:"!T:&4@4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES
M<VEO;B`H)B,X,C(P.U-%0R8C.#(R,3LI(&]N($UA<F-H(#<L(#(P,30\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/BX\+V9O;G0^("`@
M#0H@("`@/"]P/CQB<B\^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@
M,R`M($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6U1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N
M,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S$S/B`@("`-"B`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXS+B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.T%C8V]U;G1I;F<@4&]L:6-I97,\+V(^/"]F
M;VYT/B`@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I
M9#TS1%!!4D$Q,S$U/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T)SX\8CY5<V4@;V8@17-T:6UA=&5S/"]B/CPO9F]N=#X@("`@
M(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M,3,Q-SX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<^5&AE('!R97!A<F%T:6]N(&]F(&-O;F1E;G-E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I=&@@1T%!4"!R97%U:7)E<R!M86YA
M9V5M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R`\9F]N
M="!S='EL93TS1"=#3TQ/4CH@(S`P,#`P,"<^=&AA="!A9F9E8W0@=&AE(')E
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M;VYS(&]R(&-O;F1I=&EO;G,N/"]F;VYT/CPO9F]N=#X@(`T*("`@(#PO<#X\
M8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,Q.3X@("`@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^0V%S:"!A
M;F0@0V%S:"!%<75I=F%L96YT<SPO8CX\+V9O;G0^("`@(`T*("`@(#PO<#X\
M8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,R,3X@("`@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^5V4@8V]N<VED
M97(@86QL(&AI9VAL>2!L:7%U:60@:6YV97-T;65N=',@=VET:"!A(&UA='5R
M:71Y(&9R;VT@=&AE(&1A=&4@;V8@<'5R8VAA<V4@;V8@;&5S<R!T:&%N('1H
M<F5E(&UO;G1H<R!T;R!B92!C87-H(&5Q=6EV86QE;G1S+B!792!H860@8V%S
M:"!O9B`D-3<N-2!M:6QL:6]N(&%N9"`D-S(N,R!M:6QL:6]N(&%T($UA<F-H
M(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@<F5S<&5C=&EV96QY
M+B!4:&5R92!W97)E(&YO(&-A<V@@97%U:79A;&5N=',@87,@;V8@8F]T:"!D
M871E<RX@3W5R(&)A;FL@86-C;W5N=',@:&%V92!B965N('!L86-E9"!U;F1E
M<B!A(&-O;G1R;VP@86=R965M96YT(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@
M07!R:6PF(S$V,#LR,#$Q(&-O;G9E<G1I8FQE(&YO=&4@9FEN86YC:6YG("AS
M964@3F]T92`T*2X\+V9O;G0^("`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-
M05)'24XZ(#!P="<@:60],T1005)!,3,R,SX@("`@#0H@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^16%R;FEN9W,@4&5R(%-H87)E
M/"]B/CPO9F]N=#X@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,3,R-3X@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<^0F%S:6,@96%R;FEN9W,@<&5R('-H87)E("@F(S@R
M,C`[15!3)B,X,C(Q.RD@:7,@8V%L8W5L871E9"!B>2!D:79I9&EN9R!T:&4@
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M:&5N('1H96ER(&5F9F5C="!I<R!D:6QU=&EV92X\+V9O;G0^("`-"B`@("`\
M+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,C<^("`@
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
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M="!W;W5L9"!B92!A;G1I+61I;'5T:79E+CPO9F]N=#X@("`@(`T*("`@(#PO
M<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,R.3X@("`@
M#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
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M<F-H(#,Q+"`R,#$T(&%N9"`R,#$S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X@
M("`-"B`@("`\+W`^/&)R+SX\=&%B;&4@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P>#L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$S
M-#4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$S-#4N9FEN4F]W+C$^("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<V)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G/B`@("`@#0H@("`@("`@("`@/&(^
M)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,2YL96%D+D0S
M/B`@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$
M5$@Z(#$S)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,2YA;70N
M1#,@8V]L<W!A;CTS1#8^("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P
M<'0G(&ED/3-$4$%203$S,S$^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P="<^/&(^/"]B/CPO9F]N=#X@("`@(`T*("`@
M("`@("`@(#PO<#X@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED
M/3-$4$%203$S,S(^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<^/&(^5&AR964@36]N=&AS($5N9&5D/"]B/CPO9F]N
M=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/DUA<F-H(#,Q
M+#PO8CX\+V9O;G0^("`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>#L@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T14
M0DPQ,S0U+F9I;E)O=RXQ+G1R86EL+D0S/B`@("`-"B`@("`@("`@("`\8CXF
M(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T
M<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$S-#4N9FEN4F]W+C(^("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<V)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G/B`@("`@#0H@("`@("`@("`@/&(^
M)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,BYL96%D+D0R
M/B`@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ('1O<"<@:60],T140DPQ,S0U+F9I;E)O=RXR+F%M="Y$
M,B!C;VQS<&%N/3-$,CX@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T
M)R!I9#TS1%!!4D$Q,S,T/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P,30\+V(^/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#%P>#L@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ('1O<"<@:60],T140DPQ,S0U+F9I;E)O=RXR+G1R86EL
M+D0R/B`@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T14
M0DPQ,S0U+F9I;E)O=RXR+FQE860N1#,^("`@(`T*("`@("`@("`@(#QB/B8C
M,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P)R!I9#TS
M1%1"3#$S-#4N9FEN4F]W+C(N86UT+D0S(&-O;'-P86X],T0R/B`@#0H@("`@
M("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,S4^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^
M,C`Q,SPO8CX\+V9O;G0^("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,7!X.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P)R!I9#TS
M1%1"3#$S-#4N9FEN4F]W+C(N=')A:6PN1#,^("`@(`T*("`@("`@("`@(#QB
M/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\
M+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,3,T-2YF:6Y2;W<N,SX@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@-S8E)SX@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U=)1%1(.B`Q)2<@:60],T140DPQ,S0U+F9I;E)O=RXS+FQE
M860N0C(^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<@:60],T140DPQ
M,S0U+F9I;E)O=RXS+G-Y;6(N0C(^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Y)2<@:60],T140DPQ,S0U+F9I;E)O=RXS+F%M="Y",CX@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=724142#H@,24G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,RYT<F%I
M;"Y",CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<@:60],T140DPQ
M,S0U+F9I;E)O=RXS+FQE860N0C,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q)2<@:60],T140DPQ,S0U+F9I;E)O=RXS+G-Y;6(N0C,^("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U=)1%1(.B`Y)2<@:60],T140DPQ,S0U+F9I;E)O=RXS+F%M
M="Y",SX@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24G(&ED/3-$5$),,3,T
M-2YF:6Y2;W<N,RYT<F%I;"Y",SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ
M,S0U+F9I;E)O=RXT/B`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@4$%$
M1$E.1RU,1494.B`Y<'0[(%=)1%1(.B`W-B4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@("`-
M"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,
M24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,S8^
M("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T)SY3=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG
M/"]F;VYT/B`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXT+FQE860N,CX@("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-"YS>6UB+C(^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`V-RXS)3L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S
M-#4N9FEN4F]W+C0N86UT+C(^(`T*("`@("`@("`@(#<L,C<S(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$S-#4N9FEN4F]W+C0N=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C0N;&5A9"XS/B`@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,S0U+F9I;E)O=RXT+G-Y;6(N,SX@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!724142#H@.24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#8W+C,E.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2
M;W<N-"YA;70N,SX@#0H@("`@("`@("`@-"PT-C$@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T
M-2YF:6Y2;W<N-"YT<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^
M("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<@:60],T140DPQ,S0U+F9I;E)O=RXU/B`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@4$%$1$E.1RU,1494.B`Y<'0[(%=)1%1(.B`W-B4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%2
M1TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,
M24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G
M(&ED/3-$4$%203$S,SD^("`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY787)R86YT<R!O
M=71S=&%N9&EN9SPO9F]N=#X@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-2YL
M96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C4N<WEM8BXR/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@-C<N
M,R4[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,S0U+F9I;E)O=RXU+F%M="XR/B`-"B`@("`@("`@("`S+#@R
M-2`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXU+G1R86EL+C(@;F]W<F%P/3-$
M;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXU+FQE860N,SX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-2YS>6UB+C,^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`V-RXS)3L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$S-#4N9FEN4F]W+C4N86UT+C,^(`T*("`@("`@("`@(#0L,#4R(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$S-#4N9FEN4F]W+C4N=')A:6PN,R!N;W=R87`],T1N;W=R87`^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`\+W1R/B`@(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,3,T-2YF:6Y2;W<N-CX@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%!!1$1)3D<M3$5&5#H@.7!T.R!724142#H@
M-S8E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^("`@("`-"B`@("`@("`@("`\<"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203$S-#(^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY#;VUM;VX@
M<W1O8VL@=6YD97)L>6EN9R!C;VYV97)T:6)L92!N;W1E<R!O=71S=&%N9&EN
M9SPO9F]N=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-BYL96%D+C(^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C8N<WEM8BXR/B`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@-C<N,R4[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ,S0U+F9I;E)O=RXV+F%M="XR/B`-"B`@("`@("`@("`V+#,X-2`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,S0U+F9I;E)O=RXV+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXV+FQE860N,SX@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,3,T-2YF:6Y2;W<N-BYS>6UB+C,^("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`V-RXS)3L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N
M9FEN4F]W+C8N86UT+C,^(`T*("`@("`@("`@(#8L,#$V(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$S-#4N9FEN4F]W+C8N=')A:6PN,R!N;W=R87`],T1N;W=R87`^("`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\
M+W1R/B`@(`T*("`@(#PO=&%B;&4^/&)R+SX\<"!S='EL93TS1"=415A4+4%,
M24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G
M(&ED/3-$4$%203$S-#<^("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P="<^/&(^0V]M<')E:&5N<VEV92!);F-O;64@*$QO<W,I/"]B
M/CPO9F]N=#X@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I
M9#TS1%!!4D$Q,S0Y/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^0V]M<')E:&5N<VEV92!I;F-O
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M(&9R;VT@;F]N+6]W;F5R('-O=7)C97,N/"]F;VYT/B`@(`T*("`@(#PO<#X\
M8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,U,3X@("`@#0H@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^4F5C96YT
M($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V(^/"]F;VYT/B`-"B`@("`\
M+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S-3,^("`@
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T)SY792!D;R!N;W0@97AP96-T('1H870@=&AE(&%D;W!T:6]N
M(&]F(&%N>2!R96-E;G1L>2!I<W-U960@86-C;W5N=&EN9R!P<F]N;W5N8V5M
M96YT<R!W;W5L9"!H879E(&$@<VEG;FEF:6-A;G0@:6UP86-T(&]N(&]U<B!R
M97-U;'1S(&]F(&]P97)A=&EO;G,L(&9I;F%N8VEA;"!C;VYD:71I;VX@;W(@
M8V%S:"!F;&]W+CPO9F]N=#X@("`@(`T*("`@(#PO<#X\8G(O/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C-E.6$U,S%?-F,T
M.5\T-3,T7SAD.#5?,#4Q8SED,V0T-#DW#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y
M-R]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#0@+2!#;VYV97)T:6)L92!.;W1E<R!T
M;R!296QA=&5D(%!A<G1I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$96)T($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5B="!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,U
M-3X@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^
M-"X@0V]N=F5R=&EB;&4@3F]T97,@=&\@4F5L871E9"!087)T:65S/"]B/CPO
M9F]N=#X@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED
M/3-$4$%203$S-3<^("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G/DEN($%P<FEL(#(P,3$L('=E(&5N=&5R960@:6YT;R!A(%-E
M8W5R:71I97,@4'5R8VAA<V4@06=R965M96YT(&9O<B!A('!R:79A=&4@<&QA
M8V5M96YT(&]F('5P('1O("0T+C4@;6EL;&EO;B!I;B!396YI;W(@4V5C=7)E
M9"!#;VYV97)T:6)L92!.;W1E<R`H)B,X,C(P.TYO=&5S)B,X,C(Q.RDN(%=E
M(')E8V5I=F5D(&$@=&]T86P@;V8@)#0N,R!M:6QL:6]N+"!N970@;V8@:7-S
M=6%N8V4@8V]S=',L(&9R;VT@=&AE(&ES<W5A;F-E(&]F('1H97-E($YO=&5S
M+CPO9F]N=#X@("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T
M)R!I9#TS1%!!4D$Q,S4Y/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T)SY4:&4@3F]T97,@87)E('-E8W5R960@8GD@<W5B<W1A
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M=7)C:&%S97)S+B!4:&4@3F]T97,@;6%T=7)E(&]N($UA>2`R+"`R,#(Q+"!H
M;W=E=F5R+"!T:&4@:&]L9&5R<R!O9B!T:&4@3F]T97,@;6%Y(')E<75I<F4@
M<')E<&%Y;65N="!O9B!T:&4@3F]T97,@870@86YY('1I;64L(&%T(&5A8V@@
M:&]L9&5R)B,X,C$W.W,@;W!T:6]N+CPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P="<^/"]F;VYT/B`@("`@#0H@("`@/"]P/CQB<B\^/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N
M,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S8Q/B`@("`-"B`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY4:&4@3F]T97,@87)E(&-O
M;G9E<G1I8FQE(&EN=&\@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@870@
M82!R871E(&]F(#$L,C4P('-H87)E<R!F;W(@979E<GD@)#$L,#`P(&]F('!R
M:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S="!D=64@=6YD97(@=&AE($YO
M=&5S+B!4:&5R92!I<R!N;R!R:6=H="!T;R!C;VYV97)T('1H92!.;W1E<R!T
M;R!T:&4@97AT96YT('1H870L(&%F=&5R(&=I=FEN9R!E9F9E8W0@=&\@<W5C
M:"!C;VYV97)S:6]N+"!T:&4@:&]L9&5R('=O=6QD(&)E;F5F:6-I86QL>2!O
M=VX@:6X@97AC97-S(&]F(#DN.3DE(&]F(&]U<B!O=71S=&%N9&EN9R!C;VUM
M;VX@<W1O8VLN($5A8V@@:&]L9&5R(&]F('1H92!.;W1E<R!C86X@:6YC<F5A
M<V4@;W(@9&5C<F5A<V4@=&AI<R!B96YE9FEC:6%L(&]W;F5R<VAI<"!C;VYV
M97)S:6]N(&QI;6ET(&)Y('=R:71T96X@;F]T:6-E('1O('5S+"!W:&EC:"!W
M:6QL(&YO="!B92!E9F9E8W1I=F4@=6YT:6P@-C$@9&%Y<R!A9G1E<B!D96QI
M=F5R>2!O9B!T:&4@;F]T:6-E+CPO9F]N=#X@("`@(`T*("`@(#PO<#X\8G(O
M/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,V,SX@("`@#0H@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M=&AE:7(@3F]T97,N/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@
M34%21TE..B`P<'0G/B`@("`@#0H@("`@("!792!F:6QE9"!A(')E9VES=')A
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M:6-E(&]T:&5R=VES92XF(S$V,#L@("`@(`T*("`@(#PO<#X\8G(O/CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U
M.R!-05)'24XZ(#!P="<@:60],T1005)!,3,V-SX@("`@#0H@("`@("`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^5&AE($YO=&5S(&-O;G1A:6X@
M86X@96UB961D960@8V]N=F5R<VEO;B!F96%T=7)E('1H870@=V%S(&EN+71H
M92UM;VYE>2!O;B!T:&4@:7-S=6%N8V4@9&%T97,N($)A<V5D(&]N(&%N(&5F
M9F5C=&EV92!F:7AE9"!C;VYV97)S:6]N(')A=&4@;V8@,2PR-3`@<VAA<F5S
M(&9O<B!E=F5R>2`D,2PP,#`@;V8@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN
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M<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!A
M8V-R=65D(&EN=&5R97-T(&]F(&%P<')O>&EM871E;'D@)#<U+#`P,"!W87,@
M<&%I9"UI;BUK:6YD(&%N9"!R;VQL960@:6YT;R!T:&4@3F]T92!P<FEN8VEP
M86P@8F%L86YC92P@=VAI8V@@<F5S=6QT960@:6X@86X@861D:71I;VYA;"!D
M96)T(&1I<V-O=6YT(&]F(&%P<')O>&EM871E;'D@)#<U+#`P,"X@1F]R('1H
M92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,30@86YD(#(P,3,L
M(&EN=&5R97-T(&5X<&5N<V4@<F5L871I;F<@=&\@=&AE('-T871E9"!R871E
M('=A<R!A<'!R;WAI;6%T96QY("0W-RPP,#`@86YD("0W,2PP,#`L(')E<W!E
M8W1I=F5L>2P@86YD(&EN=&5R97-T(&5X<&5N<V4@<F5L871I;F<@=&\@=&AE
M("`@("`-"B`@("`@(&%M;W)T:7IA=&EO;B!O9B!T:&4@9&5B="!D:7-C;W5N
M="!W87,@87!P<F]X:6UA=&5L>2`D,3,Y+#`P,"!A;F0@)#$S,"PP,#`L(')E
M<W!E8W1I=F5L>2X\+V9O;G0^("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!
M4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S8Y/B`@("`-"B`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T)SY!<R!O9B!-87)C:"`S,2P@,C`Q-"P@
M=&AE(&-A<G)Y:6YG('9A;'5E(&]F('1H92!.;W1E<R!W87,@87!P<F]X:6UA
M=&5L>2`D,2PQ-C0L,#`P+"!W:&EC:"!I<R!C;VUP<FES960@;V8@=&AE("0U
M+#$P."PP,#`@<')I;F-I<&%L(&%M;W5N="!O9B!T:&4@3F]T97,@;W5T<W1A
M;F1I;F<L(&QE<W,@9&5B="!D:7-C;W5N="!O9B`D,RPY-#0L,#`P+B!)9B!T
M:&4@)#4N,28C,38P.VUI;&QI;VX@<')I;F-I<&%L(&%M;W5N="!O9B!.;W1E
M<R!I<R!C;VYV97)T960L('=E('=O=6QD(&ES<W5E(#8N-"!M:6QL:6]N('-H
M87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K+CPO9F]N=#X@#0H@("`@/"]P/CQB
M<B\^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T;V-K:&]L
M9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@3F]T92!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E($1I<V-L;W-U<F4@6U1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S<Q/B`@("`-"B`@("`@(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXU+B8C,38P.R8C,38P.R!3
M=&]C:VAO;&1E<G,F(S@R,3<[($5Q=6ET>3PO8CX\+V9O;G0^("`-"B`@("`\
M+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S-S,^("`@
M(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQI/CQB
M/D%M96YD;65N=',@=&\@07)T:6-L97,@;V8@26YC;W)P;W)A=&EO;CPO8CX\
M+VD^(#QB/B8C.#(Q,3L@/&D^4F5V97)S92!3=&]C:R!3<&QI=#PO:3X\+V(^
M/"]F;VYT/B`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I
M9#TS1%!!4D$Q,S<U/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T)SY%9F9E8W1I=F4@2F%N=6%R>2`Q,RP@,C`Q-"P@=V4@86UE
M;F1E9"!O=7(@0V5R=&EF:6-A=&4@;V8@26YC;W)P;W)A=&EO;B!T;R!C:&%N
M9V4@;W5R(&YA;64@=&\@2&5R;VX@5&AE<F%P975T:6-S+"!);F,N(&%N9"!T
M;R!E9F9E8W0@82`Q+69O<BTR,"!R979E<G-E('-P;&ET(&]F(&]U<B!O=71S
M=&%N9&EN9R!C;VUM;VX@<W1O8VLN(%1H92!N86UE(&-H86YG92!A;F0@4F5V
M97)S92!3=&]C:R!3<&QI="!W97)E(&%P<')O=F5D(&)Y(&]U<B!S=&]C:VAO
M;&1E<G,@;VX@4V5P=&5M8F5R)B,Q-C`[,3DL)B,Q-C`[,C`Q,RX@07,@82!R
M97-U;'0@;V8@=&AE(%)E=F5R<V4@4W1O8VL@4W!L:70L('1H92!T;W1A;"!A
M=71H;W)I>F5D('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!R961U8V5D
M(&9R;VT@,2PU,#`L,#`P+#`P,"!T;R`W-2PP,#`L,#`P('-H87)E<RX\+V9O
M;G0^("`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS
M1%!!4D$Q,S<W/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)SX\:3X\8CXR,#$Q(%!R:79A=&4@4&QA8V5M96YT/"]B/CPO:3X\
M+V9O;G0^("`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,
M24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G
M(&ED/3-$4$%203$S-SD^("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0G/DEN($IU;F4@,C`Q,2P@=V4@<V]L9"`X+C`@;6EL;&EO
M;B!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!F;W(@;F5T('!R;V-E961S
M(&]F("0R,BXX(&UI;&QI;VX@*&YE="!O9B!A<'!R;WAI;6%T96QY("0Q+C(@
M;6EL;&EO;B!I;B!I<W-U86YC92!C;W-T<RDN($9O<B!E86-H('-H87)E('!U
M<F-H87-E9"P@=&AE(&EN=F5S=&]R<R!R96-E:79E9"!O;F4@=V%R<F%N="!T
M;R!P=7)C:&%S92`P+C4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="!A;B!E
M>&5R8VES92!P<FEC92!O9B`D,RXV,"!P97(@<VAA<F4N(%1H92!W87)R86YT
M<R!W97)E(&EM;65D:6%T96QY(&5X97)C:7-A8FQE(&%N9"!E>'!I<F4@;VX@
M2G5L>28C,38P.S$L)B,Q-C`[,C`Q-BX@5&AE('=A<G)A;G1S(&UA>2!B92!E
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M8V5S<R!O9B`Y+CDY)2!O9B!O=7(@;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!O<B!S=6-H(&]T:&5R(&QI;6ET(&%S(&UA>2!B92!D97-I
M9VYA=&5D(&)Y(&%N>2!P87)T:6-U;&%R(`T*("`@("`@<'5R8VAA<V5R+B!%
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M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`@
M(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M,3,X,3X@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<^3VX@2G5L>2`R.2P@,C`Q,2P@=V4@9FEL960@82!R96=I<W1R871I;VX@
M<W1A=&5M96YT('=I=&@@=&AE(%-%0R!T;R!R96=I<W1E<B!F;W(@<F5S86QE
M('1H92!S:&%R97,@86YD('1H92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES
M<W5A8FQE('5P;VX@=&AE(&5X97)C:7-E(&]F('1H92!W87)R86YT<RX@5&AE
M(')E9VES=')A=&EO;B!S=&%T96UE;G0@=V%S(&1E8VQA<F5D(&5F9F5C=&EV
M92!O;B!!=6=U<W0@-"P@,C`Q,2X@5V4@87)E(&]B;&EG871E9"!T;R!M86EN
M=&%I;B!T:&4@969F96-T:79E;F5S<R!O9B!T:&4@<F5G:7-T<F%T:6]N('-T
M871E;65N="!U;G1I;"!T:&4@:6YV97-T;W)S(&%R92!A8FQE('1O('-E;&P@
M<VAA<F5S(&%N9"!T:&4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!U;F1E<FQY
M:6YG('1H92!W87)R86YT<R!W:71H;W5T(&QI;6ET871I;VX@;W(@<F5S=')I
M8W1I;VX@=6YD97(@4G5L92`Q-#0@;V8@=&AE(%-E8W5R:71I97,@06-T(&]F
M(#$Y,S,L(&%S(&%M96YD960@*"8C.#(R,#M2=6QE(#$T-"8C.#(R,3LI+B!4
M:&5R92!I<R!C=7)R96YT;'D@;VYL>2!O;F4@:6YV97-T;W(@=VAO(&ES(&%N
M(&%F9FEL:6%T92!O9B!O=7)S(&%N9"!I<R!T:&5R969O<F4@;F]T(&%B;&4@
M=&\@<V5L;"!W:71H;W5T(&QI;6ET871I;VX@=6YD97(@4G5L92`Q-#0L(&%N
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M9F]R(&$@9&5S:6=N871E9"!T:6UE("`@#0H@("`@("`H=VET:"!L:6UI=&5D
M(&5X8V5P=&EO;G,I(&1U<FEN9R!T:&4@<&5R:6]D('=E(&%R92!O8FQI9V%T
M960@=&\@;6%I;G1A:6X@=&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0L('=E
M(&UA>2!B92!O8FQI9V%T960@=&\@<&%Y('1O('1H92!I;G9E<W1O<G,@;&EQ
M=6ED871E9"!D86UA9V5S(&EN(&%N(&%M;W5N="!E<75A;"!T;R`Q+C`E('!E
M<B!M;VYT:"!O9B!S=6-H(&EN=F5S=&]R)B,X,C$W.W,@<')O(')A=&$@:6YT
M97)E<W0@:6X@=&AE('1O=&%L('!U<F-H87-E('!R:6-E(&]F('1H92`R,#$Q
M('!R:79A=&4@<&QA8V5M96YT+"!C87!P960@870@82!T;W1A;"!P96YA;'1Y
M(&]F(#8N,"4N/"]F;VYT/B`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G/B`@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P="<^1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L
M(#(P,30L(&]N92!W87)R86YT(&AO;&1E<B!E>&5R8VES960@,30T+#`T,"!W
M87)R86YT<R!U;F1E<B!T:&4@8V%S:&QE<W,@97AE<F-I<V4@<')O=FES:6]N
M(&EN('1H92!W87)R86YT(&%G<F5E;65N="P@=VAI8V@@<F5S=6QT960@:6X@
M=&AE(&YE="!I<W-U86YC92!O9B`Q,#@L-#`Y('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@86YD(&YO(&YE="!C87-H('!R;V-E961S('1O('1H92!#;VUP86YY
M+B!$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
M,RP@=V4@<F5C96EV960@)#`N-B!M:6QL:6]N(&9O<B!C87-H(&5X97)C:7-E
M<R!O9B!T:&5S92!W87)R86YT<RXF(S$V,#L\+V9O;G0^("`@(`T*("`@(#PO
M<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3,X-3X@("`@
M#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&D^/&(^
M,C`Q,B!0<FEV871E(%!L86-E;65N=#PO8CX\+VD^/"]F;VYT/B`@("`@#0H@
M("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S@W
M/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY)
M;B!*=6QY(#(P,3(L('=E('-O;&0@-2XQ(&UI;&QI;VX@<VAA<F5S(&]F(&]U
M<B!C;VUM;VX@<W1O8VL@870@82!P=7)C:&%S92!P<FEC92!O9B`D,3`N-3`@
M<&5R('-H87)E+"!R97-U;'1I;F<@:6X@;F5T('!R;V-E961S(&]F(&%P<')O
M>&EM871E;'D@)#4P+C4@;6EL;&EO;B`H;F5T(&]F(&%P<')O>&EM871E;'D@
M)#,N,2!M:6QL:6]N(&EN(&ES<W5A;F-E(&-O<W1S*2X\+V9O;G0^("`@#0H@
M("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,#(Y
M+3`^(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/D]N
M($%U9W5S="`R-"P@,C`Q,BP@=V4@9FEL960@82!R96=I<W1R871I;VX@<W1A
M=&5M96YT('=I=&@@=&AE(%-%0R!T;R!R96=I<W1E<B!T:&5S92!S:&%R97,@
M9F]R(')E<V%L92X@5&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0@=V%S(&1E
M8VQA<F5D(&5F9F5C=&EV92!O;B!397!T96UB97(@-BP@,C`Q,BX@268@=V4@
M9F%I;"!T;R!K965P('1H92!R96=I<W1R871I;VX@<W1A=&5M96YT(&-O;G1I
M;G5O=7-L>2!E9F9E8W1I=F4@9F]R(&$@9&5S:6=N871E9"!T:6UE("AW:71H
M(&QI;6ET960@97AC97!T:6]N<RDL('=E(&UA>2!B92!O8FQI9V%T960@=&\@
M<&%Y('1O(&5A8V@@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(",P,#`P,#`G/FEN
M=F5S=&]R/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^
M86X@86UO=6YT(&5Q=6%L('1O(#$N-24@<&5R(&UO;G1H(&]F('1H92!A9V=R
M96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@=&AE('5N<F5G:7-T97)E9"!S:&%R
M97,@:&5L9"!B>2!S=6-H(#QF;VYT('-T>6QE/3-$)T-/3$]2.B`C,#`P,#`P
M)SYI;G9E<W1O<CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<^+"!C87!P960@870@82!T;W1A;"!P96YA;'1Y(&]F(#DN,"4N/"]F;VYT
M/CPO9F]N=#X\+V9O;G0^("`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS
M1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2
M1TE..B`P<'0G(&ED/3-$4$%203$S.3$^("`@(`T*("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQI/CQB/C(P,3,@0V]M;6]N(%-T;V-K
M($]F9F5R:6YG/"]B/CPO:3X\+V9O;G0^("`@(`T*("`@(#PO<#X\8G(O/CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q
M+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,3`S,"TP/B`-"B`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SY);B!.;W9E;6)E<B`R,#$S
M+"!W92!E;G1E<F5D(&EN=&\@86X@=6YD97)W<FET:6YG(&%G<F5E;65N="P@
M<'5R<W5A;G0@=&\@=VAI8V@@=V4@<V]L9"!A('1O=&%L(&]F(&%P<')O>&EM
M871E;'D@."XV(&UI;&QI;VX@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@
M=&\@=&AE('5N9&5R=W)I=&5R<R!A="!A('!U8FQI8R!O9F9E<FEN9R!P<FEC
M92!O9B`D."XP,"!P97(@<VAA<F4N(%=E(')E8V5I=F5D('1O=&%L(&YE="!P
M<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0U-RXX(&UI;&QI;VX@*&YE="!O
M9B!A<'!R;WAI;6%T96QY("0S+CD@;6EL;&EO;B!I;B!I<W-U86YC92!C;W-T
M<RDN/"]F;VYT/B`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P
M<'0G(&ED/3-$4$%203$P,S$M,#X@#0H@("`@("`\9F]N="!S='EL93TS1"=&
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M('-T>6QE/3-$)T-/3$]2.B`C,#`P,#`P)SYO9F9E<FEN9SPO9F]N=#X@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/G=A<R!N;W0@<F5G:7-T97)E
M9"!U;F1E<B!A;GD@<W1A=&4@8FQU92!S:WD@;&%W<R!A;F0@=V%S(&QI;6ET
M960@=&\@)B,X,C(P.U%U86QI9FEE9"!);G-T:71U=&EO;F%L($)U>65R<R8C
M.#(R,3L@*&%S(&1E9FEN960@:6X@4G5L92`Q-#1!('5N9&5R('1H92!396-U
M<FET:65S($%C="!O9B`Q.3,S+"!A<R!A;65N9&5D*2!A;F0@8V5R=&%I;B!O
M=&AE<B!I;G-T:71U=&EO;F%L(&%N9"!A8V-R961I=&5D(&EN=F5S=&]R<RP@
M87,@<&5R;6ET=&5D('5N9&5R(&%P<&QI8V%B;&4@;&%W+B!);B!T:&4@/&9O
M;G0@<W1Y;&4],T0G0T],3U(Z(",P,#`P,#`G/G5N9&5R=W)I=&EN9R!A9W)E
M96UE;G0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/BP@
M=&AE($-O;7!A;GD@86=R965D('1O(&EN9&5M;FEF>2!T:&4@=6YD97)W<FET
M97)S(&%G86EN<W0@8V5R=&%I;B!L:6%B:6QI=&EE<RP@:6YC;'5D:6YG(&QI
M86)I;&ET:65S('5N9&5R('1H92!396-U<FET:65S($%C="!O9B`@("`-"B`@
M("`@(#$Y,S,L(&%S(&%M96YD960L(&]R('1O(&-O;G1R:6)U=&4@=&\@<&%Y
M;65N=',@=&AA="!T:&4@=6YD97)W<FET97)S(&UA>2!B92!R97%U:7)E9"!T
M;R!M86ME(&)E8V%U<V4@;V8@<W5C:"!L:6%B:6QI=&EE<RX\+V9O;G0^/"]F
M;VYT/CPO9F]N=#X@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,3,Y-SX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQI/CQB/E-T;V-K($]P
M=&EO;B!%>&5R8VES97,\+V(^/"]I/CPO9F]N=#X@#0H@("`@/"]P/CQB<B\^
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z
M(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,#,R+3`^(`T*("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M)SY&;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"P@
M87!P<F]X:6UA=&5L>2`R,34L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M=V5R92!I<W-U960@<'5R<W5A;G0@=&\@=&AE(&5X97)C:7-E(&]F('-T;V-K
M(&]P=&EO;G,L(')E<W5L=&EN9R!I;B!P<F]C965D<R!T;R!T:&4@0V]M<&%N
M>2!O9B!A<'!R;WAI;6%T96QY("0Y-3@L,#`P+CPO9F]N=#X@(`T*("`@(#PO
M<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30P,SX@#0H@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^4W1O8VLM0F%S
M960@0V]M<&5N<V%T:6]N/"]B/CPO9F]N=#X@("`-"B`@("`\+W`^/&)R+SX\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@
M,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T,#4^("`@(`T*("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!F;VQL;W=I;F<@
M=&%B;&4@<W5M;6%R:7IE<R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP
M96YS92!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q
M+"`R,#$T(&%N9"`R,#$S(')E;&%T960@=&\@<W1O8VL@;W!T:6]N<R!A;F0@
M16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;B`H)B,X,C(P.T534%`F(S@R
M,C$[*2!P=7)C:&%S92!R:6=H=',@8GD@97AP96YS92!C871E9V]R>2`H:6X@
M=&AO=7-A;F1S*3H\+V9O;G0^("`-"B`@("`\+W`^/&)R+SX\=&%B;&4@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P>#L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T)R!I9#TS1%1"3#$T,C0@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/B`@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$T
M,C0N9FEN4F]W+C$^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G/B`@(`T*("`@("`@("`@
M(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ('1O<"<@:60],T140DPQ-#(T+F9I;E)O=RXQ+FQE860N1#,^("`@#0H@
M("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P)R!I
M9#TS1%1"3#$T,C0N9FEN4F]W+C$N86UT+D0S(&-O;'-P86X],T0V/B`-"B`@
M("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30P-SX@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\
M8CX\+V(^/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@
M("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30P.#X@("`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CY4:')E
M92!-;VYT:',@16YD960\+V(^/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P="<^/&(^36%R8V@@,S$L/"]B/CPO9F]N=#X@("`@(`T*("`@
M("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M('1O<"<@:60],T140DPQ-#(T+F9I;E)O=RXQ+G1R86EL+D0S/B`@(`T*("`@
M("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,30R-"YF:6Y2
M;W<N,CX@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ('1O<"<^("`@#0H@("`@("`@("`@/&(^)B,Q
M-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P
M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C(N;&5A9"Y$,CX@("`-"B`@("`@("`@
M("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),
M,30R-"YF:6Y2;W<N,BYA;70N1#(@8V]L<W!A;CTS1#(^(`T*("`@("`@("`@
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z
M(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#$P/B`@(`T*("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P,30\
M+V(^/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,30R-"YF:6Y2;W<N
M,BYT<F%I;"Y$,CX@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,30R
M-"YF:6Y2;W<N,BYL96%D+D0S/B`@(`T*("`@("`@("`@(#QB/B8C,38P.SPO
M8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T140DPQ-#(T+F9I;E)O=RXR
M+F%M="Y$,R!C;VQS<&%N/3-$,CX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203$T,3$^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^,C`Q,SPO8CX\+V9O;G0^("`@
M(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ('1O<"<@:60],T140DPQ-#(T+F9I;E)O=RXR+G1R86EL+D0S/B`@
M(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,30R
M-"YF:6Y2;W<N,SX@("`@#0H@("`@("`@(#QT9#X@("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS
M1%1"3#$T,C0N9FEN4F]W+C,N;&5A9"Y",CX@("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"
M3#$T,C0N9FEN4F]W+C,N<WEM8BY",CX@("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$T
M,C0N9FEN4F]W+C,N86UT+D(R/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ-#(T+F9I
M;E)O=RXS+G1R86EL+D(R/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$T,C0N9FEN
M4F]W+C,N;&5A9"Y",SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$T,C0N9FEN4F]W
M+C,N<WEM8BY",SX@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!I9#TS1%1"3#$T,C0N9FEN4F]W+C,N
M86UT+D(S/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS+G1R86EL
M+D(S/B`@("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N-#X@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%!!1$1)3D<M3$5&5#H@.7!T
M.R!724142#H@-S`E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@("`@("`@("`@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N
M,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#$R/B`@("`-"B`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P="<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/B`-"B`@("`@
M("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$T,C0N9FEN4F]W+C0N;&5A9"XR/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXT+G-Y;6(N,CX@#0H@("`@("`@
M("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I
M;E)O=RXT+F%M="XR/B`@("`@#0H@("`@("`@("`@,2PR-C(@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30R-"YF:6Y2;W<N-"YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-"YL96%D+C,^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C0N<WEM8BXS/B`-
M"B`@("`@("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$T,C0N9FEN4F]W+C0N86UT+C,^("`@("`-"B`@("`@("`@("`R-#D@("`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-"YT<F%I;"XS(&YO=W)A<#TS1&YO
M=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ-#(T+F9I;E)O=RXU/B`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@4$%$1$E.1RU,1494.B`Y<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T
M)R!I9#TS1%!!4D$Q-#$U/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+V9O;G0^("`@#0H@("`@("`@("`@/"]P/B`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I
M;E)O=RXU+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C4N<WEM8BXR/B`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#8W+C,E.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF
M:6Y2;W<N-2YA;70N,CX@#0H@("`@("`@("`@,2PW,#<@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,7!X.R!"04-+1U)/54Y$
M+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$T,C0N9FEN4F]W+C4N=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-2YL96%D+C,^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I
M;E)O=RXU+G-Y;6(N,SX@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`V-RXS)3L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C4N86UT+C,^(`T*("`@("`@("`@
M(#$L-3@V(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#%P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXU+G1R86EL+C,@
M;F]W<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,30R-"YF
M:6Y2;W<N-CX@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%!!1$1)3D<M3$5&
M5#H@.7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@("`@("`@("`@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)
M3CH@,'!T)R!I9#TS1%!!4D$Q-#$X/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:6YC;'5D960@:6X@;W!E<F%T
M:6YG(&5X<&5N<V5S/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O
M=RXV+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O
M=RXV+G-Y;6(N,CX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$T,C0N9FEN4F]W+C8N86UT+C(^("`@("`-"B`@("`@("`@("`R+#DV
M.2`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`S
M<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-BYT<F%I;"XR(&YO=W)A
M<#TS1&YO=W)A<#X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXV+FQE860N
M,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXV+G-Y;6(N
M,SX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N
M9FEN4F]W+C8N86UT+C,^("`@("`-"B`@("`@("`@("`Q+#@S-2`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`S<'@[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30R-"YF:6Y2;W<N-BYT<F%I;"XS(&YO=W)A<#TS1&YO=W)A
M<#X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C9F9F9F9F)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C<^("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F
M)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N-RYL96%D+D(R/B`@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ
M-#(T+F9I;E)O=RXW+G-Y;6(N0C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C<N
M86UT+D(R/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C<N=')A:6PN0C(^("`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60]
M,T140DPQ-#(T+F9I;E)O=RXW+FQE860N0C,^("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!I9#TS1%1"3#$T,C0N9FEN
M4F]W+C<N<WEM8BY",SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N-RYA;70N0C,^
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G
M(&ED/3-$5$),,30R-"YF:6Y2;W<N-RYT<F%I;"Y",SX@("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@
M(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N.#X@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%!!1$1)3D<M3$5&5#H@.7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<^("`@("`-"B`@
M("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T,C$^(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/DEM<&%C
M="!O;B!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4\+V9O
M;G0^("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C@N;&5A9"XR/B`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.
M+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C@N<WEM8BXR/B`-"B`@("`@
M("`@("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N."YA
M;70N,CX@("`@(`T*("`@("`@("`@(#`N,3,@("`@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#-P>#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#(T+F9I;E)O=RXX+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C@N;&5A9"XS/B`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C@N<WEM8BXS/B`-"B`@("`@("`@("`D
M("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N."YA;70N,SX@
M("`@(`T*("`@("`@("`@(#`N,3(@("`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#-P>#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T
M+F9I;E)O=RXX+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@
M(`T*("`@(#PO=&%B;&4^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$
M4$%203$T,C8^("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
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M(&-O;7!E;G-A=&EO;B!C;W-T(&]V97(@82!P97)I;V0@;V8@,BXU)B,Q-C`[
M>65A<G,L('=H:6-H(&ES('1H92!W96EG:'1E9"UA=F5R86=E('9E<W1I;F<@
M<&5R:6]D(&9O<B!A;&P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&%W87)D
M<RX\+V9O;G0^("`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,30R.#X@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(&5S
M=&EM871E9"!T:&4@9F%I<B!V86QU92!O9B!E86-H(&]P=&EO;B!G<F%N="!O
M;B!T:&4@9W)A;G0@9&%T92!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I
M;VX@=F%L=6%T:6]N(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN9R!W96EG:'1E
M9"UA=F5R86=E(&%S<W5M<'1I;VYS.CPO9F]N=#X@(`T*("`@(#PO<#X\8G(O
M/CQT86)L92!S='EL93TS1"=415A4+4E.1$5.5#H@,'!X.R!724142#H@,3`P
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0G(&ED/3-$5$),,30T-B!B;W)D97(],T0P(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^("`@(`T*("`@("`@/'1R
M(&ED/3-$5$),,30T-BYF:6Y2;W<N,3X@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@-S`E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M,30S,#X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQI/D]P=&EO;G,Z/"]I/CPO9F]N=#X@
M("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N,2YL96%D+D0S/B`-
M"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N,2YA;70N1#,@8V]L<W!A;CTS1#8^
M("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q
M-#,Q/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\8CY-87)C:"`S,2P\+V(^/"]F;VYT
M/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C$N=')A
M:6PN1#,^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$
M5$),,30T-BYF:6Y2;W<N,CX@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(`T*("`@
M("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXR+FQE860N
M1#(^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)
M3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXR+F%M="Y$,B!C;VQS<&%N
M/3-$,CX@("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$
M4$%203$T,S(^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P,30\+V(^/"]F;VYT
M/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C(N=')A
M:6PN1#(^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I
M;E)O=RXR+FQE860N1#,^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXR+F%M
M="Y$,R!C;VQS<&%N/3-$,CX@("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203$T,S,^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P
M,3,\+V(^/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N
M9FEN4F]W+C(N=')A:6PN1#,^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@
M("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@
M("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED
M/3-$5$),,30T-BYF:6Y2;W<N,SX@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ
M(#!P="<@:60],T1005)!,30S-#X@("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E)I<VLM
M9G)E92!I;G1E<F5S="!R871E/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P
M/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V
M+F9I;E)O=RXS+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N
M,RYS>6UB+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N,RYA;70N,CX@("`@(`T*
M("`@("`@("`@(#(N,"`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXS+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("4@(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W
M+C,N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXS+G-Y;6(N
M,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ-#0V+F9I;E)O=RXS+F%M="XS/B`@("`@#0H@("`@("`@
M("`@,2XQ("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C,N=')A:6PN,R!N
M;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ-#0V+F9I;E)O
M=RXT/B`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q
M-#,W/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P="<^1&EV:61E;F0@>6EE;&0\+V9O;G0^
M(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N-"YL96%D+C(^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$T-#8N9FEN4F]W+C0N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#$Y+C4U<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I
M;E)O=RXT+F%M="XR/B`@("`-"B`@("`@("`@("`P+C`@("`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30T-BYF:6Y2;W<N-"YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`-
M"B`@("`@("`@("`E("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#0V+F9I;E)O=RXT+FQE860N,SX@("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30T-BYF:6Y2;W<N-"YS>6UB+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,3DN-35P=#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W
M+C0N86UT+C,^("`@(`T*("`@("`@("`@(#`N,"`@("`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#0V+F9I;E)O=RXT+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@
M("`@("`@("4@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@
M(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G(&ED/3-$5$),,30T-BYF:6Y2;W<N-3X@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@(`T*("`@("`@("`@(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-
M05)'24XZ(#!P="<@:60],T1005)!,30T,#X@("`@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G
M/E9O;&%T:6QI='D\+V9O;G0^("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C4N
M;&5A9"XR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXU+G-Y;6(N,CX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#0V+F9I;E)O=RXU+F%M="XR/B`@("`@#0H@("`@("`@("`@
M,34S+C`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N-2YT<F%I;"XR(&YO=W)A
M<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`E("`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXU+FQE860N,SX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N-2YS>6UB+C,^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30T-BYF:6Y2;W<N-2YA;70N,SX@("`@(`T*("`@("`@("`@(#$U,BXT(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C4N=')A:6PN,R!N;W=R87`],T1N;W=R
M87`^("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ-#0V+F9I;E)O=RXV/B`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@#0H@("`@("`@
M("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#0S/B`@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P="<^17AP96-T960@;&EF92`H>65A<G,I/"]F;VYT/B`@(`T*
M("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30T-BYF:6Y2;W<N-BYL96%D+C(^("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$T-#8N9FEN4F]W+C8N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C8N
M86UT+C(^("`@("`-"B`@("`@("`@("`V("`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I
M;E)O=RXV+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#0V+F9I;E)O=RXV+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF
M:6Y2;W<N-BYS>6UB+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$R
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!-05)'24XM3$5&5#H@,3$W<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXV+F%M="XS
M/B`@#0H@("`@("`@("`@-B`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N-BYT
M<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@/"]T
M86)L93X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30T.#X@
M("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
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M<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T(&%N9"`R
M,#$S+"!T:&5R92!W97)E(&YO(&YE=R!O9F9E<FEN9R!P97)I;V1S(&]R($53
M4%`@<'5R8VAA<V4@<FEG:'1S(&=R86YT960N/"]F;VYT/B`-"B`@("`\+W`^
M/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T-3`^("`@(`T*
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T)SY4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@=&AE('-T
M;V-K(&]P=&EO;B!A8W1I=FET>2!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E
M9"!-87)C:"`S,2P@,C`Q-#H\+V9O;G0^("`@("`-"B`@("`\+W`^/&)R+SX\
M=&%B;&4@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P>#L@5TE$5$@Z(#$P,"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$T.3`@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`@("`-"B`@("`@(#QT<B!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C$^("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`-
M"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,2YL
M96%D+D0R/B`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,2YA;70N1#(@8V]L
M<W!A;CTS1#(^("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I
M9#TS1%!!4D$Q-#8X/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SX\8CY3:&%R97,@*&EN
M('1H;W5S86YD<RD\+V(^/"]F;VYT/B`@#0H@("`@("`@("`@/"]P/B`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$T.3`N9FEN4F]W+C$N=')A:6PN1#(^(`T*("`@("`@("`@(#QB/B8C,38P
M.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ-#DP+F9I;E)O=RXQ+FQE860N1#,^(`T*("`@("`@("`@
M(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXQ+F%M="Y$,R!C;VQS<&%N/3-$,CX@("`@#0H@("`@
M("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T-CD^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQB/E=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@4')I
M8V4\+V(^/"]F;VYT/B`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN
M4F]W+C$N=')A:6PN1#,^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXQ+FQE860N1#0^(`T*("`@("`@("`@(#QB/B8C,38P
M.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I
M;E)O=RXQ+F%M="Y$-"!C;VQS<&%N/3-$,CX@("`@#0H@("`@("`@("`@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR
M-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T-S`^("`@#0H@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQB/E=E:6=H=&5D+4%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L
M(%1E<FT@*%EE87)S*3PO8CX\+V9O;G0^("`-"B`@("`@("`@("`\+W`^(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30Y,"YF:6Y2;W<N,2YT<F%I;"Y$-#X@#0H@("`@("`@("`@/&(^)B,Q
M-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^
M("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<@:60],T140DPQ-#DP+F9I;E)O=RXR/B`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#4U)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`-"B`@("`@("`@
M("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@
M,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T-S$^(`T*("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T)SY"86QA;F-E(&%T($IA;G5A<GD@,2P@,C`Q-#PO9F]N=#X@("`-"B`@
M("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C(N;&5A9"XR/B`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#DP+F9I;E)O=RXR+G-Y;6(N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXR+F%M
M="XR/B`@("`@#0H@("`@("`@("`@-BPS-38@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF
M:6Y2;W<N,BYT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30Y,"YF:6Y2;W<N,BYL96%D+C,^("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C(N<WEM8BXS/B`-"B`@("`@("`@
M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN
M4F]W+C(N86UT+C,^("`@("`-"B`@("`@("`@("`X+C(R("`@("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ-#DP+F9I;E)O=RXR+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXR+FQE860N-#X@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,30Y,"YF:6Y2;W<N,BYS>6UB+C0^("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2
M;W<N,BYA;70N-#X@("`@(`T*("`@("`@("`@(#@N,30@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$T.3`N9FEN4F]W+C(N=')A:6PN-"!N;W=R87`],T1N;W=R87`^("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`\+W1R/B`@(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8G(&ED/3-$5$),,30Y,"YF:6Y2;W<N,SX@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%!!1$1)3D<M3$5&5#H@,3AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03$T-S4^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T)SY'<F%N=&5D/"]F;VYT/B`@("`-"B`@
M("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C,N;&5A9"XR/B`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#DP+F9I;E)O=RXS+G-Y;6(N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXS+F%M
M="XR/B`@("`@#0H@("`@("`@("`@,2PR,#,@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF
M:6Y2;W<N,RYT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30Y,"YF:6Y2;W<N,RYL96%D+C,^("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C,N<WEM8BXS/B`-"B`@("`@("`@
M("`D("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN
M4F]W+C,N86UT+C,^("`@("`-"B`@("`@("`@("`Y+CDY("`@("`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ-#DP+F9I;E)O=RXS+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30Y,"YF:6Y2;W<N,RYL96%D+D(T/B`@(`T*("`@("`@("`@("8C,38P
M.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,RYS
M>6UB+D(T/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXS
M+F%M="Y"-#X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,RYT<F%I;"Y"-#X@("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R
M/B`@(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8G(&ED/3-$5$),,30Y,"YF:6Y2;W<N-#X@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%!!1$1)3D<M3$5&5#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@
M("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,
M24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T-S@^
M(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T)SY%>&5R8VES960\+V9O;G0^(`T*("`@("`@("`@
M(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N-"YL96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN
M4F]W+C0N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C0N86UT+C(^("`@
M("`-"B`@("`@("`@("`H,C<U("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O
M=RXT+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U
M.R!-05)'24XZ(#!P="<@:60],T1005)!,30X,#X@#0H@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G
M/BD\+V9O;G0^("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXT+FQE860N,SX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N
M-"YS>6UB+C,^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-"YA;70N,SX@("`@(`T*("`@("`@
M("`@(#8N,3<@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C0N=')A:6PN
M,R!N;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXT+FQE860N0C0^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ-#DP+F9I;E)O=RXT+G-Y;6(N0C0^("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C0N86UT+D(T/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXT
M+G1R86EL+D(T/B`@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ-#DP+F9I;E)O
M=RXU/B`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@4$%$1$E.1RU,1494.B`Q
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ
M(#!P="<@:60],T1005)!,30X,CX@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D5X<&ER960@
M86YD(&9O<F9E:71E9#PO9F]N=#X@("`-"B`@("`@("`@("`\+W`^(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W
M+C4N;&5A9"XR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-2YS>6UB+C(^("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@
M5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N
M-2YA;70N,CX@("`@#0H@("`@("`@("`@*#$Q("`@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXU+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@#0H@
M("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#@T/B`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SXI/"]F
M;VYT/B`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXU+FQE860N,SX@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-2YS>6UB
M+C,^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,30Y,"YF:6Y2;W<N-2YA;70N,SX@("`@(`T*("`@("`@("`@(#$W
M+C,R(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXU+G1R86EL+C,@;F]W
M<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXU+FQE860N0C0^("`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#DP+F9I;E)O=RXU+G-Y;6(N0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#DP+F9I;E)O=RXU+F%M="Y"-#X@("`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P<'@[
M($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C4N
M=')A:6PN0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,30Y,"YF:6Y2;W<N
M-CX@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@("`@
M#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.
M12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#@V/B`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P="<^0F%L86YC92!A="!-87)C:"`S,2P@,C`Q-#PO9F]N
M=#X@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-BYL96%D+C(^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y
M,"YF:6Y2;W<N-BYS>6UB+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)
M3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXV+F%M="XR/B`@("`@#0H@
M("`@("`@("`@-RPR-S,@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,'!X.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C8N
M=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF
M:6Y2;W<N-BYL96%D+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS
M1%1"3#$T.3`N9FEN4F]W+C8N<WEM8BXS/B`-"B`@("`@("`@("`D("`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C8N86UT
M+C,^("`@("`-"B`@("`@("`@("`X+C4W("`@("`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N-BYT<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#DP+F9I;E)O=RXV+FQE860N-#X@("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N-BYS>6UB+C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-BYA
M;70N-#X@("`@(`T*("`@("`@("`@(#@N-#(@("`@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXV+G1R86EL+C0@;F]W<F%P/3-$;F]W<F%P/B`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\
M+W1R/B`@(`T*("`@(#PO=&%B;&4^/&)R+SX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U
M7S`U,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B
M,V4Y834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H965T
M<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^3F]T92`V("T@26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!487@@1&ES8VQO<W5R92!;5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@
M34%21TE..B`P<'0G(&ED/3-$4$%203$T.30^("`@(`T*("`@("`@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C8N($EN8V]M92!487AE<SPO
M8CX\+V9O;G0^("`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,30Y-CX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&
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M:"`S,2P@,C`Q-"X\+V9O;G0^(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'
M24XZ(#!P="<@:60],T1005)!,30Y.#X@("`@#0H@("`@("`\9F]N="!S='EL
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M9VYI>F5D(&EF(&ET(&AA<R!L97-S('1H86X@82`U,"4@;&EK96QI:&]O9"!O
M9B!B96EN9R!S=7-T86EN960N(%1H97)E(&AA=F4@8F5E;B!N;R!M871E<FEA
M;"!C:&%N9V5S(&EN('1H92!#;VUP86YY)B,X,C$W.W,@=6YR96-O9VYI>F5D
M('1A>"!B96YE9FET<R!S:6YC92!$96-E;6)E<B8C,38P.S,Q+"`R,#$S(&%N
M9"!A<R!S=6-H+"!D:7-C;&]S=7)E<R!I;F-L=61E9"!I;B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(#(P,3,@06YN=6%L(%)E<&]R="!O;B!&;W)M)B,Q-C`[,3`M
M2R!C;VYT:6YU92!T;R!B92!R96QE=F%N="!F;W(@=&AE('!E<FEO9"!E;F1E
M9"!-87)C:"`S,2P@,C`Q-"X\+V9O;G0^("`-"B`@("`\+W`^/&)R+SX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(S93EA-3,Q
M7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]B,V4Y834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S
M9#0T.3<O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%641!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S+"!B
M>2!0;VQI8WD@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^57-E(&]F($5S=&EM871E<RP@4&]L:6-Y(%M0;VQI8WD@5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@
M34%21TE..B`P<'0G(&ED/3-$4$%203$S,34^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQB/E5S92!O9B!%<W1I;6%T97,\+V(^/"]F;VYT/B`@
M(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M,3,Q-SX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<^5&AE('!R97!A<F%T:6]N(&]F(&-O;F1E;G-E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<R!I;B!C;VYF;W)M:71Y('=I=&@@1T%!4"!R97%U:7)E<R!M86YA
M9V5M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R`\9F]N
M="!S='EL93TS1"=#3TQ/4CH@(S`P,#`P,"<^=&AA="!A9F9E8W0@=&AE(')E
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M;VYS(&]R(&-O;F1I=&EO;G,N/"]F;VYT/CPO9F]N=#X\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N
M9"!#87-H($5Q=6EV86QE;G1S+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'
M24XZ(#!P="<@:60],T1005)!,3,Q.3X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P="<^/&(^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO8CX\+V9O
M;G0^("`@("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED
M/3-$4$%203$S,C$^("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&
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M+C,@;6EL;&EO;B!A="!-87)C:"`S,2P@,C`Q-"!A;F0@1&5C96UB97(@,S$L
M(#(P,3,L(')E<W!E8W1I=F5L>2X@5&AE<F4@=V5R92!N;R!C87-H(&5Q=6EV
M86QE;G1S(&%S(&]F(&)O=&@@9&%T97,N($]U<B!B86YK(&%C8V]U;G1S(&AA
M=F4@8F5E;B!P;&%C960@=6YD97(@82!C;VYT<F]L(&%G<F5E;65N="!I;B!A
M8V-O<F1A;F-E('=I=&@@=&AE($%P<FEL)B,Q-C`[,C`Q,2!C;VYV97)T:6)L
M92!N;W1E(&9I;F%N8VEN9R`H<V5E($YO=&4@-"DN/"]F;VYT/CPO<#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI
M<75I9&ET>2!$:7-C;&]S=7)E(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=415A4+4%,
M24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G
M(&ED/3-$4$%203$S,C$^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G
M/E=E(&AA9"!C87-H(&]F("0U-RXU(&UI;&QI;VX@86YD("0W,BXS(&UI;&QI
M;VX@870@36%R8V@@,S$L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S+"!R
M97-P96-T:79E;'DN/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5A<FYI;F=S(%!E<B!3:&%R92P@
M4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S
M,C,^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/D5A<FYI;F=S
M(%!E<B!3:&%R93PO8CX\+V9O;G0^("`-"B`@("`\+W`^/&)R+SX\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@
M34%21TE..B`P<'0G(&ED/3-$4$%203$S,C4^("`@(`T*("`@("`@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/D)A<VEC(&5A<FYI;F=S('!E<B!S
M:&%R92`H)B,X,C(P.T504R8C.#(R,3LI(&ES(&-A;&-U;&%T960@8GD@9&EV
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M/B`@#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!
M4D$Q,S(W/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T)SY"96-A=7-E('=E(&AA=F4@:6YC=7)R960@82!N970@;&]S<R!F;W(@
M8F]T:"!P97)I;V1S('!R97-E;G1E9"!I;B!T:&4@=6YA=61I=&5D(&-O;F1E
M;G-E9"!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,L(&]U='-T86YD:6YG('-T
M;V-K(&]P=&EO;G,L('=A<G)A;G1S(&%N9"!C;VUM;VX@<W1O8VL@=6YD97)L
M>6EN9R!C;VYV97)T:6)L92!N;W1E<R!A<F4@;F]T(&EN8VQU9&5D(&EN('1H
M92!C;VUP=71A=&EO;B!O9B!N970@;&]S<R!P97(@<VAA<F4@8F5C875S92!T
M:&5I<B!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU=&EV92X\+V9O;G0^("`@
M("`-"B`@("`\+W`^/&)R+SX\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03$S,CD^("`@(`T*("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
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M<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"!A;F0@,C`Q,R`H:6X@=&AO=7-A;F1S
M*3H\+V9O;G0^("`@#0H@("`@/"]P/CQB<B\^/'1A8FQE('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'@[(%=)1%1(.B`Q,#`E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<@
M:60],T140DPQ,S0U(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X@("`@#0H@("`@("`\='(@:60],T140DPQ,S0U+F9I;E)O
M=RXQ/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`W-B4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@("`@(`T*("`@
M("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$S-#4N9FEN4F]W
M+C$N;&5A9"Y$,SX@("`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([(%=)1%1(.B`Q,R4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$S-#4N9FEN
M4F]W+C$N86UT+D0S(&-O;'-P86X],T0V/B`@(`T*("`@("`@("`@(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S,Q/B`@(`T*("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/CPO8CX\+V9O;G0^
M("`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`@(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)
M3CH@,'!T)R!I9#TS1%!!4D$Q,S,R/B`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E1H<F5E($UO;G1H<R!%;F1E
M9#PO8CX\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\
M8CY-87)C:"`S,2P\+V(^/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T
M;W`G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,2YT<F%I;"Y$,SX@("`@#0H@("`@
M("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@:60],T140DPQ,S0U+F9I;E)O
M=RXR/B`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`W-B4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@("`@(`T*("`@
M("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$S-#4N9FEN4F]W
M+C(N;&5A9"Y$,CX@("`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,3,T-2YF:6Y2
M;W<N,BYA;70N1#(@8V]L<W!A;CTS1#(^("`-"B`@("`@("`@("`\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-
M05)'24XZ(#!P="<@:60],T1005)!,3,S-#X@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\8CXR,#$T/"]B/CPO9F]N
M=#X@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,3,T-2YF:6Y2
M;W<N,BYT<F%I;"Y$,CX@("`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@
M("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T
M;W`G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,BYL96%D+D0S/B`@("`-"B`@("`@
M("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)
M3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M('1O<"<@:60],T140DPQ,S0U+F9I;E)O=RXR+F%M="Y$,R!C;VQS<&%N/3-$
M,CX@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q
M,S,U/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQB/C(P,3,\+V(^/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W`^
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P
M>#L@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M('1O<"<@:60],T140DPQ,S0U+F9I;E)O=RXR+G1R86EL+D0S/B`@("`-"B`@
M("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$S-#4N9FEN
M4F]W+C,^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<V)2<^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24G(&ED/3-$5$),,3,T-2YF
M:6Y2;W<N,RYL96%D+D(R/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24G
M(&ED/3-$5$),,3,T-2YF:6Y2;W<N,RYS>6UB+D(R/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=724142#H@.24G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,RYA;70N0C(^
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)R!I9#TS1%1"3#$S-#4N9FEN
M4F]W+C,N=')A:6PN0C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24G
M(&ED/3-$5$),,3,T-2YF:6Y2;W<N,RYL96%D+D(S/B`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"=724142#H@,24G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,RYS>6UB+D(S
M/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=724142#H@.24G(&ED/3-$5$),,3,T-2YF
M:6Y2;W<N,RYA;70N0C,^(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)R!I
M9#TS1%1"3#$S-#4N9FEN4F]W+C,N=')A:6PN0C,^("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*
M("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G
M(&ED/3-$5$),,3,T-2YF:6Y2;W<N-#X@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%!!1$1)3D<M3$5&5#H@.7!T.R!724142#H@-S8E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS
M1%!!4D$Q,S,V/B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^4W1O8VL@;W!T:6]N<R!O
M=71S=&%N9&EN9SPO9F]N=#X@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-"YL
M96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C0N<WEM8BXR/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@-C<N
M,R4[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ,S0U+F9I;E)O=RXT+F%M="XR/B`-"B`@("`@("`@("`W+#(W
M,R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXT+G1R86EL+C(@;F]W<F%P/3-$
M;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXT+FQE860N,SX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-"YS>6UB+C,^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`V-RXS)3L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$S-#4N9FEN4F]W+C0N86UT+C,^(`T*("`@("`@("`@(#0L-#8Q(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$S-#4N9FEN4F]W+C0N=')A:6PN,R!N;W=R87`],T1N;W=R87`^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`\+W1R/B`@(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G(&ED/3-$5$),,3,T-2YF:6Y2;W<N-3X@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%!!1$1)3D<M3$5&5#H@.7!T.R!72414
M2#H@-S8E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^("`@#0H@("`@("`@("`@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!
M4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S,Y/B`@("`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^
M5V%R<F%N=',@;W5T<W1A;F1I;F<\+V9O;G0^("`-"B`@("`@("`@("`\+W`^
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N
M9FEN4F]W+C4N;&5A9"XR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXU
M+G-Y;6(N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@.24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.
M+4Q%1E0Z(#8W+C,E.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-2YA;70N,CX@#0H@("`@
M("`@("`@,RPX,C4@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-2YT<F%I;"XR
M(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N
M-2YL96%D+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C4N<WEM8BXS
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M-C<N,R4[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,S0U+F9I;E)O=RXU+F%M="XS/B`-"B`@("`@("`@("`T
M+#`U,B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)
M3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXU+G1R86EL+C,@;F]W<F%P
M/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!I9#TS1%1"3#$S-#4N9FEN4F]W
M+C8^("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!0041$24Y'+4Q%1E0Z(#EP
M=#L@5TE$5$@Z(#<V)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@("`@#0H@("`@("`@("`@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N
M,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S0R/B`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M="<^0V]M;6]N('-T;V-K('5N9&5R;'EI;F<@8V]N=F5R=&EB;&4@;F]T97,@
M;W5T<W1A;F1I;F<\+V9O;G0^("`@("`-"B`@("`@("`@("`\+W`^(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W
M+C8N;&5A9"XR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXV+G-Y;6(N
M,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@.24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#8W+C,E.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-BYA;70N,CX@#0H@("`@("`@("`@
M-BPS.#4@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-BYT<F%I;"XR(&YO=W)A
M<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-BYL96%D
M+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C8N<WEM8BXS/B`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@-C<N,R4[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ,S0U+F9I;E)O=RXV+F%M="XS/B`-"B`@("`@("`@("`V+#`Q-B`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ,S0U+F9I;E)O=RXV+G1R86EL+C,@;F]W<F%P/3-$;F]W
M<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@/"]T<CX@("`-"B`@("`\+W1A8FQE/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV
M92!);F-O;64L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I
M9#TS1%!!4D$Q,S0W/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)SX\
M8CY#;VUP<F5H96YS:79E($EN8V]M92`H3&]S<RD\+V(^/"]F;VYT/B`@("`@
M#0H@("`@/"]P/CQB<B\^/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>3L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q
M,S0Y/B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[
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M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE=R!!8V-O=6YT:6YG(%!R
M;VYO=6YC96UE;G1S+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,3,U,3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P
M="<^/&(^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V(^/"]F
M;VYT/B`@(`T*("`@(#PO<#X\8G(O/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60]
M,T1005)!,3,U,SX@("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E=E(&1O(&YO="!E>'!E8W0@=&AA
M="!T:&4@861O<'1I;VX@;V8@86YY(')E8V5N=&QY(&ES<W5E9"!A8V-O=6YT
M:6YG('!R;VYO=6YC96UE;G1S('=O=6QD(&AA=F4@82!S:6=N:69I8V%N="!I
M;7!A8W0@;VX@;W5R(')E<W5L=',@;V8@;W!E<F%T:6]N<RP@9FEN86YC:6%L
M(&-O;F1I=&EO;B!O<B!C87-H(&9L;W<N/"]F;VYT/CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(S93EA-3,Q7S9C-#E?
M-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]B,V4Y834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<O
M5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3F]T92`S("T@06-C;W5N=&EN9R!0;VQI8VEE<R`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U
M;&4@;V8@06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#
M;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6U1A8FQE(%1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'@[(%=)1%1(.B`Q,#`E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P="<@:60],T140DPQ,S0U(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X@("`-"B`@("`@(#QT<B!I9#TS1%1"
M3#$S-#4N9FEN4F]W+C$^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#<V)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G
M/B`@("`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),
M,3,T-2YF:6Y2;W<N,2YL96%D+D0S/B`@("`-"B`@("`@("`@("`\8CXF(S$V
M,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#$S)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$
M5$),,3,T-2YF:6Y2;W<N,2YA;70N1#,@8V]L<W!A;CTS1#8^("`@#0H@("`@
M("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%
M24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,S$^("`@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^
M/"]B/CPO9F]N=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@("`@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@
M,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,S(^("`@#0H@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^5&AR964@
M36]N=&AS($5N9&5D/"]B/CPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQB/DUA<F-H(#,Q+#PO8CX\+V9O;G0^("`@("`-"B`@("`@
M("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#%P>#L@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ('1O<"<@:60],T140DPQ,S0U+F9I;E)O=RXQ+G1R86EL+D0S
M/B`@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"
M3#$S-#4N9FEN4F]W+C(^("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#<V)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G
M/B`@("`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),
M,3,T-2YF:6Y2;W<N,BYL96%D+D0R/B`@("`-"B`@("`@("`@("`\8CXF(S$V
M,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T14
M0DPQ,S0U+F9I;E)O=RXR+F%M="Y$,B!C;VQS<&%N/3-$,CX@(`T*("`@("`@
M("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q,S,T/B`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P
M,30\+V(^/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>#L@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T14
M0DPQ,S0U+F9I;E)O=RXR+G1R86EL+D0R/B`@("`-"B`@("`@("`@("`\8CXF
M(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ('1O<"<@:60],T140DPQ,S0U+F9I;E)O=RXR+FQE860N1#,^
M("`@(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C(N86UT+D0S
M(&-O;'-P86X],T0R/B`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G
M(&ED/3-$4$%203$S,S4^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P="<^/&(^,C`Q,SPO8CX\+V9O;G0^("`@(`T*("`@
M("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,7!X.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C(N=')A:6PN
M1#,^("`@(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$
M5$),,3,T-2YF:6Y2;W<N,SX@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=7
M24142#H@-S8E)SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<@:60]
M,T140DPQ,S0U+F9I;E)O=RXS+FQE860N0C(^("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U=)1%1(.B`Q)2<@:60],T140DPQ,S0U+F9I;E)O=RXS+G-Y;6(N0C(^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Y)2<@:60],T140DPQ,S0U+F9I;E)O
M=RXS+F%M="Y",CX@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,24G(&ED/3-$
M5$),,3,T-2YF:6Y2;W<N,RYT<F%I;"Y",CX@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)U=)1%1(.B`Q)2<@:60],T140DPQ,S0U+F9I;E)O=RXS+FQE860N0C,^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<@:60],T140DPQ,S0U+F9I;E)O
M=RXS+G-Y;6(N0C,^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Y)2<@:60]
M,T140DPQ,S0U+F9I;E)O=RXS+F%M="Y",SX@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=7
M24142#H@,24G(&ED/3-$5$),,3,T-2YF:6Y2;W<N,RYT<F%I;"Y",SX@("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9B<@:60],T140DPQ,S0U+F9I;E)O=RXT/B`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@4$%$1$E.1RU,1494.B`Y<'0[(%=)1%1(.B`W
M-B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203$S,S8^("`@(`T*("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T)SY3=&]C
M:R!O<'1I;VYS(&]U='-T86YD:6YG/"]F;VYT/B`@#0H@("`@("`@("`@/"]P
M/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U
M+F9I;E)O=RXT+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N
M-"YS>6UB+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)
M3BU,1494.B`V-RXS)3L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C0N86UT+C(^(`T*("`@
M("`@("`@(#<L,C<S(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C0N=')A:6PN
M,B!N;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W
M+C0N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXT+G-Y;6(N
M,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@.24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#8W+C,E.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-"YA;70N,SX@#0H@("`@("`@("`@
M-"PT-C$@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-"YT<F%I;"XS(&YO=W)A
M<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ,S0U+F9I;E)O
M=RXU/B`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@4$%$1$E.1RU,1494
M.B`Y<'0[(%=)1%1(.B`W-B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@("`-"B`@("`@("`@
M("`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!,24Y%+4A%24=(
M5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S,SD^("`@(`T*("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T)SY787)R86YT<R!O=71S=&%N9&EN9SPO9F]N=#X@(`T*("`@
M("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,3,T-2YF:6Y2;W<N-2YL96%D+C(^("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S
M-#4N9FEN4F]W+C4N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(
M.B`Y)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!-05)'24XM3$5&5#H@-C<N,R4[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXU+F%M
M="XR/B`-"B`@("`@("`@("`S+#@R-2`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O
M=RXU+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M,S0U+F9I;E)O=RXU+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2
M;W<N-2YS>6UB+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#DE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`V-RXS)3L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C4N86UT+C,^(`T*
M("`@("`@("`@(#0L,#4R(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C4N=')A
M:6PN,R!N;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),
M,3,T-2YF:6Y2;W<N-CX@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%!!1$1)
M3D<M3$5&5#H@.7!T.R!724142#H@-S8E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@("`-
M"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%
M+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$S-#(^(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T)SY#;VUM;VX@<W1O8VL@=6YD97)L>6EN9R!C;VYV97)T
M:6)L92!N;W1E<R!O=71S=&%N9&EN9SPO9F]N=#X@("`@(`T*("`@("`@("`@
M(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,3,T-2YF:6Y2;W<N-BYL96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN
M4F]W+C8N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Y)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@-C<N,R4[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXV+F%M="XR/B`-
M"B`@("`@("`@("`V+#,X-2`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I;E)O=RXV+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ,S0U+F9I
M;E)O=RXV+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,3,T-2YF:6Y2;W<N-BYS
M>6UB+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#DE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`V-RXS)3L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C8N86UT+C,^(`T*("`@("`@
M("`@(#8L,#$V(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$S-#4N9FEN4F]W+C8N=')A:6PN,R!N
M;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@(#PO=&%B;&4^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M(/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T;V-K:&]L9&5R<R<@
M17%U:71Y("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@3F]T92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y38VAE9'5L92!O9B!%;7!L;WEE92!397)V:6-E(%-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E
M<FEO9"!#;W-T<R!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\=&%B;&4@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P>#L@5TE$5$@Z(#$P,"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T)R!I9#TS1%1"3#$T
M,C0@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`@("`@#0H@("`@("`\='(@:60],T140DPQ-#(T+F9I;E)O=RXQ/B`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@=&]P)SX@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@
M("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),
M,30R-"YF:6Y2;W<N,2YL96%D+D0S/B`@(`T*("`@("`@("`@(#QB/B8C,38P
M.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T140DPQ-#(T+F9I;E)O
M=RXQ+F%M="Y$,R!C;VQS<&%N/3-$-CX@#0H@("`@("`@("`@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%2
M1TE..B`P<'0G(&ED/3-$4$%203$T,#<^("`@#0H@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P="<^/&(^/"]B/CPO9F]N=#X@("`@
M(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P
M<'0G(&ED/3-$4$%203$T,#@^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P="<^/&(^5&AR964@36]N=&AS($5N9&5D/"]B
M/CPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/DUA
M<F-H(#,Q+#PO8CX\+V9O;G0^("`@("`-"B`@("`@("`@("`\+W`^(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$5$),,30R
M-"YF:6Y2;W<N,2YT<F%I;"Y$,SX@("`-"B`@("`@("`@("`\8CXF(S$V,#L\
M+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-
M"B`@("`@(#QT<B!I9#TS1%1"3#$T,C0N9FEN4F]W+C(^("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`@(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ('1O<"<@:60],T140DPQ-#(T+F9I
M;E)O=RXR+FQE860N1#(^("`@#0H@("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@
M("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C(N86UT
M+D0R(&-O;'-P86X],T0R/B`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,30Q,#X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T)SX\8CXR,#$T/"]B/CPO9F]N=#X@("`@#0H@
M("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@=&]P)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C(N=')A:6PN1#(^("`@#0H@
M("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@=&]P)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C(N;&5A9"Y$
M,SX@("`-"B`@("`@("`@("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!T;W`G(&ED/3-$5$),,30R-"YF:6Y2;W<N,BYA;70N1#,@8V]L<W!A;CTS
M1#(^(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q
M-#$Q/B`@(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQB/C(P,3,\+V(^/"]F;VYT/B`@("`-"B`@("`@("`@("`\+W`^
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P
M>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G(&ED/3-$
M5$),,30R-"YF:6Y2;W<N,BYT<F%I;"Y$,SX@("`-"B`@("`@("`@("`\8CXF
M(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T
M<CX@("`-"B`@("`@(#QT<B!I9#TS1%1"3#$T,C0N9FEN4F]W+C,^("`@(`T*
M("`@("`@("`\=&0^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS
M+FQE860N0C(^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS+G-Y
M;6(N0C(^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS+F%M="Y"
M,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D(&ED/3-$5$),,30R-"YF:6Y2;W<N,RYT<F%I;"Y",CX@
M("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS+FQE860N0C,^("`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS+G-Y;6(N0C,^("`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@:60],T140DPQ-#(T+F9I;E)O=RXS+F%M="Y",SX@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M(&ED/3-$5$),,30R-"YF:6Y2;W<N,RYT<F%I;"Y",SX@("`@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@
M("`-"B`@("`@(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C0^("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!0041$24Y'+4Q%1E0Z(#EP=#L@5TE$5$@Z(#<P)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@
M:60],T1005)!,30Q,CX@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E)E<V5A<F-H(&%N
M9"!D979E;&]P;65N=#PO9F]N=#X@#0H@("`@("`@("`@/"]P/B`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXT
M+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30R
M-"YF:6Y2;W<N-"YS>6UB+C(^(`T*("`@("`@("`@("0@(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-"YA;70N,CX@("`@
M(`T*("`@("`@("`@(#$L,C8R(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C0N
M=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N
M9FEN4F]W+C0N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ-#(T+F9I;E)O=RXT+G-Y;6(N,SX@#0H@("`@("`@("`@)"`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!72414
M2#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXT+F%M
M="XS/B`@("`@#0H@("`@("`@("`@,C0Y("`@(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N
M9FEN4F]W+C0N=')A:6PN,R!N;W=R87`],T1N;W=R87`^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@
M(`T*("`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N-3X@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8[(%!!1$1)3D<M3$5&5#H@.7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(`T*
M("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30Q-3X@
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0G/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M/"]F;VYT/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-2YL96%D+C(^("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#(T+F9I;E)O=RXU+G-Y;6(N,CX@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`V-RXS)3L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C4N86UT+C(^(`T*
M("`@("`@("`@(#$L-S`W(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#%P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXU
M+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N
M9FEN4F]W+C4N;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-2YS>6UB+C,^("`-
M"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@-C<N,R4[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T
M+F9I;E)O=RXU+F%M="XS/B`-"B`@("`@("`@("`Q+#4X-B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,30R-"YF:6Y2;W<N-2YT<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@/"]T<CX@("`-"B`@("`@(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C8^("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!0041$24Y'+4Q%1E0Z(#EP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!
M,30Q.#X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E(&EN8VQU9&5D(&EN(&]P97)A=&EN9R!E>'!E;G-E<SPO9F]N
M=#X@("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-BYL96%D+C(^("`@#0H@
M("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'
M24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N-BYS>6UB+C(^(`T*("`@
M("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!7
M24142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXV
M+F%M="XR/B`@("`@#0H@("`@("`@("`@,BPY-CD@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$T,C0N9FEN4F]W+C8N=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(
M.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30R-"YF:6Y2;W<N-BYL96%D+C,^("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30R-"YF:6Y2;W<N-BYS>6UB+C,^(`T*("`@("`@("`@("0@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I;E)O=RXV+F%M="XS/B`@
M("`@#0H@("`@("`@("`@,2PX,S4@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,W!X.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T,C0N9FEN
M4F]W+C8N=')A:6PN,R!N;W=R87`],T1N;W=R87`^("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@
M("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@
M:60],T140DPQ-#(T+F9I;E)O=RXW/B`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!I9#TS1%1"3#$T,C0N
M9FEN4F]W+C<N;&5A9"Y",CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N-RYS>6UB
M+D(R/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<@:60],T140DPQ-#(T+F9I;E)O=RXW+F%M="Y",CX@(`T*("`@("`@
M("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ
M-#(T+F9I;E)O=RXW+G1R86EL+D(R/B`@("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G(&ED/3-$5$),,30R-"YF:6Y2;W<N
M-RYL96%D+D(S/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T
M9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9B<@:60],T140DPQ-#(T+F9I;E)O=RXW+G-Y;6(N0C,^("`@
M#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!I
M9#TS1%1"3#$T,C0N9FEN4F]W+C<N86UT+D(S/B`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!I9#TS1%1"3#$T,C0N9FEN
M4F]W+C<N=')A:6PN0C,^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!I9#TS1%1"3#$T,C0N
M9FEN4F]W+C@^("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!0041$24Y'+4Q%
M1E0Z(#EP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!T;W`G/B`@("`@#0H@("`@("`@("`@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[($U!4D=)
M3CH@,'!T)R!I9#TS1%!!4D$Q-#(Q/B`-"B`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T)SY);7!A8W0@;VX@8F%S:6,@86YD(&1I
M;'5T960@;F5T(&QO<W,@<&5R('-H87)E/"]F;VYT/B`@#0H@("`@("`@("`@
M/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#(T+F9I;E)O=RXX+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#(T+F9I;E)O=RXX+G-Y;6(N,CX@#0H@("`@("`@("`@)"`@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T,C0N9FEN4F]W+C@N86UT+C(^("`@("`-"B`@("`@
M("`@("`P+C$S("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`S<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)
M1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N."YT
M<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I
M;E)O=RXX+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#(T+F9I
M;E)O=RXX+G-Y;6(N,SX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T,C0N9FEN4F]W+C@N86UT+C,^("`@("`-"B`@("`@("`@("`P
M+C$R("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`S<'@[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30R-"YF:6Y2;W<N."YT<F%I;"XS
M(&YO=W)A<#TS1&YO=W)A<#X@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@4W1O8VL@
M3W!T:6]N<RP@5F%L=6%T:6]N($%S<W5M<'1I;VYS(%M486)L92!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQT86)L92!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!X.R!724142#H@,3`P)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0G(&ED/3-$5$),,30T-B!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^("`@(`T*("`@("`@/'1R(&ED/3-$5$),
M,30T-BYF:6Y2;W<N,3X@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!724142#H@-S`E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^("`@(`T*
M("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30S,#X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQI/D]P=&EO;G,Z/"]I/CPO9F]N=#X@("`@#0H@("`@
M("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N,2YL96%D+D0S/B`-"B`@("`@("`@
M("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30T-BYF:6Y2;W<N,2YA;70N1#,@8V]L<W!A;CTS1#8^("`@(`T*("`@
M("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#,Q/B`@(`T*
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T)SX\8CY-87)C:"`S,2P\+V(^/"]F;VYT/B`@("`@#0H@
M("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C$N=')A:6PN1#,^(`T*
M("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R(&ED/3-$5$),,30T-BYF
M:6Y2;W<N,CX@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(`T*("`@("`@("`@(#QB
M/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXR+FQE860N1#(^(`T*("`@
M("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@("`@
M#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#0V+F9I;E)O=RXR+F%M="Y$,B!C;VQS<&%N/3-$,CX@("`@
M#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!,
M24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T,S(^
M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P,30\+V(^/"]F;VYT/B`@("`@#0H@
M("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C(N=')A:6PN1#(^(`T*
M("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXR+FQE
M860N1#,^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXR+F%M="Y$,R!C;VQS
M<&%N/3-$,CX@("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED
M/3-$4$%203$T,S,^("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/C(P,3,\+V(^/"]F
M;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C(N
M=')A:6PN1#,^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$5$),,30T
M-BYF:6Y2;W<N,SX@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.
M+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60]
M,T1005)!,30S-#X@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E)I<VLM9G)E92!I;G1E
M<F5S="!R871E/"]F;VYT/B`@("`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXS
M+FQE860N,CX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N,RYS>6UB+C(^
M("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30T-BYF:6Y2;W<N,RYA;70N,CX@("`@(`T*("`@("`@("`@
M(#(N,"`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXS+G1R86EL+C(@;F]W
M<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("4@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C,N;&5A9"XS
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXS+G-Y;6(N,SX@("`-"B`@
M("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#0V+F9I;E)O=RXS+F%M="XS/B`@("`@#0H@("`@("`@("`@,2XQ("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C,N=')A:6PN,R!N;W=R87`],T1N
M;W=R87`^("`@#0H@("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ-#0V+F9I;E)O=RXT/B`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@#0H@("`@
M("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(
M14E'2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#,W/B`@("`-
M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P="<^1&EV:61E;F0@>6EE;&0\+V9O;G0^(`T*("`@("`@
M("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$
M5$),,30T-BYF:6Y2;W<N-"YL96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N
M9FEN4F]W+C0N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@
M("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q
M,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#$Y+C4U<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXT+F%M
M="XR/B`@("`-"B`@("`@("`@("`P+C`@("`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF
M:6Y2;W<N-"YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@
M("`E("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#0V+F9I;E)O=RXT+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2
M;W<N-"YS>6UB+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,3DN-35P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C0N86UT+C,^
M("`@(`T*("`@("`@("`@(#`N,"`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O
M=RXT+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("4@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`\+W1R/B`@(`T*("`@("`@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&ED/3-$
M5$),,30T-BYF:6Y2;W<N-3X@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P
M="<@:60],T1005)!,30T,#X@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/E9O;&%T:6QI
M='D\+V9O;G0^("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C4N;&5A9"XR/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXU+G-Y;6(N,CX@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#0V+F9I;E)O=RXU+F%M="XR/B`@("`@#0H@("`@("`@("`@,34S+C`@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30T-BYF:6Y2;W<N-2YT<F%I;"XR(&YO=W)A<#TS1&YO=W)A
M<#X@("`-"B`@("`@("`@("`E("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXU+FQE860N,SX@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED
M/3-$5$),,30T-BYF:6Y2;W<N-2YS>6UB+C,^("`@#0H@("`@("`@("`@)B,Q
M-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2
M;W<N-2YA;70N,SX@("`@(`T*("`@("`@("`@(#$U,BXT(`T*("`@("`@("`\
M+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$T-#8N9FEN4F]W+C4N=')A:6PN,R!N;W=R87`],T1N;W=R87`^("`@#0H@
M("`@("`@("`@)2`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^
M("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<@:60],T140DPQ-#0V+F9I;E)O=RXV/B`@(`T*("`@("`@("`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`@#0H@("`@("`@("`@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#0S/B`@("`-"B`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M="<^17AP96-T960@;&EF92`H>65A<G,I/"]F;VYT/B`@(`T*("`@("`@("`@
M(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30T-BYF:6Y2;W<N-BYL96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN
M4F]W+C8N<WEM8BXR/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q,B4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T-#8N9FEN4F]W+C8N86UT+C(^("`@
M("`-"B`@("`@("`@("`V("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXV+G1R
M86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*("`@("`@("`@("8C,38P.R`-
M"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#0V+F9I
M;E)O=RXV+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N-BYS
M>6UB+C,^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM
M3$5&5#H@,3$W<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<@:60],T140DPQ-#0V+F9I;E)O=RXV+F%M="XS/B`@#0H@("`@
M("`@("`@-B`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30T-BYF:6Y2;W<N-BYT<F%I;"XS(&YO
M=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@
M(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@/"]T86)L93X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06-T:79I='D@
M6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'1A8FQE('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'@[(%=)1%1(
M.B`Q,#`E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P="<@:60],T140DPQ-#DP(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@("`@(`T*("`@
M("`@/'1R(&ED/3-$5$),,30Y,"YF:6Y2;W<N,3X@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I
M;E)O=RXQ+FQE860N1#(^(`T*("`@("`@("`@(#QB/B8C,38P.SPO8CX@("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXQ+F%M
M="Y$,B!C;VQS<&%N/3-$,CX@("`@#0H@("`@("`@("`@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE.
M.B`P<'0G(&ED/3-$4$%203$T-C@^("`@#0H@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/CQB/E-H
M87)E<R`H:6X@=&AO=7-A;F1S*3PO8CX\+V9O;G0^("`-"B`@("`@("`@("`\
M+W`^(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#%P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M(&ED/3-$5$),,30Y,"YF:6Y2;W<N,2YT<F%I;"Y$,CX@#0H@("`@("`@("`@
M/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C$N;&5A9"Y$,SX@#0H@
M("`@("`@("`@/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C$N86UT+D0S(&-O;'-P86X],T0R/B`@
M("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30V
M.3X@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P="<^/&(^5V5I9VAT960M079E<F%G92!%>&5R
M8VES92!0<FEC93PO8CX\+V9O;G0^("`-"B`@("`@("`@("`\+W`^(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N,2YT<F%I;"Y$,SX@#0H@("`@("`@("`@/&(^)B,Q-C`[
M/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C$N;&5A9"Y$-#X@#0H@("`@("`@("`@
M/&(^)B,Q-C`[/"]B/B`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@
M("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"
M3#$T.3`N9FEN4F]W+C$N86UT+D0T(&-O;'-P86X],T0R/B`@("`-"B`@("`@
M("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30W,#X@("`-"B`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P="<^/&(^5V5I9VAT960M079E<F%G92!296UA:6YI;F<@0V]N
M=')A8W1U86P@5&5R;2`H665A<G,I/"]B/CPO9F]N=#X@(`T*("`@("`@("`@
M(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ-#DP+F9I;E)O=RXQ+G1R86EL+D0T/B`-"B`@("`@("`@
M("`\8CXF(S$V,#L\+V(^("`@("`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@/"]T<CX@("`-"B`@("`@(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C(^("`@#0H@("`@
M("`@(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@-34E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(`T*
M("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M
M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T1005)!,30W,3X@#0H@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0G/D)A;&%N8V4@870@2F%N=6%R>2`Q+"`R,#$T/"]F;VYT
M/B`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,BYL96%D+C(^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C(N<WEM8BXR/B`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN
M4F]W+C(N86UT+C(^("`@("`-"B`@("`@("`@("`V+#,U-B`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXR+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ-#DP+F9I;E)O=RXR+FQE860N,SX@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,BYS>6UB+C,^(`T*
M("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N,BYA;70N,SX@("`@(`T*("`@("`@("`@(#@N,C(@("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C(N=')A:6PN,R!N;W=R87`],T1N
M;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C(N;&5A9"XT/B`@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@
M5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXR+G-Y;6(N-#X@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ
M-#DP+F9I;E)O=RXR+F%M="XT/B`@("`@#0H@("`@("`@("`@."XQ-"`@("`@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,BYT<F%I;"XT(&YO=W)A<#TS1&YO
M=W)A<#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<@:60],T140DPQ-#DP+F9I;E)O=RXS/B`@
M(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@4$%$1$E.1RU,1494.B`Q.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@
M:60],T1005)!,30W-3X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D=R86YT960\+V9O;G0^
M("`@(`T*("`@("`@("`@(#PO<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,RYL96%D+C(^("`@#0H@("`@
M("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@
M,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C,N<WEM8BXR/B`@(`T*("`@("`@("`@("8C
M,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[(%=)1%1(.B`Q,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN
M4F]W+C,N86UT+C(^("`@("`-"B`@("`@("`@("`Q+#(P,R`-"B`@("`@("`@
M/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXS+G1R86EL+C(@;F]W<F%P/3-$;F]W<F%P/B`@(`T*
M("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@
M("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@5TE$
M5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ-#DP+F9I;E)O=RXS+FQE860N,SX@("`-"B`@("`@("`@
M("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-
M05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N,RYS>6UB+C,^(`T*
M("`@("`@("`@("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N,RYA;70N,SX@("`@(`T*("`@("`@("`@(#DN.3D@("`@
M(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%
M1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C,N=')A:6PN,R!N;W=R87`],T1N
M;W=R87`^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@
M("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<@:60],T140DPQ-#DP+F9I;E)O=RXS+FQE860N0C0^("`@#0H@("`@("`@
M("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I
M;E)O=RXS+G-Y;6(N0C0^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N
M9FEN4F]W+C,N86UT+D(T/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C9F9F9F9F.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXS+G1R86EL+D(T/B`@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<@:60],T140DPQ-#DP+F9I;E)O=RXT/B`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9CL@4$%$1$E.1RU,1494.B`Q.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^("`@(`T*("`@("`@("`@(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!-05)'24XZ(#!P="<@:60],T10
M05)!,30W.#X@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-E9#PO9F]N=#X@#0H@
M("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#DP+F9I;E)O=RXT+FQE860N,CX@("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),
M,30Y,"YF:6Y2;W<N-"YS>6UB+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*
M("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$
M5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-"YA
M;70N,CX@("`@(`T*("`@("`@("`@("@R-S4@("`@(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T
M.3`N9FEN4F]W+C0N=')A:6PN,B!N;W=R87`],T1N;W=R87`^("`@#0H@("`@
M("`@("`@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'
M2%0Z(#$N,C4[($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#@P/B`-"B`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P="<^*3PO9F]N=#X@("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C0N
M;&5A9"XS/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP
M+F9I;E)O=RXT+G-Y;6(N,SX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO
M=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,3(E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!
M4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXT+F%M="XS/B`@("`@
M#0H@("`@("`@("`@-BXQ-R`@("`@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[
M(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N
M-"YT<F%I;"XS(&YO=W)A<#TS1&YO=W)A<#X@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C0N
M;&5A9"Y"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^
M("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C0N<WEM8BY"-#X@("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-"YA;70N0C0^("`-"B`@("`@
M("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N
M9FEN4F]W+C0N=')A:6PN0C0^("`@(`T*("`@("`@("`@("8C,38P.R`-"B`@
M("`@("`@/"]T9#X@("`@(`T*("`@("`@/"]T<CX@("`-"B`@("`@(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!I9#TS1%1"3#$T
M.3`N9FEN4F]W+C4^("`@#0H@("`@("`@(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!0041$24Y'
M+4Q%1E0Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@("`@#0H@("`@("`@("`@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E'2%0Z(#$N,C4[
M($U!4D=)3CH@,'!T)R!I9#TS1%!!4D$Q-#@R/B`-"B`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P="<^
M17AP:7)E9"!A;F0@9F]R9F5I=&5D/"]F;VYT/B`@(`T*("`@("`@("`@(#PO
M<#X@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8[(%=)1%1(.B`Q)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y
M,"YF:6Y2;W<N-2YL96%D+C(^("`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@
M("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXU+G-Y;6(N,CX@
M(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@
M("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP
M+F9I;E)O=RXU+F%M="XR/B`@("`-"B`@("`@("`@("`H,3$@("`@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,'!X.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C4N=')A:6PN,B!N;W=R87`],T1N;W=R
M87`^("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%203$T
M.#0^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z(#$P
M<'0G/BD\+V9O;G0^("`-"B`@("`@("`@("`\+W`^(`T*("`@("`@("`\+W1D
M/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C4N;&5A9"XS
M/B`@(`T*("`@("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O
M=RXU+G-Y;6(N,SX@#0H@("`@("`@("`@)"`@#0H@("`@("`@(#PO=&0^("`@
M("`-"B`@("`@("`@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!724142#H@,3(E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,
M1494.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXU+F%M="XS/B`@("`@#0H@("`@
M("`@("`@,3<N,S(@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,'!X.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!72414
M2#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C4N=')A
M:6PN,R!N;W=R87`],T1N;W=R87`^("`-"B`@("`@("`@("`F(S$V,#L@#0H@
M("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C4N;&5A9"Y"
M-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C4N<WEM8BY"-#X@("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M)R!I
M9#TS1%1"3#$T.3`N9FEN4F]W+C4N86UT+D(T/B`@("`@#0H@("`@("`@("`@
M)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!P>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9CL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF
M:6Y2;W<N-2YT<F%I;"Y"-#X@("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@(#PO='(^("`@#0H@("`@("`\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@:60],T140DPQ-#DP
M+F9I;E)O=RXV/B`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`@("`-"B`@("`@("`@("`\<"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!,24Y%+4A%24=(5#H@,2XR-3L@34%21TE..B`P<'0G(&ED/3-$4$%2
M03$T.#8^(`T*("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T)SY"86QA;F-E(&%T($UA<F-H(#,Q+"`R
M,#$T/"]F;VYT/B`@#0H@("`@("`@("`@/"]P/B`-"B`@("`@("`@/"]T9#X@
M("`@(`T*("`@("`@("`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I;E)O=RXV+FQE860N,CX@
M("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@
M("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60]
M,T140DPQ-#DP+F9I;E)O=RXV+G-Y;6(N,CX@("`-"B`@("`@("`@("`F(S$V
M,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q
M,B4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@34%21TE.+4Q%1E0Z(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C8N86UT+C(^
M("`@("`-"B`@("`@("`@("`W+#(W,R`-"B`@("`@("`@/"]T9#X@("`@(`T*
M("`@("`@("`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P<'@[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF
M:6Y2;W<N-BYT<F%I;"XR(&YO=W)A<#TS1&YO=W)A<#X@(`T*("`@("`@("`@
M("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\=&0@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T14
M0DPQ-#DP+F9I;E)O=RXV+FQE860N,SX@("`-"B`@("`@("`@("`F(S$V,#L@
M#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8[(%=)1%1(.B`Q)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!-05)'24XM3$5&
M5#H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG(&ED/3-$5$),,30Y,"YF:6Y2;W<N-BYS>6UB+C,^(`T*("`@("`@("`@
M("0@(`T*("`@("`@("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9CL@5TE$5$@Z(#$R)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!-05)'24XM3$5&5#H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG(&ED/3-$5$),,30Y,"YF:6Y2
M;W<N-BYA;70N,SX@("`@(`T*("`@("`@("`@(#@N-3<@("`@(`T*("`@("`@
M("`\+W1D/B`@("`@#0H@("`@("`@(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!P>#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z(#$E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P
M<'0[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#DP+F9I;E)O=RXV+G1R86EL+C,@;F]W<F%P/3-$;F]W<F%P
M/B`@#0H@("`@("`@("`@)B,Q-C`[(`T*("`@("`@("`\+W1D/B`@("`@#0H@
M("`@("`@(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M.R!724142#H@,24[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C8N;&5A9"XT/B`@(`T*("`@
M("`@("`@("8C,38P.R`-"B`@("`@("`@/"]T9#X@("`@(`T*("`@("`@("`\
M=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9CL@5TE$5$@Z
M(#$E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@
M:60],T140DPQ-#DP+F9I;E)O=RXV+G-Y;6(N-#X@("`-"B`@("`@("`@("`F
M(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F.R!724142#H@,3(E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[($U!4D=)3BU,1494.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<@:60],T140DPQ-#DP+F9I
M;E)O=RXV+F%M="XT/B`@("`@#0H@("`@("`@("`@."XT,B`@("`@#0H@("`@
M("`@(#PO=&0^("`@("`-"B`@("`@("`@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,'!X.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F.R!724142#H@,24[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@34%21TE.+4Q%1E0Z
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)R!I9#TS1%1"3#$T.3`N9FEN4F]W+C8N=')A:6PN-"!N;W=R87`],T1N;W=R
M87`^("`-"B`@("`@("`@("`F(S$V,#L@#0H@("`@("`@(#PO=&0^("`@("`-
M"B`@("`@(#PO='(^("`@#0H@("`@/"]T86)L93X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X
M9#@U7S`U,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]B,V4Y834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H
M965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5T)!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY.;W1E(#$@+2!"=7-I;F5S<R`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIA;BX@,3,L(#(P,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@
M,2`M($)U<VEN97-S("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO
M;&1E<G,G($5Q=6ET>2!.;W1E+"!3=&]C:R!3<&QI="P@0V]N=F5R<VEO;B!2
M871I;SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M971A:6YE9"!%87)N:6YG<R`H06-C=6UU;&%T960@1&5F:6-I="D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C,X+#@W,"PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-38L
M-#`X+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@27-S=6%N8V4@;V8@3&]N9RUT
M97)M($1E8G0@86YD($-A<&ET86P@4V5C=7)I=&EE<RP@3F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S4L-#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD($-A<V@@17%U:79A;&5N=',L(&%T($-A<G)Y:6YG(%9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<R+#(X-RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4W+#0W
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0U+#<R,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#4S+#4P-BPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15A$04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^3F]T92`S("T@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T
M86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',L(&%T($-A
M<G)Y:6YG(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4W+#0W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-S(L,C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`T-2PW,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S+#4P-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C-E.6$U,S%?-F,T.5\T-3,T
M7SAD.#5?,#4Q8SED,V0T-#DW#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-R]7;W)K
M<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+1T%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DYO=&4@,R`M($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E
M=&%I;',I("T@17%U:71Y($5X8VQU9&5D($9R;VT@0V%L8W5L871I;VX@;V8@
M1&EL=71E9"!%87)N:6YG<R!097(@4VAA<F4\8G(^26X@5&AO=7-A;F1S+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17%U:71Y($]P=&EO;B!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I
M;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O
M9B!%87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&5X8VQU
M9&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(W,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#8Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L
M=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,@97AC;'5D960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PP-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($1E8G0@4V5C
M=7)I=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D
M960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F5S(&5X8VQU9&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#,X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P150Q04D^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^3F]T92`T("T@0V]N=F5R=&EB;&4@3F]T97,@=&\@4F5L871E9"!087)T
M:65S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6PN(#(Y+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^26YI=&EA;"!#
M;&]S:6YG($%M;W5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$Q/&)R/E!U<F-H87-E($]P=&EO;B!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/DYO=&5S(%!A>6%B;&4L($]T:&5R(%!A>6%B;&5S(%M-
M96UB97)=/&)R/DEN($-A<V4@;V8@1&5B="!#;VYV97)S:6]N(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3$\8G(^3F]T97,@4&%Y86)L92P@3W1H97(@4&%Y86)L97,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CY.;W1E<R!087EA8FQE+"!/=&AE<B!087EA8FQE<R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$Q
M/&)R/DYO=&5S(%!A>6%B;&4L($]T:&5R(%!A>6%B;&5S(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\
M8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^4')I;F-I<&%L($%M;W5N
M="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;W1E(#0@+2!#;VYV97)T:6)L92!.;W1E<R!T;R!296QA
M=&5D(%!A<G1I97,@*$1E=&%I;',I(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!$96)T($ES<W5A8FQE($EN($-O;FYE8W1I;VX@5VET:"!0
M<FEV871E(%!L86-E;65N=#$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-"PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&5S($%U=&AO<FEZ960@
M56YD97(@4')I=F%T92!0;&%C96UE;G0@26YI=&EA;"!#;&]S:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4'5R8VAA<V4@3W!T:6]N(%5N9&5R(%!R:79A=&4@4&QA8V5M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E8G0@26YS=')U;65N="P@36%T=7)I='D@1&%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA>2`R+`T*"0DR,#(Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5B="!);G-T<G5M96YT($-O;G9E<G-I;VX@4F%T:6\L(%-H87)E<R`H:6X@
M4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT($-O;G9E<G-I;VX@4F%T:6\L
M($UU;'1I<&QE(&]F(%!R:6YC:7!A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5N969I8VEA;"!/=VYE<G-H
M:7`@069T97(@0V]N=F5R<VEO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDN.3DE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T:6-E(%!E<FEO9"!!<W-O8VEA
M=&5D('=I=&@@0F5N969I8VEA;"!/=VYE<G-H:7`@4&5R8V5N=&%G92!,:6UI
M=&%T:6]N+"!#;VYV97)T:6)L92!.;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<V,2!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-H87)E
M<R!296=I<W1E<F5D($9O<B!297-A;&4@26X@0V]N;F5C=&EO;B!7:71H($-O
M;G9E<G1I8FQE($YO=&5S("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%I9"UI;BU+
M:6YD($EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT+"!5;F%M;W)T:7IE
M9"!$:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L.30T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@17AP96YS92P@1&5B
M="P@17AC;'5D:6YG($%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T
M:6]N(&]F($1E8G0@1&ES8V]U;G0@*%!R96UI=6TI/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<G)Y:6YG(%9A;'5E(&]F($YO=&5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-C0L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#$V-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E8G0@26YS=')U;65N="P@1F%C92!!;6]U;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PQ,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-2PQ,#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$96)T($EN<W1R=6UE;G0L($-O;G9E<G1I8FQE
M+"!.=6UB97(@;V8@17%U:71Y($EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C-E.6$U,S%?-F,T
M.5\T-3,T7SAD.#5?,#4Q8SED,V0T-#DW#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y
M-R]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$554D1)/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T;V-K:&]L9&5R<R<@17%U
M:71Y("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XR."!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIA;BX@,3,L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2F%N+B`Q,RP@,C`Q-#QB<CY38V5N87)I;RP@
M4')E=FEO=7-L>2!297!O<G1E9"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/D-O;6UO;B!3=&]C
M:R!;365M8F5R73QB<CY0<FEV871E(%!L86-E;65N="`R,#$Q(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,30\8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/E!R:79A=&4@4&QA8V5M
M96YT(#(P,3$@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5L+B`S,2P@,C`Q,CQB<CY#;VUM;VX@4W1O8VL@6TUE;6)E<ET\
M8G(^4')I=F%T92!0;&%C96UE;G0@,C`Q,B!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#,P+"`R,#$S/&)R/D-O;6UO
M;B!3=&]C:R!;365M8F5R73QB<CY*969F97)I97,@3$Q#(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,3,L(#(P,30\
M8G(^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^5V%R<F%N="!;365M8F5R
M73QB<CY0<FEV871E(%!L86-E;65N="`R,#$Q(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,CDL(#(P,3$\8G(^4')I
M=F%T92!0;&%C96UE;G0@,C`Q,2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/E!R:79A=&4@4&QA
M8V5M96YT(#(P,3$@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY0<FEV871E(%!L86-E;65N="`R
M,#$Q(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3$\8G(^4')I=F%T92!0;&%C96UE;G0@,C`Q,2!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/E!R:79A=&4@4&QA8V5M96YT(#(P,3(@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,CQB
M<CY0<FEV871E(%!L86-E;65N="`R,#$R(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@-2`M(%-T
M;V-K:&]L9&5R<R<@17%U:71Y("A$971A:6QS*2!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4L(%-T;V-K(%-P
M;&ET+"!#;VYV97)S:6]N(%)A=&EO/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!3:&%R
M97,@075T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M27-S=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3F5W($ES<W5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PT
M,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQA<W,@;V8@5V%R<F%N
M="!O<B!2:6=H="P@3G5M8F5R(&]F(%-E8W5R:71I97,@0V%L;&5D(&)Y(%=A
M<G)A;G1S(&]R(%)I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N=',@;V8@4W1O
M8VL@27-S=6%N8V4@0V]S=',@*&EN($1O;&QA<G,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@079A:6QA8FQE(%!E<B!787)R
M86YT($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC92!!<G)A;F=E;65N
M="P@5V%R<F%N=',@5&\@4'5R8VAA<V4@4VAA<F5S+"!0=7)C:&%S92!0<FEC
M92!097(@56YI="`H:6X@1&]L;&%R<R!P97(@4VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EM
M:71A=&EO;B!/;B!%>&5R8VES86)L92!787)R86YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2XY.24\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C
M=&EV92!2871E($]F($QI<75I9&%T960@1&%M86=E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<FEV871E(%!L86-E;65N="!#87!P960@4&5N871L>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"P@3F]N+4]P=&EO;B!%<75I='D@26YS=')U
M;65N=',L($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30T+#`T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!)<W-U
M86YC92!O9B!#;VUM;VX@4W1O8VL@*&EN($1O;&QA<G,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L.#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]C965D<R!F<F]M(%=A<G)A;G0@17AE<F-I<V5S("AI;B!$;VQL87)S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F5S($ES<W5E9"P@4')I8V4@4&5R(%-H
M87)E("AI;B!$;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`N-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S
M=65D($1U<FEN9R!097)I;V0L(%9A;'5E+"!.97<@27-S=65S("AI;B!$;VQL
M87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!3=&]C:RP@4')I8V4@4&5R(%-H
M87)E("AI;B!$;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE
M;G0@07=A<F0L($]P=&EO;G,L($5X97)C:7-E<R!I;B!097)I;V0L($YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!3=&]C:R!/<'1I;VYS($5X97)C:7-E
M9"`H:6X@1&]L;&%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDU."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC
M92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($YO;G9E<W1E9"!!=V%R9',L
M($-O;7!E;G-A=&EO;B!#;W-T($YO="!Y970@4F5C;V=N:7IE9"`H:6X@1&]L
M;&%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#4L-#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92UB
M87-E9"!#;VUP96YS871I;VXL($YO;G9E<W1E9"!!=V%R9',L($-O;7!E;G-A
M=&EO;B!#;W-T($YO="!Y970@4F5C;V=N:7IE9"P@4&5R:6]D(&9O<B!296-O
M9VYI=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(@>65A
M<G,@-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U
M7S`U,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B
M,V4Y834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H965T
M<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%-49!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY.;W1E(#4@+2!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL
M<RD@+2!3=&]C:RUB87-E9"!#;VUP96YS871I;VX@17AP96YS92`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D
M(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS
M871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+#DV.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PX,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEM<&%C="!O;B!B87-I8R!A;F0@9&EL=71E9"!N
M970@;&]S<R!P97(@<VAA<F4@*&EN($1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@
M4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@
M;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES=')A
M=&EV92!%>'!E;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E
M<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I
M;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#<P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PU.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V(S93EA-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,V4Y834S,5\V8S0Y7S0U
M,S1?.&0X-5\P-3%C.60S9#0T.3<O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%2$9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#4@
M+2!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL<RD@+2!/<'1I;VX@5F%L
M=6%T:6]N($%S<W5M<'1I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<'1I;VX@5F%L=6%T:6]N($%S<W5M
M<'1I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C$P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E
M;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-3(N-#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E("AY96%R<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(S93EA
M-3,Q7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-PT*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]B,V4Y834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C
M.60S9#0T.3<O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%24=!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#4@+2!3=&]C:VAO;&1E
M<G,G($5Q=6ET>2`H1&5T86EL<RD@+2!/<'1I;VX@4W5M;6%R>2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<'1I;VX@4W5M
M;6%R>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPS-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@4')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@N,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D+4%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S(#$U,R!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S@@>65A<G,@-3$@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Y+CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PR,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(W-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXQ-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER960@86YD(&9O
M<F9E:71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AP:7)E9"!A;F0@9F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$W+C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#(W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@
M4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."XU-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D+4%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S(#$U,R!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S@@>65A<G,@-3$@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8C-E.6$U,S%?-F,T.5\T-3,T7SAD.#5?,#4Q8SED
M,V0T-#DW#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(S93EA-3,Q
M7S9C-#E?-#4S-%\X9#@U7S`U,6,Y9#-D-#0Y-R]7;W)K<VAE971S+V9I;&5L
M:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$
M(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(Q+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%]B,V4Y
D834S,5\V8S0Y7S0U,S1?.&0X-5\P-3%C.60S9#0T.3<M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Convertible Notes to Related Parties<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1355">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>4. Convertible Notes to Related Parties</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1357">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5 million in Senior Secured Convertible Notes (&#8220;Notes&#8221;). We received a total of $4.3 million, net of issuance costs, from the issuance of these Notes.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1359">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Notes are secured by substantially all of our assets, including placing our bank accounts under a control agreement. The Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Notes, at the election of the purchasers. The Notes mature on May 2, 2021, however, the holders of the Notes may require prepayment of the Notes at any time, at each holder&#8217;s option.</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1361">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes. There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1363">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">As of March 31, 2014, we were in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require us to redeem all or a portion of their Notes.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt">
      We filed a registration statement with the SEC to register for resale 3.5 million shares (as adjusted for the Reverse Stock Split) underlying the Notes. The registration statement was declared effective on July 29, 2011. The Purchasers have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.&#160;
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1367">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates and we began amortizing the resultant debt discount over the respective 10-year term of the Notes. During the three months ended March 31, 2014, accrued interest of approximately $75,000 was paid-in-kind and rolled into the Note principal balance, which resulted in an additional debt discount of approximately $75,000. For the three months ended March 31, 2014 and 2013, interest expense relating to the stated rate was approximately $77,000 and $71,000, respectively, and interest expense relating to the
      amortization of the debt discount was approximately $139,000 and $130,000, respectively.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1369">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">As of March 31, 2014, the carrying value of the Notes was approximately $1,164,000, which is comprised of the $5,108,000 principal amount of the Notes outstanding, less debt discount of $3,944,000. If the $5.1&#160;million principal amount of Notes is converted, we would issue 6.4 million shares of our common stock.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Balance Sheets (Current Period Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
        <td class="nump">$ 57,475<span></span></td>
        <td class="nump">$ 72,287<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">2,262<span></span></td>
        <td class="nump">638<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">59,737<span></span></td>
        <td class="nump">72,925<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">2,926<span></span></td>
        <td class="nump">2,882<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
        <td class="nump">130<span></span></td>
        <td class="nump">130<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">62,793<span></span></td>
        <td class="nump">75,937<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">3,603<span></span></td>
        <td class="nump">1,264<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">2,617<span></span></td>
        <td class="nump">4,703<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Convertible notes payable to related parties, net of discount</a></td>
        <td class="nump">1,164<span></span></td>
        <td class="nump">1,025<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">7,384<span></span></td>
        <td class="nump">6,992<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
        <td class="nump">239<span></span></td>
        <td class="nump">237<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">311,578<span></span></td>
        <td class="nump">307,578<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(256,408)<span></span></td>
        <td class="num">(238,870)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#x2019; equity</a></td>
        <td class="nump">55,409<span></span></td>
        <td class="nump">68,945<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump">$ 62,793<span></span></td>
        <td class="nump">$ 75,937<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_CurrentAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_CurrentAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_CurrentLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_CurrentLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Accounting [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1309">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2.&#160;&#160;&#160;&#160;&#160;Basis of Presentation</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1311">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#160;31,&#160;2014 are not necessarily indicative of the results that may be expected for other quarters or the year ending December&#160;31, 2014. The condensed balance sheet at December 31, 2013 has been derived from the audited financial statements as of that date, but does not include all of the
      information and disclosures required by GAAP. The presentation of prior year amounts was reclassified to conform to the current year presentation. For more complete financial information, these unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended December&#160;31, 2013 included in the Company&#8217;s Annual Report on Form</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#160;10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 7, 2014</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccounting</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureTextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1313">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>3.&#160;&#160;&#160;&#160;&#160;Accounting Policies</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1315">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Use of Estimates</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1317">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions <font style="COLOR: #000000">that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates on historical experience and on assumptions that it believes to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</font></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1319">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Cash and Cash Equivalents</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1321">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively. There were no cash equivalents as of both dates. Our bank accounts have been placed under a control agreement in accordance with the April&#160;2011 convertible note financing (see Note 4).</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1323">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Earnings Per Share</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1325">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1327">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Because we have incurred a net loss for both periods presented in the unaudited condensed statements of operations, outstanding stock options, warrants and common stock underlying convertible notes are not included in the computation of net loss per share because their effect would be anti-dilutive.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1329">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The following table includes the number of outstanding stock options, warrants and common stock underlying convertible notes not included in the computation for the three months ended March 31, 2014 and 2013 (in thousands):</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1345" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1345.finRow.1">
        <td style="WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1331">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b></b></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1332">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Three Months Ended</b></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1345.finRow.2">
        <td style="WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1334">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1335">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1345.finRow.3">
        <td style="WIDTH: 76%">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.lead.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.symb.B2">
          &#160;
        </td>
        <td style="WIDTH: 9%" id="TBL1345.finRow.3.amt.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.trail.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.lead.B3">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.symb.B3">
          &#160;
        </td>
        <td style="WIDTH: 9%" id="TBL1345.finRow.3.amt.B3">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1345.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1336">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Stock options outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.amt.2">
          7,273
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.amt.3">
          4,461
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1345.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1339">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Warrants outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.amt.2">
          3,825
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.amt.3">
          4,052
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1345.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1342">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Common stock underlying convertible notes outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.amt.2">
          6,385
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.amt.3">
          6,016
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1347">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Comprehensive Income (Loss)</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1349">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of its net loss and there were no other changes in equity from non-owner sources.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1351">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Recent Accounting Pronouncements</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1353">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">We do not expect that the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3OAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 11,771<span></span></td>
        <td class="nump">$ 7,140<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">5,551<span></span></td>
        <td class="nump">5,612<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">17,322<span></span></td>
        <td class="nump">12,752<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(17,322)<span></span></td>
        <td class="num">(12,752)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(216)<span></span></td>
        <td class="num">(201)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (17,538)<span></span></td>
        <td class="num">$ (12,953)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in Dollars per share)</a></td>
        <td class="num">$ (0.74)<span></span></td>
        <td class="num">$ (0.85)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share (in Shares)</a></td>
        <td class="nump">23,686<span></span></td>
        <td class="nump">15,254<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ET1AI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Convertible Notes to Related Parties (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 29, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Initial Closing Amount [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Purchase Option [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Notes Payable, Other Payables [Member]

</div>
          <div>In Case of Debt Conversion [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Notes Payable, Other Payables [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Notes Payable, Other Payables [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Notes Payable, Other Payables [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011

</div>
          <div>Principal Amount [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems', window );"><strong>Note 4 - Convertible Notes to Related Parties (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1', window );">Convertible Debt Issuable In Connection With Private Placement1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing', window );">Notes Authorized Under Private Placement Initial Closing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_PurchaseOptionUnderPrivatePlacement', window );">Purchase Option Under Private Placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">May
				02,
				 2021<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_DebtInstrumentConversionRatioShares', window );">Debt Instrument Conversion Ratio, Shares (in Shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,250<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal', window );">Debt Instrument Conversion Ratio, Multiple of Principal</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_BeneficialOwnershipAfterConversion', window );">Beneficial Ownership After Conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.99%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes', window );">Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">61 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes', window );">Common Shares Registered For Resale In Connection With Convertible Notes (in Shares)</a></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-Kind Interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,944,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense, Debt, Excluding Amortization</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">77,000<span></span></td>
        <td class="nump">71,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">139,000<span></span></td>
        <td class="nump">130,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Carrying Value of Notes Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,164,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,025,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,164,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,108,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Debt Instrument, Convertible, Number of Equity Instruments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_BeneficialOwnershipAfterConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage amount the holder would beneficially own of the company's outstanding common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_BeneficialOwnershipAfterConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares registered for resale in connection with convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible debt issuable in connection with private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The multiple of principal used in calculating the number of shares converted from the notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_DebtInstrumentConversionRatioShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares per $1,000 of principal of note.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_DebtInstrumentConversionRatioShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_Note4ConvertibleNotestoRelatedPartiesDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notes authorized under private placement initial closing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_NotesAuthorizedUnderPrivatePlacementInitialClosing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice period associated with beneficial ownership percentage limitation, convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_PurchaseOptionUnderPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase option under private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_PurchaseOptionUnderPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebtExcludingAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">HERON THERAPEUTICS, INC. /DE/<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,901,497<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000818033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EURDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">28 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">15 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 13, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 13, 2014

</div>
          <div>Scenario, Previously Reported [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Common Stock [Member]

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Common Stock [Member]

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>Private Placement 2012 [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2013

</div>
          <div>Common Stock [Member]

</div>
          <div>Jefferies LLC [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 13, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Warrant [Member]

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 29, 2011

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Private Placement 2011 [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Private Placement 2012 [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Private Placement 2012 [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_Note5StockholdersEquityDetailsLineItems', window );"><strong>Note 5 - Stockholders' Equity (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,000,000<span></span></td>
        <td class="nump">1,500,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="nump">108,409<span></span></td>
        <td class="nump">5,100,000<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,100,000<span></span></td>
        <td class="nump">$ 3,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_SharesAvailablePerWarrantExercised', window );">Shares Available Per Warrant Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit', window );">Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_LimitationOnExercisableWarrants', window );">Limitation On Exercisable Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.99%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_EffectiveRateOfLiquidatedDamages', window );">Effective Rate Of Liquidated Damages</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_PrivatePlacementCappedPenatly', window );">Private Placement Capped Penatly</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,040<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.50<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues (in Dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share (in Dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</a></td>
        <td class="nump">215,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised (in Dollars)</a></td>
        <td class="nump">958,000<span></span></td>
        <td class="nump">12,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)</a></td>
        <td class="nump">$ 45,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
        <td class="text">2 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_EffectiveRateOfLiquidatedDamages">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Failure to keep the registration statement continuously effective for a designated time will result in the rated penalty of liquidated damages</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_EffectiveRateOfLiquidatedDamages</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase Price Unit (1 Warrant to Purchase 0.5 shares of Common Stock)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_ExercisePriceArrangementWarrantsToPurchaseSharesPurchasePricePerUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_LimitationOnExercisableWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>There is no right to exercise the Warrants to the extent that the holder would beneficially own in excess of the stated percentage of The Company's outstanding shares of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_LimitationOnExercisableWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_Note5StockholdersEquityDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_Note5StockholdersEquityDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_PrivatePlacementCappedPenatly">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of penalty that may not exceed stated percentage of original purchase price of Private Placement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_PrivatePlacementCappedPenatly</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_SharesAvailablePerWarrantExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of shares available to be exercised per warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_SharesAvailablePerWarrantExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period, net of shares retained for cashless exercises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssuedPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (17,538,000)<span></span></td>
        <td class="num">$ (12,953,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">114,000<span></span></td>
        <td class="nump">70,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">2,969,000<span></span></td>
        <td class="nump">1,835,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="nump">139,000<span></span></td>
        <td class="nump">130,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(1,624,000)<span></span></td>
        <td class="nump">157,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">2,238,000<span></span></td>
        <td class="nump">1,330,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="num">(2,011,000)<span></span></td>
        <td class="nump">1,470,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
        <td class="num">(15,713,000)<span></span></td>
        <td class="num">(7,961,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(57,000)<span></span></td>
        <td class="num">(435,000)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
        <td class="num">(57,000)<span></span></td>
        <td class="num">(435,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
        <td class="nump">958,000<span></span></td>
        <td class="nump">12,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">958,000<span></span></td>
        <td class="nump">612,000<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
        <td class="num">(14,812,000)<span></span></td>
        <td class="num">(7,784,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump">72,287,000<span></span></td>
        <td class="nump">53,506,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump">$ 57,475,000<span></span></td>
        <td class="nump">$ 45,722,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_AdjustmentsToReconcileNetLossToNetCashUsedForOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_ChangesInOperatingAssetsAndLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1345" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1345.finRow.1">
        <td style="WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1331">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b></b></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1332">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Three Months Ended</b></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1345.finRow.2">
        <td style="WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1334">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1335">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1345.finRow.3">
        <td style="WIDTH: 76%">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.lead.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.symb.B2">
          &#160;
        </td>
        <td style="WIDTH: 9%" id="TBL1345.finRow.3.amt.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.trail.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.lead.B3">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.symb.B3">
          &#160;
        </td>
        <td style="WIDTH: 9%" id="TBL1345.finRow.3.amt.B3">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1345.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1336">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Stock options outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.amt.2">
          7,273
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.amt.3">
          4,461
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1345.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1339">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Warrants outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.amt.2">
          3,825
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.amt.3">
          4,052
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1345.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1342">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Common stock underlying convertible notes outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.amt.2">
          6,385
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.amt.3">
          6,016
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1315"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Use of Estimates</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1317">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions <font style="COLOR: #000000">that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates on historical experience and on assumptions that it believes to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</font></font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1319"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Cash and Cash Equivalents</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1321">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively. There were no cash equivalents as of both dates. Our bank accounts have been placed under a control agreement in accordance with the April&#160;2011 convertible note financing (see Note 4).</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1321"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We had cash of $57.5 million and $72.3 million at March 31, 2014 and December 31, 2013, respectively.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1323"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Earnings Per Share</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1325">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1327">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Because we have incurred a net loss for both periods presented in the unaudited condensed statements of operations, outstanding stock options, warrants and common stock underlying convertible notes are not included in the computation of net loss per share because their effect would be anti-dilutive.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1329">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The following table includes the number of outstanding stock options, warrants and common stock underlying convertible notes not included in the computation for the three months ended March 31, 2014 and 2013 (in thousands):</font>
    </p><br/><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1345" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1345.finRow.1">
        <td style="WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1331">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b></b></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1332">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Three Months Ended</b></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1345.finRow.2">
        <td style="WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1334">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1335">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1345.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1345.finRow.3">
        <td style="WIDTH: 76%">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.lead.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.symb.B2">
          &#160;
        </td>
        <td style="WIDTH: 9%" id="TBL1345.finRow.3.amt.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.trail.B2">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.lead.B3">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.symb.B3">
          &#160;
        </td>
        <td style="WIDTH: 9%" id="TBL1345.finRow.3.amt.B3">
          &#160;
        </td>
        <td style="WIDTH: 1%" id="TBL1345.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1345.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1336">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Stock options outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.amt.2">
          7,273
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.amt.3">
          4,461
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1345.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1339">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Warrants outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.amt.2">
          3,825
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.amt.3">
          4,052
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1345.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 76%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1342">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Common stock underlying convertible notes outstanding</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.amt.2">
          6,385
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.amt.3">
          6,016
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1345.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1347"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Comprehensive Income (Loss)</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1349">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of its net loss and there were no other changes in equity from non-owner sources.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1351"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Recent Accounting Pronouncements</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1353">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">We do not expect that the adoption of any recently issued accounting pronouncements would have a significant impact on our results of operations, financial condition or cash flow.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details) - Stock-based Compensation Expense (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">$ 2,969<span></span></td>
        <td class="nump">$ 1,835<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare', window );">Impact on basic and diluted net loss per share (in Dollars per share)</a></td>
        <td class="nump">$ 0.13<span></span></td>
        <td class="nump">$ 0.12<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">1,262<span></span></td>
        <td class="nump">249<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump">$ 1,707<span></span></td>
        <td class="nump">$ 1,586<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impact on basic and diluted net loss per common share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareinDollarsPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
        <td class="nump">$ 57,475<span></span></td>
        <td class="nump">$ 72,287<span></span></td>
        <td class="nump">$ 45,722<span></span></td>
        <td class="nump">$ 53,506<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1424" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1424.finRow.1">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1407">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b></b></font>
          </p>
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1408">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Three Months Ended</b></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1424.finRow.2">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1410">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1411">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top" id="TBL1424.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1424.finRow.3">
        <td>
          &#160;
        </td>
        <td id="TBL1424.finRow.3.lead.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.symb.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.amt.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.trail.B2">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.lead.B3">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.symb.B3">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.amt.B3">
          &#160;
        </td>
        <td id="TBL1424.finRow.3.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1424.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1412">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Research and development</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.symb.2">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.amt.2">
          1,262
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.amt.3">
          249
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1415">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">General and administrative</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.amt.2">
          1,707
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.symb.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 67.3%; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.amt.3">
          1,586
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1424.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1418">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Stock-based compensation expense included in operating expenses</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.amt.2">
          2,969
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.amt.3">
          1,835
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7">
        <td style="BACKGROUND-COLOR: #ffffff">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.lead.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.symb.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.amt.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.trail.B2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.lead.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.symb.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.amt.B3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff" id="TBL1424.finRow.7.trail.B3">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1424.finRow.8">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: top">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1421">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Impact on basic and diluted net loss per share</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.symb.2">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.amt.2">
          0.13
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.lead.3">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.symb.3">
          $
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.amt.3">
          0.12
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1424.finRow.8.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1446" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1446.finRow.1">
        <td style="TEXT-ALIGN: left; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1430">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><i>Options:</i></font>
          </p>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.1.amt.D3" colspan="6">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1431">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>March 31,</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr id="TBL1446.finRow.2">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1432">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>2014</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1433">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>2013</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.2.trail.D3">
          <b>&#160;</b>
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1446.finRow.3">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1434">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Risk-free interest rate</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.amt.2">
          2.0
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.trail.2" nowrap="nowrap">
          %
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.amt.3">
          1.1
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.3.trail.3" nowrap="nowrap">
          %
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1446.finRow.4">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1437">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Dividend yield</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.amt.2">
          0.0
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.trail.2" nowrap="nowrap">
          %
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 19.55pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.amt.3">
          0.0
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.4.trail.3" nowrap="nowrap">
          %
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1446.finRow.5">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1440">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Volatility</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.amt.2">
          153.0
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.trail.2" nowrap="nowrap">
          %
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.amt.3">
          152.4
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.5.trail.3" nowrap="nowrap">
          %
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1446.finRow.6">
        <td style="TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1443">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Expected life (years)</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.amt.2">
          6
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.symb.3">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 117pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.amt.3">
          6
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1446.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Compensation, Activity [Table Text Block]</a></td>
        <td class="text"><table style="TEXT-INDENT: 0px; WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id="TBL1490" border="0" cellspacing="0" cellpadding="0">
      <tr id="TBL1490.finRow.1">
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.lead.D2">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.amt.D2" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1468">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Shares (in thousands)</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.trail.D2">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.lead.D3">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.amt.D3" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1469">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted-Average Exercise Price</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.trail.D3">
          <b>&#160;</b>
        </td>
        <td style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.lead.D4">
          <b>&#160;</b>
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.amt.D4" colspan="2">
          <p style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1470">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><b>Weighted-Average Remaining Contractual Term (Years)</b></font>
          </p>
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.1.trail.D4">
          <b>&#160;</b>
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1490.finRow.2">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 55%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1471">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Balance at January 1, 2014</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.amt.2">
          6,356
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.amt.3">
          8.22
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.lead.4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.amt.4">
          8.14
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.2.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1490.finRow.3">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1475">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Granted</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.amt.2">
          1,203
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.amt.3">
          9.99
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.amt.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.3.trail.B4">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1490.finRow.4">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1478">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Exercised</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.lead.2">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.symb.2">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.amt.2">
          (275
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.trail.2" nowrap="nowrap">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1480">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.amt.3">
          6.17
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.amt.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.4.trail.B4">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #ffffff" id="TBL1490.finRow.5">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 18pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1482">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Expired and forfeited</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.amt.2">
          (11
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.trail.2" nowrap="nowrap">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1484">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">)</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.amt.3">
          17.32
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.lead.B4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.symb.B4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.amt.B4">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.5.trail.B4">
          &#160;
        </td>
      </tr>
      <tr style="BACKGROUND-COLOR: #cceeff" id="TBL1490.finRow.6">
        <td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
          <p style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1486">
            <font style="FONT-FAMILY: Times New Roman, Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Balance at March 31, 2014</font>
          </p>
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.lead.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.symb.2">
          &#160;
        </td>
        <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.amt.2">
          7,273
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.trail.2" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.lead.3">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.symb.3">
          $
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.amt.3">
          8.57
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.trail.3" nowrap="nowrap">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.lead.4">
          &#160;
        </td>
        <td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.symb.4">
          &#160;
        </td>
        <td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.amt.4">
          8.42
        </td>
        <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id="TBL1490.finRow.6.trail.4" nowrap="nowrap">
          &#160;
        </td>
      </tr>
    </table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Business (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">36 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jan. 13, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_Note1BusinessDetailsLineItems', window );"><strong>Note 1 - Business (Details) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
        <td class="num">$ (238,870,000)<span></span></td>
        <td class="num">$ (256,408,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Proceeds from Issuance of Long-term Debt and Capital Securities, Net</a></td>
        <td class="nump">135,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
        <td class="nump">$ 72,287,000<span></span></td>
        <td class="nump">$ 57,475,000<span></span></td>
        <td class="nump">$ 45,722,000<span></span></td>
        <td class="nump">$ 53,506,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_Note1BusinessDetailsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_Note1BusinessDetailsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies (Details) - Equity Excluded From Calculation of Diluted Earnings Per Share<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equity Option [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded</a></td>
        <td class="nump">7,273<span></span></td>
        <td class="nump">4,461<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded</a></td>
        <td class="nump">3,825<span></span></td>
        <td class="nump">4,052<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Debt Securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded</a></td>
        <td class="nump">6,385<span></span></td>
        <td class="nump">6,016<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details) - Option Summary (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_OptionSummaryAbstract', window );"><strong>Option Summary [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,356<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8.22<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
        <td class="text">8 years 153 days<span></span></td>
        <td class="text">8 years 51 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 9.99<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump">1,203<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(275)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="nump">$ 6.17<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired and forfeited</a></td>
        <td class="num">(11)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired and forfeited</a></td>
        <td class="nump">$ 17.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares</a></td>
        <td class="nump">7,273<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
        <td class="nump">$ 8.57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
        <td class="text">8 years 153 days<span></span></td>
        <td class="text">8 years 51 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_OptionSummaryAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_OptionSummaryAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Business<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1285">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>1.&#160;&#160;&#160;&#160;&#160;Business</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1287">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is a specialty pharmaceutical company developing product candidates using its proprietary Biochronomer&#8482; polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1289">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Our lead product candidate, SUSTOL<sup style="vertical-align: baseline; position: relative; bottom: .33em">TM</sup> (formerly known as APF530), is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;) for patients undergoing both moderately or highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. SUSTOL contains the 5-HT3 antagonist granisetron formulated in our proprietary Biochronomer polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for
      five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1021-0">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In May 2009, we filed the original New Drug Application (&#8220;NDA&#8221;) seeking approval for SUSTOL with the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The FDA issued a Complete Response Letter for the SUSTOL NDA in March 2010. In September 2012, we resubmitted our NDA for SUSTOL and, in March 2013, we received a second Complete Response Letter, which identified several remaining issues that need to be addressed prior to approval of the SUSTOL NDA. We are currently working on addressing these issues and expect to resubmit the SUSTOL NDA in <font style="COLOR: #000000">mid-</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2014.</font></font></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1293">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We own the worldwide rights to SUSTOL and are in the early stages of building the commercial infrastructure necessary to commercialize SUSTOL in the U.S. on our own, assuming approval by the FDA.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1295">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In addition, to resubmitting the SUSTOL NDA, we are seeking to expand the labeled indication for SUSTOL following its potential approval. In 2014, we initiated a Phase 3 clinical study with SUSTOL for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy, an indication for which no 5-HT3 antagonist is approved. The 1,000 patient study is expected to be completed in late 2014.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1297">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Our core Biochronomer technology, on which SUSTOL and our other product candidates are based, consists of bioerodible polymers designed to release drugs over a defined period of time. We have completed over 100 <i>in vivo</i> and <i>in vitro</i> studies demonstrating that our Biochronomer technology is potentially applicable to a range of therapeutic areas, including, among others, prevention of CINV, pain management and control of inflammation. We have also completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymers are safe and well tolerated. Furthermore, our Biochronomer technology can be designed to deliver drugs over periods varying from days to potentially multiple weeks. We are exploring the potential use of our Biochronomer polymer with other drugs and intend to pursue the clinical development of one or more other drug candidates based on our
      proprietary delivery platform.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt">
      <font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In November 2013, we initiated a program to expand our pipeline of sustained-release products, including a new program targeting the relief of post-surgical pain. Preliminary animal studies indicate <font style="COLOR: #000000">that</font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">formulations using <font style="COLOR: #000000">our</font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Biochronomer polymer-based drug delivery platform provided sustained analgesic effects for three to five days. We plan to formalize optimization in 2014 and initiate a Phase 1 study in mid-2014. As of 2012, approximately 25 million<font style="COLOR: #000000"><sup style="vertical-align: baseline; position: relative; bottom:.33em;">1</sup></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">procedures associated with post-operative pain were conducted in the U.S. In addition, post-operative pain market sales were approximately $3.1 billion<font style="COLOR: #000000"><sup style="vertical-align: baseline; position: relative; bottom:.33em;">2</sup></font> <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">in 2012.</font></font></font></font></font></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1301">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">In January 2014, we changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. Effective January&#160;13,&#160;2014, we effected a 1-for-20 reverse split of our outstanding common stock (&#8220;Reverse Stock Split&#8221;) (See Note 5). All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split. All stock options, convertible notes and warrants outstanding were appropriately adjusted to give effect to the Reverse Stock Split.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1302">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>Liquidity</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1304">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We have incurred significant operating losses and negative cash flows from operations and we have an accumulated deficit of $256.4 million as of March 31, 2014. During 2011, 2012 and 2013, we completed a total of four rounds of equity and/or debt financings, which provided us with cash of approximately $135.4 million, net of issuance costs, to fund operations (see Notes 4 and 5). As of March 31, 2014, we had cash on hand of $57.5 million.</font><font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#160;</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1307">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">We believe that our current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies prior to 2015 or begin preparations for potential commercialization of SUSTOL, we will need to raise additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureTextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 6 - Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1494">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><b>6. Income Taxes</b></font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1496">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company's ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of March 31, 2014.</font>
    </p><br/><p style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id="PARA1498">
      <font style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There have been no material changes in the Company&#8217;s unrecognized tax benefits since December&#160;31, 2013 and as such, disclosures included in the Company&#8217;s 2013 Annual Report on Form&#160;10-K continue to be relevant for the period ended March 31, 2014.</font>
    </p><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>46</ContextCount>
  <ElementCount>114</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Disclosure - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Balance Sheets (Current Period Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Disclosure - Note 1 - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note1Business</Role>
      <ShortName>Note 1 - Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note2BasisofPresentation</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 3 - Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note3AccountingPolicies</Role>
      <ShortName>Note 3 - Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 4 - Convertible Notes to Related Parties</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://herontx.com/role/Note4ConvertibleNotestoRelatedParties</Role>
      <ShortName>Note 4 - Convertible Notes to Related Parties</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note5StockholdersEquity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 6 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note6IncomeTaxes</Role>
      <ShortName>Note 6 - Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 3 - Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note3AccountingPoliciesTables</Role>
      <ShortName>Note 3 - Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 5 - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note5StockholdersEquityTables</Role>
      <ShortName>Note 5 - Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note1BusinessDetails</Role>
      <ShortName>Note 1 - Business (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 3 - Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note3AccountingPoliciesDetails</Role>
      <ShortName>Note 3 - Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 3 - Accounting Policies (Details) - Equity Excluded From Calculation of Diluted Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/EquityExcludedFromCalculationofDilutedEarningsPerShareTable</Role>
      <ShortName>Note 3 - Accounting Policies (Details) - Equity Excluded From Calculation of Diluted Earnings Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 4 - Convertible Notes to Related Parties (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://herontx.com/role/Note4ConvertibleNotestoRelatedPartiesDetails</Role>
      <ShortName>Note 4 - Convertible Notes to Related Parties (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 5 - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/Note5StockholdersEquityDetails</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 5 - Stockholders' Equity (Details) - Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/StockbasedCompensationExpenseTable</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details) - Stock-based Compensation Expense</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 5 - Stockholders' Equity (Details) - Option Valuation Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/OptionValuationAssumptionsTable</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details) - Option Valuation Assumptions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 5 - Stockholders' Equity (Details) - Option Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/role/OptionSummaryTable</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details) - Option Summary</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element hrtx_ConvertibleNotesPayableRelatedPartiesCurrent had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromStockOptionsExercised had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromWarrantExercises had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '003 - Statement - Condensed Statements of Cash Flows (Unaudited)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '013 - Disclosure - Note 1 - Business (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '016 - Disclosure - Note 4 - Convertible Notes to Related Parties (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '017 - Disclosure - Note 5 - Stockholders' Equity (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 001 - Statement - Condensed Balance Sheets (Current Period Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Condensed Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Condensed Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>hrtx-20140331.xml</File>
    <File>hrtx-20140331.xsd</File>
    <File>hrtx-20140331_cal.xml</File>
    <File>hrtx-20140331_def.xml</File>
    <File>hrtx-20140331_lab.xml</File>
    <File>hrtx-20140331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details) - Option Valuation Assumptions<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_OptionValuationAssumptionsAbstract', window );"><strong>Option Valuation Assumptions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">2.00%<span></span></td>
        <td class="nump">1.10%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">153.00%<span></span></td>
        <td class="nump">152.40%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">6 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_OptionValuationAssumptionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>hrtx_OptionValuationAssumptionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
